0001144204-13-059444.txt : 20131107 0001144204-13-059444.hdr.sgml : 20131107 20131107094242 ACCESSION NUMBER: 0001144204-13-059444 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 11 CONFORMED PERIOD OF REPORT: 20130930 FILED AS OF DATE: 20131107 DATE AS OF CHANGE: 20131107 FILER: COMPANY DATA: COMPANY CONFORMED NAME: REPROS THERAPEUTICS INC. CENTRAL INDEX KEY: 0000897075 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 760233274 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-15281 FILM NUMBER: 131198816 BUSINESS ADDRESS: STREET 1: 2408 TIMBERLOCH PL STREET 2: SUITE B-7 CITY: WOODLANDS STATE: TX ZIP: 77380 BUSINESS PHONE: 2817193400 MAIL ADDRESS: STREET 1: 2408 TIMBERLOCH PLACE B-7 CITY: THE WOODLANDS STATE: TX ZIP: 77380 FORMER COMPANY: FORMER CONFORMED NAME: REPROS THERAPEUTICS INC DATE OF NAME CHANGE: 20060503 FORMER COMPANY: FORMER CONFORMED NAME: ZONAGEN INC DATE OF NAME CHANGE: 19930208 10-Q 1 v358180_10q.htm 10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)

x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2013

¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ____________ to ____________

Commission file number: 001-15281

REPROS THERAPEUTICS INC.

(Exact Name of Registrant as Specified in its Charter)

Delaware

(State or other jurisdiction of
incorporation or
organization)

2408 Timberloch Place, Suite B-7

The Woodlands, Texas 77380

(Address of principal executive offices
and zip code)

(281) 719-3400

(Registrant's telephone number,
including area code)

76-0233274

(IRS Employer
Identification No.)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No ¨

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes x No ¨

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or smaller reporting company. See definition of "accelerated filer", "large accelerated filer" and "smaller reporting company" in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer ¨ Accelerated filer x Non-accelerated filer ¨ Smaller reporting company ¨

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ¨ No x

As of November 1, 2013, there were outstanding 23,009,882 shares of Common Stock, par value $.001 per share, of the Registrant.

REPROS THERAPEUTICS INC.

(A development stage company)

For the Quarter Ended September 30, 2013

INDEX

	Page

FACTORS AFFECTING FORWARD-LOOKING STATEMENTS	3

PART I. FINANCIAL INFORMATION

Item 1. Financial Statements (unaudited)	4
Unaudited Condensed Consolidated Balance Sheets as of September 30, 2013 and December 31, 2012	5
Unaudited Condensed Consolidated Statements of Operations for the three months and nine months ended September 30, 2013 and 2012 and from Inception (August 20, 1987) through September 30, 2013	6
Unaudited Condensed Consolidated Statements of Stockholders' Equity for the nine months ended September 30, 2013	7
Unaudited Condensed Consolidated Statements of Cash Flows for the nine months ended September 30, 2013 and 2012 and from Inception (August 20, 1987) through September 30, 2013	8
Notes to Unaudited Condensed Consolidated Financial Statements	9
Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations	12
Item 3. Quantitative and Qualitative Disclosures About Market Risk	23
Item 4. Controls and Procedures	24

PART II. OTHER INFORMATION
Item 1. Legal Proceedings	25
Item 1A. Risk Factors	25
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds	26
Item 3. Defaults Upon Senior Securities	26
Item 4. Mine Safety Disclosures	26
Item 5. Other Information	26
Item 6. Exhibits	26

SIGNATURES	28

	2

FACTORS AFFECTING FORWARD-LOOKING STATEMENTS

This quarterly report on Form 10-Q includes "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The words "may," "anticipate," "believe," "expect," "estimate," "project," "suggest," "intend" and similar expressions are intended to identify forward-looking statements. Such statements are subject to certain risks, uncertainties and assumptions. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those anticipated, believed, expected, estimated, projected, suggested or intended. These risks and uncertainties include risks associated with success of the clinical trials for Androxal® and Proellex®; uncertainty related to the Company's ability to obtain approval of the Company's products by the Food and Drug Administration, or FDA, and regulatory bodies in other jurisdictions; uncertainty relating to the Company's patent portfolio; and other risks and uncertainties described in the Company's filings with the Securities and Exchange Commission. For additional discussion of such risks, uncertainties and assumptions, see "Part I. Financial Information - Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations - Liquidity and Capital Resources" included elsewhere in this quarterly report on Form 10-Q and “Item 1A. Risk Factors” to Part I of Form 10-K for the fiscal year ended December 31, 2012.

	3

PART I. FINANCIAL INFORMATION

Item 1. Financial Statements

The following unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information and with the instructions to Form 10-Q and Rule 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by accounting principles generally accepted in the United States of America for complete financial statements. In the opinion of management, all adjustments (which include only normal recurring adjustments) considered necessary for a fair statement of the interim periods presented have been included. The year-end balance sheet data was derived from audited financial statements, but does not include all the disclosures required by accounting principles generally accepted in the United States of America. Operating results for the three and nine month periods ended September 30, 2013 are not necessarily indicative of the results that may be expected for the year ended December 31, 2013. For further information, refer to the financial statements and footnotes thereto included in the Company's Annual Report on Form 10-K for the year ended December 31, 2012.

	4

REPROS THERAPEUTICS INC. AND SUBSIDIARY

(A development stage company)

CONDENSED CONSOLIDATED BALANCE SHEETS

(unaudited and in thousands except share and per share amounts)

	September 30,		December 31,
	2013		2012
ASSETS

Current Assets
Cash and cash equivalents	$	81,828	$	24,212
Prepaid expenses and other current assets		193		406
Total current assets		82,021		24,618
Fixed assets, net		87		53
Other assets, net		2,734		2,161
Total assets	$	84,842	$	26,832

LIABILITIES AND STOCKHOLDERS' EQUITY

Current Liabilities
Accounts payable	$	2,829	$	3,240
Accrued expenses		382		558
Total current liabilities		3,211		3,798

Commitments and contingencies (note 5)

Stockholders' Equity
Undesignated Preferred Stock, $.001 par value, 5,000,000 shares authorized, none issued and outstanding		-		-
Common Stock, $.001 par value, 75,000,000 shares authorized, 23,121,959 and 17,272,505 shares issued, respectively and 23,009,609 and 17,160,155 shares outstanding, respectively		23		17
Additional paid-in capital		313,469		234,299
Cost of treasury stock, 112,350 shares		(1,380)		(1,380)
Deficit accumulated during the development stage		(230,481)		(209,902)
Total stockholders' equity		81,631		23,034
Total liabilities and stockholders' equity	$	84,842	$	26,832

The accompanying notes are an integral part of these condensed consolidated financial statements.

	5

REPROS THERAPEUTICS INC.

(A development stage company)

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(unaudited and in thousands except per share amounts)

									From Inception
									(August 20, 1987)
									through
	Three Months Ended September 30,				Nine Months Ended September 30,				September 30,
	2013		2012		2013		2012		2013

Revenues
Licensing fees	$	-	$	-	$	-	$	-	$	28,755
Product royalties		-		-		-		-		627
Research and development grants		-		-		-		-		1,219
Interest income		3		1		6		1		16,308
Gain on disposal of fixed assets		-		-		-		-		102
Other Income		-		-		-		-		1,003
Total revenues and other income		3		1		6		1		48,014
Expenses
Research and development		4,786		3,131		17,132		6,776		212,391
General and administrative		1,215		1,453		3,453		3,348		56,373
Other Expense		-		-		-		-		388
Total expenses		6,001		4,584		20,585		10,124		269,152

Loss from continuing operations		(5,998)		(4,583)		(20,579)		(10,123)		(221,138)
Loss from discontinued operations		-		-		-		-		(1,828)
Gain on disposal of discontinued operation		-		-		-		-		939
Net loss before cumulative effect of change in accounting principle		(5,998)		(4,583)		(20,579)		(10,123)		(222,027)
Cumulative effect of change in accounting principle		-		-		-		-		(8,454)
Net loss	$	(5,998)	$	(4,583)	$	(20,579)	$	(10,123)	$	(230,481)

Loss per share - basic and diluted:	$	(0.26)	$	(0.30)	$	(1.03)	$	(0.69)

Weighted average shares used in loss per share calculation:
Basic		23,006		15,422		20,066		14,746
Diluted		23,006		15,422		20,066		14,746

The accompanying notes are an integral part of these condensed consolidated financial statements.

	6

REPROS THERAPEUTICS INC. AND SUBSIDIARY

(A development stage company)

CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY

(unaudited and in thousands except share and per share amounts)

									Deficit
									Accumulated
				Additional					During the		Total
	Common Stock			Paid-in		Treasury Stock			Development		Stockholders'
	Shares	Amount		Capital		Shares	Amount		Stage		Equity
Balance at December 31, 2012	17,272,505	$	17	$	234,299	112,350	$	(1,380)	$	(209,902)	$	23,034
Stock based compensation	-		-		2,258	-		-		-		2,258
Issuance of 871,634 shares of common stock for the cashless exercise of 872,133 Series A Warrants	871,634		1		(1)	-		-		-		-
Issuance of 614,564 shares of common stock for the cashless exercise of 716,463 Series B Warrants	614,564		1		(1)	-		-		-		-
Exercise of 42,849 Series B Warrants to purchase common stock for cash @ $2.49 per share	42,849		-		107	-		-		-		107
Issuance of 5,407 shares of common stock for the cashless exercise of 8,332 stock options	5,407		-		-	-		-		-		-
Exercise of 2,500 stock options to purchase common stock for cash @ $18.74 per share	2,500		-		47	-		-		-		47
Issuance of 4,312,500 shares of common stock at $19.00 per share, net of offering costs of $5.2 million	4,312,500		4		76,760	-		-		-		76,764
Net loss	-		-		-	-		-		(20,579)		(20,579)
Balance at September 30, 2013	23,121,959	$	23	$	313,469	112,350	$	(1,380)	$	(230,481)	$	81,631

Balance at December 31, 2011	12,470,694	$	12	$	197,769	112,350	$	(1,380)	$	(191,735)	$	4,666
Stock based option compensation	-		-		1,902	-		-		-		1,902
Issuance of 100 shares of common stock at a share price of $5.07	100		-		-	-		-		-		-
Issuance of 2,463,537 shares of common stock at a share price of $4.50, net of offering costs of $777	2,463,537		3		10,307	-		-		-		10,310
Exercise of stock options to purchase common stock for cash ($1.33 to $10.88 per share)	16,488		-		121	-		-		-		121
Issuance of 11,173 shares of common stock for the cashless exercise of 27,915 stock options	11,173		-		-	-		-		-		-
Exercise of 121,079 Series B Warrants to purchase common stock for cash @ $2.49 per share	121,079		-		301	-		-		-		301
Issuance of 2,145,636 shares of common stock at a share price of $11.00, net of offering costs of $586	2,145,636		2		23,016	-		-		-		23,018
Net loss	-		-		-	-		-		(10,123)		(10,123)
Balance at September 30, 2012	17,228,707	$	17	$	233,416	112,350	$	(1,380)	$	(201,858)	$	30,195

The accompanying notes are an integral part of these consolidated financial statements.

	7

REPROS THERAPEUTICS INC. AND SUBSIDIARY

(A development stage company)

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(unaudited and in thousands)

					From Inception
					(August 20, 1987)
					through
	Nine Months Ended September 30,				September 30,
	2013		2012		2013

Cash Flows from Operating Activities
Net loss	$	(20,579)	$	(10,123)		(230,481)
Gain on disposal of discontinued operations		-		-		(939)
Gain on disposal of fixed assets		-		-		(102)
Adjustments to reconcile net loss to net cash used in operating activities:
Noncash financing costs		-		-		316
Noncash inventory impairment		-		-		4,417
Noncash patent impairment		-		-		2,614
Noncash other income		-		-		(709)
Noncash decrease in accounts payable		-		-		(1,308)
Depreciation and amortization		177		106		4,478
Noncash stock-based compensation		2,258		1,902		14,576
Common stock issued for agreement not to compete		-		-		200
Series B Preferred Stock issued for consulting services		-		-		18
Changes in operating assets and liabilities
(net effects of purchase of businesses in 1988 and 1994):
Increase in receivables		-		-		(199)
Increase in inventory		-		-		(4,447)
(Increase) decrease in prepaid expenses and other current assets		213		(352)		110
Increase (decrease) in accounts payable and accrued expenses		(532)		367		11,087
Net cash used in operating activities		(18,463)		(8,100)		(200,369)

Cash Flows from Investing Activities
Change in trading marketable securities		-		-		(191)
Capital expenditures		(63)		(54)		(2,486)
Purchase of other assets		(776)		(578)		(6,310)
Proceeds from sale of PP&E		-		-		225
Cash acquired in purchase of FTI		-		-		3
Proceeds from sale of subsidiary, less $12,345 for operating losses during 1990 phase-out period		-		-		138
Proceeds from sale of the assets of FTI		-		-		2,250
Increase in net assets held for disposal		-		-		(213)
Net cash used in investing activities		(839)		(632)		(6,584)

Cash Flows from Financing Activities
Proceeds from issuance of common stock, net of offering costs		76,764		33,328		284,195
Exercise of stock options & warrants		154		422		951
Proceeds from a shareholder transaction		-		-		327
Proceeds from issuance of preferred stock		-		-		23,688
Purchase of treasury stock		-		-		(21,487)
Proceeds from issuance of notes payable		-		-		2,839
Principal payments on notes payable		-		-		(1,732)
Net cash provided by financing activities		76,918		33,750		288,781
Net increase in cash and cash equivalents		57,616		25,018		81,828
Cash and cash equivalents at beginning of period		24,212		4,565		-
Cash and cash equivalents at end of period	$	81,828	$	29,583	$	81,828

The accompanying notes are an integral part of these condensed consolidated financial statements.

	8

REPROS THERAPEUTICS INC. AND SUBSIDIARY

(A development stage company)

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

September 30, 2013

(Unaudited)

NOTE 1 — Organization, Operations and Liquidity

Repros Therapeutics Inc. (the “Company”, “RPRX,” “Repros,” or “we,” “us” or “our”) was organized on August 20, 1987. We are a development stage biopharmaceutical company focused on the development of new drugs to treat hormonal and reproductive system disorders.

Our primary product candidate, Androxal®, is a single isomer of clomiphene citrate and is an orally active proprietary small molecule compound. We are developing Androxal® for men of reproductive age with low testosterone levels. Androxal® treats the underlying mechanism that causes secondary hypogonadism and restores normal testicular function. We have completed two pivotal efficacy Phase 3 studies for Androxal® conducted under a Special Protocol Assessment (“SPA”).

Proellex®, our product candidate for female reproductive health, is a new chemical entity that acts as a selective blocker of the progesterone receptor and is being developed for the treatment of symptoms associated with uterine fibroids and endometriosis. We completed a low dose study in late 2011 to demonstrate both safety and signals of efficacy in low oral doses of Proellex® and in November 2012 we initiated a Phase 2 study in the treatment of endometriosis. Additionally, we have completed a Phase 1/2 vaginal administration study for uterine fibroids in the first quarter of 2013.

Our product development pipeline is summarized in the table below:

Product Candidate (Indication) Androxal®	Status	Next Expected Milestone(s)

Secondary Hypogonadism	Phase 3	Complete DEXA study (Q4 2014) pending FDA guidance

Proellex®

Uterine Fibroids	Phase 2B (vaginal)	Initiate a Phase 2B study (vaginal delivery) (Q1 2014)

	Phase 2 (oral)	Lift full clinical hold and initiate efficacy study (low dose oral) (Q1 2014)

Endometriosis	Phase 2	Complete Phase 2 study (oral delivery) (Q3 2014)

We also continue to maintain our patent portfolio of our phentolamine-based products for the treatment of sexual dysfunction.

On June 25, 2013, we completed a public offering of 4,312,500 shares of our common stock at a price per share of $19.00. Net proceeds to us, after deducting underwriter’s fees and offering expenses, were approximately $76.8 million.

As of September 30, 2013, we had accumulated losses of $230.5 million, approximately $81.8 million in cash and cash equivalents, and our accounts payable and accrued expenses were approximately $3.2 million. We anticipate that our current liquidity will be sufficient to continue the development of our product candidates through the NDA filing of both products. We continue to explore potential corporate partnering opportunities for assistance in the clinical development funding and commercialization of our products, as appropriate; however, there can be no assurance that an acceptable corporate partnering opportunity will be successfully completed or that our current liquidity will be sufficient to fund all of our product development needs.

	9

NOTE 2 — Patents and Patent Applications

As of September 30, 2013, we had approximately $2,734,000 in capitalized patent and patent application costs reflected on its balance sheet. Of this amount, $1,726,000 relates to patent and patent application costs for Androxal® and $1,008,000 relates to patent and patent application costs for Proellex®.

Should we not continue development of either drug candidate or should we not continue as a going concern, the remaining capitalized patent and patent application costs may not be recoverable, which would result in charges to operating results in future periods.

NOTE 3 — Accrued Expenses

Accrued expenses consist of the following (in thousands):

	September 30, 2013		December 31, 2012

Patent costs	$	152	$	245
Research and development costs		87		192
Personnel related costs		42		30
Other		101		91

Total	$	382	$	558

NOTE 4 — Loss Per Share

Basic loss per share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the period. Diluted loss per share is computed using the average share price for the period and applying the treasury stock method to potentially dilutive outstanding options. In all applicable periods, all potential common stock equivalents were anti-dilutive and, accordingly, were not included in the computation of diluted loss per share.

The following table presents information necessary to calculate loss per share for the three and nine month periods ended September 30, 2013 and 2012 (in thousands, except per share amounts):

	Three Months Ended Sept. 30,				Nine Months Ended Sept. 30,
	2013		2012		2013		2012

Net Loss	$	(5,998)	$	(4,583)	$	(20,579)	$	(10,123)
Average common shares outstanding		23,006		15,422		20,066		14,746
Basic and diluted loss per share	$	(0.26)	$	(0.30)	$	(1.03)	$	(0.69)

Potential common stock of 3,975,430 and 5,264,207 common shares underlying stock options and warrants for the periods ended September 30, 2013 and 2012, respectively, were excluded from the above calculation of diluted loss per share because they were anti-dilutive. Other potential common stock at September 30, 2013 includes Series A Warrants to purchase 877,137 shares of our common stock at an exercise price of $0.01 and Series B Warrants to purchase 810,109 shares of our common stock at an exercise price of $2.49 issued in February 2011. Other potential common stock at September 30, 2012 includes Series A Warrants to purchase 1,749,270 shares of our common stock at an exercise price of $0.01 and Series B Warrants to purchase 1,569,421 shares of our common stock at an exercise price of $2.49 issued in February, 2011.

	10

NOTE 5 — Commitments and Contingencies

Therapeutic uses of our Androxal product candidate are covered in the United States by eight issued U.S. patents and four pending patent applications. Foreign coverage of therapeutic uses of our Androxal product candidate includes 61 issued foreign patents and 52 foreign pending patent applications. The issued patents and pending applications relate to methods for treating certain conditions including the treatment of testosterone deficiency in men, the treatment of diabetes mellitus Type 2, the treatment of metabolic syndrome and conditions associated therewith, and the treatment of infertility in hypogonadal men. Androxal (the trans-isomer of clomiphene) is purified from clomiphene citrate. A third party individual holds two issued patents related to the use of an anti-estrogen such as clomiphene citrate and others for use in the treatment of androgen deficiency and disorders related thereto. We requested re-examination of one of these patents by the U.S. Patent and Trademark Office (“PTO”) based on prior art. The patent holder amended the claims in the re-examination proceedings, which led the PTO to determine that the amended claims were patentable in view of those publications under consideration and a re-examination certificate was issued. We subsequently filed a second request for re-examination by the PTO in light of a number of additional publications. The request was granted and all of the claims were finally rejected by the PTO in the re-examination. The patent holder appealed the rejections to the PTO Board of Patent Appeals and Interferences (the “PTO Board”) which ultimately reversed the rejections of several dependent claims in view of those publications under consideration. The patent holder filed a Notice of Appeal to the Federal Circuit on September 28, 2010 contesting the rejections maintained by the PTO Board. A decision was rendered by the Federal Circuit on December 12, 2011, affirming the rejection of the appealed claims. The PTO issued an Ex Parte Reexamination Certificate on April 29, 2013, cancelling the rejected claims and confirming patentability of the remaining claims. Nevertheless, we believe that our development of Androxal does not infringe any of the remaining claims and that all of the remaining claims are invalid on various grounds including additional prior art publications. We also believe that the second of these two patents is invalid in view of published prior art not considered by the PTO. If necessary, we intend to vigorously defend any and all claims against the holder of such patents in a court of competent jurisdiction in order to develop Androxal further. Adverse determinations in litigation proceedings could require us to seek licenses from patent holders which may not be available on commercially reasonable terms, or at all, or may subject us to significant liabilities, in which case we may not be able to successfully commercialize or out-license Androxal until such patents expire or are otherwise no longer in force.

On July 19, 2013, we received a letter from Dr. Harry Fisch threatening to file a lawsuit against us and two of our executive officers (Joseph S. Podolski, President and Chief Executive Officer and Ron Wiehle, Executive Vice President), seeking addition of Dr. Harry Fisch as an inventor on three of our patents, U.S. Patent Nos. 7,173,064, 7,737,185 and 7,759,360, covering therapeutic uses of Androxal®. We believe that these allegations are without merit and on August 2, 2013, we commenced a lawsuit against Dr. Fisch in the U.S. District Court for the Southern District of Texas seeking a declaratory judgment that he should not be added as inventor to any of these patents. On October 2, 2013, Dr. Fisch filed his answer and counterclaims to our complaint. Dr. Fisch asserted counterclaims seeking correction of inventorship of the three patents at issue to name Dr. Fisch as a co-inventor of the applications leading these patents. Dr. Fisch also seeks reasonable attorney’s fees. Due to the preliminary status of the lawsuit and uncertainties related to litigation, we are unable to evaluate the likelihood of either a favorable or unfavorable outcome.

	11

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations

The following discussion contains forward-looking statements, within the meaning of Section 27A of the Securities Act of 1933, as amended (the "Securities Act") and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act") that involve risk and uncertainties. Any statements contained in this quarterly report that are not statements of historical fact may be forward-looking statements. When we use the words "may," "anticipates," "believes," "plans," "expects" and similar expressions, we are identifying forward-looking statements. Forward-looking statements involve risks and uncertainties which may cause our actual results, performance or achievements to be materially different from those expressed or implied by forward-looking statements. The following discussion of financial condition should be read in conjunction with the accompanying consolidated financial statements and related notes.

Repros Therapeutics Inc.

Repros Therapeutics Inc. (the “Company,” “Repros,” or “we,” “us” or “our”) was organized on August 20, 1987. We are a development stage biopharmaceutical company focused on the development of new drugs to treat hormonal and reproductive system disorders. Both of our product candidates have exhibited consistent efficacy results in studies that we have completed to date, and we believe the studies presently underway or scheduled to start this year will significantly progress both clinical development programs.

We are developing Androxal, an oral therapy that normalizes testicular function, for the treatment of low testosterone due to secondary hypogonadism. Secondary hypogonadism is associated with obesity and we believe it is among the most common causes of low testosterone in men. It is estimated that 13 million men in the U.S. experience low levels of testosterone, and the condition is becoming recognized with more frequency. In 2012, sales of preparations for the treatment of low testosterone exceeded $1 billion in the U.S. and first tier pharmaceutical companies have entered the low testosterone marketplace.

We believe that Androxal is highly differentiated from currently marketed testosterone treatments or those treatments in late stage development because it is an oral therapy and it treats the cause of secondary hypogonadism, which is inadequate pituitary hormones. We believe that by treating the cause of secondary hypogonadism Androxal also has the potential to maintain reproductive status and potentially improve overall metabolic profiles.

We have completed two Phase 3 pivotal efficacy studies for the treatment of secondary hypogonadism conducted under a Special Protocol Assessment, or SPA. On September 16, 2013, we announced that the top-line results from our second pivotal Phase 3 study, ZA-302, met both co-primary endpoints mandated by the Food and Drug Administration (“FDA”) and that Androxal was generally well tolerated in the six-month safety study, ZA-300. Additionally, on October 22, 2013, we announced that we received guidance from the FDA on the Androxal clinical program, instructing the Company to request a meeting to discuss the adequacy of ZA-301 and ZA-302 as evidence of pivotal efficacy. Furthermore, the FDA now wants to ensure that the DEXA study is conducted for one year after up-titration of subjects at the time of the New Drug Application (“NDA”) submission. This requirement will delay the NDA submission until the third quarter of 2014. If the FDA requires that the expanded DEXA study (the Company increased the study size from 150 men to 300 men to insure overall exposure requirements are met) be included in the NDA submission, then the submission would occur during the fourth quarter of 2014. In addition to the above guidance, the FDA has now agreed to allow the Company to run head-to-head studies against approved testosterone replacement products.

We are also developing Proellex, an orally administered selective blocker of the progesterone receptor in women, for the treatment of uterine fibroids and endometriosis. Uterine fibroids and endometriosis affect millions of women of reproductive age. Proellex has shown statistically significant results in previous Phase 2 studies for endometriosis and uterine fibroids. We completed a low dose escalating study as permitted by the FDA in late 2011, to determine both signals of efficacy and safety for low oral doses of the drug. There was no evidence of elevations of liver enzymes over baseline, suggesting these lower doses avoid the type of adverse events seen at much higher doses in earlier studies. In October 2012, we announced that the FDA has agreed to a reclassification of the full clinical hold to a partial clinical hold on low dose oral Proellex to allow us to conduct a Phase 2 study in the treatment of endometriosis. We initiated this study in November 2012. To date, we have experienced difficulty enrolling subjects into this study due to changes in the current treatment of this disorder. Depending on study enrollment, we believe we can release results from this study in the third quarter of 2014.

On October 31, 2013, the Company held a meeting with the FDA to discuss the clinical development plan for low dose oral Proellex® in the treatment of uterine fibroids. During the meeting, the FDA provided guidance for endpoints it believed acceptable for the treatment of uterine fibroids in an efficacy study and instructed the Company to submit a request for lifting the full clinical hold. The Company will follow the FDA’s recommendations and submit a protocol and the request for the full hold lift in a timely fashion. The Company believes it may be able to initiate this study in early 2014.

	12

The FDA has accepted an Investigational New Drug Application, or IND, for vaginally delivered Proellex and, as a result, we commenced a Phase 2 vaginal administration study for uterine fibroids in the first quarter of 2012 and reported final study results in January 2013. We held an end of Phase 2 meeting with the FDA, in the last half of May 2013, to discuss a Phase 3 study design for the vaginally delivered Proellex as a treatment for uterine fibroids. The FDA recommended that a Phase 2B study should be conducted prior to commencing a Phase 3 program. The Company believes it may be able to initiate the Phase 2B study in early 2014. Additionally, we have begun enrolling subjects who completed the Phase 2 study into a one year open label safety trial in order to begin collecting long term safety data which we expect the FDA to require in connection with the submission of an NDA.

Our Research and Development Program

Our product development pipeline is summarized in the table below:

Product Candidate (Indication) Androxal®	Status	Next Expected Milestone(s)
Secondary Hypogonadism	Phase 3	Complete DEXA study (Q4 2014) pending FDA guidance
Proellex®
Uterine Fibroids	Phase 2B (vaginal)	Initiate a Phase 2B study (vaginal delivery) (Q1 2014)
	Phase 2 (oral)	Lift full clinical hold and initiate efficacy study (low dose oral) (Q1 2014)
Endometriosis	Phase 2	Complete Phase 2 study (oral delivery) (Q3 2014)

Androxal®

Product Overview

Our primary product candidate, Androxal®, is a single isomer of clomiphene citrate and is an orally active proprietary small molecule compound. We are developing Androxal® for men of reproductive age with low testosterone levels. Androxal® treats the underlying mechanism that causes secondary hypogonadism and restores normal testicular function. Unlike testosterone replacement which suppresses testicular function, Androxal® does not impair the reproductive status of men being treated for low testosterone.

	13

Testosterone is an important male hormone. Testosterone deficiency in men is linked to several negative physical and mental conditions, including loss of muscle tone, reduced sexual desire and deterioration of memory and certain other cognitive functions. Testosterone production normally decreases as men age and this decline can be accelerated by obesity, sometimes leading to testosterone deficiency. The leading therapy for low testosterone is AndroGel®, a commercially available testosterone replacement cream marketed by Abbott Laboratories for the treatment of low testosterone, which we believe has had and continues to have significant sales in North America.

Based on our own clinical trial screening data, we believe over 70% of men that have low testosterone suffer from secondary hypogonadism, a pituitary defect which is characterized by suboptimal levels of LH (luteinizing hormone) and FSH (follicle stimulating hormone). LH and FSH are the pituitary hormones that stimulate testicular testosterone and sperm production, respectively. Men with secondary hypogonadism can be readily distinguished from those that have primary testicular failure via assessment of the levels of secretions of pituitary hormones, as men with primary testicular failure experience elevated secretions of pituitary hormones. In secondary hypogonadism, the low levels of LH and FSH fail to provide adequate hormone signaling to the testes, causing testosterone levels to drop to a level where we believe pituitary secretions fall under the influence of estrogen, which is enhanced in obese men, thus further suppressing the testicular stimulation from the pituitary.

Androxal® acts centrally to restore testicular function and, hence, normal testosterone in the body. The administration of exogenous testosterone can restore serum testosterone levels, but does not restore testicular function and thereby generally leads to the cessation of, or significant reduction in, sperm production. Androxal®, by contrast, restores levels of both LH and FSH, which stimulate testicular testosterone and sperm production, respectively.

We tested Androxal® in two studies designed to show that Androxal® improved testosterone levels as well as AndroGel® in men with secondary hypogonadism. These studies indicated that Androxal® had a superior ability to improve testosterone levels when compared to AndroGel® and that the improvement was statistically significant. The FDA determined that improved testosterone levels would be sufficient provided that both placebo and Androxal® maintained sperm counts in a statistically significant manner.

Androxal® is required to undergo the full regulatory approval process, including pivotal Phase 3 trials, long-term open label safety studies and a dual-energy X ray absorptiometry (DEXA) study, as well as other requirements. Androxal® is closely related chemically to the drug, Clomid®, which is approved for use in women to treat certain infertility disorders. Clomid® contains both the trans and cis isomers of clomiphene citrate; Androxal® contains only the trans isomer. The FDA has indicated that testicular tumors, gynecomastia and adverse ophthalmologic events, which have been reported in males taking Clomid®, are potential risks that should be included in informed consent forms for our Androxal® clinical trials. We do not believe that Androxal® will present with the same adverse events given its reduced half-life and lack of cis isomer as compared to Clomid®. In our preclinical studies and our clinical trials to date, we have observed no evidence of any of these events except for certain ophthalmologic events in our preclinical dog study at doses significantly higher than those administered in the clinical trials. All clinical trial results are subject to review by the FDA and the FDA may disagree with our conclusions about safety and efficacy.

	14

Treatment for Secondary Hypogonadism in Men Wishing to Preserve Testicular Function (Reproductive Status)

In July 2012, we announced that we reached an agreement with the FDA for the design of the pivotal efficacy studies for Androxal® for the treatment of secondary hypogonadism. The pivotal studies are being conducted under an SPA. The primary testosterone endpoint in the pivotal studies require that 75% of the subjects in the drug arm exhibit a 24 hour average total testosterone in the normal range (300 – 1040 ng/dL) at the end of 12 weeks of treatment. After six weeks of dosing, men are allowed to up-titrate from the 12.5 mg dose to the 25 mg dose if their morning testosterone is below 300 ng/dL. The co-primary sperm count endpoint prescribed by the FDA is that the drug is to exhibit non-inferiority to placebo with respect to the percent of subjects whose sperm count drops greater than 50% from baseline. On September 16, 2013, we announced that the top-line results from our second pivotal Phase 3 study, ZA-302, met both co-primary endpoints mandated by the FDA. On October 22, 2013, we announced that we received guidance from the FDA on the Androxal clinical program, instructing the Company to request a meeting to discuss the adequacy of ZA-301 and ZA-302 as evidence of pivotal efficacy. The Company believes that both pivotal studies meet the FDA mandated co-primary endpoints.

Additionally, on September 16, 2013, we reported top-line results from the 500 subject, six month open label safety study, ZA-300. Top line data suggested that Androxal was generally well tolerated and there were no dose dependent adverse events in this study.

We have completed enrollment into a one year, 150 subject DEXA study in January 2013, however, the Company expanded the study size to 300 men to insure overall exposure requirements were met. The FDA now wants to ensure that the DEXA study is conducted for one year after up-titration of subjects at the time of the NDA submission. This requirement will delay the NDA submission until the third quarter of 2014. If the FDA requires that the full expanded DEXA study be included in the NDA submission, then the submission would occur during the fourth quarter of 2014.

In addition to the above guidance, the FDA has now agreed to allow the Company to run head-to-head studies against approved testosterone replacement products. The Company believes it may be able to initiate these studies in December 2013.

Unlike testosterone replacement therapies, Androxal® maintains the normal daily rhythm of testosterone peaks and valleys. We previously conducted three studies in which 24 hour testosterone levels were obtained and, unlike topical testosterone, morning testosterone was the maximum concentration observed, consistent with the normal circadian rhythm in men. These studies provide evidence that one assessment of testosterone between 8 a.m. and 10 a.m. correlates to the maximum value of testosterone for a given subject on a given day. Additionally, we conducted one additional 24 hour study which showed that Androxal®’s action in maintaining the normal rhythm is both predictable and dose-dependent.

In addition, the Company continues to consider the potential for use of Androxal® as an adjuvant therapy in hypogonadal men with Type 2 diabetes. The Company has an active IND open with the Division of Endocrine and Metabolic Products at the FDA for this indication. We believe there may be an association between the restoration of normal pituitary function and improvement of metabolic conditions such as Type 2 diabetes. Research has been published which demonstrates that increased insulin resistance, a characteristic implicated in Type 2 diabetes, is associated with the onset of secondary hypogonadism. Based on our own clinical trial screening data from our previously conducted Phase 2 study, we have found hypogonadism, obesity and Type 2 diabetes to be co-morbid conditions in a significant number of men. The results from this Phase 2 study indicated that the Androxal® treated subjects showed statistically significant improvement in HbA1c and insulin, as well as HOMA-IR compared to placebo in men less than 65 years of age.

We believe the advantages of oral delivery, maintenance of testicular function and additional metabolic benefits will be important differentiating factors for Androxal®, should it be approved. There can be no assurance, however, that we will be successful in implementing this strategy or that the FDA will approve our drug for commercial use.

	15

Proellex®

Product Overview

Proellex®, our product candidate for female reproductive health, is a new chemical entity that acts as a selective blocker of the progesterone receptor and is being developed for the treatment of symptoms associated with uterine fibroids and endometriosis. There are currently no FDA-approved orally administered drug treatments for the long-term treatment of either uterine fibroids or endometriosis. The National Uterine Fibroids Foundation estimates that 80% of all women in the U.S. have uterine fibroids, and one in four of these women have symptoms severe enough to require treatment. According to the Endometriosis Association, endometriosis affects 6.3 million women in the U.S. and Canada and millions more worldwide.

The current standards of care for uterine fibroids and endometriosis consist of surgery or short-term treatment with gonadotropin-releasing hormone (“GnRH”) agonists drugs, such as Lupron®. GnRH agonists induce a low estrogen, menopausal-like state and promote bone loss and are not recommended for use for more than six months.

We have conducted numerous studies with Proellex® dosing approximately 700 women with the drug. All Proellex® studies completed to date exhibited strong efficacy signals, whether in uterine fibroids or endometriosis. In a 120 patient study of Proellex® as a treatment of uterine fibroids conducted in the United States (roughly 40 subjects per arm), both a 12.5 and 25 mg dose of Proellex® were compared to placebo. In this study each of the 12.5 and 25 mg doses achieved highly statistically significant results when compared to placebo when menstrual bleeding was assessed (p<0.0001). The two doses also achieved highly statistically significant improvement in quality of life measures using the Uterine Fibroid Symptom Quality of Life questionnaire developed and validated by Georgetown University and used in the development of device like treatments of uterine fibroids such as uterine artery embolization. There was no statistical difference in efficacy measures between the two doses. Importantly, in the Phase 2 U.S. trial a significant percentage of women stopped menstruating. Proellex® resulted in the induction of amenorrhea (cessation of menses), which we believe is a strong surrogate signal of efficacy. Over 80% of women on both the 12.5 and 25 mg doses exhibited no menses during the three month trial, whereas all women on placebo exhibited at least one menses.

Up until the summer of 2009, all side effects exhibited in the studies were considered manageable and the benefit of Proellex® far outweighed the risk. However, in Phase 3 efficacy and larger Phase 3 safety studies in diverse populations, a small number of subjects exhibited serious adverse effects associated with elevated liver enzymes. As a result of these findings, we elected to stop the trials and the FDA subsequently placed Proellex® on full clinical hold. All women that experienced elevated liver enzymes and returned for follow-up visits returned to baseline conditions with no overnight hospitalization necessary. An analysis of all the subjects that experienced such serious adverse effects showed that the effect only occurred in a small percentage of subjects that were exposed to the 50 mg dose of the drug for any period of time. Based on these findings, we petitioned the FDA to allow us to conduct a low dose study to demonstrate both safety and signals of efficacy in low oral doses of Proellex®, up to 12 mg administered per day. The FDA upgraded the full clinical hold to a partial hold to allow the low dose study to be conducted. In addition, we undertook the exploration of vaginal delivery as an alternative administrative route to bypass first-pass liver effects and reduce systemic exposure, which is currently in a Phase 2 study.

	16

Low Dose Study

Pursuant to the terms of the partial clinical hold currently in place as a result of the liver toxicity exhibited by Proellex®, the FDA allowed us to run a single study to test low oral doses of Proellex® for signals of safety and efficacy. The study tested 5 different doses of Proellex® (1, 3, 6, 9 and 12 mg), with 1 mg being the first dose tested. Each dose was then compared to placebo with weekly assessments of liver function during both the placebo and drug period. Subjects were dosed with the active drug for 10 weeks, which allowed for adequate time to determine the impact of a given dose on trends in liver function. Each dose was tested in up to 12 different subjects and assessment of pharmacokinetic parameters was obtained at the start of dosing and the end of the dosing period to determine overall and maximum drug exposure for a given dose. We also monitored changes in menstrual bleeding patterns and ovulation as well as changes in endometrial thickness. The FDA required that an independent Drug Safety Monitoring Board be established and that the informed consent clearly state the liver toxicity previously experienced with Proellex®. We have completed this study and have announced that there was no evidence of elevations of liver enzymes over baseline, suggesting these lower doses avoid the type of adverse events seen at much higher doses in earlier studies.

In July 2012, we announced that we held a teleconference with the FDA to discuss the development of low dose oral Proellex® as a treatment for endometriosis. Subsequently, in October 2012, we announced that the FDA has agreed to reclassify the full clinical hold to a partial clinical hold on low dose oral Proellex® to allow us to conduct a Phase 2 study in the treatment of endometriosis. We initiated this 90 subject, four month active dosing study in November 2012. To date, we have experienced difficulty enrolling subjects into this study due to changes in the current treatment of this disorder. Depending on study enrollment, we believe we can release results from this study in the third quarter of 2014.

Vaginal Administration

We are assessing vaginal administration of Proellex® to avoid first pass liver effects and achieve higher reproductive tract concentrations of the drug while minimizing systemic exposure. We reported results from two in vivo animal studies which confirmed reduced maximum circulating concentrations of the drug when administered vaginally, as well as efficacy signals at substantially lower doses than oral administration. The FDA has accepted an IND for vaginally delivered Proellex and, as a result, we commenced a Phase 2 vaginal administration study for uterine fibroids in the first quarter of 2012 and reported final study results in January 2013. We held an end of Phase 2 meeting with the FDA, in the last half of May 2013, to discuss a Phase 3 study design for the vaginally delivered Proellex as a treatment for uterine fibroids. The FDA recommended that a Phase 2B study should be conducted prior to commencing a Phase 3 program. The Company believes it may be able to initiate the Phase 2B study in early 2014. Additionally, we have begun enrolling subjects who completed the Phase 2 study into a one year open label safety trial in order to begin collecting long term safety data which we expect the FDA to require in connection with the submission of an NDA. The majority of the women being dosed with 12 mg in the Phase 2 study have elected to enroll into the open label safety study.

Other Products

VASOMAX® has been on partial clinical hold in the U.S. since 1998, and no further development activities are planned.

Business Strategy

We plan to focus our clinical program on (i) conducting Phase 3 secondary hypogonadism trials for Androxal®, (ii) conducting a Phase 2B vaginal administration trial for Proellex® for uterine fibroids; (iii) conducting a Phase 2 trial for low dose oral Proellex® for endometriosis and (iv) conducting an efficacy trial for low dose oral Proellex® for uterine fibroids. We anticipate that our current liquidity will be sufficient to continue the development of our product candidates through the NDA filing of both products. We continue to explore potential corporate partnering opportunities for assistance in the clinical development funding and commercialization of our products, as appropriate; however, there can be no assurance that an acceptable corporate partnering opportunity will be successfully completed or that our current liquidity will be sufficient to fund all of our product development needs.

	17

Risks Affecting Us

Our business is subject to numerous risks as discussed more fully in “Item 1A. Risk Factors" in our annual report on Form 10-K for the year ended December 31, 2012 and the section entitled “Risk Factors” in this quarterly report. We anticipate that our current liquidity will be sufficient to continue the development of our product candidates through the NDA filing of both products. We continue to explore potential corporate partnering opportunities for assistance in the clinical development funding and commercialization of our products, as appropriate; however, there can be no assurance that an acceptable corporate partnering opportunity will be successfully completed or that our current liquidity will be sufficient to fund all of our product development needs.

In addition, we have not received regulatory approval for any of our product candidates, have not successfully earned any significant commercial revenues from any of our product candidates and may never launch either of our product candidates. If we do not successfully commercialize any of our product candidates, we will be unable to achieve our business objectives. In addition, the reported results of our clinical trials completed to date may not be indicative of results that will be achieved in later-stage clinical trials involving larger and more diverse patient populations. As of September 30, 2013, we had accumulated losses of $230.5 million, approximately $81.8 million in cash and cash equivalents, and our accounts payable and accrued expenses were approximately $3.2 million.

Corporate Information

We were organized as a Delaware corporation in August 1987. Our principal executive offices are located at 2408 Timberloch Place, Suite B-7, The Woodlands, Texas, 77380, and our telephone number is (281) 719-3400. We maintain an internet website at www.reprosrx.com. The information on our website or any other website is not incorporated by reference into this quarterly report and does not constitute a part of this quarterly report. Our Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K and all amendments to such reports are made available free of charge through the Investor Relations section of our website as soon as reasonably practicable after they have been filed or furnished with the Securities and Exchange Commission.

General

We have 25 full-time employees. We utilize the services of contract research organizations, contract manufacturers and various consultants to assist us in performing clinical and regulatory services for the clinical development of our products. We are substantially dependent on our various contract groups to adequately perform the activities required to obtain regulatory approval of our products.

We have accumulated net operating losses through September 30, 2013 and the value of the tax asset associated with these accumulated net operating losses can be substantially diminished in value due to various tax regulations, including change in control provisions in the tax code. The Company’s public offerings completed on February 5, 2007, October 2, 2008, September 11, 2009, October 13, 2009, February 8, 2011, February 1, 2012, June 25, 2013, the sale and issuance of the ATM Shares, the issuance of unregistered shares as part of the settlement agreements we entered into with certain of our creditors since October of 2009 and the private placement of shares completed on September 7, 2012, may have created a change of ownership for Federal Income tax purposes. The Company has not completed a study to determine if this has occurred. A change in ownership for Federal income tax purposes may result in a limitation on the use of net operating loss and tax credit carryforwards in future periods.

Losses have resulted principally from costs incurred in conducting clinical trials for our product candidates, in research and development activities related to efforts to develop our products and from the associated administrative costs required to support those efforts. There can be no assurance that we will be able to successfully complete the transition from a development stage company to the successful introduction of commercially viable products. Our ability to achieve profitability will depend on, among other things, successfully completing the clinical development of our products in a reasonable time frame and at a reasonable cost, obtaining regulatory approvals, establishing marketing, sales and manufacturing capabilities or collaborative arrangements with others that possess such capabilities, and, if applicable, continuing to raise sufficient funds to finance our activities. There can be no assurance that we will be able to achieve profitability.

	18

Critical Accounting Policies and the Use of Estimates

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

Capitalized Patent and Patent Application Costs

We capitalize the cost associated with building our patent library for Androxal® and Proellex®. As of September 30, 2013, other assets consist of capitalized patent and patent application costs in the amount of $2,734,000. Patent costs, which include legal and application costs related to the patent portfolio, are being amortized over the lesser of the legal life of the patent (typically 20 years) or the estimated economic life of the patent. Amortization of patent costs was $51,000 and $34,000 for the three month periods ended September 30, 2013 and 2012, respectively, and was $148,000 and $96,000 for the nine month periods ended September 30, 2013 and 2012, respectively.

We review capitalized patent and patent application costs for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. An impairment exists when estimated undiscounted cash flows expected to result from the patent are less than its carrying amount. The impairment loss recognized represents the excess of the patent cost as compared to its estimated fair value. We believe that our remaining capitalized patent and patent application costs are not impaired as of September 30, 2013.

Should the Company not continue development of either drug candidate or should the Company not continue as a going concern, capitalized patent and patent application costs may not be recoverable, which would result in a charge to operating results in future periods.

Accrued Expenses

We estimate accrued expenses as part of our process of preparing financial statements. Examples of areas in which subjective judgments may be required include costs associated with services provided by contract organizations for clinical trials, preclinical development and manufacturing of clinical materials. We accrue for costs incurred as the services are being provided by monitoring the status of the trials or services provided and the invoices received from our external service providers. In the case of clinical trials, a portion of the estimated cost normally relates to the projected cost to treat a patient in our trials, and we recognize this cost over the estimated term of the study based on the number of patients enrolled in the trial on an ongoing basis, beginning with patient enrollment. As actual costs become known to us, we adjust our accruals. To date, our estimates have not differed significantly from the actual costs incurred. However, subsequent changes in estimates may result in a material change in our accruals, which could also materially affect our balance sheet and results of operations.

R&D Expense

Research and development, or R&D, expenses include salaries and related employee expenses, contracted regulatory affairs activities, insurance coverage for clinical trials and prior product sales, contracted research and consulting fees, facility costs, amortization of capitalized patent costs and internal research and development supplies. We expense research and development costs in the period they are incurred. These costs consist of direct and indirect costs associated with specific projects as well as fees paid to various entities that perform research on our behalf.

Share-Based Compensation

We had one stock-based compensation plan at September 30, 2013, the 2011 Equity Incentive Plan. Accounting for stock based compensation generally requires the recognition of the cost of employee services for share-based compensation based on the grant date fair value of the equity or liability instruments issued. We use the Black-Scholes option pricing model to estimate the fair value of our stock options. Expected volatility is determined using historical volatilities based on historical stock prices for a period equal to the expected term. The expected volatility assumption is adjusted if future volatility is expected to vary from historical experience. The expected term of options represents the period of time that options granted are expected to be outstanding and falls between the options' vesting and contractual expiration dates. The risk-free interest rate is based on the yield at the date of grant of a zero-coupon U.S. Treasury bond whose maturity period equals the option's expected term.

	19

Income Taxes

Our losses from inception to date have resulted principally from costs incurred in conducting clinical trials and in research and development activities related to efforts to develop our products and from the associated administrative costs required to support those efforts. We have recorded a deferred tax asset for our net operating losses (“NOL”); however, as the Company has incurred losses since inception, and since there is no certainty of future profits, a valuation allowance has been provided in full on our deferred tax assets in the accompanying consolidated financial statements. If the Company has an opportunity to use this NOL to off-set tax liabilities in the future, the use of this asset would be restricted based on Internal Revenue Service, state and local NOL use guidelines. The Company’s public offerings completed on February 5, 2007, October 2, 2008, September 11, 2009, October 13, 2009, February 8, 2011, February 1, 2012, June 25, 2013, the sale and issuance of the ATM Shares, the issuance of unregistered shares as part of the settlement agreements we entered into with certain of our creditors since October of 2009 and the private placement of shares completed on September 7, 2012, may have created a change of ownership for Federal Income tax purposes. The Company has not completed a study to determine if this has occurred. A change in ownership for Federal income tax purposes may result in a limitation on the use of net operating loss and tax credit carryforwards in future periods.

Results of Operations

Comparison of the three-month and nine-month periods ended September 30, 2013 and 2012

Revenues and Other Income

Total revenues and other income increased to $3,000 for the three month period ended September 30, 2013 as compared to $1,000 for the same period in the prior year. Total revenue and other income was $6,000 for the nine month period ended September 30, 2013 as compared to $1,000 for the same period in the prior year. The increase for the three and nine month periods ended September 30, 2013 as compared to the same periods in the prior year was primarily due to increased cash balances as a result of the public offering completed on June 25, 2013 for net proceeds of approximately $76.8 million.

Research and Development Expenses

Research and development, or R&D, expenses include contracted services relating to our clinical product development activities which include preclinical studies, clinical trials, regulatory affairs and bulk manufacturing scale-up activities and bulk active ingredient purchases for preclinical and clinical trials primarily relating to our two products in clinical development, which are Androxal^® and Proellex^®. Research and development expenses also include internal operating expenses relating to our general research and development activities. R&D expenses increased 53% or approximately $1.7 million to $4.8 million for the three month period ended September 30, 2013 as compared to $3.1 million for the same period in the prior year. Our primary R&D expenses for the three month periods ended September 30, 2013 and 2012 are shown in the following table (in thousands):

	20

	Three-months		Three-months
	ended		ended				Change
Research and Development	September 30, 2013		September 30, 2012		Variance		(%)
Androxal® clinical development	$	2,743	$	1,969	$	774	39	%
Proellex® clinical development		422		389		33	8	%
Payroll and benefits		1,058		543		515	95	%
Operating and occupancy		563		230		333	145	%
Total	$	4,786	$	3,131	$	1,655	53	%

R&D expenses increased 153% or approximately $10.4 million to $17.1 million for the nine month period ended September 30, 2013 as compared to $6.8 million for the same period in the prior year. Our primary R&D expenses for the nine month periods ended September 30, 2013 and 2012 are shown in the following table (in thousands):

	Nine-months		Nine-months
	ended		ended				Change
Research and Development	September 30, 2013		September 30, 2012		Variance		(%)
Androxal® clinical development	$	11,609	$	3,275	$	8,334	254	%
Proellex® clinical development		1,104		1,287		(183)	(14)	%
Payroll and benefits		2,835		1,455		1,380	95	%
Operating and occupancy		1,584		759		825	109	%
Total	$	17,132	$	6,776	$	10,356	153	%

The increase in R&D expenses for both the three and nine month periods ended September 30, 2013 as compared to the same periods in the prior year, is primarily due to the increased clinical development expenses related to Androxal® as a result of the ongoing Phase 3 studies, including two pivotal studies being conducted under an SPA, a six month open label safety study and a one year DEXA study. Clinical development expenses related to Proellex® for both the three and nine month periods ended September 30, 2013 as compared to the same periods in the prior year decreased due to the completion of the Phase 2 vaginal administration study for uterine fibroids.

Payroll and benefits expenses increased for both the three and nine month periods ended September 30, 2013 as compared to the same periods in the prior year by $515,000 and $1.4 million, respectively. Included in payroll and benefits expenses is a charge for non-cash stock based compensation of $506,000 and $1.3 million for the three and nine month periods ended September 30, 2013, respectively, as compared to $227,000 and $633,000 for the same periods in the prior year. Additionally, salaries for the three and nine month periods ended September 30, 2013 were $459,000 and $1.2 million, respectively, as compared to $251,000 and $670,000 for the same periods in the prior year. The increase in both non-cash stock based compensation and salaries expenses is due to increased headcount in R&D employees.

Operating and occupancy expenses increased for the three and nine month periods ended September 30, 2013 as compared to the same periods in the prior year due to an increase in costs associated with our patent portfolio, increased travel and professional services.

To date through September 30, 2013 we have incurred approximately $40.0 million for the development of Androxal® and approximately $60.2 million for the development of Proellex®. These accumulated costs exclude any internal operating expenses.

	21

General and Administrative Expenses

General and administrative expenses, or G&A, decreased 16% or approximately $238,000 to $1.2 million for the three month period ended September 30, 2013 as compared to $1.5 million for the same period in the prior year. Our primary G&A expenses for the three month period ended September 30, 2013 and 2012 are shown in the following table (in thousands):

	Three-months		Three-months
	ended		ended
	September 30,		September 30,				Change
General and Administrative	2013		2012		Variance		(%)
Payroll and benefits	$	626	$	953	$	(327)	(34)	%
Operating and occupancy		589		500		89	18	%
Total	$	1,215	$	1,453	$	(238)	(16)	%

G&A payroll and benefits expenses include salaries, bonuses, relocation expense, severance costs, non-cash stock based compensation expense and fringe benefits. Included in payroll and benefits expense is a charge for non-cash stock based compensation of $368,000 for the three month period ended September 30, 2013 as compared to $653,000 for the same period in the prior year. Additionally, salaries for the three month period ended September 30, 2013 were $230,000 as compared to $275,000 for the same period in the prior year.

G&A operating and occupancy expenses, which include expenses to operate as a public company, increased 18% or approximately $89,000 to $589,000 for the three month period ended September 30, 2013 as compared to $500,000 for the same period in the prior year. The increase in operating and occupancy expenses for the three month period ended September 30, 2013 as compared to the same period in the prior year is primarily due to an increase in professional services.

G&A expenses increased 3% or approximately $105,000 to $3.5 million for the nine month period ended September 30, 2013 as compared to $3.3 million for the same period in the prior year. Our primary G&A expenses for the nine month period ended September 30, 2013 and 2012 are shown in the following table (in thousands):

	Nine-months		Nine-months
	ended		ended
	September 30,		September 30,				Change
General and Administrative	2013		2012		Variance		(%)
Payroll and benefits	$	1,725	$	2,026	$	(301)	(15)	%
Operating and occupancy		1,728		1,322		406	31	%
Total	$	3,453	$	3,348	$	105	3	%

G&A payroll and benefits expenses include salaries, bonuses, relocation expense, severance costs, non-cash stock option compensation expense and fringe benefits. Included in payroll and benefits expense is a charge for non-cash stock based compensation expense of $937,000 for the nine month period ended September 30, 2013 as compared to $1.3 million for the same period in the prior year. Additionally, salaries for the nine month period ended September 30, 2013 were $687,000 as compared to $664,000 for the same period in the prior year.

G&A operating and occupancy expenses, which include expenses to operate as a public company, increased 31% or approximately $406,000 to $1.7 million for the nine month period ended September 30, 2013 as compared to $1.3 million for the same period in the prior year. The increase is primarily due to an increase in professional services.

	22

Off-Balance Sheet Arrangements

As of September 30, 2013, the only off-balance sheet arrangement we have is the operating lease relating to our facility.

Liquidity and Capital Resources

Since our inception, we have financed our operations primarily with proceeds from private placements and public offerings of equity securities and with funds received under collaborative agreements.

On June 25, 2013, we completed a public offering of 4,312,500 shares of our common stock at a price per share of $19.00 (the “2013 Public Offering”). Net proceeds to us, after deducting underwriter’s fees and offering expenses, were approximately $76.8 million.

Our primary use of cash to date has been in operating activities to fund research and development, including preclinical studies and clinical trials, and general and administrative expenses. We had cash and cash equivalents of approximately $81.8 million as of September 30, 2013 as compared to $24.2 million as of December 31, 2012. All cash and cash equivalents as of September 30, 2013 and December 31, 2012 were held in an account backed by U.S. government securities.

Net cash of approximately $18.5 million and $8.1 million was used in operating activities during the nine month periods ended September 30, 2013 and 2012, respectively. The major use of cash for operating activities for the nine month period ended September 30, 2013 was to fund our clinical development programs and associated administrative costs. Cash used in investing activities during the nine month period ended September 30, 2013 was approximately $839,000 primarily for capitalized patent and patent application costs for Androxal® and Proellex®. Cash provided by financing activities during the nine month period ended September 30, 2013 was approximately $76.9 million as a result of completing the 2013 Public Offering.

We have experienced negative cash flows from operations since inception. We will require substantial funds for research and development, including preclinical studies and clinical trials of our product candidates, and to commence sales and marketing efforts if appropriate, if the FDA or other regulatory approvals are obtained. Based on our current and planned clinical activities, we believe that our current liquidity will be sufficient to continue the development of our product candidates through the NDA filing of both products. It is possible that our clinical trial activities will be more costly and take longer than we anticipate; accordingly, there can be no assurance that additional capital will not be necessary prior to the time anticipated. Our capital requirements will depend on many factors, which are discussed in detail in “Item 1A. Risk Factors” to Part I of Form 10-K for the fiscal year ended December 31, 2012. Additionally, as discussed in Note 5, there is a third party individual patent holder that claims priority over our patent application for Androxal®.

Our results of operations may vary significantly from quarter to quarter and year to year, and depend on, among other factors, our ability to raise additional capital on acceptable terms or at all, our ability to be successful in our clinical trials, the regulatory approval process in the United States and other foreign jurisdictions and the ability to complete strategic licenses and product development agreements. The timing of our revenues may not match the timing of our associated product development expenses. To date, research and development expenses have usually exceeded revenue in any particular period and/or fiscal year.

Item 3. Quantitative and Qualitative Disclosures About Market Risk

Interest Rate Risk. We had cash and cash equivalents of approximately $81.8 million at September 30, 2013 which is held in an account backed by U.S. government securities. Although this cash account is subject to fluctuations in interest rates and market conditions, no significant gain or loss on this account is expected to be recognized in earnings. We do not invest in derivative securities.

	23

Item 4. Controls and Procedures

Disclosure Controls and Procedures

Based on their evaluation as of the end of the period covered by this Quarterly Report on Form 10-Q, our Chief Executive Officer and Chief Financial Officer have concluded that our disclosure controls and procedures (as defined in Rule 13a-15(e)) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), were effective as of September 30, 2013.

Changes in Internal Control over Financial Reporting

In connection with the evaluation described above, we identified no change in internal control over financial reporting that occurred during the quarter ended September 30, 2013 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

	24

PART II - OTHER INFORMATION

Item 1. Legal Proceedings

Item 1A. Risk Factors

There were no material changes from the risk factors previously disclosed in the registrant’s Form 10-K for the fiscal year ended December 31, 2012 in response to “Item 1A. Risk Factors” to Part I of Form 10-K.

	25

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

None

Item 3. Defaults Upon Senior Securities.

None

Item 4. Mine Safety Disclosures.

None

Item 5. Other Information

None

Item 6. Exhibits

	3.1(a)	Restated Certificate of Incorporation (incorporated by reference to Exhibit 3.3 to the Company's Registration Statement on Form SB-2 (No. 33-57728-FW), as amended ("Registration Statement")).

	3.1(b)	Certificate of Amendment to the Company's Restated Certificate of Incorporation, dated as of May 2, 2006 (incorporated by reference to Exhibit 3.1 to the Company's Current Report on Form 8-K as filed with the Securities and Exchange Commission (the "Commission") on May 2, 2006).

	3.1(c)	Certificate of Amendment to the Company's Restated Certificate of Incorporation, as amended, dated as of December 16, 2008 (incorporated by reference to Exhibit 3.1(d) to the Company's Current Report on Form 8-K as filed with the Commission on December 23, 2008).

	3.1(d)	Certificate of Designation of Series One Junior Participating Preferred Stock dated September 2, 1999 (incorporated by reference to Exhibit A to Exhibit 4.1 to the Company's Registration Statement on Form 8-A as filed with the Commission on September 3, 1999).

	3.1(e)	Certificate of Amendment to Restated Certificate of Incorporation, dated as of November 18, 2009. Exhibit 3.1(e) to the Company’s Current Report on Form 8-K dated November 19, 2009 is incorporated herein by reference.

	3.1(f)	Certificate of Amendment to Restated Certificate of Incorporation, dated October 14, 2010. Exhibit 3.1(f) to the Company’s Current Report on Form 8-K dated October 14, 2010 is incorporated herein by reference.

	3.2	Restated Bylaws of the Company (incorporated by reference to Exhibit 3.4 to the Registration Statement).

	4.1	Form of Series A Warrant Certificate. Exhibit 4.10 to the Company’s Registration Statement on Form S-1/A (No. 333-171196) as filed with the Commission on February 2, 2011 is incorporated herein by reference.

	4.2	Form of Series B Warrant Certificate. Exhibit 4.11 to the Company’s Registration Statement on Form S-1/A (No. 333-171196) as filed with the Commission on February 2, 2011 is incorporated herein by reference.

	26

	4.3	Series A Warrant Agreement dated February 8, 2011 by and among the Company and Computershare Inc. and its wholly-owned subsidiary, Computershare Trust Company, N.A. Exhibit 4.1 to the Company’s Current Report on Form 8-K as filed with the Commission on February 9, 2011 is incorporated herein by reference.

	4.4	Series B Warrant Agreement dated February 8, 2011 by and among the Company and Computershare Inc. and its wholly-owned subsidiary, Computershare Trust Company, N.A. Exhibit 4.2 to the Company’s Current Report on Form 8-K as filed with the Commission on February 9, 2011 is incorporated herein by reference.

	31.1*	Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 (Chief Executive Officer).

	31.2*	Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 (Chief Financial Officer).

	32.1*	Certification furnished pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (Chief Executive Officer).

	32.2*	Certification furnished pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (Chief Financial Officer).

	*	Filed herewith.

	27

SIGNATURES

In accordance with the requirements of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	REPROS THERAPEUTICS INC.

Date: November 7, 2013
	By:	/s/ Joseph S. Podolski
		Joseph S. Podolski
		Chief Executive Officer and Director
		(Principal Executive Officer)

Date: November 7, 2013
	By:	/s/ Katherine A. Anderson
		Katherine A. Anderson
		Chief Financial Officer
		(Principal Financial Officer)

	28

EX-31.1 2 v358180_ex31-1.htm EX-31.1

EXHIBIT 31.1

I, Joseph S. Podolski, certify that:

1. I have reviewed this quarterly report of Repros Therapeutics Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) Designed such internal controls over financial reporting, or caused such internal controls over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Dated: November 7, 2013	By: /s/ Joseph S. Podolski
	Joseph S. Podolski
	Chief Executive Officer
	Repros Therapeutics Inc.

EX-31.2 3 v358180_ex31-2.htm EX-31.2

EXHIBIT 31.2

I, Katherine A. Anderson, certify that:

1. I have reviewed this quarterly report of Repros Therapeutics Inc.;

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Dated: November 7, 2013	By: /s/ Katherine A. Anderson
	Katherine A. Anderson
	Chief Financial Officer
	Repros Therapeutics Inc.

EX-32.1 4 v358180_ex32-1.htm EX-32.1

EXHIBIT 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Repros Therapeutics Inc. (the "Company") on Form 10-Q for the quarter ended September 30, 2013 as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, Joseph S. Podolski, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

1. The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Dated: November 7, 2013	By: /s/ Joseph S. Podolski
	Joseph S. Podolski
	Chief Executive Officer
	Repros Therapeutics Inc.

A signed original of this written statement required by Section 906 has been provided to Repros and will be retained by Repros and furnished to the Securities and Exchange Commission or its staff upon request.

EX-32.2 5 v358180_ex32-2.htm EX-32.2

EXHIBIT 32.2

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Repros Therapeutics Inc. (the "Company") on Form 10-Q for the quarter ended September 30, 2013 as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, Katherine A. Anderson, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

1. The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Dated: November 7, 2013	By: /s/ Katherine A. Anderson
	Katherine A. Anderson
	Chief Financial Officer
	Repros Therapeutics Inc.

EX-101.INS 6 rprx-20130930.xml XBRL INSTANCE DOCUMENT 0000897075 2012-01-01 2012-09-30 0000897075 2013-01-01 2013-09-30 0000897075 2012-07-01 2012-09-30 0000897075 2013-07-01 2013-09-30 0000897075 1987-08-20 2013-09-30 0000897075 2012-09-30 0000897075 2013-09-30 0000897075 2013-11-01 0000897075 2012-12-31 0000897075 2011-12-31 0000897075 1987-08-19 0000897075 us-gaap:MinimumMember 2012-01-01 2012-09-30 0000897075 us-gaap:MaximumMember 2012-01-01 2012-09-30 0000897075 us-gaap:CommonStockMember 2012-12-31 0000897075 us-gaap:AdditionalPaidInCapitalMember 2012-12-31 0000897075 us-gaap:TreasuryStockMember 2012-12-31 0000897075 us-gaap:AccumulatedDeficitDuringDevelopmentStageMember 2012-12-31 0000897075 us-gaap:CommonStockMember 2013-01-01 2013-09-30 0000897075 us-gaap:AdditionalPaidInCapitalMember 2013-01-01 2013-09-30 0000897075 us-gaap:TreasuryStockMember 2013-01-01 2013-09-30 0000897075 us-gaap:AccumulatedDeficitDuringDevelopmentStageMember 2013-01-01 2013-09-30 0000897075 us-gaap:CommonStockMember 2013-09-30 0000897075 us-gaap:AdditionalPaidInCapitalMember 2013-09-30 0000897075 us-gaap:TreasuryStockMember 2013-09-30 0000897075 us-gaap:AccumulatedDeficitDuringDevelopmentStageMember 2013-09-30 0000897075 us-gaap:CommonStockMember 2011-12-31 0000897075 us-gaap:AdditionalPaidInCapitalMember 2011-12-31 0000897075 us-gaap:TreasuryStockMember 2011-12-31 0000897075 us-gaap:AccumulatedDeficitDuringDevelopmentStageMember 2011-12-31 0000897075 us-gaap:CommonStockMember 2012-01-01 2012-09-30 0000897075 us-gaap:AdditionalPaidInCapitalMember 2012-01-01 2012-09-30 0000897075 us-gaap:TreasuryStockMember 2012-01-01 2012-09-30 0000897075 us-gaap:AccumulatedDeficitDuringDevelopmentStageMember 2012-01-01 2012-09-30 0000897075 us-gaap:CommonStockMember 2012-09-30 0000897075 us-gaap:AdditionalPaidInCapitalMember 2012-09-30 0000897075 us-gaap:TreasuryStockMember 2012-09-30 0000897075 us-gaap:AccumulatedDeficitDuringDevelopmentStageMember 2012-09-30 0000897075 rprx:AndroxalMember rprx:SecondaryHypogonadismMember 2013-01-01 2013-09-30 0000897075 rprx:ProellexMember rprx:UterineFibroids1Member 2013-01-01 2013-09-30 0000897075 rprx:ProellexMember rprx:EndometriosisMember 2013-01-01 2013-09-30 0000897075 us-gaap:IPOMember 2013-06-20 2013-06-25 0000897075 us-gaap:IPOMember 2013-06-25 0000897075 rprx:ProellexMember rprx:Uterinefibroids2Member 2013-01-01 2013-09-30 0000897075 rprx:AndroxalMember 2013-09-30 0000897075 rprx:ProellexMember 2013-09-30 0000897075 rprx:SeriesWarrantMember 2013-01-01 2013-09-30 0000897075 rprx:SeriesBWarrantMember 2013-01-01 2013-09-30 0000897075 rprx:SeriesWarrantMember 2012-01-01 2012-09-30 0000897075 rprx:SeriesBWarrantMember 2012-01-01 2012-09-30 0000897075 rprx:ForeignMember 2013-09-30 0000897075 rprx:DomesticMember 2013-09-30 0000897075 rprx:ThirdPartyMember 2013-09-30 xbrli:shares iso4217:USD xbrli:shares iso4217:USD xbrli:pure 10-Q false 2013-09-30 2013 Q3 RPRX 23009882 REPROS THERAPEUTICS INC. 0000897075 --12-31 Accelerated Filer

0.001

75000000

23121959

17272505

23009609

17160155

112350

5000000

81828000

24212000

193000

406000

82021000

24618000

87000

53000

2734000

2161000

84842000

26832000

2829000

3240000

382000

558000

3211000

3798000

23000

17000

313469000

234299000

1380000

230481000

209902000

81631000

23034000

84842000

26832000

28755000

627000

1219000

3000

1000

6000

1000

16308000

102000

1003000

3000

1000

6000

1000

48014000

4786000

3131000

17132000

6776000

212391000

1215000

1453000

3453000

3348000

56373000

388000

6001000

4584000

20585000

10124000

269152000

-5998000

-4583000

-20579000

-10123000

-221138000

-1828000

939000

-5998000

-4583000

-20579000

-10123000

-222027000

-8454000

-5998000

-4583000

-20579000

-10123000

-230481000

-0.26

-0.30

-1.03

-0.69

23006

15422

20066

14746

23006

15422

20066

14746

12345000

316000

4417000

2614000

709000

1308000

177000

106000

4478000

2258000

1902000

14576000

-200000

18000

199000

4447000

-213000

352000

-110000

-532000

367000

11087000

-18463000

-8100000

-200369000

191000

63000

54000

2486000

776000

578000

6310000

225000

3000

138000

2250000

213000

-839000

-632000

-6584000

76764000

33328000

284195000

154000

422000

951000

327000

23688000

21487000

2839000

1732000

76918000

33750000

288781000

57616000

25018000

81828000

4565000

29583000

872133 716463 2.49 8332 18.74

5200000

5.07

777

27915 586 1.33 10.88 2.49 4.50 11.00

17000

234299000

-1380000

-209902000

17272505

112350

2258000

0 1000 -1000 0 0 871634 0 0 1000 -1000 0 0 614564 0 42849 0 107000 0 107000 0 0

5407

47000

2500

4312500

76764000

4000

76760000

-20579000

23000

313469000

-1380000

-230481000

23121959

112350

4666000

12000

197769000

-1380000

-191735000

12470694

112350

1902000

100 0

2463537

10310000

3000

10307000

121000

16488

11173

121079 0 301000 0 301000 0 0

-10123000

30195000

17000

233416000

-1380000

-201858000

17228707

112350

2145636 0 23018000 2000 23016000 0 0

<div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="COLOR: black; FONT-SIZE: 10pt">Our product development pipeline is summarized in the table below:</font></div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt">  </font></div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="center"> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid" cellspacing="0" cellpadding="0"> <tr style="HEIGHT: 20px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="32%"> <div>Product Candidate (Indication)  <br/> Androxal®</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="23%"> <div>Status</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="45%"> <div>Next Expected Milestone(s)</div> </td> </tr> <tr style="HEIGHT: 7px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="32%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="23%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="45%"> <div> </div> </td> </tr> <tr style="HEIGHT: 20px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="32%"> <div>Secondary Hypogonadism</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="23%"> <div>Phase 3</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"> <div> Complete DEXA study (Q4 2014) pending FDA guidance</div> </td> </tr> <tr style="HEIGHT: 7px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="32%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="23%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="45%"> <div> </div> </td> </tr> <tr style="HEIGHT: 20px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="32%"> <div>Proellex®</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="23%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"> <div> </div> </td> </tr> <tr style="HEIGHT: 7px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="32%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="23%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="45%"> <div> </div> </td> </tr> <tr style="HEIGHT: 20px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: top; FONT-WEIGHT: 400" width="32%"> <div>Uterine Fibroids</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: top; FONT-WEIGHT: 400" width="23%"> <div>Phase 2B (vaginal)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: top; FONT-WEIGHT: 400" width="45%"> <div> Initiate a Phase 2B study (vaginal delivery) (Q1 2014)</div> </td> </tr> <tr style="HEIGHT: 7px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="32%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="23%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="45%"> <div> </div> </td> </tr> <tr style="HEIGHT: 20px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="32%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="23%"> <div>Phase 2 (oral)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="45%"> <div> Lift full clinical hold and initiate efficacy study (low dose oral) (Q1 2014)</div> </td> </tr> <tr style="HEIGHT: 7px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="32%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="23%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="45%"> <div> </div> </td> </tr> <tr style="HEIGHT: 20px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="32%"> <div>Endometriosis</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="23%"> <div>Phase 2</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"> <div> Complete Phase 2 study (oral delivery) (Q3 2014)</div> </td> </tr> </table> </div> </div> </div> <table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

Phase 3 Complete DEXA study (Q4 2014) pending FDA guidance Initiate a Phase 2B study (vaginal delivery) (Q1 2014) Phase 2 Complete Phase 2 study (oral delivery) (Q3 2014)

4312500

19.00

76800000

3200000

Phase 2B (vaginal) Phase 2 (oral)

<div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><strong><font style="FONT-SIZE: 10pt; COLOR: black">NOTE 1<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font> Organization, Operations and Liquidity</font></strong></div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">Repros Therapeutics Inc. (the “Company”, “RPRX,” “Repros,” or “we,” “us” or “our”) was organized on August 20, 1987. We are a development stage biopharmaceutical company focused on the development of new drugs to treat hormonal and reproductive system disorders.</font></div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">Our primary product candidate, Androxal®, is a single isomer of clomiphene citrate and is an orally active proprietary small molecule compound.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font> We are developing Androxal® for men of reproductive age with low testosterone levels.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font> Androxal® treats the underlying mechanism that causes secondary hypogonadism and restores normal testicular function.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font> We have completed two pivotal efficacy Phase 3 studies for Androxal® conducted under a Special Protocol Assessment (“SPA”).<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font></font></div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt">  </font></div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt"> Proellex®, our product candidate for female reproductive health, is a new chemical entity that acts as a selective blocker of the progesterone receptor and is being developed for the treatment of symptoms associated with uterine fibroids and endometriosis.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font> We completed a low dose study in late 2011 to demonstrate both safety and signals of efficacy in low oral doses of Proellex® and in November 2012 we initiated a Phase 2 study in the treatment of endometriosis.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font> Additionally,</font> <font style="FONT-SIZE: 10pt">we have completed a Phase 1/2 vaginal administration study for uterine fibroids in the first quarter of 2013.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font> <strong><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">   </font></strong> <font style="COLOR: black"> </font></font></div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="COLOR: black; FONT-SIZE: 10pt">Our product development pipeline is summarized in the table below:</font></div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt">  </font></div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="center"> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid" cellspacing="0" cellpadding="0"> <tr style="HEIGHT: 20px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="32%"> <div>Product Candidate (Indication)  <br/> Androxal®</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="23%"> <div>Status</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="45%"> <div>Next Expected Milestone(s)</div> </td> </tr> <tr style="HEIGHT: 7px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="32%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="23%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="45%"> <div> </div> </td> </tr> <tr style="HEIGHT: 20px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="32%"> <div>Secondary Hypogonadism</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="23%"> <div>Phase 3</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"> <div> Complete DEXA study (Q4 2014) pending FDA guidance</div> </td> </tr> <tr style="HEIGHT: 7px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="32%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="23%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="45%"> <div> </div> </td> </tr> <tr style="HEIGHT: 20px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="32%"> <div>Proellex®</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="23%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"> <div> </div> </td> </tr> <tr style="HEIGHT: 7px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="32%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="23%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="45%"> <div> </div> </td> </tr> <tr style="HEIGHT: 20px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: top; FONT-WEIGHT: 400" width="32%"> <div>Uterine Fibroids</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: top; FONT-WEIGHT: 400" width="23%"> <div>Phase 2B (vaginal)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: top; FONT-WEIGHT: 400" width="45%"> <div> Initiate a Phase 2B study (vaginal delivery) (Q1 2014)</div> </td> </tr> <tr style="HEIGHT: 7px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="32%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="23%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="45%"> <div> </div> </td> </tr> <tr style="HEIGHT: 20px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="32%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="23%"> <div>Phase 2 (oral)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="45%"> <div> Lift full clinical hold and initiate efficacy study (low dose oral) (Q1 2014)</div> </td> </tr> <tr style="HEIGHT: 7px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="32%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="23%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="45%"> <div> </div> </td> </tr> <tr style="HEIGHT: 20px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="32%"> <div>Endometriosis</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="23%"> <div>Phase 2</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"> <div> Complete Phase 2 study (oral delivery) (Q3 2014)</div> </td> </tr> </table> </div> </div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">We also continue to maintain our patent portfolio of our phentolamine-based products for the treatment of sexual dysfunction.</font></div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">On June 25, 2013, we completed a public offering of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 4,312,500</font> shares of our common stock at a price per share of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">19.00</font>.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font> Net proceeds to us, after deducting underwriter’s fees and offering expenses, were approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">76.8</font> million.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font></font></div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">As of September 30, 2013, we had accumulated losses of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">230.5</font> million, approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">81.8</font> million in cash and cash equivalents, and our accounts payable and accrued expenses were approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">3.2</font> million. We anticipate that our current liquidity will be sufficient to continue the development of our product candidates through the NDA filing of both products.<font style="COLOR: black"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font></font> We continue to explore potential corporate partnering opportunities for assistance in the clinical development funding and commercialization of our products, as appropriate; however, there can be no assurance that an acceptable corporate partnering opportunity will be successfully completed or that our current liquidity will be sufficient to fund all of our product development needs.</font></div> </div> <table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

Lift full clinical hold and initiate efficacy study (low dose oral) (Q1 2014)

1726000

1008000

<div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <font size="2"></font> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font size="2"><b><font style="FONT-SIZE: 10pt; COLOR: black">NOTE<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font> 2<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font> Patents and Patent Applications</font></b></font></div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in" align="justify"><font style="FONT-SIZE: 10pt">As of September 30, 2013, we had approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">2,734,000</font> in capitalized patent and patent application costs reflected on its balance sheet.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font> Of this amount, $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1,726,000</font> relates to patent and patent application costs for Androxal® and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1,008,000</font> relates to patent and patent application costs for Proellex®.<font style="COLOR: black"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font></font></font></div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in" align="justify"><font style="FONT-SIZE: 10pt">Should we not continue development of either drug candidate or should we not continue as a going concern, the remaining capitalized patent and patent application costs may not be recoverable, which would result in charges to operating results in future periods.</font></div> </div> <table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

<div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in" align="justify"><font style="FONT-SIZE: 10pt; COLOR: black"><font style="FONT-FAMILY:times new roman,times,serif"></font></font> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in" align="justify"><font style="FONT-FAMILY:times new roman,times,serif"><font style="FONT-SIZE: 10pt; COLOR: black"><font style="FONT-FAMILY:times new roman,times,serif">Accrued expenses consist of the following (in thousands): </font></font></font></div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in" align="justify"><font style="FONT-SIZE: 10pt; COLOR: black"> </font><strong><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; COLOR: black; MARGIN: 0in; TEXT-INDENT: 0in"> <font style="FONT-FAMILY:times new roman,times,serif"></font></font></strong> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <strong><font style="FONT-FAMILY:times new roman,times,serif"> </font></strong> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"> <strong><font style="FONT-FAMILY:times new roman,times,serif"><font style="FONT-SIZE: 10pt; COLOR: black"></font></font></strong></div> <strong><font style="FONT-SIZE: 10pt; COLOR: black"></font></strong></div> </div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in" align="justify"> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt; WIDTH: 100%; TEXT-INDENT: 0in" align="center"> <table style="OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid; BORDER-COLLAPSE: collapse; BORDER-BOTTOM: #9eb6ce 0px solid; MARGIN: 0px:auto; BORDER-LEFT: #9eb6ce 0px solid; WIDTH: 86%" cellspacing="0" cellpadding="0" align="center"> <tr style="HEIGHT: 12px"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="57%"> <div> </div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div> </div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; FONT-WEIGHT: 700; FONT-STYLE: normal; TEXT-ALIGN: center" width="13%" colspan="2"> <div>September 30, 2013</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div> </div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; FONT-WEIGHT: 700; FONT-STYLE: normal; TEXT-ALIGN: center" width="13%" colspan="2"> <div>December 31, 2012</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="57%"> <div> </div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div> </div> </td> <td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div> </div> </td> <td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right" width="12%"> <div> </div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div> </div> </td> <td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div> </div> </td> <td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right" width="12%"> <div> </div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="57%"> <div>Patent costs</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div> </div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>$</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="12%"> <div>152</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div> </div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>$</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="12%"> <div>245</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="57%"> <div>Research and development costs</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div> </div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div> </div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="12%"> <div>87</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div> </div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div> </div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="12%"> <div>192</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="57%"> <div>Personnel related costs</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div> </div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div> </div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="12%"> <div>42</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div> </div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div> </div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="12%"> <div>30</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="57%"> <div>Other</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div> </div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; BORDER-BOTTOM: #000000 1px solid; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div> </div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; BORDER-BOTTOM: #000000 1px solid; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="12%"> <div>101</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div> </div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; BORDER-BOTTOM: #000000 1px solid; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div> </div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; BORDER-BOTTOM: #000000 1px solid; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="12%"> <div>91</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="57%"> <div> </div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div> </div> </td> <td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div> </div> </td> <td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right" width="12%"> <div> </div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div> </div> </td> <td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div> </div> </td> <td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right" width="12%"> <div> </div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="57%"> <div>Total</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div> </div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; BORDER-BOTTOM: #000000 3px double; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>$</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; BORDER-BOTTOM: #000000 3px double; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="12%"> <div>382</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div> </div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; BORDER-BOTTOM: #000000 3px double; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>$</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; BORDER-BOTTOM: #000000 3px double; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="12%"> <div>558</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div> </div> </td> </tr> </table> </div> </div> </div> </div> <table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

<div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><strong><font style="FONT-SIZE: 10pt; COLOR: black"><font style="FONT-FAMILY:times new roman,times,serif"><font style="FONT-SIZE: 10pt; COLOR: black">NOTE<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font> 3<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font> Accrued Expenses</font></font></font></strong> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt">  <font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; COLOR: black"><font style="FONT-FAMILY:times new roman,times,serif">  </font></font></div> </div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in" align="justify"><font style="FONT-SIZE: 10pt; COLOR: black"><font style="FONT-FAMILY:times new roman,times,serif">Accrued expenses consist of the following (in thousands): </font></font></div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in" align="justify"><font style="FONT-SIZE: 10pt; COLOR: black"> </font><strong><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; COLOR: black; MARGIN: 0in; TEXT-INDENT: 0in"> <font style="FONT-FAMILY:times new roman,times,serif"></font></font></strong> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <strong><font style="FONT-FAMILY:times new roman,times,serif"> </font></strong> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"> <strong><font style="FONT-FAMILY:times new roman,times,serif"><font style="FONT-SIZE: 10pt; COLOR: black"></font></font></strong></div> <strong><font style="FONT-SIZE: 10pt; COLOR: black"></font></strong></div> </div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in" align="justify"> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt; WIDTH: 100%; TEXT-INDENT: 0in" align="center"> <table style="OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid; BORDER-COLLAPSE: collapse; BORDER-BOTTOM: #9eb6ce 0px solid; MARGIN: 0px:auto; BORDER-LEFT: #9eb6ce 0px solid; WIDTH: 86%" cellspacing="0" cellpadding="0" align="center"> <tr style="HEIGHT: 12px"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="57%"> <div> </div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div> </div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; FONT-WEIGHT: 700; FONT-STYLE: normal; TEXT-ALIGN: center" width="13%" colspan="2"> <div>September 30, 2013</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div> </div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; FONT-WEIGHT: 700; FONT-STYLE: normal; TEXT-ALIGN: center" width="13%" colspan="2"> <div>December 31, 2012</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="57%"> <div> </div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div> </div> </td> <td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div> </div> </td> <td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right" width="12%"> <div> </div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div> </div> </td> <td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div> </div> </td> <td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right" width="12%"> <div> </div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="57%"> <div>Patent costs</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div> </div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>$</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="12%"> <div>152</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div> </div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>$</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="12%"> <div>245</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="57%"> <div>Research and development costs</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div> </div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div> </div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="12%"> <div>87</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div> </div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div> </div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="12%"> <div>192</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="57%"> <div>Personnel related costs</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div> </div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div> </div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="12%"> <div>42</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div> </div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div> </div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="12%"> <div>30</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="57%"> <div>Other</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div> </div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; BORDER-BOTTOM: #000000 1px solid; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div> </div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; BORDER-BOTTOM: #000000 1px solid; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="12%"> <div>101</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div> </div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; BORDER-BOTTOM: #000000 1px solid; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div> </div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; BORDER-BOTTOM: #000000 1px solid; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="12%"> <div>91</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="57%"> <div> </div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div> </div> </td> <td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div> </div> </td> <td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right" width="12%"> <div> </div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div> </div> </td> <td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div> </div> </td> <td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right" width="12%"> <div> </div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="57%"> <div>Total</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div> </div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; BORDER-BOTTOM: #000000 3px double; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>$</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; BORDER-BOTTOM: #000000 3px double; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="12%"> <div>382</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div> </div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; BORDER-BOTTOM: #000000 3px double; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>$</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; BORDER-BOTTOM: #000000 3px double; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="12%"> <div>558</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"></td> </tr> </table> </div> </div> </div> <table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

152000 245000 87000 192000 42000 30000

101000

91000

<div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><strong><font style="FONT-SIZE: 10pt; COLOR: black">NOTE 4<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font> Loss Per Share</font></strong></div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in" align="justify"><font style="FONT-SIZE: 10pt">Basic loss per share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the period.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font> Diluted loss per share is computed using the average share price for the period and applying the treasury stock method to potentially dilutive outstanding options.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font> In all applicable periods, all potential common stock equivalents were anti-dilutive and, accordingly, were not included in the computation of diluted loss per share.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font></font></div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in" align="justify"><font style="FONT-SIZE: 10pt; COLOR: black">  </font></div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in" align="justify"><font style="FONT-SIZE: 10pt; COLOR: black">The following table presents information necessary to calculate loss per share for the three and nine month periods ended September 30, 2013 and 2012 (in thousands, except per share amounts):</font></div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in" align="justify"><font style="FONT-SIZE: 10pt; COLOR: black">  </font></div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt" align="center"> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt; WIDTH: 100%; TEXT-INDENT: 0in"> <table style="OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid; BORDER-COLLAPSE: collapse; BORDER-BOTTOM: #9eb6ce 0px solid; MARGIN: 0in; BORDER-LEFT: #9eb6ce 0px solid; WIDTH: 100%" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700; FONT-STYLE: normal; TEXT-ALIGN: center" width="39%"> <div> </div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; FONT-WEIGHT: 700; FONT-STYLE: normal; TEXT-ALIGN: center" width="1%"> <div> </div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; FONT-WEIGHT: 700; FONT-STYLE: normal; TEXT-ALIGN: center" width="29%" colspan="5"> <div>Three Months Ended Sept. 30,</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; FONT-WEIGHT: 700; FONT-STYLE: normal; TEXT-ALIGN: center" width="1%"> <div> </div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; FONT-WEIGHT: 700; FONT-STYLE: normal; TEXT-ALIGN: center" width="29%" colspan="5"> <div>Nine Months Ended Sept. 30,</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700; FONT-STYLE: normal; TEXT-ALIGN: center" width="39%"> <div> </div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; FONT-WEIGHT: 700; FONT-STYLE: normal; TEXT-ALIGN: center" width="1%"> <div> </div> </td> <td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; FONT-WEIGHT: 700; FONT-STYLE: normal; TEXT-ALIGN: center" width="14%" colspan="2"> <div>2013</div> </td> <td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; FONT-WEIGHT: 700; FONT-STYLE: normal; TEXT-ALIGN: center" width="1%"> <div> </div> </td> <td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; FONT-WEIGHT: 700; FONT-STYLE: normal; TEXT-ALIGN: center" width="14%" colspan="2"> <div>2012</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; FONT-WEIGHT: 700; FONT-STYLE: normal; TEXT-ALIGN: center" width="1%"> <div> </div> </td> <td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; FONT-WEIGHT: 700; FONT-STYLE: normal; TEXT-ALIGN: center" width="14%" colspan="2"> <div>2013</div> </td> <td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; FONT-WEIGHT: 700; FONT-STYLE: normal; TEXT-ALIGN: center" width="1%"> <div> </div> </td> <td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; FONT-WEIGHT: 700; FONT-STYLE: normal; TEXT-ALIGN: center" width="14%" colspan="2"> <div>2012</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="39%"> <div> </div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div> </div> </td> <td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div> </div> </td> <td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right" width="13%"> <div> </div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div> </div> </td> <td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div> </div> </td> <td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right" width="13%"> <div> </div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div> </div> </td> <td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div> </div> </td> <td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right" width="13%"> <div> </div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div> </div> </td> <td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div> </div> </td> <td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right" width="13%"> <div> </div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="39%"> <div>Net Loss</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div> </div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>$</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right" width="13%"> <div>(5,998)</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div> </div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>$</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right" width="13%"> <div>(4,583)</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div> </div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>$</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right" width="13%"> <div>(20,579)</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div> </div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>$</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right" width="13%"> <div>(10,123)</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="39%"> <div>Average common shares outstanding</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div> </div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div> </div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="13%"> <div>23,006</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div> </div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div> </div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="13%"> <div>15,422</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div> </div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div> </div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="13%"> <div>20,066</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div> </div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div> </div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="13%"> <div>14,746</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="39%"> <div>Basic and diluted loss per share</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div> </div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>$</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right" width="13%"> <div>(0.26)</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div> </div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>$</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right" width="13%"> <div>(0.30)</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div> </div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>$</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right" width="13%"> <div>(1.03)</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div> </div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>$</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right" width="13%"> <div>(0.69)</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div> </div> </td> </tr> </table> </div> </div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in" align="justify"><font style="FONT-SIZE: 10pt; COLOR: black">  </font></div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in" align="justify"><font style="FONT-SIZE: 10pt">Potential common stock of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 3,975,430</font> and <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 5,264,207</font> common shares underlying stock options and warrants for the periods ended September 30, 2013 and 2012, respectively, were excluded from the above calculation of diluted loss per share because they were anti-dilutive.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font> Other potential common stock at September 30, 2013 includes Series A Warrants to purchase <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 877,137</font> shares of our common stock at an exercise price of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.01</font> and Series B Warrants to purchase <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 810,109</font> shares of our common stock at an exercise price of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">2.49</font> issued in February 2011.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font> Other potential common stock at September 30, 2012 includes Series A Warrants to purchase <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 1,749,270</font> shares of our common stock at an exercise price of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.01</font> and Series B Warrants to purchase <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 1,569,421</font> shares of our common stock at an exercise price of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">2.49</font> issued in February, 2011.</font></div> </div> <table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

<div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in" align="justify"><font style="FONT-SIZE: 10pt; COLOR: black">The following table presents information necessary to calculate loss per share for the three and nine month periods ended September 30, 2013 and 2012 (in thousands, except per share amounts):</font></div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in" align="justify"><font style="FONT-SIZE: 10pt; COLOR: black">  </font></div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt" align="center"> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt; WIDTH: 100%; TEXT-INDENT: 0in"> <table style="OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid; BORDER-COLLAPSE: collapse; BORDER-BOTTOM: #9eb6ce 0px solid; MARGIN: 0in; BORDER-LEFT: #9eb6ce 0px solid; WIDTH: 100%" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700; FONT-STYLE: normal; TEXT-ALIGN: center" width="39%"> <div> </div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; FONT-WEIGHT: 700; FONT-STYLE: normal; TEXT-ALIGN: center" width="1%"> <div> </div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; FONT-WEIGHT: 700; FONT-STYLE: normal; TEXT-ALIGN: center" width="29%" colspan="5"> <div>Three Months Ended Sept. 30,</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; FONT-WEIGHT: 700; FONT-STYLE: normal; TEXT-ALIGN: center" width="1%"> <div> </div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; FONT-WEIGHT: 700; FONT-STYLE: normal; TEXT-ALIGN: center" width="29%" colspan="5"> <div>Nine Months Ended Sept. 30,</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700; FONT-STYLE: normal; TEXT-ALIGN: center" width="39%"> <div> </div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; FONT-WEIGHT: 700; FONT-STYLE: normal; TEXT-ALIGN: center" width="1%"> <div> </div> </td> <td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; FONT-WEIGHT: 700; FONT-STYLE: normal; TEXT-ALIGN: center" width="14%" colspan="2"> <div>2013</div> </td> <td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; FONT-WEIGHT: 700; FONT-STYLE: normal; TEXT-ALIGN: center" width="1%"> <div> </div> </td> <td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; FONT-WEIGHT: 700; FONT-STYLE: normal; TEXT-ALIGN: center" width="14%" colspan="2"> <div>2012</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; FONT-WEIGHT: 700; FONT-STYLE: normal; TEXT-ALIGN: center" width="1%"> <div> </div> </td> <td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; FONT-WEIGHT: 700; FONT-STYLE: normal; TEXT-ALIGN: center" width="14%" colspan="2"> <div>2013</div> </td> <td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; FONT-WEIGHT: 700; FONT-STYLE: normal; TEXT-ALIGN: center" width="1%"> <div> </div> </td> <td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; FONT-WEIGHT: 700; FONT-STYLE: normal; TEXT-ALIGN: center" width="14%" colspan="2"> <div>2012</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="39%"> <div> </div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div> </div> </td> <td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div> </div> </td> <td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right" width="13%"> <div> </div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div> </div> </td> <td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div> </div> </td> <td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right" width="13%"> <div> </div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div> </div> </td> <td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div> </div> </td> <td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right" width="13%"> <div> </div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div> </div> </td> <td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div> </div> </td> <td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right" width="13%"> <div> </div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="39%"> <div>Net Loss</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div> </div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>$</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right" width="13%"> <div>(5,998)</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div> </div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>$</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right" width="13%"> <div>(4,583)</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div> </div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>$</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right" width="13%"> <div>(20,579)</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div> </div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>$</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right" width="13%"> <div>(10,123)</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="39%"> <div>Average common shares outstanding</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div> </div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div> </div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="13%"> <div>23,006</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div> </div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div> </div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="13%"> <div>15,422</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div> </div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div> </div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="13%"> <div>20,066</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div> </div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div> </div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="13%"> <div>14,746</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="39%"> <div>Basic and diluted loss per share</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div> </div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>$</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right" width="13%"> <div>(0.26)</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div> </div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>$</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right" width="13%"> <div>(0.30)</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div> </div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>$</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right" width="13%"> <div>(1.03)</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div> </div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>$</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right" width="13%"> <div>(0.69)</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div> </div> </td> </tr> </table> </div> </div> </div> <table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

3975430

5264207

877137

0.01

810109

2.49

1749270

0.01

1569421

2.49

23006

15422

20066

14746

61 52 8 4 2

EX-101.CAL 7 rprx-20130930_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 8 rprx-20130930_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 9 rprx-20130930_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization Consolidation and Presentation Of Financial Statements Disclosure [Text Block] Organization, Operations and Liquidity Goodwill and Intangible Assets Disclosure [Abstract] Intangible Assets Disclosure [Text Block] Patents and Patent Applications Accrued Expenses [Abstract] Accounts Payable and Accrued Liabilities Disclosure [Text Block] Accrued Expenses Earnings Per Share [Abstract] Earnings Per Share [Text Block] Loss Per Share Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Text Block] Commitments and Contingencies Schedule Of Product Information [Table Text Block] Product Development Pipeline Schedule Of Accrued Liabilities Table [Text Block] Accrued Expenses Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Calculation of Loss Per Share Schedule of Product Information [Table] Products and Services [Axis] Products and Services [Domain] Androxal [Member] Proellex [Member] Products Or Services Secondary Categorization [Axis] Products Or Services Secondary Categorization [Domain] Secondary Hypogonadism [Member] Uterine Fibroids 1 [Member] UterineFibroids 2 [Member] Uterine Fibroids 2 [Member] Product Information [Line Items] Product Information [Line Items] Product Status Status Product Status Product Next Expected Milestone Next Expected Milestone(s) Product Next Expected Milestone Legal Entity [Axis] Entity [Domain] Subsidiary, Sale of Stock [Axis] Sale of Stock, Name of Transaction [Domain] IPO [Member] Development Stage Enterprise, Deficit Accumulated During Development Stage Deficit accumulated during the development stage Cash and Cash Equivalents, at Carrying Value, Total Cash and cash equivalents Cash and cash equivalents at beginning of period Cash and cash equivalents at end of period Accounts Payable and Accrued Liabilities, Current, Total Accounts payable and accrued expenses Stock Issued During Period, Shares, New Issues Common stock issued during the period Issuance of shares of common stock, net of offering costs (in shares) Sale of Stock, Price Per Share Price per share Issuance of 100 shares of common stock at a share price Public Offering Net Proceeds Public Offering Net Proceeds Public offering, net proceeds. Schedule of Finite-Lived Intangible Assets [Table] Finite-Lived Intangible Assets [Line Items] Finite-Lived Intangible Assets [Line Items] Intangible Assets, Net (Excluding Goodwill), Total Capitalized patent and patent application costs Other assets, net Schedule Of Accrued Liabilities [Table] Schedule of Accrued Liabilities [Table] Schedule Of Accrued Liabilities [Line Items] Schedule of Accrued Liabilities [Line Items] Accrued Personnel Expense Current Patent costs Accrued Personnel Expense Current Accrued Patent Expense Current Research and development costs Accrued Patent Expense, Current Accrued Research and Development Expense Current Personnel related costs Accrued Research and Development Expense, Current Other Accrued Liabilities Current Other Accrued Expenses Total Accrued expenses Statement [Table] Statement [Line Items] Net Income (Loss) Attributable to Parent, Total Net loss Net loss Weighted Average Number Of Shares Outstanding, Basic and Diluted Average common shares outstanding Earnings Per Share, Basic and Diluted, Total Basic and diluted loss per share Loss per share - basic and diluted: Earnings Per Share Disclosure [Table] Class of Stock [Axis] Class of Stock [Domain] Series Warrant [Member] Series A Warrants [Member] Series B Warrant [Member] Series B Warrants [Member] Series B Warrant Earnings Per Share Disclosure [Line Items] Earnings Per Share Disclosure [Line Items] Antidilutive Securities Excluded From Computation Of Earnings Per Share, Amount Anti-dilutive shares of common stock excluded from computation of earning per share Antidilutive Securities Excluded From Computation Of Earnings Per Share Weighted Average Exercise Price Warrants, exercise price per share Antidilutive Securities Excluded from Computation of Earnings Per Share, Weighted Average Exercise Price Commitments and Contingencies [Table] Commitments and Contingencies [Table] Scenario [Axis] Scenario, Unspecified [Domain] Third Party [Member] Third Party [Member] Third Party [Member] Junior Participating Preferred Stock [Member] Geographical [Axis] Geographical [Domain] Domestic [Member] Domestic [Member] U.S. Foreign [Member] Foreign [Member] Foreign Commitments and Contingencies [Line Items] Commitments and Contingencies [Line Items] Commitments and Contingencies [Line Items] Number Of Patents Number of patents Number of Patents Number Of Patents Pending Number of pending patent applications Number of Patents Pending Statement Of Financial Position [Abstract] Assets [Abstract] ASSETS Assets Current [Abstract] Current Assets Prepaid Expense and Other Assets, Current Prepaid expenses and other current assets Assets, Current, Total Total current assets Property, Plant and Equipment, Net, Total Fixed assets, net Assets, Total Total assets Liabilities and Stockholders Equity [Abstract] LIABILITIES AND STOCKHOLDERS' EQUITY Liabilities Current [Abstract] Current Liabilities Accounts Payable Current Accounts payable Liabilities, Current, Total Total current liabilities Commitments and Contingencies Commitments and contingencies (note 5) Stockholders Equity [Abstract] Stockholders' Equity Preferred Stock Value Undesignated Preferred Stock, $.001 par value, 5,000,000 shares authorized, none issued and outstanding Common Stock Value Common Stock, $.001 par value, 75,000,000 shares authorized, 23,121,959and 17,272,505 shares issued, respectively and 23,009,609 and 17,160,155 shares outstanding, respectively Additional Paid in Capital, Total Additional paid-in capital Treasury Stock Value Cost of treasury stock, 112,350 shares Stockholders Equity Attributable to Parent, Total Total stockholders' equity Beginning Balance Ending Balance Liabilities and Equity, Total Total liabilities and stockholders' equity Preferred Stock, Par or Stated Value Per Share Preferred Stock, par value Preferred Stock Shares Authorized Preferred Stock, shares authorized Preferred Stock Shares Issued Preferred Stock, issued Preferred Stock Shares Outstanding Preferred Stock, outstanding Common Stock, Par or Stated Value Per Share Common Stock, par value Common Stock Shares Authorized Common Stock, shares authorized Common Stock, Shares, Issued Common Stock, shares issued Common Stock, Shares, Outstanding Common Stock, shares outstanding Treasury Stock Shares Treasury stock, shares Income Statement [Abstract] Revenues [Abstract] Revenues Licenses Revenue Licensing fees Royalty Revenue, Total Product royalties Revenue From Grants Research and development grants Investment Income, Interest Interest income Gain (Loss) on Disposition of Assets for Financial Service Operations Gain on disposal of fixed assets Gain on disposal of fixed assets Other Nonoperating Income Other Income Revenues, Total Total revenues and other income Costs and Expenses [Abstract] Expenses Research and Development Expense, Total Research and development General and Administrative Expense, Total General and administrative Other Cost and Expense, Operating Other Expense Costs and Expenses, Total Total expenses Income (Loss) from Continuing Operations Attributable to Parent, Total Loss from continuing operations Income Loss From Discontinued Operations Net Of Tax Loss from discontinued operations Discontinued Operation, Gain (Loss) on Disposal of Discontinued Operation, Net of Tax, Total Gain on disposal of discontinued operation Gain on disposal of discontinued operations Income (Loss) from Operations before Extraordinary Items, Total Net loss before cumulative effect of change in accounting principle New Accounting Pronouncement or Change in Accounting Principle, Effect of Change on Net Income Cumulative effect of change in accounting principle Weighted Average Number Of Shares Outstanding [Abstract] Weighted average shares used in loss per share calculation: Weighted Average Number of Shares Outstanding, Basic, Total Basic Weighted Average Number of Shares Outstanding, Diluted Diluted Statement Of Stockholders' Equity [Abstract] Equity Components [Axis] Equity Component [Domain] Common Stock [Member] Common Stock Additional Paid-in Capital [Member] Additional Paid-in Capital Treasury Stock [Member] Treasury Stock Accumulated Deficit during Development Stage [Member] Deficit Accumulated During the Development Stage Shares, Issued Beginning Balance (in shares) Ending Balance (in shares) Adjustments To Additional Paid In Capital, Share-Based Compensation, Stock Options, Requisite Service Period Recognition Stock based option compensation Issuance Of Common Stock During Period Shares Issuance of 100 shares of common stock at a share price of $5.07 (in shares) The number of common stock issued during the period. Stock Issued During Period Value Warrants Exercised Cashless Issuance of 871,634 shares of common stock for the cashless exercise of 872,133 Series A Warrants Stock Issued During Period, Value, Warrants Exercised Cashless Stock Issued During Period Shares Warrants Exercised Cashless Issuance of 871,634 shares of common stock for the cashless exercise of 872,133 Series A Warrants (in shares) Stock Issued During Period, Shares, Warrants Exercised Cashless Stock Issued During Period Value Warrants Exercised Cashless1 Issuance of 614,564 shares of common stock for the cashless exercise of 716,463 Series B Warrants Stock Issued During Period, Value, Warrants Exercised Cashless1 Stock Issued During Period Shares Warrants Exercised Cashless1 Issuance of 614,564 shares of common stock for the cashless exercise of 716,463 Series B Warrants (in shares) Stock Issued During Period, Shares, Warrants Exercised Cashless1 Stock Issued During Period, Value, Stock Options Exercised Exercise of stock options to purchase common stock for cash Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period Exercise of stock options to purchase common stock for cash (in shares) Stock Issued During Period, Shares, Share-based Compensation, Net of Forfeitures, Total Issuance of shares of common stock for the cashless exercise of stock options (in shares) Stock Issued During Period Value Warrants Exercised Cash Exercise of Series B Warrants to purchase common stock for cash @ $2.49 per share Stock issued during period for exercise value of warrants. Stock Issued During Period Shares Warrants Exercised Cash Exercise of Series B Warrants to purchase common stock for cash @ $2.49 per share (in shares) Stock issued during period for exercise value of warrant. Stock Issued During Period Value New Issues 1 Issuance of shares of common stock, net of offering costs 1 Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering. Stock Issued During Period Shares New Issues 1 Issuance of shares of common stock, net of offering costs 1 (in shares) Number of new stock issued during the period. Stock Issued During Period, Value, New Issues Issuance of shares of common stock, net of offering costs Range [Axis] Stock Issued During Period Shares Warrants Exercised Issuance of 871,634 shares of common stock for the cashless exercise of Series A Warrants Number of warrants exercised during the current period. Stock Issued During Period Shares Warrants Exercised1 Issuance of shares of common stock for the cashless exercise of Series B Warrants stock options Number of warrants exercised during the current period1. Warrants Exercise Price Exercise of Series B Warrants to purchase common stock for cash, share price Exercise price of the warrants. Common StockOption Shares Issuance of shares of common stock for the cashless exercise of stock options Common Stock Option Shares Payments of Stock Issuance Costs Issuance of shares of common stock, offering costs StockOptionExercisePrice Exercise of stock option to purchase common stock for cash, share price Exercise price of the option. Sale Of Stock Price Per Shares Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction. Statement Of Cash Flows [Abstract] Net Cash Provided By Used In Operating Activities [Abstract] Cash Flows from Operating Activities Adjustments Noncash Items To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract] Adjustments to reconcile net loss to net cash used in operating activities: Amortization Of Financing Costs Noncash financing costs Inventory Write Down Noncash inventory impairment Impairment of Intangible Assets (Excluding Goodwill), Total Noncash patent impairment Other Noncash Income Noncash other income Gains (Losses) on Extinguishment of Debt, Total Noncash decrease in accounts payable Depreciation, Depletion and Amortization, Nonproduction, Total Depreciation and amortization Share-based Compensation, Total Noncash stock-based compensation Other Noncash Income (Expense), Total Common stock issued for agreement not to compete Issuance of Stock and Warrants for Services or Claims Series B Preferred Stock issued for consulting services Increase Decrease In Operating Capital [Abstract] Changes in operating assets and liabilities (net effects of purchase of businesses in 1988 and 1994): Increase (Decrease) in Receivables, Total Increase in receivables Increase (Decrease) in Inventories, Total Increase in inventory Increase (Decrease) in Prepaid Expense and Other Assets, Total (Increase) decrease in prepaid expenses and other current assets Increase (Decrease) in Accounts Payable and Accrued Liabilities, Total Increase (decrease) in accounts payable and accrued expenses Net Cash Provided by (Used in) Operating Activities, Total Net cash used in operating activities Net Cash Provided By Used In Investing Activities [Abstract] Cash Flows from Investing Activities Payments to Acquire Marketable Securities, Total Change in trading marketable securities Payments to Acquire Property, Plant, and Equipment, Total Capital expenditures Purchase Of Other Assets Purchase of other assets Proceeds from Sale of Property, Plant, and Equipment, Total Proceeds from sale of PP&E Cash Acquired From Acquisition Cash acquired in purchase of FTI Proceeds From Divestiture Of Interest In Consolidated Subsidiaries Proceeds from sale of subsidiary, less $12,345 for operating losses during 1990 phase-out period Proceeds from Divestiture of Businesses, Net of Cash Divested, Total Proceeds from sale of the assets of FTI Payments For Proceeds From Other Investing Activities Increase in net assets held for disposal Net Cash Provided by (Used in) Investing Activities, Total Net cash used in investing activities Net Cash Provided By Used In Financing Activities [Abstract] Cash Flows from Financing Activities Proceeds From Issuance Of Common Stock Proceeds from issuance of common stock, net of offering costs Proceeds from Stock Options Exercised Exercise of stock options & warrants Proceeds From Contributed Capital Proceeds from a shareholder transaction Proceeds From Issuance Of Preferred Stock and Preference Stock Proceeds from issuance of preferred stock Payments For Repurchase Of Common Stock Purchase of treasury stock Proceeds From Notes Payable Proceeds from issuance of notes payable Repayments Of Notes Payable Principal payments on notes payable Net Cash Provided by (Used in) Financing Activities, Total Net cash provided by financing activities Cash and Cash Equivalents, Period Increase (Decrease), Total Net increase in cash and cash equivalents Operating Losses During Phase Out Period From Divestiture Of Interest In Consolidated Subsidiaries Proceeds from sale of subsidiary, operating losses during 1990 phase-out period Operating Losses During Phase-out Period From Divestiture of Interest in Consolidated Subsidiaries EX-101.PRE 10 rprx-20130930_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE EX-101.SCH 11 rprx-20130930.xsd XBRL TAXONOMY EXTENSION SCHEMA 101 - Document - Document And Entity Information link:presentationLink link:definitionLink link:calculationLink 102 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS link:presentationLink link:definitionLink link:calculationLink 103 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) link:presentationLink link:definitionLink link:calculationLink 104 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS link:presentationLink link:definitionLink link:calculationLink 105 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY link:presentationLink link:definitionLink link:calculationLink 106 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Parenthetical) link:presentationLink link:definitionLink link:calculationLink 107 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS link:presentationLink link:definitionLink link:calculationLink 108 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Parenthetical) link:presentationLink link:definitionLink link:calculationLink 109 - Disclosure - Organization, Operations and Liquidity link:presentationLink link:definitionLink link:calculationLink 110 - Disclosure - Patents and Patent Applications link:presentationLink link:definitionLink link:calculationLink 111 - Disclosure - Accrued Expenses link:presentationLink link:definitionLink link:calculationLink 112 - Disclosure - Loss Per Share link:presentationLink link:definitionLink link:calculationLink 113 - Disclosure - Commitments and Contingencies link:presentationLink link:definitionLink link:calculationLink 114 - Disclosure - Organization, Operations and Liquidity (Tables) link:presentationLink link:definitionLink link:calculationLink 115 - Disclosure - Accrued Expenses (Tables) link:presentationLink link:definitionLink link:calculationLink 116 - Disclosure - Loss Per Share (Tables) link:presentationLink link:definitionLink link:calculationLink 117 - Disclosure - Organization, Operations and Liquidity (Product Development Pipeline) (Details) link:presentationLink link:definitionLink link:calculationLink 118 - Disclosure - Organization, Operations and Liquidity (Additional Information) (Details) link:presentationLink link:definitionLink link:calculationLink 119 - Disclosure - Patents and Patent Applications (Additional Information) (Details) link:presentationLink link:definitionLink link:calculationLink 120 - Disclosure - Accrued Expenses (Details) link:presentationLink link:definitionLink link:calculationLink 121 - Disclosure - Loss Per Share (Calculation of Loss Per Share) (Details) link:presentationLink link:definitionLink link:calculationLink 122 - Disclosure - Loss Per Share (Additional Information) (Details) link:presentationLink link:definitionLink link:calculationLink 123 - Disclosure - Commitments and Contingencies (Additional Information) (Details) link:presentationLink link:definitionLink link:calculationLink XML 12 R17.htm IDEA: XBRL DOCUMENT

Organization, Operations and Liquidity (Product Development Pipeline) (Details)	9 Months Ended
	Sep. 30, 2013
Androxal [Member] \| Secondary Hypogonadism [Member]
Product Information [Line Items]
Status	Phase 3
Next Expected Milestone(s)	Complete DEXA study (Q4 2014) pending FDA guidance
Proellex [Member] \| Uterine Fibroids 1 [Member]
Product Information [Line Items]
Status	Phase 2B (vaginal)
Next Expected Milestone(s)	Initiate a Phase 2B study (vaginal delivery) (Q1 2014)
Proellex [Member] \| Uterine Fibroids 2 [Member]
Product Information [Line Items]
Status	Phase 2 (oral)
Next Expected Milestone(s)	Lift full clinical hold and initiate efficacy study (low dose oral) (Q1 2014)
Proellex [Member] \| Endometriosis [Member]
Product Information [Line Items]
Status	Phase 2
Next Expected Milestone(s)	Complete Phase 2 study (oral delivery) (Q3 2014)

EXCEL 13 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0`!@`(````(0":BN0#M@$``$X0```3``@"6T-O;G1E;G1?5'EP97-= M+GAM;""B!`(HH``"```````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M``````````````````````````````````````#,F%U/@S`4AN]-_`^DMP9* M4>#T;*N M@@486RJ9$A;%)`"9*5'*:4H^)B]AGP36<2EXI22D9`66C(:7%X/)2H,-?+6T M*2FFYL[?FBG5/)OQ*=`DCGLT4]*!=*%K>I#AX`ER M/J]<\+STC]2KA1B'QEN\86I;97'H/0 M3H5FYG>!3=V;WQI3"@C&W+A77GL,NJSHES*S3Z5FT>$F'90JS\L,A,KFM=^! MR&H#7-@"P-55U(Y1S4NYY3Z@WRZVM!W8F4&:]VL;G\B1(.&X1L)Q@X3C%@E' M#PG''1*./A*.>R0<+,8"@L51&19+95@\E6$Q58;%51D66V58?)5A,5:&Q5D3 M+,Z:8''6!(NS)O_EK,ZG-:#M]>\?I6US)"Y8MZK`GOD7OVYZ3+G@!L2[,S[7 MGAW@9^]#'#[UC8W2UN=?`Z?OPC;@-M6A]HW`N!)V$;]=J>*V?5@^@8B)G:13'&HX<85?=WFQ?>*24FV+7 M^ZBRBXL:NI3\(V(T'4\4"_'L)MI<3_3_MCAQ(DN)T$C@\SS?BG-`Z^N!+I]HJ?B]SCSBIX3A363X M8<'%#U1?````__\#`%!+`P04``8`"````"$`C`BHSJ(!``#W#@``&@`(`7AL M+U]R96QS+W=O"%2J_/'JE**O-9]=F[\JZQNB52M]^).KF]YE(8MV.:N][Q\X M=T6M.NE&IE3?'6*>VO7,$_C#VX6BD?DDI;*9^S&'+\]&0Q"HH9ORX&)L1J M8(+*H88#*!TQ3TG'U=*J\L7;8$4WU.LBC,&A+A5:*0$IT43/#EABZ&QC`1B; M>V(U]Y@8$,1J0*!RJ.$`2D?,4M)Q_MB&"1ZGW_<9PT%='+PV22=,[)F!1PR= MVPCF*)OPMB1].8DQ)H=ZQJ`CAKI2:*&`'`W*1DQ3^L:'94L-%CX=^>D7%9%T MKL2^&73$T+F59JAUJ=4`*D=0+P\"W1Z`>LX`/F>6*>T;??*[=6")>2=I,_U# MS1030XT&)0/4:`!E(\AWB;A,\(O/U?47````__\#`%!+`P04``8`"````"$` M\9DE*<`"```?"```#P```'AL+W=O\Z3"8JY7+5=__&C[^N7<=8*E,JE&1]]YT9]W[P\\?=1NFW M5Z7>'`"0IN]FUA:WGF>2C.74G*F"27BS5#JG%I9ZY9E",YJ:C#&;"R_T_4LO MIURZ-<*M_@J&6BYYPD8J6>=,VAI$,T$MT#<9+XP[N%MRP9YK10XMBAG-@?=6 MN(Z@QHY3;EG:=R]@J39L[X%>%P]K+N#M3<_ON=Z@$?FDG90MZ5K8&.3MT,&O M\#P,+\LO2RN>.=N8=E.Y=+8O7*9J4WX*UKXWJQX0V%2O7GAJ,WCO^W[S[#?C MJ\SN'@*\A_`K!^$_U=61E;R=(R22*1E+R^T[F@JD, M_P*;10RD_F`VF,SY$3*MDL^]LWA!YH]D$<\1EQ#<;ZRY^!X,UG2)8*IH?%T3 MAKE",%='V!PKU*>\$*F"]FU$71_"S/6*2OY1=0^9%TS7?42@W`MS M[WO0NXV-02>IIWW$ M5>W!H@7JA/70`1+35['/!(K;`G1BNF_$D>VXXX)./$\+P;D*]DK9">AI("#1 MC@#SA:T-]DK="6G'VA&SE`L#JE(UO7)0]22 M($DA+C(L3N-$*1Q)<'Q144ULC(-K'7XOO'M\<-'#*KU>Y3\<(@FH@-.MO)3' M0R7:VYWM@_\```#__P,`4$L#!!0`!@`(````(0"/)[B0/@8``/4;```8```` M>&PO=V]R:W-H965T&ULE%G;CJ,X$'U?:?\!\=X)-N&2J-.C M(<#N2+/2:K679YJ0#IH0(J"G9_Y^R]C!5(5VZ)=TAW-<^)PJFPI^_/2C.EG? MBZ8MZ_/69@O'MHIS7N_+\\O6_N?O]"&TK;;+SOOL5)^+K?VS:.U/3[_^\OA6 M-]_:8U%T%D0XMUO[V'67S7+9YL>BRMI%?2G.@!SJILHZ^-J\+-M+4V3[?E!U M6G+'\9=55IYM&6'3S(E1'PYE7L1U_EH5YTX&:8I3UL'\VV-Y::_1JGQ.N"IK MOKU>'O*ZND"(Y_)4=C_[H+95Y9LO+^>ZR9Y/H/L'6V7Y-7;_Y29\5>9-W=:' M;@'AEG*BMYK7R_42(CT][DM0(&RWFN*PM3^S3_GTV!OT;UF\M:/_K?98 MO_W6E/NOY;D`MR%/(@//=?U-4+_LQ248O+P9G?89^+.Q]L4A>SUU?]5OOQ?E MR[&#='N@2`C;['_&19N#HQ!F(:>1UR>8`'Q:52E*`QS)?O1_W\I]=]S:KK_P M`L=E0+>>B[9+2Q'2MO+7MJNK_R2)B4D-0;@*`B-4$,87//28YW\@BJ^BP-]K ME&#N5)925N]2G'79TV-3OUE0>C#Q]I*)0F8;"'RU1XH9#'O/+]`H@GP64?I8 M8$4+2?[^Y#N/R^^0EUQ1(DD);$M3.*;LKA1AG0@;7R_H,0P/2:Z,ZY!47H!/ M?1MW&+,$T8-R2`I5[D)Y31?&5:@81(22*46W%*KSEN&OACE*Y;<4$B2Y9=`@ MZ2U%!T%6N-@*LP6"#*M@[+"'9Q])RFI$(8S=749\EY'<9:0F!C(`ICJN!;,! M@KRUP5Q=8CXQ0%+"?B60A;`S8+$!2PQ8.L9X&'C:;B03]I_Y,@69R`R(3$E9 M3#1,(N-E^D(!.1(1$I*=,B#5ALP!(#EDK,[TUEG*V' MZ2"5L)'.5RG(1*4.VV\XD:1(E7K#[+'=&".[73S&R"I(QA@9ETI,J?1=1[N. M9(HV;/1X,B],0<8R`[+X(DF93J8!BPU88L#2,<:<=[;?]4=$"C(12;R-)&5: MI`&+#5ABP%*)J5PZCBX?E$H&#]?YN>S91*>V3]:LXDP7+0*)0S$":=DBD(Q, M%2C%KD*'Z2+E05QD")[U.2 M^Y342,$^B"9DO@^R91D_6P-ML/)!2%9(;'X?0O/"#F>.UY(RB1!!.8P M3B*DB,#]-?/T(L'B1;^`['N0`V1V$1OW3:2!V9G`V`0F)C!5H"R9 M!Q;R]]2*AF:D5KPON/^KFC M<"L7ZNU$KGK%F"#`1B88QQ>(%/"`DF.`M?K^Y^"JDB3#?+6#[IXV:6O>S5X'/HU^F# M..*2,SV'?IJ[^Y3X/B6Y3TF-%.R'Z,5&&^*=G+/+\H"J:EV)7G$ZME=>OX@2% MPV(>KLK3G8AMX*T^O)PGUV.V@5?W<'TY`'#HBC^RYJ4\M]:I.$!(9Q'` MK!IY;"._=/6E?P'_7'=PW-+_>X3CM0+."YP%D`]UW5V_B!L,!W9/_P,``/__ M`P!02P,$%``&``@````A`'FXU=<<`P``M`@``!D```!X;"]W;W)K&ULE%;;CILP$'VOU']`O"^W`$E0DM7F0ENIE:JJEV<'3+`6 M,+*=S>[?=XP#Q*9=[;Y`\)PYS)F9S+"Z?ZXKZPDS3FBSMGW'LRW<9#0GS6EM M__J9WBULBPO4Y*BB#5[;+YC;]YN/'U87RAYYB;&P@*'A:[L4HDUQ M$\V]F0]PZXBY2(FDM*WLS`6M_RB0+X,:2((K"7A<2?S`"1:1'\7O8(FO+'#O M6>9O#<55LKHL[9%`FQ6C%PLZ#P+G+9)]["=`W*='B1D2]K]\@49)\B!9.BY( M!8<:/VV">+ERGZ`PV16S59BY;0V8.-`ANQXBT;NDZ@"N MXVMF@X\+J@?I4!53^@SZZ]^=T2N53KK2V`AI.X68.J>(.!QB5,JG$(/D,$68 M).D4,I)HJ9CIJ7@]!1*\MH%[R/!BS'`7_59!%ETGW$7+Y4)7M]/L863Z[S5[ MX$5SHYD.&L#W_,"((-4`PZ1+L"X]"")=VU9A8O4OF,&PU^V[ M6[L?A<%8$E7Y6[O<%8;_X=;NA_/0L*?*#M>A/&.$FG*81K?]_WK1)=A4;KQY MJS!+5768IX9]9]B-DNTU,VQDPW[0[)YC#AC8(C+$UX2K+:'F7XW9">]P57$K MHV>Y`0((?#A5RVGK)S"48+88YWL_@P?%]."0E!(55#U=U*N])JM8=K!PQ8!8QL MIVG??L=VRJE5-[UI@^?WSS^+B05:4*@0.K4QPI507NZ[,*MH0Z?".MA`I MN&B(@D=1NK(3E.1F4U.[@>>MW(:P%EN'6%SBP8N"9?269\>&MLJ:"%H3!?RR M8IU\<6NR2^P:(AZ.W57&FPXL#JQFZMF88M1D\7W93]Y"])]N)M'E[9 M-RP37/)".6#G6M#7.6_`;/TXC[.ZVICY_&#W)T6\D M*W[Z(EC^C;44B@UMT@TXY7H+-[JO==Z8!/P3*:4&.M?K)3U\I*RL% MW0XA(9U7G#_?4IE!0<'&"4+ME/$:`.`O:I@^&5`0\F3^GUBNJ@0O5DZX]A8^ MR-&!2G7'M"5&V5$JWORU(O]L94V"L\D"Z,_QP`FBT`]7_W=Q+9%)\)8HLML* M?D)P:."=LB/Z"/HQ.+^=$:2BM3=:;+8`K(0N/.Z"U7KK/D+ILK-F;S5KC`;- M5)&^H8AZB0M($0[I#=_Q@^N:]U42FOWXX MBZ;C:+`(*T^@J3%9&T>$ZTZGTMD=58(M_SI]%T'-T,P0F2OJ\N MG@9:/$7:#)E:(BNQ1VD1S8LTCH;A\(E8)#N-[;!JJ"AI2NM:HHP?]:0-X"CT MJ_82V/OQ/M#?]&P]AGG0%TA_K^_^`0``__\#`%!+`P04``8`"``` M`"$`YPJXALP"``#="```&0```'AL+W=OJ,E+RF M"7ZC$M\O/G^:'[C8R8)2A4"AE@DNE&IFOB_3@E9$>KRA-5S)N:B(@J78^K(1 ME&0FJ"K]*`ABOR*LQE9A)MZCP?.^0J M(G;[YB[E50,2&U8R]69$,:K2V=.VYH)L2LC[-1R2]*1M%A?R%4L%ESQ7'LCY MUNAESE-_ZH/28IXQR$"7'0F:)_@AG*VFV%_,37U^,WJ0K=](%OSP1;#L&ZLI M%!O:I!NPX7RGT:=,_P7!_D7THVG`=X$RFI-]J7[PPU?*MH6";H\@(9W7+'M; M4YE"04'&BT9:*>4E&(!/5#$]&5`0\FJ^#RQ318('L3<:!X,0<+2A4CTR+8E1 MNI>*5W\L%!ZEK$AT%!F`^^/UR(LFHW`4WU;QK2.3X)HHLI@+?D`P-'!/V1`] M@N$,E'5FPW]F!BGIF`<=9$*!EM"-ET441W/_!4J8'IGE%<8E5E>(R1GQP=_9 M)*3>-3F`)EXO_\FD#H)"8]0R.3CKFT26EAFVF)%+K/H(QR/N@Z5E)K;,X\$P"`*76#E$&(=MPO$(B;8]]M=/PUUOG>HL+=-7OS["\09# MU_:F!_%VCW70K1Y;IL]C'^%XC#_B40=UZ]CML65BT^-P',7M#II)75GB>A:. MQ['KL;_'&NYZB]WI6EKF^IVMMS["\::/P\YF<[O'.NA6CRW3Y[&/<#Q./^)1 M!W7KV.VQ9>QS#(_HY++'EKB>A?5H3RB[@3=D2Y^)V+):HI+F\+P$WAA&6=CS MR2X4;\Q&O>$*SA7SLX#7"`J[>.`!G'.N3@M]`IY?3!9_`0``__\#`%!+`P04 M``8`"````"$`!#^T(OH#``"]#@``&0```'AL+W=O_/ MKP)=R.B_1$[XDK1%_JVH$9@-::()V&/\0M&O.0W!8'4V.NX3\*.5BKP[ M;6334>R59NJ`2WM$NKB@DK*4G4F'J]\,TJ]23,2XBI@P^^MU4UGIFF>N'A>Q MKB(PXB9B*(9KZ[;SB:DX5Q4X?JA8AKUR/[.@U54%CC<54W%MVW)<\8I49G&? ML3#MTNVZQ1<)=@&82)J4[BG=!V6:*A,2SHP=DO>GW$'2J,@S5=G(,!Z&$ZBW MUZUAFVOU%8HDNS*[.\R4".X0[A0)YXAC39%HCA@VQ\3W&'NJDS`&?D=K<@9& M!?\&$Z'6QB;>K_.;5Q2F7M&ZI^;M^$#`!T(^$/&!F`\D+#"=_>K^[&&'/#Y[ M"D.)C%VQM$&7+8@QL'<&YSAO`R$1"HE(2,1"(EDB)AF&Q8P]NFV3Y4S301L9 M,C'X8'VD@%G%$+??,D^&J5FNKFFJNX[YDPE&B.6 M[=@S(F:$U4^%FV9RNW8O"Q-_X%TP]N>Q@J*#ICX9-O>$W#&&&652"_A*"1BQ M4"FAD(B$1"PDDB5BXA6\5S[O%1W$>^5Q#RK&+#@1"(E02$1"(A82"2-85BW: M!XVR.O&*MM"C]_GROJ,PYY'#5?2.,4L>"8F0$5Z_8VQ%XQZ"D5`@%A()(]B# M5/_(\\0;[S/>4)CW1N?JAS%+W@B)4$A$0B(6$M#MT]4P>U8.?7C."HBU\ZPY MK%![1`$J2R)E^$Q;=5IZ0W3XBG@V:!O#Q7>Z#SW-/![H/K0V\WBH^]#AS..1 M[D.C,X_'N@_]#L35X<;P]="D1_0];8]%3:02'6#*FD+[XI9]?["3#C=]R[O' M'7PW]']/\)F(H`W3%(`/&'>W$WJ#X<-S^S\```#__P,`4$L#!!0`!@`(```` M(0#NY:'';`,```P+```9````>&PO=V]R:W-H965TA1"%3DZK;I$V:IGU<.V""5<#(=IKVW^\<3`B0E62] M2`.\?O.<#YNS^OA2E<8S%9+Q.C%=RS$-6J<\8_4^,7_]?/QP9QI2D3HC):]I M8KY2:7YULV M@I*L7525MN'BM9*FPA:$@7\LF"-/+E5Z2UV M%1%/A^9#RJL&+':L9.JU-36-*EU^V==[UJ$_2;T:,& MEJ:1'J3BU1\M)U)C[0=\\]R[L+W7!QW<761&V`#T21]4KPHP%=`[\I M&X(]Z"[!^129YNAC?2M4B!%-[M$E,2/3@"@DU.=Y[47.RGZ&G*:=9G.I<<>* M[4F!I0"\GA$B'S+^.^LG%!0C"E8!V3;Z!GB?V2:_>ZE8!+UD1`(9&I)@MGSH MIGDB7`2Z(4`T"7VC-<%`$_8$;1C;.<6($4RFC,&;O7K*&BY*3$C$.4F1-R;8 M:,VB+:\?1V'@3TJ\'2I";Q%X3M1[C!B!9\@XGS\43]G\WE<766O@]WO^:?[F M%".VQ9CMMAKCHFLUUIHYQCG%B!%VVC!_R'B]QKAHFL=IC;5&U_@NBES_7$#= MAD.!&P7Q<)^/$/'=-SA8YDN,XBG:>0OJ$FM-T+:?8SF3';1]\_&(*OX?*A1/ MJ29MM=&:N:+.*49L+IPDPY3=UGGMJFNMUXGF,&EO:W[7'VZSQ\Q MG:CK/]=QG7B\T;9\!\+X<%GL:0MV(MV#GA7$SO!O MLI=P(D'+JVI-K8$UZE@@ MSCE7IPM\2?=S[/HO````__\#`%!+`P04``8`"````"$`FMA**L@"``#N"``` M&0```'AL+W=O[DE MA"0*J5I5W:VT*ZU6>WEVP`2K@)'M-.W?[]B3DD"JE.X+Q.',.3-GS)C5]7-= MD2>NM)!-2D,OH(0WFJ2 MWWRF^A2[K\HD7\3#0>WH4^V`QLI'RWT(;=_ M0;!_%GWO.O!#D9P7;%>9GW+_E8MM::#=,51D"UOF+W=<9^`HT'A1;)DR64$" M<"6UL%L#'&'/[KX7N2E3.IEY<1),0H"3#=?F7EA*2K*=-K+^BZ#P0(4DT8$$ M[@>2,/*B>1S&L_=9?,S(%7C'#%NOE-P3V#6@J5MF]V"X!&9;V03\>;LR*,G& MW-@@%PIH#>UX6D?);.4_@879`7/[!J9#^"#>90"JIQE<5K;@E,+U1#GI>%UV MMXB9GF#B#M%3GO25Q]5N@\"C$_8HF7?\F`%B1F0`D/&U6_"P]L5`&3%3UY-C M5KVJ8<>-U[3@@>8\&&@B!C6GW;.>YNPCFA8\U`P[7G08,2,<3OK*XWIL@][K M,6)&9&`/@9,W[/+^MN!![F;'/!]`(F\/_FV0XIBZ_SHXZI6.2^-`P@R/KS/BS;A]`Z/S1 M'C0>3RP&PO=&AE;64O=&AE;64Q+GAM;.Q93V_;-A2_#]AW('1O;2>V&P=U MBMBQFZU-&\1NAQYIF9984Z)`TDE]&]KC@`'#NF&7`;OM,&PKT`*[=)\F6X>M M`_H5]DA*LAC+2](&&];5AT0B?WS_W^,C=?7:@XBA0R(DY7';JUVN>HC$/A_3 M.&A[=X;]2QL>D@K'8\QX3-K>G$COVM;[[UW%FRHD$4&P/I:;N.V%2B6;E8KT M81C+RSPA,S*A/D%#3=+; MRHCW&+S&2NH!GXF!)DV<%08[GM8T0LYEEPETB%G;`SYC?C0D#Y2'&)8*)MI> MU?R\RM;5"MY,%S&U8FUA7=_\TG7I@O%TS?`4P2AG6NO76U=VJ^>?__J^5/T MZOF3XX?/CA_^=/SHT?'#'RTM9^$NCH/BPI???O;GUQ^C/YY^\_+Q%^5X6<3_ M^L,GO_S\>3D0,F@AT8LOG_SV[,F+KS[]_;O')?!M@4=%^)!&1*);Y`@=\`AT M,X9Q)2"M.69EN`YQC7=70/$H`UZ?W7=D'81B MIF@)YQMAY`#W.&<=+DH-<$/S*EAX.(N#UO5D"53,+ M2L?VW9`X8NXS'"LY1ZMAUC_J"2SY1Z!Y%'4Q+33*D(R>0 M%HMV:01^F9?I#*YV;+-W%W4X*]-ZAQRZ2$@(S$J$'Q+FF/$ZGBD".S1P1%H$B)Z9B1)?7B?-AOZ'&(KA\1J MCX_M\+H>SHX;.1DC56#.M!FC=4W@K,S6KZ1$0;?785;30IV96\V(9HJBPRU7 M69O8G,O!Y+EJ,)A;$SH;!/T06+D)QW[-&LX[F)&QMKOU4>86XX6+=)$,\9BD M/M)Z+_NH9IR4Q>Q,O91&\ M\!)0.YF.+"XF)XO14=MK-=8:'O)QTO8F<%2&QR@!KTO=3&(6P'V3KX0-^U.3 MV63YPINM3#$W"6IP^V'MOJ2P4P<2(=4.EJ$-#3.5A@"+-2[\JIB4OR!5BF'\/U-%[R=P!;$^UA[PX7988*0SI>UQH4(.52@) MJ=\7T#B8V@'1`E>\,`U!!7?4YK\@A_J_S3E+PZ0UG"35`0V0H+`?J5`0L@]E MR43?*<1JZ=YE2;*4D(FH@K@RL6*/R"%A0UT#FWIO]U`(H6ZJ25H&#.YD_+GO M:0:-`MWD%//-J63YWFMSX)_N?&PR@U)N'38-36;_7,2\/5CLJG:]69[MO45% M],2BS:IG60',"EM!*TW[UQ3AG%NMK5A+&J\U,N'`B\L:PV#>$"5PD83T']C_ MJ/"9_>"A-]0A/X#:BN#[A28&80-1?F#R`Y+</B'W33Y*4-S->3CV?&8SOK+Z]UY;WPMBM%L_')+/0]WA1B5S:' MC?_?OP]WB>]U?=[L\DHT?.._\<[_LOW]M_59M$_=D?/>`P]-M_&/?7]:!4%7 M''F==S-QX@U8]J*M\QX>VT/0G5J>[X9!=170,(R#.B\;'SVLVFM\B/V^+/B] M*)YKWO3HI.55W@-_=RQ/W;NWNKC&79VW3\^GNT+4)W#Q6%9E_S8X];VZ6'T[ M-*+-'RN8]RMA>?'N>WB8N*_+HA6=V/E?"#&38O9;O M-_Y7LLHH]8/M>@C0CY*?.^.SUQW%^8^VW/U5-ARB#7F2&7@4XDE*O^WD*Q@< M3$8_#!GXN_5V?)\_5_T_XOPG+P_''M(]AQG)B:UV;_>\*R"BX&9&Y])3(2H` M@+]>7:K'#0,!74'Z7C9TG@=O$`$"R5)4;+P/2VQ%=D'BF24!(`W,L+,;V>4 M@QS&Q>A^F$:*DL4093FOS'AA`4!@3(#+P9%B"*(Y\Z7SQ2AAAF1N*[)+"@L- MG%R/)L4;'V8Y)B4*[2].49(,24U(0G5*AIAEIITR2N@XWL*"LC:QKBLK.7938>$Z7OYQ+@IW9:A-.`:5*H[*94*?#998]HDRW M&1M,=MRKBXQ@?[;`]&I2<4,-UGV4Z'P-YDRY0/-\KD?;6++]7H^%S=K"`F)HPF< M*0!\XUQ@H\F^?G/G@TNA>P1@NGH4(FK4D?>#,X!R@H*/#@%X;\1K5(9[EG9#"R7!\B_?5E*S2X;KJO,_D/7:XB8X&N$:>\@/_GK>'LNF\BN_! M93A;0+-J\2**#[TX#;>=1]'#!7+X>(0?##A<:\(9B/="].\/\JH[_@2Q_1\` M`/__`P!02P,$%``&``@````A`+OV)@CK`@``)`D``!@```!X;"]W;W)KF]EZID(RW$X3]$'FTS7G! MVN4$_?[U>'.+/*E(6Y":MW2"WJE$=]//G\9K+EYD1:GRP*&5$U0IU8V"0.85 M;8CT>4=;&"FY:(B"2[$,9"1N,2#ER7+Z0//5PUM ME341M"8*^&7%.KEU:_)+[!HB7E;=3XW M/"3YUMM<'-@W+!=<\E+Y8!=8T,.:LR`+P&DZ+AA4H&/W!"TGZ!Z/YCA$P71L M`OK#Z%KN??=DQ==?!2N>64LA;5@GO0(+SE^T]*G0/\'DX&#VHUF!'\(K:$E6 MM?K)U]\H6U8*ECN&BG1AH^+]@0F94,#9H+ M=7RLAP-;_/*DM-C!&?9SF%G)<9SC8SV+P(_<>7'8-G!8[D'H@[CD7&TO=!_=/=],_P$``/__`P!02P,$ M%``&``@````A``=R[*@Z'@``/%\``!0```!X;"]S:&%R9613=')I;F=S+GAM M;,12=!L!WG M6:0^Z30+D_CM1G=[9T/I>)2,P_CV[<;'ZY.MUQLJRX-X'$1)K-]N+'2V\=MW M__HO;[(L5Y@;9V\WIGD^_^[ERVPTU;,@VT[F.L:;29+.@AQ_IKW7CW)@O?O[Z[\\3SYMJYWN\I7=GZP?_81_G'LO93Z+@UG_[?!)$66NAA3L.$&!NKHR!?/>XDS$9! MI/ZD@U2=`-=9:Y]EN"JWL=/M;LL7^*&%ZNLT().IJ\7L)HE:.UX.+__H/[2D M'R2S61*KJSP9_=Q15],@U9FZ*')A4RRY8MJEO@VS/`W`1^?!K(6-YY?'P\N+ M*W7]_?%E?WC\\?IT<*5.SP?;*Y8;@"%38.T43/99_4$O_''/=_"_UX<'.P?[ M_JM!D:;DYSKB5U'I^=96M[>UV_77L,@X"2.=J@'(>YND;1CZHY'&`+P>8S?\ M\I<97)P?'9]?'1\I_+JZ.#L]ZE_CC_?]L_[YX%A=?7]\?'VE-C]>':EG+_S) MI[&ZGB9%!O60=2"_D13G=Z%F5;97(_"2=B6P2,]@@P:,>OYBSKD]+-, MYRU6'`395&$_->(/_9ZM;I0%?JR4S- M@T5P$[6X&>_3`B"ZT_OP-0\9K=Z(PA;FU$`&@R.H5L@8;`2@4IMQDFNUWV*, MYP_W#_?^GB*PTR0:P]H\5\<@7=YBV(^0IBR\C85A0<*)AJ2,G:P_V][9Z>+( MJ0+1"]U1^QW(&/]1F5$#09%/DS3\JQZ#+#!8*LPRXD&(OUI%-%5*:YN#M?OT M=CO=7K=SN'_(7;H'G=Y!K[._L^]@,B!T%-04!"(//^EH(0!AXL[.8>?5SJ'\ MB9G=5SN=[GXY,ZD@;D[W4=L?C\$F20S&)=-OA3'D8QZ"D?V1@P1V.YFH'`8Y M*](%C+NHT6ZWU]G==WCT9QWI23@*,O.)FFP(*C,PR#/#JLQ@W^V";_KH2U.>Q10)<.7P[LTJ%K`+[VV,_`TCK6'X'(;IXD1=#&&PKT]AO581LVFF].>1GN?&;U#C(`^^Q'+MKO4M=[OK MW]=]SY;=NX00Q45;U9^%(Q@PBMI$M]\.TV1TN_@M2LX7^,PFR<9U`U4R:1F#'T*&CMXNG0M M(^JI/;91T6(VEV]];`VYO\6J`_KC?J=C.$*1[!.,9V$LWB#5L3_2`&WW\U\: MJ%?9U;,$'M`D36:(;&@H"](-`1$\,*CG%K:KX4"HG0%KM7K",OPOG^K#?:YS M%1&Z&XW(2V4?FZ`<)P,$L/8&CRA,XJGD" M5\L\@?>(PN*8;/4^B()XI%60JWH\T`ITVC,V04UC,%X\.EL.0>X1L2*U(9DS MA@1">O]XIW`7!2H(0[=R*RD:)NH43X2[!I8U(1TX!`8\V]_>.5`UV-:M;6VO MMZZ$$EPK@42*=S6"NP8WNSJPO^CQ9YV.&&QAEH$MF8NJ47FBY@44/X[>!![B M+]'3K[C4.@CK*%U^;$6(Z$.U2ECEB'H%]E@U^&ME7/O5=5=K=AWSKP^ZG5>[>\XL>:*_7@9>(Z+L[N[B M<,+6_9*M?51^\PV?RA"ONGN=_5=?=]J#[JO.WJORM)40KSOM-]EPW6D]-O18 M;]>'U1ON<5&=:UM3O]C%>%J,^VOQRA!"/Z6B4/6!2`VAC-Z(C3):[K'P6VJM218 MXR2G',HB[:)>J?"\O*1+A(OSCTQ$@601J)'I]!/BEQ9+#"01D#%NKM%9ZB5R MY'J"=I.L87((J/Y,JJ@#OV\*9*Y0%8(OCJ6ZAZ]?R_3NX>'>BQ:S($U4$@$8 MUBCMH+31@JT^K&08GTLVW:@7R$Y7RX)R7U<5VC@&6W%%S M1LM;R%LS"$3M_&G[,70UIR?[+P&S9!Z*Z)$'X!5WD.FA.CJSH;D_KPF$#:_8LI% MY%]D;&!GVNT>S6EUV"'LMGXHZK2U7XV%F^6PUL@&$]>WB%'_+(6_/2UDXE2* M<@M30D7Z:>V4DN+S-/D4HGU%W2QJQG,UU3D1NY7Z4_3+4^KD1N26%-093-^4 MV3HP]G*16#M?L^:^N$7Z0"+M+;(+;&OJ,NC&<& M@RJ:_PP=3-`\[;)F<]8`XY,H1/&)^4A2"=8Z@S=C'E")&*$%ZR"+BN8BO,O4 MG_LW;&`9Y2V_]/SB^EAU'^[5/__VW_AW<[>GPG@)OR;)T-$!9W.N"Q1(,W2W MH%-CDPKNGW_['_@F\R!>_/-O_]OAGVS1Z>`/^2USY2\X*WAYI]VK(N,8\S0I M4OSQ`BH`GH)!)/.RL>H7MW!!T9/5H9-PL*U^A$I%E2)HUY;539A`3Z.Y;"1` M`D?TA0`8="F:E\R"!+E>[0).8WVGQFEQF]%]HL#G"KT":"6R12&X!J:8QII( MMLB`=M:YDI0-"ZTVH(LB964$!G6!_YHBW`BD)%71F="/QVGR.8@>_M&!Z\5L M,=PM&#^L-T/(`W!&43(+YU-4I11*ZVS1$4[@8#A=J%2Q2X">M>;ZV`IVF_7Z M&=ZH61+!?&,]'AV%FO$VR&YQ9H\MX4()A=@9L!%W;AR4E9*[,)_"T;]34&8Y M,LXZ9>M$Q%Q^QH6KPQB\`8-`+W;5:;3@/C,]@L,89C.\`%I'`+>7(+1`.=,SDE2XRH0F70AB!D)!N'K,>D:E+$HN?-B1[NIZCGR#$CS>I. M?H>\=OA)FG3@=***/UH\W`\ES;V+%'@Q9N*7;FX-:L*!*BFF"]`@QQ5[D[#Q M,$W0`)%$JD]G(!,/>Q/\>S7LDU,!1%.KIVQ(Q"0=1?HSB0N6;M-?]I^@&Q(4 M:F![JE&EG5J6($.R9Y*=".BZE+Y&P1_(#BX0KD'WEN&!FPA]&H9SB'RPQ"UP M:"A%9WD.?#H&NM$DBN4#'-KEUX7IY8C@@FPQPYP9-\H2AC,8*(R`ZAIJ#QIF MYR9-0KANX&J`-P;CYG"*LE!X`LQ&WC-$"81[Q@D"*%(`X1OJ;>1H-`YV*6YC M#3FC\L*S&_B+*@LF&FV<7%KZ?2()'1Q!93[XD6*@N*R\K=!N#AHK]&M*H,Y] M>NJ.X1L\6CE*H`Q/]"J(B+<&"EJ'JJIDT:)C"`^"\_]#_"O[*_N.T"6[L_'R MW1LP#3".-6=HB^WR27J"FJ\90'^Z_ MKVED?R,1G(?[7?_YP,K[P_W1\1_[#_?";3C1#WL/]V"C/9P'A57&F0_W)T<8 M<`MGB(&$OU`ER/Z;CT;W8+Y5/OX`"UOO/?:U0M`ZYJE5`@_W@;4,@`\3'+QV MWL/]&'1%L\`"@&_^`/=)#K%J1XRA.FKM=A9.0(!)$44/]R/P";4YK!;Z'+%_ MC'\YG?1P[]1;!0JX!F!`P3WQ^GT!>>SMFT;]#I5EW1C-BYL(W2)EMA>P M['5VD038;Y3T"1^FL9E<`D1&/`$L*POZ\.MM'0"3GW4/T7E*+:AZ+=+>@7W2&UHN'L_AW'1-N6&*P2'M<]1,#IY,ZQ)!+/0"$, MQ+.#5]NO%6P%L!@O]S_Z8@Y1,X*+BC1U>9U!$#$-T`)3Z\ZP:0X>H[>[L[WO ME@;@S7U?=ZM]J=U6AI"8R;@.V+-=0F4$+"_PL-%[O/20N]L]!XAQ]L%7C)7A M'X@+)+2Q?=J1BZK@G\#WO8&34=#S"\EQ($+%E#!P=-!WS^F_IDEQ.Q4- M?G[4AUF$Y*)3"QE+>B>.1:W7_XB52F]OWFZ8?=A^)JPJ%$ M;YUDD*R1='JQ01W(M^0DR4P40S:R!)$-K4O]894%>`Y"1(:%?`*"WR!VNT.` MDG9(0T")V(N<$2?T9PNDBR#$QIF69C;(BACJ1XZPJ+$8KDYD4$*,PRKE(BX? M],27\"XBFHJ MGU[G8'=/.OE%\TCONKA95`D0]5[)?JAFI2%+`;;!N+R^R)%Q8##=]OG:Q81E, M5N2G!E@5<7P#;5/CMBO>5M5(&-#F(9M"P3.^K8)L9,NG M2RQ[FU!=8,F13F,16Q".3H0\-LV(3R;Y+%@(A!!YUBNA""C>,(#3$+W.=W(( M!%,HMF\2^0[)&B&%(OG MWC\N6O"SK&CY?.>6JY!V(A`T6XG'@R%=,Z35+M4\?.TVHO5YX39ME7M!3V(Z^NI3(AL))C,HAIY% MY28J$$%05_$0ACIE-4"6P%NA34E&`.KST37F5B)G/)XY,A@1TDA>KB'Z M'?B5S%;6MC%&.6LW!%S+OA^XG;W-+?O(_6W_Z.>$[(E#P>:4&G^)/JW(K6!? M8D++XM4E/'^"$2ZZ`,LIY(\?.A9L\@V$:+=SB$N&>[L[@K7]3N_57J>'=G(G M7`84B2P-JYN`U?5Z$P175BVI9EGV<0(U[Q9:M@25#$O*;18R97`#,ULR"RM7 M`'SYP>&)2PV`S`R76H+]A*.LF*2X9W7!RL"[NJYKP]P MDW+WH*:CQ%OW(_T8G,B8`TEKHUIPG&<[V[AA2G3:+:KFT^8675S4W#G\JBVD MR=RV]D#>3_1-BG3L@IG8[EZ:IPNR')?Q*JAB$N27 MH*:+OM_#SEZO^VLB1Q(]7>L@5S[#`#2MWTX>2'K*WD[VI6_MX*<$1N*,G;/4 MNN^L+_Y;6];L2.?=^N_?+H>^PDM[,@2_DK/XCJ*R!.M`0,U+A%ER)65DS."' M0](HDGU;GBPCXBJ68/%7W/K**'Y$BH&6A@5Q<5'$.W&-;1^WK[9MA&BR;1,) MM6&=Z$VXR*X*';-M?.LBQ1*\$&05/\"B4K+5[Z>"6FJE5UT'#)P46=EL:^#9 M[U$SF\?KH`*RW#+UZ3:S[GP2<\?'^*'43,;/L3E5UK9Y:@1:DJ"%4V[NA],) MH%IW#E:C&M8H_H[EQC>N^4LM#S5#$[`U)J#%ZD:3%C-40]$FAMX!?-<$GON2 ML8`/]H-9V6Q!JL^,/U&#K%:&)!$T:Y'PE\!?^+-9MX,G@Y/QTP@"75E=1HH* MD&Y7?"6="]([M+6L\(X6/K@[12H?J;#7-EM5>2P'",*4^8=4-A1_F4EJ)OD1 M5*(B;=6Y(YB+#T`8`@^>)\M#K>+*;;B%^@RKM\@Z%[R7"V>\M:F<6_KJ#$FY M@O4-&R0`>LQ2-7H1967?0AFJ"$[S1)*M*3Q5%H_'>+NE/S,Y7_J:K/P;.:!= MM+DG&P^(C`VKA,PUN@H1P:<_([^"?*Q6K)P/KR^DQ\/>N4,/'WQ_I(K3?)N] M)4X4;6,7OL0B_B/1-(J"$/5H>TX/-"3-F'4'Y\()-U%^A`-P'G:D"(S!BRGK M#'@((\8W;G6[LC@BYDSBU&.G3R%JM')>%J]-X<`DUFRK`#@4S810"F6O3N!C MC6(&%D)"#B$3R&F803#-MB,B.\X1=2#)#(C1"B)E.*PB5!!_S3NLQ3S.9IHSU3^9-%IS M?PYO`KB4DO,YFALL2)RA;B,"8LY`/"BJ[T3 MN.(:SE8CAJ"""@E-R"$_V27\!IQAMVKDDLVKQ`FJ8.)I0K5"9BDO)M8N*6:E MGX;&T-/@S6!!.-)TI4.;'7\&)=%(H"YU78L,:O(`$/M0`*@S]@Y=M0Y6'E\E MDH)+=6J`;PE$1@5B''!.7HVZ-ZH)[%@F#D5I;*,R!WIC.3;\,H1!"!*%>&:4 M`7T!+X?9=\['.`'#Q1*%3UC1H&5:."SX&XD8F;H"$@$KH(&RH[I&JP<^0`0, M?$++`#)?$$6V:M6-<%V*G9IL:"%3'&/IM7$>XLVJ$0,#E)=T1EF%#;OF]J\I M.5%OR(G#E)6;\>!.QU4L!#IOJU/VS-D\@:`4]5ZP&GG\4XC/3>%(S*6@R9:J M!3AS*L81\A;)7>0"":Q5]Q1,&CU#5-'U`;8O4M%OB$/F4.*0U9]@E#/T28C2 MQ0FD"<\H>?G43&7B)Y@+=P%",19=`'B,&;!:7/1G'MX:_5VS(MP6F6ZJ2G2; MPT9S^4SKGZ%O^<4-,(6$O@94>X#,FIY:^CGX%(21F!-0&B>P=2Q1IT&&IC>F MCP@2V))V,*<6EI]:&PAB\`WB)D M!RQP9$>Z%8U=L"Z/@YB('.`L]8CH''@Q6CT"Q[]$(OI"/H+$02Z=5 M2RT`=*!^Y8S@+J/Z#"PG@4CD,7(Z.(E"C1!^A%95IO+$!4EA.WX/4SZ?*L0# MPV2<1-G/84<:;&'&;25I,`WU!.K+S37NB^F?NP09?PPU+J)W:B/^@VI^B%2: M+/("]]S`*=2=3H()D'\HECU0D+*7FJ@)3";-PFZ%H*/J?M5YDFTKY"\.\'$H M)('P\V`7?[[>EY/CK_W#SBX^$P56`[];[=T*69QR>_@',PH_>MH01`47@0VU M$0N`"9+3X>;5!_`-40X\`V#7F.MT-R@J/`X-+B3U"$0,\*MV4W()Y5Z.AJ(C M.@?!Y0.1='"/O+O";F"OF+&W>0_$7,.2L'748I>6#EVA@5P*^ZD8WTK[HBA@ MJD!3;J(.N\&!QLQ$T@%S&`<+V"6,1=SM"/P.]L>]2 M,8PS^$B"#B@,?AW':C>L30:DSH()BG,N6AT?T0S,$(*P1JT1&_;F=X4`P,V;"P&A,-"#"@!9UJ62[\&3M-4=WF!K8` M&:A)\`D="52Q8*HBKOU9Y""-!KAOO.^#/JT[7FU><]EV$QWJM>STP4=+JH^> M#6V+H+^5*X^5A<%5BS(=796'5NX]J#Y:0RPT9_F;/_6 MG(HI+\NJ_X*/"U=".K[K_87E"!]"M_.3/Z@J/6RJ519D#R1TM6F!5.LZ()\/ M;`^C8@LC.);-RIL_[-$EWGN!FH1)%Z%[43W6O%B>"N?^"+7`P--U+:IN^=8_ M\W/7A[>N@_&Y:V&$:)LS]]X[8%WK;]F\"/B[!GY_+^`7?C8^3^KN,R\#M5>^ M]:>7H*YJ?7S.WDX^V:,*WZ#!3BM/++ MJ*W;Z;#%V^)<\8J,3RQT1&Z7'9'^R]/AQ4ID04?1KJWOX?,7A!A)B4PJ!C;Y M92]24EF;TI,_:=CLK&R]-EV;\,6,7\->2W#PB)U1K;$VSJ&7,I3?"#.E6&OL MW>974P`WKY!FWCJ#2[FL?VK=]Y[MO=FG]K#X9VHI5']`2YS]`6USXY3W*GZ[ MPOV3,>\174SP;0'3Q7)6?0UV[>>MF]9';:XU3D_@?7^]KR;ADFZ*>MO;&37U M\B]V]^M%REK]"IY$Q>[-RBA>H9'"1)=T3$PG!R7`S/=I=`7FA@]4?<)GI6"Z M3U>Q8MZH4SZV=JUFZ12_#P7E=V7A3#TN/?YZ1W"UD,<:K3S,^@W72=5YV7-B MG6%_[]H`:[[-P$:IQ)]T8DLQJQ!T+1E_9K<62\[T$E^_?_=_`@```/__`P!0 M2P,$%``&``@````A`$DG<_#C"@``>V````T```!X;"]S='EL97,N>&ULW%UM M;^/&$?Y>H/^!X+5%`M261%&6Y%@.3K+9'G!U@YR+%FB*@I8HFS%?5(JZLQ/T MOW=F^;*SDB@NS94VZ1EW%BGNS#//S,Z^O*\U``1T7IB M/J7IZK+36<^?O-!=G\;,ZF\?ARDW]!S_PTU6'QRA.W(<`H+[T;'=>R&87 M.^)#?Y[$ZWB9GH.X3KQ<^G-O%^6X,^Z`I.NK:!,Z8;HVYO$F2B>F5=XRLF\^ M+";FA6ED)L_B!8#XPW\V/75^M M?S(^NP'1S$B9&"E\$^=B=R0R][8N8&_D/BXV-+-_2#U^RVA3=88.3/ MA3ZX"6]V,@VGU?.`:`J;1@A#L*F/=ZA-(9CDXLW#-KD_[K%)T#6HU]6&/T$7 ML^*P7)Z3B00WK=+M)*'78D9>-9%_2=3-G%X&26 M]9V^,U1JF1"+NWY#A7U')94U"IWWPYN3T:E>695U>1H^50W`"J>611^J[H'Z M/73PYQ1Q8U*%I,^J'L^-]W[HK8T[[XOQ?1RZ$1)+&S7VM-`F"X%W M.O%E>M^-M\8FE.%%X*N1SYA:`X5^$)3=POX`.TYPY_H*>JBIET0.7!CYY_O7 M%72;(NA,(_>=[+F:IQ\3][5GLQT/<#_%$LU($_,V6D M/@ZNNN?#\7@\ZEV,1J.QW>_9-B/Y(8]H/UIX+QZ.MY31M(M@``C&_='XP@(@ M77O$5)T401\`#`>#T:`WMFSXR_+S\1&HYG1@ZO8J0:#)JP2!)J^R_GU'0>;/ M:PI,=6BNJP2!)J\2!)J\.E2<@8?:O4H0:/(J0:#)JVQ62F%=A2E$S765(-#D M58)`DU>5=3[S##S6[E6"0)-7"8)3>[485LV*CO5NSTQ9_SC7A9UXA\V'--'% M1HTP3GV(DP6L]10+&#T;QHC9O>NKP%NF,")-_,[0 M'E@7V8!-D>K06_B;<->Z4O?>N`0:D=MZPPF'4:DD#P<^/=9!+^3NDRS!7,T\ M+5D`8J(("Y"B87\0:6+;<=[#BC M;C>;E9/5(G#MH8P%>RN M`WKXU93U5?CU^\!_C$*/S0V:F9CODCCUYBG;NL+F]JOP]"OP]')!,GC:Z++;6"]Q-Z0HMQ0AH(!%T9DD2# MI2M%4@RZ&))[H'SE%=NBT:3:)2N=/AV^:/S5>EK43J;VJ01/XO2B> MC9ZRD2/X@HVER%`:7^-RB[E3XRE._)]@D(FO<\UA,M5+3'S]+_7G],Z7Q%W= M>R\P%,V6GEZ6U7.]@*28W]@.1A%A)2:N'R;Q3:.)(L"UROU%F[`']A<#A? MC1O!$Y#%T;W)FZKK?3MO2J.I[+$TB9WVVCCYS4-#6OO_7<95G4&:^%QY6],N MX'LP4#U:-GU+0JCD!TZ8V.J]BG$YS1=C:GL&+0FK:A^/@H_M-7M[`][?GIP3 MAUTB@0Y;3CLA?:=!QU-DVW`\-MZVSMZ>!?UE.?LDZ!0Z^\AXE3H;5XSEO:TA M4_8%-D\`MRV]0N*L2^UBYFQ!K\+P/;4!.>$*+1!#!J9Q?TT1?GRX;XGPJLY> M785\4TB_J;FM0EB3X"J'8[2S5P!J&:-5$.NR1"L26V(^::_(B M,]YTY%+35=P_[]ZZ.RZ;$JI`"QEWI\9I!HW3%<6\?F45!,L.M1*MJN"^43Y; M_8/U/O+VA/CN1+DZ:.!!2W`P9/?WQIGQ?HZYJ!S0XB#\8>,'\!HV+OOARNU\ MLX8W`*?9S7RM[9"LLKVQL.$GLL"G3665)%JXFD]D019I*@O49P[I@[5$%KQ8 MTE@6[+#(9>%>"X[+AO64IKB@2"Y+Y'X@R;V]SX]L5Q+'A2;+X**RN!^Q,A)9 M8')36=R/X#@J"TQN*HO[$1`2638H:2J+^Q&\0&5!N#655?K1!L<160-)[B_V M^E&,5=Q"((.+RN)^%&.U+QFK5!;WHQBK:')37-R/()7P9<,7365Q/XIYPI;, M$]1&[D>1^X$D]]L958QX2S+B,RG<=_")<(2-N@Q'F13N-3'*^Y)1GDGA_A+C MVY:,[TP*]Q3((Q;9\(6\1:6/^B*[MB2[4W=19%TQ8+"=D8$!1PC/-P$<[1SC MP=!LBPQVNHE!N"%22M*3-W\V9O#&8RE(K`_8C,H(NGU9!6[DIG'R:N"VF%*< MZ/2!I+@_Q7')D2C!@DL90'^&8[3AA&X#>,D8$F,8MT0T$5/6!9$>W"/?1`R4 MSM"(\8==YB9BH'0F1DRJV'^2$?,A6FU*#XFY%)MN&1$?_>C96XB1(S)L`4@9 M27?>)DW<,O[$*F5)$G.'[\F6,L04D1UI6;S4F_<_[^"UV()$W#)$Z@Y.`L@` M_^LF)31B*2($%YQEA-S[*9QH4%1B003"DA(1PU:U4L161I&4\7^\S_'*1,Q,?GGCW@("]1B>,4:TLW'-1SL`;^-3>)/S)]OI\/QS:UCG8VZ MT]&9W?<&9^/!].9L8,^F-S?.N&MU9_\%RO!4_DLXUKW%J??L='[8^M>S+]Q.37&3PV&PO=V]R:W-H965T&ULE)==;Z,X%(;O5]K_@'P_`9./)E'(J*'J[DB[TFH^KQUP$E3`K.TT[;^? MM,$\O*>Q\?GF-/-QY$JS,F6Y*'E$7KDB'[=__K&Y"/FD3IQK#QQ*%9&3UM7:]U5RX@53$U'Q$GXY M"%DP#9?RZ*M*,PW\ MZI15ZNI6)&/L"B:?SM6'1!056.RS/-.OM2GQBF3]Z5@*R?8YK/N%SEAR]:XO M!O9%EDBAQ$%/P,XWH,,UK_R5#T[;39K!"C#MGN2'B-S3=4QGQ-]NZ@1]S_A% M];Y[ZB0N?\DL_2>\T3S%':.>+@C>R&>\-%/<"N`(*H68!#U M_S7,?8A1_#9,__LUY&.];?])+^4'=L[U9W'YFV?'DX9(EB,K\+IA3DWIXK_9BA)?&2L]*B M^&%$M+$R)F%C`I\7\WNXF(3+.9TOWN$R;5S@LW&AX5@4WRRKSM@#TVR[D>+B M0;T"N*H85C]=@_';:8%\H/8>Q1&Y@XV+B(*]>=X&&_\9LI\TBIU1P-]606U% M?%7@!@)#"P*Y&0^"8@3!_4*RG;G1CQLZ<8>*::NP0"`+XT%0#"716^^L=35D M1C'K*>:V(OZ5PB(#D_%D*(X(K+K=B84==V<4?;([6Q$/%1V[10:M,)X,Q3;9 MTHZ[,XH^V\A0;)-1M\"-9%X7_XS.9V[*S.]]]!M@T$7C4X9B M!\SIJYV1]`-3MP6&DAML^,8]A0[+!U MMH;-2"PVIU'BH:0SL=J`PCNMGSA\V4SAWF].57S*H73*:E<[1Z2/V3'4"XD; MR:(NS7`:!*OELJL`FQ,/X=$;3,V1W3]*J-NQC:;/1]V>?4/3K<'FP\-Z/)\Y MVOM\H=NVU&CZ?*'30?$;FEM\>&2/YS,'O,77;8RI0CI\"81.%\5O:&[QP3K? MP8=JN_Y"ISUW,->AQLI?%[PIP*&FDYC]-2.;&4`*+H\\YGFNO$2<<02C4+KM MW7:F;(:]]@>8SBIVY/\R>7\`(\&DSMX)4@SWYD++:IZO-D+#7-9_?4$ MPSN'<2&8@/@@A+Y>X##2_CNP_0D``/__`P!02P,$%``&``@````A`"<\_=AG M`P``(PP``!D```!X;"]W;W)K&ULG%9=;YLP%'V? MM/]@^;TA..13(56[JENE59JF?3P[8()5P,AVFO;?[QHGQ(20T+U$`8[//?># MPUW>ON49>F52<5&$V!\,,6)%)&)>;$+\^]?CS0PCI6D1TTP4+,3O3.';U>=/ MRYV0+RIE3"-@*%2(4ZW+A>>I*&4Y50-1L@*>)$+F5,.EW'BJE(S&U:$\\\AP M./%RR@ML&1:R#X=($AZQ!Q%M-H60=)U!WF]^0*,#=W71HL]Y)(42B1X`G6>%MG.>>W,/ MF%;+F$,&INQ(LB3$=_[BWI]A;[6L"O2'LYUR_B.5BMU7R>/OO&!0;>B3ZZS3$H\E@/!V.?("C-5/ZD1M*C**MTB+_ M:T%^)J*:KI10[!/T&M"JIF1Y_`<1&TP@RLPRURBZ1H,Z0W!F6$$\Q M@N,**ONZ(J/9TGN%:D1[S+W%P&^-\6N$!VIJ22##E72^/(?(!FPBFW(9*??V MAAN&G`\S:H8Y9'XYG#E4=:!.@HSF-;]58#&!D^BX1C02!4C_1`T8>N.PDF!8 M\]K(%M,C,LQ+_\@&W,S9GXU.(EN,&YD$'>V=-&/WJ[LYU-1`@F-?;?86T]1P MU-FH/$RJFW\_#>;0J8;@I`X6XVKHZ+TQ=>>]NSQU!GRM]Q;3(_+\(Y$-N)ES MN_<6XT8F04?6/EB+FW:_PE>GFBK:W=^#FC(F=7L:[?>-%SG5[RG#.A@8S/'E M#Z9U!#N$%76(71E=M?B0S_G6URZ__WM0G^#&I)P*7)X_WUJ:FWE[#/8@-S@) MCA^!9@,`Y8;OV0!SZNH<6%!3QM&BFS).?+"GC+8ADO&I%9L/.VAU973-P8DA M7FF%=;DK<]"VPJ[@)TYX)7C;`L_,0=L#R;CC6P#KUO_,@?4Z=QS/^$';$,GX M^,FP690I%8FOV,!\VF?INO2/>D6JAJA_`BE;2#7NFF\[$ M-@U4%_A0UJ>U^>?/^-O"--HNKP_Y!==H;7ZBUOR^^?67U0TWK^T9HNNP:6U19G5.7M!%]1#7>.N*GR#GXV)ZN]-B@_]$[5Q7)M>V95>5F;E"%H MGN'`QV-9H`@7;Q6J.TK2H$O>P?.WY_+:(:NRIO7M^NW`E=7H'@I+V7W MV9.:1E4$V:G&3?YR@;@_G&E><.[^AT9?E46#6WSL)D!GT0?58UY:2PN8-JM# M"1$0V8T&'=?FU@DR9VI:FU4OT%\ENK7"_T9[QK>D*0\_RAJ!VI`GDH$7C%^) M:78@$#A;FG?<9^#WQCB@8_YVZ?[`MQ25IW,'Z?8A(A)8PV)-231 MD%1#,A&1`IW)@=)V."%=O#N7Q>L.0P#00.X(X$';H\V0<,CQ4\3UAJX0,IL1 MB2CB2?7BV+)&^\&(:Q1K1,E@(XCM**TV'8PX428229)`5W\^]\18CITA8Z2A MAD048=,!Z?Q[ALP&Q6+-*]&\4LTK$[VDJ&#+/1\5,9:CHH@+]&-%.ZZIZ)J)%)("#CS\ M\Q+TUK(&#%*J1M''Q/_9'ATY@\&KDR=TQ2"D398`(N950)QP:V\N>0U.Z?VRE]<7\ M_LB2<&AD23E$698*2<9O]R2R1&30$B2Z\ZJ`1L??%0X=RR0M*.2.*0R9E0!% M#/+H%U7?,SDD-$W=,>%6HV/*H=$QDQSE^,C<),3WOUZ1#AN^Q!*@D%0"2Z4R M0^;GC;F+."2W8K6G0MLW;/61..$N#XE3;D6)?7\A-Z:,W[]3*&3: M>B#D3WR%-G)WUA`+B,ULHI(4ZC_Y:>KHMSO][JM0P??D;.'>[@;P`>)SK/S`IC+=7P[#;;T M#$-YH-TT@*E5=]CY`0QY@%N#`YPY7/,3^BUO3F7=&A=TA-CMOG&PO=V]R:W-H965T&UL MC)1;C]HP$(7?*_4_6'[?.!&T M&HMD1](XGA%)A<*!L#"W,'1="\97FNTD5RY`#.^H`_^V%;T]TR2[!2>IV>[Z M.Z9E#XB-Z(0[CE",)%L\-TH;NND@]R&94'9FCXVU<,G(ZHO0G%H-HS)#V"C M]=9+GRO_$Q23J^KU.(!O!E6\IKO.?=?#9RZ:UL&TIQ#(YUI4QQ6W#!H*F"B= M>A+3'1B`3R2%WPQH"#V,ST%4KBUP-HNF\SA+0(XVW+JU\$B,V,XZ+7\'47)" M!4AZ@L#S!$GFMT)(,#3F6U%'R]SH`<'.P)6VIWX#DP6`?;#)/X-!(E_SY(O& M4E!;&,:^3.9I3O;007;2+*\UL^PB(7#[Q0)<^]9"!A-ZO[=G"[[HM85T?L&/ M+I?O2"Z*5P:R:P/_[X$O*C#<\:('?P,&!T%S'SJ49I/IF_O#OH5Y]+3A7ZEI MA+*HXS50XV@.DS!AV\+!Z7X,O=$.MF3\VL)+@<-0X@C$M=;N?/#[?'G-E'\` M``#__P,`4$L#!!0`!@`(````(0!IO'L0T@<``-8C```8````>&PO=V]R:W-H M965T&ULG%K;;N,V$'TOT'\P_.X+2=T<)"EJ$=L6:(&BZ.59 ML>586-LR)&6S^_<=:L8BAY9E95^RR9[#T9GA<(YLZ?&GK\?#Y$M>U45Y>IJ* M^7(ZR4^;3W]Z?G''Q[?R^ISO<_S M9@(13O73=-\TYX?%HM[L\V-6S\MS?@)D5U;'K($_J]=%?:[R;-LN.AX6L.$TQPD,U)D:YVQ6;7)>;MV-^:C!(E1^R!O37^^)<7Z(=-V/"';/J\]MY MMBF/9PCQ4AR*YEL;=#HY;AY^>SV55?9R@+R_BB#;7&*W?UR%/Q:;JJS+73.' M<`L4>IWS:K%:0*3GQVT!&9BR3ZI\]S3]63SH()@NGA_;`OU;Y.^U\_NDWI?O MOU3%]O?BE$.U89_,#KR4Y6=#_6UK_@L6+ZY6?VIWX,]JLLUWV=NA^:M\_S4O M7O<-;'<(&9G$'K;?=%YOH*(09BY#$VE3'D``_)P<"],:4)'L:_OO>[%M]D]3 M%*D$T"=U\*DS(Z63S5C?E\3\D"0J%020%4:"><#F722C"Z`-1`HH" M_UZBQ&.E+#"MMDHZ:[+GQZI\GT#K@?#ZG)E&%@\0^%(>3*8KV*UZ0:%,D)]- ME#86E**&3?[R+)1X7'R!C=D09XV<>#JQ',Y(+PRS"R:LO@X;J6[-`C+HTH`* M^VDHZ)7^7;ZH-HNX:AEWX5L%ZQX*9Z37C"C@%'U-D1V#90']X68QK-Z0H1O= M>BH;%^4C!_:UJWG87;EEI'<9>HC!U,-EQJLWY*Z.07WV\HC52^M4.8-K%9F)INY"IA:/_\2*;17Z7>^=K MC1S8[*Z7_"Z_R]!##):%N3%P!N9PS0V9UUPH3]L:.?U%'\"TBRD1=.KV[)]P38R"B92O^(A4!.( MFF4D;-MQS<:E1G>$0$]S!Y]02;=YI!E)-S0/@)K"X\I9O+PQ.(2QI/&:T<"X M9AN9-"/IAN8!4+=BGJ98YYE02UL.7FCC1.-%HV\QT8$_\,3%W-I;EMCKG93# M2^\L:((O31W?TFUL:+QN-"VNV]H6%1M)U)HRM%=N\52XN%@Y$[G%-<>#,+:I M\9(;'W*DCS-&AM)LU`^#C5'1XNW9C2QZ6CE?'J M^Z8N7+^SEZ?2#X":K11VU[ARXT6>\@"J-6PU`AT,&KIS01'8D45%'[(YTG^7 MHNE2T&/=I:RI\52,23FIW$D!+8T7WT:F%%S?NRK^`*B%"\[$RDXPKME8U7C- M:&Q,<=U#;59Z!.E=`\43"LRB%=QA2 M!L]4Z)USS7`A[(YQ_9Z)CM3?8Z:!/56DW_7+6>A_1DJEBZO(%KA=K@G&'0#] MB27P#*`%QK>--&R_\K8A23F2:/-%$CB??EM&2F&(D0AG&))Z%@*&I8KL5;C^ M#[FK1.-DTR:T>TOZD=0_)RB!NQ1-E^J/PE,PKN>R5L3"37/KGO'->!9Z%F%IM746C)([%#C MPCV?O2.\QU]#;Z2LI6NAL]BY.:&F87CHW'=1TR-.TB-U<^AX1GM'.AHC'*C. M]81?M;6\N*>YH?3.0SH$:@9*:6V/5]MXF-/B=R2CXW')-C*=4M<6KR0/@%JZ MH-U$+MAS4W,F[]_,R!Y7#6T#DO`!XTPI0N^!U0QT/WXQZ>8;H/&U;MG^&+%> M@9*)U*LJ'0(U@=C3T!YVH[AFST>'^T/U^*?_66)-I!N:7?.TFO`-;JG%3H:[VGK:51G)-'H2YSOSUH\I2"$1_X]@2;\,D'"Q$Y'+MW8UWCI M:';PTTZ0R"O:6MUUQ/0^10]2>`K?99JJQS0C:VVT"TC"*L91['\QGE(4)"BE MI'?OIAE!)H%8V>G%L_B0?:H>^XQ\^R02]LC5I$\9'$AOM6;PRKF?X+*-4SG] M,^Z.1:&_L2/@V_N:2#>.K>N@7@=JME(YCT2X=,\\1TKO,5&_+=9JR$2'0$T@ M34D5);:AN'CC7$[=[XQ)]#E>;]N(U.RN&7HE3=4`J`FD82-%<.LCANKQ4N,+ M=]3W>&GD>VD;&IRY]T'%$*@)I)*[HY95//B0F;9LSTS]3V9K(O5K'@(U@51Q M$3OSGXOVW'1(SF,(R@*C4'>$2S]-S2(D(G$L@&^%Y[0C MDT`S94E0EI$S`*$N0J])^TFA?L-?\CJUZ+4STYY#M8NIS'X,45OI>!?S3EN7TH M_U(V\#Y%^^L>WI_)X86`Y1S(N[)L+G^8"W1OY#S_#P``__\#`%!+`P04``8` M"````"$`J7-F%N(#``"?#0``&````'AL+W=OY[T!X7Z!!08VZ&9W,W2:[R69SM_O<0JMD@"9T.\Y\^ZNB M$*%5G!T>5.#?Q:_^U727\R^O>6:]B$JELEC8S/%L2Q2Q3-)BM[#_^_?I\\2V ME.9%PC-9B(7])I3]9?G7I_E15L]J+X2V($*A%O9>ZW+FNBK>BYPK1Y:B@#M; M6>5%C9%F%7OB2&WVS06CS(^Y*+0%*02&=?` MK_9IJ4[1\O@]X7)>/1_*S[',2PBQ2;-4O]5!;2N/9U]WA:SX)H.\7]F(QZ?8 M]W"?F"S-0MM=SFO#?J5 MBJ/J_+;47A[_KM+D6UH(?Q'I+N]AG*/(2-,;):\/0H5@Z,0QO''&"F6&0#`IY6G.#7`$?Y:?Q_31.\7 M=A`ZX\@+&,BMC5#Z*<60MA4?E);Y;Q*Q)A0%\9L@`=`W]WW'GXS9.+P?Q26B M.L%'KOER7LFC!;,&GJE*CG.0S2`R9A:`/\31YGHK5<@1@SQ@E(4=V18,5U"? MER5CD[G[`I[&C69U1=-7K$\*+`7@M8R0>9?QNNLG%!0C"E8!V59T`6*W;+[Q MW$M%.&HE/1)PJ$N";HUNSH,3$0Y:V/"0%H"Q:1N?($D3UM9-(I\%05^P)L&H M$V3<*GJ((/ES1!QD(/I>&Y\024.($0M'H8E(`OAL\[R!"([].2(.,A&9@4B: M:>VB[XRF7O=V_[T93=,!9> M0-/8^W@XR,0S2KLBS:0V=@R;#QQ]Z]==111%[=V>?;@?7EELANW#02;?^?6D MN4F:ZU.O5JQ)05-C['@W`*7WHH^&"WT$[;7IW$&F;Z",:I5LQ$@TBDJ1YF2;G`O09C:WF M#MN5/<8W]Q@VM(0$V9233H(4F:]\ES)N:.BU?VF,!8Z%;8]T$*@W1#DC[?AS84:'7?X2*)!CE)TKCH='H.@J1^F-K% M7%0[L199IJQ8'K#7]6$W:*^V??B#CYV7<7V%_3E>=]L;T!Z7?">^\VJ7%LK* MQ!9">DX$UE748-.)EF7=I&ZDAL:X_KF'/T(".CO/`?%62GTZP0>T?ZV6_P,` M`/__`P!02P,$%``&``@````A`!5ST%LB"```B"<``!@```!X;"]W;W)KQ/+MUS0=C"VY=T%=H'%8B_/ M;N*TQB1Q8+O3F;]?RE1'N5@X M\UE^WI7[XOS\,/_G[_1N/9_537;>9\?RG#_,O^?U_-/CSS_=OY75E_HESYL9 M6#C7#_.7IKELE\MZ]Y*?LGI17O(S2`YE=HX5M-<5&>3@4NSPI=Z^G_-R@D2H_9@V,OWXI+O75VFDWQ=PIJ[Z\7NYV MY>D")IZ*8]%\;XW.9Z?=]K?GMP3]6^1O=>__6?U2OOU2 M%?O?BW,.;$.<5`2>RO*+@OZV5X]`>3G03ML(_%G-]ODA>STV?Y5OO^;%\TL# MX0[`(^78=O\]R>L=,`IF%FX[C%UYA`'`W]FI4*D!C&3?VL^W8M^\/,R]ZU;LK3?P@2:E"=$5<;@4]M!-)KHJZG=>%3ZPI_X:X# M$80?&(&OK<"GMN+"OQ.'`(ZV',#G=0C>8AT$?KA>32^9>Q%"X&]'T/L`VEC&B`A;?H3KKYQP\YY%+209-2*)$>%Z M`2?"9H(0`86D3X2=``5F!*QH?".$:/ZP4F(.\PJ%$.#[9L2O"%7@A,.]ODIOZLLK0NDS[?0J,VD3]Z&$ M_G(O'.9$)!"$V>\Y+%=B(F9)G!#A0%<2,=-- M;PC)#!"JZ?FXV]@J4;?9&AVUIF$)L=1]#='Q=X6S8L4S&3'W!=:?$BP,86"029^<=V3T,T.\(/0H]92<:MR`YBS`+;*"@5JD_Z>!9@ M=T6S@*WAD=K<`U\ZV6&?SD(5:X"N$[P2,FV'F9=$FYE.;PBIZZI3ZKEN[_L$ M]E5]E]>#PH<8]/A..-"&4Z]B;85G)S;Y-J&T"5,M-+Z8^JQ:H^D^8R/5]UDX M;"Y'`D'X;ICK&U8-8@U`GP4+8T+47<_S!9L,DB!,6SP*<*'D0=:)CW;TA%BY[GK%LSH9-R,U1)LQ;?6L1B@AJG'J$3(R M![#-(D3P61T)!.'P7,_QV#H9:\"M?*#JOKMA3$OR`F,^]$W5&SAL\B3C9B0U8\H'JQ%*".L*[?G@#KO! M#9O?D<;H='![,Q-70RTW5\0196E33F\(J;^0R_W\GU807*5%$X!G::0QUOBC M&:3&5^?8@Z.`<2NR@Y@:@4XXNA]P#>W@^'Z@U:),"'Z&%VF0,<0Q$;))E!#A M'9-*(N4=P`TAC;YJDWK5;]H)D#JO9]$7@BWTD099PX]V,/SKE0AYI4S&C<@. M8HP^OL$\",J$H0V<$'U#&RA8N8_4;R-`UXWH]X4LO@G1'$:_KSJ(OEE(?6;] MW\3H#_M`(5C5CEP$F8G7=:_?*X9J%\"(2\:-R`YBC+YM$)0)UA5.K(*F[I`% M(G(1A-'WV>(0$RE338B0JTHB9:KI#2%U^H=Z0=?4"[+$C33(&OY^+V@J_"BW MF)#=6XS!M^E3'E2W]/$BB#T6:07YT7[D(LCB1*PA6`0#?]`/CYN0'<3(@VT( MA`?5]WVZF,-T%62IDS=_W>\`AP@Q;,$"?M`9 M:X2Q+4AL0FD3IK874Y\A+?O3?<1GA69AY@<5D8<@_*%[#?T<6Q=B`N!G0PF1 M>L+SA[]U]U]@VOD2$W>P^?;7[V.@[JL&B55]52Y&:,"VBE1]?J(3P24B;/A, M4PZ;'PW!]'!AYP.G1H.9/VI&$C.P[QC^Z&T="Q*"%Y;P+LLIKY[S.#\>Z]FN M?%67D0+X7;I[BA>E(K&-7'7Q@CV/Q38V/4_$%BYC#/%2;.%.QO!Y"A>QVN?+ M[@5P#^J2/>=_9-5S<:YGQ_P`0W,6ZLY/A3>I\$M37MI[(T]E`S>@VG]?X,9; M#A=$G`6`#V797+_`BY?=';K'_P$``/__`P!02P,$%``&``@````A``+3(IY1 M!@``&AH``!D```!X;"]W;W)K&ULK)E=CZ)(%(;O M-]G_8+@?$<0OHD[:1A`4W6SVXYI&5-(B!NCIF7\_IR@.4'5@2IOOXGJ(DR+OI-;K`+XW/ M3_$U1[4D?$0N";+WC^N7,$VN(/$6G^/B1RFJ=)+0=(^7-`O>SO#H8&P-].$K/2`$>"[^7U M,]X7IYFBCY3.6Y07=LRDE$[XD1=I\B__4:LD>+)>)<.U2NX/NX-1KZ_!O>XE M]JM$N%:)FMX=#P;&<#RZGVE4F7#%]CYT1U`MGQ.N51Z,@#N/-JSBX?ID"\&^ M\DYP?:J%T)XR#ZX/M7!2QS`!`AN MY=>`3:>:R>1PE/("K,?M?PU;&*],Y87)S!0H+!B9.H\&D6`<-Q)#7.J2VG)`E(38A#B$K0EQ"/$+6 MA&P(\0G9$K)K$\%^F,I^A?U,!B8D>'_4UNK]D6CNH@JZYW\=4OM/R)(0FQ"' MD!4A+B$>(6M"-H3XA&P)V;6)X#],X,1_?=`%_.1\SH3*'D#G%ISH,/":/M'E M";P.PC2+D"4A-B$.(2M"7$(\0M:$;`CQ"=D2LFL3P7!8A`F&WU[<-(7YAE=%^>991V$ M7603XA"R(L3EI'5[KXYI#ZF^>/MU'82WWQ#B$[(E9,<)W_`)_L,$^O_]9R*B M_YRT_>>D98!5D2%?,/8TZ=F7]>_X['9%^&:/+1&=.J9<=/8TJ?M6]>^HX5:D MJ0.OCJDTI':LZ]]18U.1IAU^'7.['=OZ=]38<7*C1Z`>A1ZY4?FPB\729]&B M]14I]_9EH;\28G%B-!//LB)-EDVR')*U(EDNR?)(UIID;4B63[*V)&O7SA** MFFTDG_"P#!=-K!`[9BQ$0B(I[2K*,,K:_S*83*3UI8TZ MC;2#Z*[T2I(V!F.IGEW4::0]1'>EUY*TWAN,)J(C&Q1JM'U$=[6WDK8&0UEJ M]PZ%2FVQO]EVJ[V/O3]FV&F!-&@JU(?":?6WO*+'J&;@6XB:^619(8,-4K83 MAH-'T24;DQH=!U&CLQ)UM($AOYQ<3&IT/$2-SEK48>>@4GLVF-3H^(@:G:VH MHQDC0]+985*I(_80V[(]T4-\AP=[`)PO%^QX!CI-&I%2"UXQJJD_"]'=^EMB MU(2/2#B5E*1MC&BD'41WI5<854M+A>UB0*/L(;JKO,:H2AF.TR7I#48TTCZB MN]);C*H;/92&^@XC2FFQL]D.\8G.KC:4[<[FJ%R^<6E^T,P/KY(H.T:OT?F< M=\+T@QTBPRG:?%KC^H3[I7S!27S!3KY97Y-39AS42Y,S9A'42Y-S9A M;4.Y/S9AO0)&PO=V]R:W-H965T&ULK%E= MCZLV$'VOU/^`>+\A0+Z5Y&H3:]LK]4I5U8]GEC@)V@`1L)O=?]\9V\",X>:C MZLMF'Q\/Q\99?OU(3\Z[+,HDSU:N/QBZCLSB?)=DAY7[UY_/7V:N4U91 MMHM.>297[J0I MJH!_>4S.99TMC>])ET;%Z]OY2YRG9TCQDIR2ZE,E=9TT7GP[9'D1O9Q@WA_^ M*(KKW.I+)WV:Q$5>YOMJ`.D\3;0[Y[DW]R#3>KE+8`8HNU/(_\OP50[_M$(+.7J?WLUJ!WPMG M)_?1VZGZ([_\*I/#L8+E'L.,<&*+W:>090R*0II!,,9,<7X"`O#721,L#5`D M^E"?EV17'5=N.!F,I\/0AW#G19;5'S8;Z>GKN24D15M%X6^<6!^H39E><( MJ]U?0.):0TVC4?5'HH*:F.0)LZSN`7B54POO:GXZ6WCNL7FQB-CTQ/&); M1^!285I!``_X-J1![/^!-&9!TO5PFQIH9Q%8#.N(NHL@`&,(JVLS'/VP-&L5 ML1,4(5-QS!EL=(P/'M9(;85LFY"&)44835AQFR8^00^N/F:!^ID33MWE-T'7 MB#>E$>!%99I:,C5!C4P4 M851QYR5F&K%DFEDR-4&- M3!1A5'VH2\KUNDXJFA,R4!`TWK;M0H)!G``:+UDH%&L*>^/#)>5K!P=KJ&>] M,1!PHT4UM]1JH^J.@D&<+KHPH7M#+^W9C).&:&7Y'4@PB!-`@[V?@+%C*HJ& MN"BSH2U*$]6*0B'.";WS?D[&:2DG#;$BZD#"IQ`G@&YY/P&,MJK80+`2K4O/ M?%L4$P6F0Z)"'B5P5\/T/*H]HG#FZ+7W,]?.S.K)0)RY?9CP351[`A$,XIS0 M5._GI"V8<3*0.I"KX]46U4!16D@PB!-`9R4$T!."B=IG;CQOVI(9%P-![9`U ML\\Q>,A!>CS*VJ5%?U2[2?%)H.>22=Q@KAV:,3=0*]D6FCLJ4H@1P"/'_014 M-'\H:HB7EKW9U%&CQG<%@S@GR^VOBX+;G/6@UA`1I0L)!G$"Z+5D551IC7&[ MN4$%^UGR&`CZDLJR=Q?T6>S(HN:6W8K^J-9_^!S0B,D<;C#7MDTK*S`0%;$# M"1;%":`1$P)WBZ@-G%$Q$*5B(+"L5M>YY6@B:#K2J-:+.6&T9$+XAF(8;:VU M@2C-#B3P((P=510G@/Y+"-SM:/B&;W,Q$`A`]&GW%VVX=4<>9?F>Z(]J?8]/ MXJ%](>CN"P:"I[,^5&R[D&`0)]"W+ZB']\&WR*"[3Q@(G8.HVGJ[455W)#,0 M;4>8%*>+UDP6_4;5&2,GQZ)`0V2T;1<2#&($0FL'P*K[;^]K*A-_)`QD"6;O M#FU4O>2"09SO0[M#V-T=#$0%ZT*"09Q`S^[@#P%\L+Y"8_ID+0UDR67O%FU4 M*Y?.I>?$V=)]`**NUQ= M_;HM6W^\V,*)O=L"KQO0IZ\%[L2?^G)M3!L8O#<>%DOM:)923Z/%D[YS MMQHVL(:]2PA,U>6X'3]9P)433,UK&N#N_!P=Y/>H."19Z9SD'LIOJ*Y0"GW[ MKK]4^1E<"6[0\PINS=6_1_B51,*]UA`/=?L\K^HO.$#SN\OZ7P```/__`P!0 M2P,$%``&``@````A`&$*+A&0!0``"Q4``!D```!X;"]W;W)K&ULK)C;CJ-&$(;O(^4=$/=K#/B(;*_&G*5$BJ)-"-U4]!J:]J3J6F0*J>'HCIM MS;^^15]6IM&T677(+K0B6_,[:#.D=9EUL+/^F0UUYIDA\ZIO%C.=+JPRJRH3*[@U8]HT..QR$E` M\]>25"T7JBTO1?N]$3:/,O?14 MT3I[OD#<'_8LRU&[^Z')ET5>TX8>VPG(6?Q%]9C7UMH"I=WF4$`$+.U&38Y; M\\GV4GMA6KM-EZ"_"_+>"/\;S9F^QW5Q^*VH"&0;QHF-P#.E+\PT/3`$SI;F M'74C\$=M',@Q>[VT?]+WA!2G(6&#>X7M`FAPR"C(39\Z4MZ2PF\^74M<'<>"9-&Q5,TC3RUZ:EY3_9CR]RY^'PA"X"N/9^]G2RFL]GBQ5[^AW/9>\) MU^&),V>^7'6QWW&$R=,]$J[C(X>DZ8X63WHWAD'69KM-3=\-F!B0UN::L6EF M>VO3P,'C"L-P_F@T81B9R!-3V9H0!0Q4`R7XMG.F\XWU!F63]S9[W<:6+7RT M8#7"9`,5A"J(5!"K(%%!*@`+DC!D`DKG$S+!5%@F,(8]`B$U2MAH@2Z!"D(5 M1"J(59"H(!6`%+;[*6$SE:T)?X4"6,AQ[KF-#24[&"DUX@\F0RXT$FHDTDBL MD40CJ4BDC,#T_X1"8"HPJ6!.#='J2P61(B49"C40:B362:"05B902 M6,7$E-Q>VG$Q8,9=Y/C&>TX0@`P7C=* MVH6-C&]O3$..GQ/''=9YO[<92<")*ZT`]E3.43@888XB32@>;(1DV\KFF0Q& M*)2*0E)*X(W$E-P('3HOC)T9R['W9(S4UTC`2=_OL;T\[$G7B'99C32O6/-* M-*]4])*BLF%Y>3RLSEJ.JT<.E-)8U+8C#YB/5JMAZ`-$LJ,K.X9HM>[Z(WNN M"$=X?Q2.$=T53M"*"SLS95--\7XG+*>,]4)"]W>_$FS>.<&6AB6V[Y$KK>SV M3([<1RO>LO/.CFN!(VJ%:.5T^5DIVT.$MT>1&-$HDB#B(O9:27**]SL5.1>L M07H\%[R=DG+!D5(^RF#X=F\UCG*`:&P:0T1\2&=*%!'>'D5B1*-(@HB+N,K* MD^+M&V7!6B,A%3^U9MI]?R56"T=*M2AMHM\[NN-`!XC&)2=$-..S::HLAQ'> M'U5B1*-*@HBKK!61%&_?J!;6*@DI^H^9TS=68BXXP)XC54"/ M[JZ$(3JNNJ)P5]J\T81C=+DKG*`5%Y[/E98NQ?LW"H5U8'<2^8U>?]1_")LP MG-^HNW"/9FP!Y4/'3VCXUWU)ZA/QR>72&#E]9:
-$P@H M/%AYT)CH/%YYT&?H'(Z8GIP;?,^.GFYQQX/O45UG[WKP6:;SIYGWQ(^PE!?= MSSSX:-$=]G,/>OP;?.%!2PS<&H3@*.J:G&ULK%==;Z,X%'T?:?\#XGU"3+Y1DE&(U9V19J75:C^>*7$25,`(DZ;]]W.O M;8AMTI9*^U+*R?'U\;W7!WO][:7(O6=6BXR7&Y^,QK['RI0?LO*T\?_Y^^'K MTO=$DY2').1"C%QC\W314%@4C/K$C$B%>L MA%^.O"Z2!E[K4R"JFB4'.:C(@W`\G@=%DI6^BA#50V+PXS%+&>7II6!EHX+4 M+$\:T"_.627::$4Z)%R1U$^7ZFO*BPI"/&9YUKS*H+Y7I-&/4\GKY#&'=;^0 M:9*VL>5++WR1I347_-B,(%R@A/;7O`I6`43:K@\9K`#3[M7LN/%W)*)DY0?; MM4S0OQF["N-_3YSY]?/!$ M#X:G'DQFHW`Y([/Y)R1,=11X?GH=@(6,%;A*&P9[1!J`)9"J+2K$= MI1-N(I9P$&D*OV\%;5Z1+/6U<6.%A%"]+HMD.;85[SM2.XR:B"4'K&"X'"3; M;]^2+9%:\06'3KUTZ3;!J7%"BC%T=&J35 MQRUDY+`/40NR!:`3#Q>`;"=U&K)[:MDM5\K<$\V:=J6F%F1K0M\=KDF[M#Q) MZ:1HR$Q*#Z+$A&P!Z)^&`-E:L]''G:5]UY2B(1AK=-;*3<\]ULHQ5DKNLFZ> M8Z\!3==8P_M6@5\OM[`:,I/8@V@[4+)L`>B\AH#!252.;36YADPI&H+'+:\K MQ\HHZ0::K)L!VX+1B`W!'V1,V[99:PV9,GL0)29D"T"?-00,=S1MT*86#4'+ M&/FY?57TMKS+Q%HV,8B/LBBMG=3N8*D4ZC(ZH:CCM\% MJT]LS_)<>"F_X.T%_':[[F!UM=HOHOT2K<;!Z2*"CUD?AZO83IXB''Z,5[0[ M_#B,X`C;CQ-/(BJK[\393:.=:FCGAW@:4;E2%Y]%<&JZ,\$\@A,-X$$W`*YL M57)B?R3U*2N%E[,C)&4\6L!>K=6E3[TTO()DP=V+-W!9D_^>X7+.X,(P1FL[ M&ULC%7;;J,P$'U?:?_!\GLQD%N# M0JITJ^Y6VI56J[T\.\:`58R1[33MW^_83A$T:9H7!,/Q.7-FAF%U\RP;],2U M$:K-<1+%&/&6J4*T58[__+Z_NL;(6-H6M%$MS_$+-_AF_?G3:J_THZDYMP@8 M6I/CVMHN(\2PFDMJ(M7Q%MZ42DMJX5%7Q'2:T\(?D@U)XWA.)!4M#@R9OH1# ME:5@_$ZQG>2M#22:-]1"_J86G7EED^P2.DGUXZZ[8DIV0+$5C;`OGA0CR;*' MJE6:;AOP_9Q,*7OE]@]']%(PK8PJ;01T)"1Z['E)E@28UJM"@`-7=J1YF>-- MDMTF,2;KE2_07\'W9G"/3*WV7[4HOHN60[6A3ZX#6Z4>'?2A<"$X3(Y.W_L. M_-2HX"7=-?:7VG_CHJHMM'L&CIRQK'BYXX9!18$F2F>.B:D&$H`KDL*-!E2$ M/N:;5' MT&]`FXZZZ4DR(#Z="R3AL!L'SO$"(Y`Q4,"G=9I>K\@3F&8'S&W`P+7')#V" M@&BO#&J7*SNP4W95<:G6=.W?J] M^`MQX+'4(7+L!EH\Y/6#.5M$BP^;XPZ.-0Z1L9UWO@?8<"/=\Z7SZ+'8(33U M:\6W)VR\L%8DUQ7_PIO&(*9V;INEL"CZ:+]I-ZD[_S8^S39A`Y/^#6S`CE;\ M!]65:`UJ>`F=O:_C7<5@6<00U+96RKP^@3/J_ MY_H_````__\#`%!+`P04``8`"````"$`.G#R'[H"``!_!P``&0```'AL+W=O M;CQ_6!VT>;"6$(\#0V(Q6SK5I M&%I>"<5LH%O1P)M"&\4<'$T9VM8(EG>75!TF4;0,%9,-]0RI.8=#%X7DXD;S MO1*-\R1&U,Q!_K:2K7UA4_P<.L7,P[Z]X%JU0+&3M73/'2DEBJ=W9:,-V]7@ M^RF>,_["W1V.Z)7D1EM=N`#H0I_HL>=5N`J!:;/.)3C`LA,CBHQNX_0ZCFBX M67<%^BW%P8Z>B:WTX8N1^3?9"*@V]`D[L-/Z`:%W.8;@U^Z,-7(.JW^>%#<)>6YNM1NF&.;M=$'`OT&M&T9 M3D^<`O'I7"`)Q&X1G-%+2D#&0@$?-S!"Z_`13/,><^TQ\#M@X@$1@NB@#&KG M*R,8E;$JF,JU#XQEDM,RLZD,%GT&K7O;*%X"W,A$$OVSX3/PF/D(LSB=`4#. M-XI@Z,5J1'M<8P\Z0QKF8BR-YI,E3M<[_O%>E\50[SX"E1OZFD3_*?ERJOIV MJ1$\E>HC?F['$P.#]]I-'"7!Y;MV\.)4HX],YB>:G>X?[M^S_R((GDKUD6,[ MT.,Q+S9G]>YDXJ4I?Q^96IF?M@+K;:+Y=FLZ]%2L#\V[G=+UQJ\[OU.4,*7X M+.K:$J[WN,H2V!)#=%BSVP3OOX[/TZU?O^'P!M9?RTIQSTPI&TMJ40!GU'7< M^`7J#TZWD"U@\76/%7SH!&R**(#Q*+1V+P=0#H=/Y^8O````__\#`%!+ M`P04``8`"````"$`I?7RML8'```4(P``&0```'AL+W=OTOS8 MYPK6^2L:Q>MKOLE6Q>;CD!TK+G+.]FE%[2]W^:D4:H?-5^0.Z?G]X_1M4QQ. M)/&2[_/J9RW:[QTVEO=V+,[IRY[>^X3Z<#TGIZ6&;TQNPL/?.V>MC_]FP$F/>'SX]U`'Z;YY]EIW_>^6N^'3.^3;, MCQE%F_J)]^!?Y]XV>TT_]M6_BT\WR]]V%77WE-Z( MO9BU_;G*R@U%E&0&YI0I;8H]-8#^]@XY2PV*2/JCOG[FVVKWV#=G_=Y+5E9V MSJ3ZOZ-HYW@XDYG=W_TQ-)MGY/NC:.QOQ+3[QK'.EZ6U,IC/43Z7I;4VEH MUHYTO:VI\\:1KK%=IE3X]G(O/'LV(%*SRE++YU;"8 MFABV?+"U`_GOQC$-8*;RS&0>^Y1A-%1+FGR^/YG&[&'XG2:,36.S0!M#M5@* M"S8[,-F5#M8ZL'7@Z,#5@:<#7P>!#D(=1#J(=9!TP)!BW0:<4NQ7!)S)L("+ M4"T$Z/2`%EUA(5Q6.ECKP-:!HP-7!YX.?!T$.@AU$.D@UD'2`4IT:13^BN@R MF<<^_>VD\[T:S@6W,6AR;(VFJLFR-6E##F0-Q`;B`'&!>$!\(`&0$$@$)`:2 M=(D2?IK)?D7XF0Q-2/3UT886IY/&Z%K\6Y,V_D#60&P@#A`7B`?$!Q(`"8%$ M0&(@29RNC42;BL@:R`V$`>( M"\0#X@,)@(1`(B`QD*1+E*C2BNN&J#)K-:J( M!\0'$@`)@41`8B!)ER@AI)6!$D*VS#"G`PKYC0L-)J1&EQ.*;B=GS9&6LZU1 MF[-`UD!L(`X0%X@'Q`<2``F!1$!B($F7*`&G:5$)^/69@%FK4>7$--L%QA+( M"L@:B`W$`>("\8#X0`(@(9`(2`PDZ1(EA/3U\K5&; MF$#60&P@#A`7B`?$!Q(`"8%$0&(@29#FB*-6XVIR^6JP335&7C=.)*5R'0;D8/( M1>0UJ-,(7UIU&S%6&Q%(*]&($%&$*$:4-(@*?])2^X-5)_]_?_`:1^D/CI3^ MX*@3BA7;Q:!>F]SQ.GQD:%%82P,1!5L@N49Q!&IEM!YUI8&0\022V>$+U,IH MK0FD@9`)!9*MB01J9;36Q-)`R"0-NM1#K(+I]M"%D4$[A^W0:`H>F;L+MM_# MYONZ]^MQL$2T:M!$?HVN!9*.-CHZPDHZN@))1P\=?6$E'0.!I&.(CI&PDHZQ M0-(Q41S5I&=%R0TA;6J8;D@Y8MN^G7EDH@[A)=LM8W/2?3N/K`12'#'KN>-D M4@^+;]/Y7*OH;:$CI1V!KDJ[C960GDSOM23WA(Z4]@6Z*AUHTN9H.M/JL5`( M2>U(H*O:L:9MC`Q3:W8))ZGC"R1U`E6' M'45I[0F%D]2)!)(ZL:IC3&8332<13K6.VD.L&KNAAWCQIO104\\I:61J+5@: MC97,OY5`BB..R,9QSDE76'52FN)[0D#J>P+=%4Y$%:- M,IUH:M*AL)#2D4!7I6-AU3;Z3AOJB;"HI=7.)NE;.IN9:\MJCI1E-:"5`6B- MR$;D('(1>8A\1`&B$%&$*$:4*$@-*:L,N^.';5J,[]GQY:V[%FR76`]W4W?2 MXKGS;:>=F2P;Q\[>T0K1&I&-R$'D(O(0^8@"1"&B"%&,*%&0V@.LBNSVP#\L MTWC1J3-=R9T9WZ<`;NW-.=>OAJ=^A\_KE>>VE\P<[M+SW=M.@4Y$*K MQA;MSR-_GEC//#+Z`R86;2BCPV)JT9;H!7YGT3[?!4[O?/&5Z8TOO?#*,"Q6 MW*$2%7,6J[CP#M4V%BM?\`Z5*Z1VZ0Y5(!8K,M"'B@IZ3GUGV`:%?I-P2M^R M*#V_Y<>RM\]>*2U&=2U]YK]JX!^JXE37U"]%1;]*J/_=T:]/,MK>';%]S=>B MJ,0'>O2P_3W+TU\```#__P,`4$L#!!0`!@`(````(0`LZF"D,0$``$`"```1 M``@!9&]C4')O<',O8V]R92YX;6P@H@0!**```0`````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M``````````````````"&>PMLBQK2LD3-3BXQ<<;%&\*W MC5@H`;3;OY=V79W1DT?ROCP\WTE-(QV7AX](T#'S6$+)%L8-)5:!>C8Q@'N0,C0I$: M-H6;QAL1T]%OL1/R76P!3PBYP@:B4"(*W`%S-Q+1@%1R1+H/7_<`)3'48,#& M@&E!\70S']C[HL=BV;=%.>XWD3_%Z^?#4 MCYIKV^U*`N+=?FH1XC*M9G>W:\6B$\(G>:4YN1Z16=L-F.$O);XU!KN\Q%H!H%_$T\`WGO__'/^!0`` M__\#`%!+`P04``8`"````"$`@,7WLFP"``!-!P``$``(`61O8U!R;W!S+V%P M<"YX;6P@H@0!**```0`````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M``````````````````````````````````````````````````````````"< M55MOVC`4?I^T_Q#EO0W0:IHJDRH+5*U$"5+2[M%RG1.P&NS(-HCVU^\D'I!T M*>IX.S[7[UQ-;G?KTMN"-D+)L3^\'/@>2*YR(9=C_RF[N_CI>\8RF;-221C[ M;V#\V_#[-[+0J@)M!1@/74@S]E?65C=!8/@*ULQ^\WBSM>-7-(OF\?0, MD^'_V*091GO\-,P1SU_%>9;2Y(ZF6?)9E!,FYR`[QV;4BRW12R;%>S/N-,$U M;2A#<8WI3/2:+!BNH74JCJ:MM>@UB3C7&\#F[W#3#72F]=#SF3*&+D#3=,4T M;LQ!4,^^FZ18K=?"UA?!A8\53I-0>K[`N:R?QBN&@ MY7N=?P7UQ_'L?L=P>'TYN!K@G]#BD>#X#X9_````__\#`%!+`0(M`!0`!@`( M````(0":BN0#M@$``$X0```3``````````````````````!;0V]N=&5N=%]4 M>7!E&UL4$L!`BT`%``&``@````A`+55,"/U````3`(```L````````` M````````[P,``%]R96QS+RYR96QS4$L!`BT`%``&``@````A`(P(J,ZB`0`` M]PX``!H`````````````````%0<``'AL+U]R96QS+W=O;C5UQP#``"T"```&0````````````````!8$P`` M>&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A`.<*N(;,`@``W0@``!D````````````` M````S!D``'AL+W=O&PO=V]R:W-H965T M&UL4$L!`BT` M%``&``@````A`)K82BK(`@``[@@``!D`````````````````HR0``'AL+W=O M&PO=&AE;64O=&AE;64Q+GAM;%!+`0(M M`!0`!@`(````(0`<#%I_CP0``,<0```8`````````````````&&PO=V]R:W-H965T&UL M4$L!`BT`%``&``@````A``=R[*@Z'@``/%\``!0`````````````````338` M`'AL+W-H87)E9%-T&UL4$L!`BT`%``&``@````A`$DG<_#C"@`` M>V````T`````````````````N50``'AL+W-T>6QE&PO=V]R:W-H M965T&UL4$L!`BT`%``&``@````A`"<\_=AG`P``(PP``!D` M````````````````F&,``'AL+W=O&PO M=V]R:W-H965T&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A`*ES M9A;B`P``GPT``!@`````````````````^78``'AL+W=O&PO=V]R:W-H965T M&PO=V]R M:W-H965T6``!X;"]W;W)K&UL M4$L!`BT`%``&``@````A``_1`'Z_`@``@@<``!D`````````````````P9H` M`'AL+W=O&PO=V]R:W-H965T&UL4$L!`BT`%``&``@` M```A`"SJ8*0Q`0``0`(``!$`````````````````I:@``&1O8U!R;W!S+V-O M&UL4$L!`BT`%``&``@````A`(#%][)L`@``30<``!`````````````` M````#:L``&1O8U!R;W!S+V%P<"YX;6Q02P4&`````"``(`"2"```KZX````` ` end XML 14 R4.htm IDEA: XBRL DOCUMENT v2.4.0.8

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (USD $)
In Thousands, except Share data, unless otherwise specified
3 Months Ended 9 Months Ended 313 Months Ended

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Revenues

Licensing fees $ 0 $ 0 $ 0 $ 0 $ 28,755

Product royalties 0 0 0 0 627

Research and development grants 0 0 0 0 1,219

Interest income 3 1 6 1 16,308

Gain on disposal of fixed assets 0 0 0 0 102

Other Income 0 0 0 0 1,003

Total revenues and other income 3 1 6 1 48,014

Expenses

Research and development 4,786 3,131 17,132 6,776 212,391

General and administrative 1,215 1,453 3,453 3,348 56,373

Other Expense 0 0 0 0 388

Total expenses 6,001 4,584 20,585 10,124 269,152

Loss from continuing operations (5,998) (4,583) (20,579) (10,123) (221,138)

Loss from discontinued operations 0 0 0 0 (1,828)

Gain on disposal of discontinued operation 0 0 0 0 939

Net loss before cumulative effect of change in accounting principle (5,998) (4,583) (20,579) (10,123) (222,027)

Cumulative effect of change in accounting principle 0 0 0 0 (8,454)

Net loss $ (5,998) $ (4,583) $ (20,579) $ (10,123) $ (230,481)

Loss per share - basic and diluted: $ (0.26) $ (0.30) $ (1.03) $ (0.69)

Weighted average shares used in loss per share calculation:

Basic 23,006 15,422 20,066 14,746

Diluted 23,006 15,422 20,066 14,746

X

- Definition

Total costs of sales and operating expenses for the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_CostsAndExpenses

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_CostsAndExpensesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount of gain (loss), after tax expense or benefit and not previously recognized, resulting from the sale of a business component.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 20

-Section 45

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6892542&loc=d3e957-107759

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 20

-Section 50

-Paragraph 1

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6360339&loc=d3e1361-107760

+ Details

Name: us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements. Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period. Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.

+ References

No definition available.

+ Details

Name: us-gaap_EarningsPerShareBasicAndDiluted

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount of gain (loss) on sale or disposal of assets utilized in financial service operations.

+ References

No definition available.

+ Details

Name: us-gaap_GainsLossesOnSalesOfAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.4)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_GeneralAndAdministrativeExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Income or Loss from continuing operations, net of taxes, including net Income or Loss from discontinued operations but before extraordinary items.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.14)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.15)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 16

-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 14

-Article 7

+ Details

Name: us-gaap_IncomeLossBeforeExtraordinaryItemsAndCumulativeEffectOfChangeInAccountingPrinciple

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Amount of income (loss) from continuing operations attributable to the parent. Also defined as revenue less expenses and taxes from ongoing operations before extraordinary items but after deduction of those portions of income or loss from continuing operations that are allocable to noncontrolling interests.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 45

-Paragraph 18

-URI http://asc.fasb.org/extlink&oid=7656940&loc=SL4613673-111683

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.13)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_IncomeLossFromContinuingOperations

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Amount of income (loss) from a disposal group, net of income tax before extraordinary items allocable to noncontrolling interests. Includes, net of tax, income (loss) from operations during the phase-out period, gain (loss) on disposal, provision (or any reversals of earlier provisions) for loss on disposal, and adjustments of a prior period gain (loss) on disposal.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 20

-Section 45

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6892542&loc=d3e957-107759

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.12)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 13

-Article 7

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 20

-Section 50

-Paragraph 1

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=6360339&loc=d3e1361-107760

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.14)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 15

-Article 5

+ Details

Name: us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 7

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.7(b))

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_InvestmentIncomeInterest

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Revenue earned during the period relating to consideration received from another party for the right to use, but not own, certain of the entity's intangible assets. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, manufacturing process, software or trademark. Licensing fees are generally, but not always, fixed as to amount and not dependent upon the revenue generated by the licensing party. An entity may receive licensing fees for licenses that also generate royalty payments to the entity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.1(e))

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_LicensesRevenue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 20

-Article 9

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Other Comprehensive Income

-URI http://asc.fasb.org/extlink&oid=6519514

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Net Income

-URI http://asc.fasb.org/extlink&oid=6518256

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.19)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.18)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.22)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=28358780&loc=d3e565-108580

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 19

-Article 5

+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Amount of the effect of a change in accounting principle on net income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 250

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=28359718&loc=d3e22580-107794

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 250

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (b)(2)

-URI http://asc.fasb.org/extlink&oid=28359718&loc=d3e22499-107794

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 250

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=28359718&loc=d3e22583-107794

+ Details

Name: us-gaap_NewAccountingPronouncementOrChangeInAccountingPrincipleEffectOfChangeOnNetIncome

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The total amount of other operating cost and expense items that are associated with the entity's normal revenue producing operation.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.3)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 3

-Article 5

+ Details

Name: us-gaap_OtherCostAndExpenseOperating

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The aggregate amount of other income amounts, the components of which are not separately disclosed on the income statement, resulting from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business) also known as other nonoperating income recognized for the period. Such amounts may include: (a) dividends, (b) interest on securities, (c) profits on securities (net of losses), and (d) miscellaneous other income items.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.7)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 7

-Article 5

+ Details

Name: us-gaap_OtherNonoperatingIncome

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 985

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 730

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373

+ Details

Name: us-gaap_ResearchAndDevelopmentExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Revenue earned during the period from non-repayable sum of money awarded to an entity to carry out a specific purpose as provided in grant agreements.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.1(e))

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_RevenueFromGrants

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.1)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 1

-Article 5

+ Details

Name: us-gaap_Revenues

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: us-gaap_RevenuesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Revenue earned during the period from the leasing or otherwise lending to a third party the entity's rights or title to certain property. Royalty revenue is derived from a percentage or stated amount of sales proceeds or revenue generated by the third party using the entity's property. Examples of property from which royalties may be derived include patents and oil and mineral rights.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.1(e))

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 1

-Article 5

+ Details

Name: us-gaap_RoyaltyRevenue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 16

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1505-109256

+ Details

Name: us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 10

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1448-109256

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Weighted-Average Number of Common Shares Outstanding

-URI http://asc.fasb.org/extlink&oid=6528421

+ Details

Name: us-gaap_WeightedAverageNumberOfSharesOutstandingBasic

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

XML 15 R10.htm IDEA: XBRL DOCUMENT v2.4.0.8

Patents and Patent Applications
9 Months Ended

Sep. 30, 2013

Goodwill and Intangible Assets Disclosure [Abstract]

Patents and Patent Applications

NOTE 2 — Patents and Patent Applications

As of September 30, 2013, we had approximately $2,734,000 in capitalized patent and patent application costs reflected on its balance sheet. Of this amount, $1,726,000 relates to patent and patent application costs for Androxal® and $1,008,000 relates to patent and patent application costs for Proellex®.

Should we not continue development of either drug candidate or should we not continue as a going concern, the remaining capitalized patent and patent application costs may not be recoverable, which would result in charges to operating results in future periods.

X

- Details

Name: us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for all or part of the information related to intangible assets.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16323-109275

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16373-109275

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16265-109275

+ Details

Name: us-gaap_IntangibleAssetsDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 16 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 17 R18.htm IDEA: XBRL DOCUMENT v2.4.0.8

Organization, Operations and Liquidity (Additional Information) (Details) (USD $)
0 Months Ended

Sep. 30, 2013

Dec. 31, 2012

Sep. 30, 2012

Dec. 31, 2011

Aug. 19, 1987

Jun. 25, 2013

IPO [Member]

Product Information [Line Items]

Deficit accumulated during the development stage $ (230,481,000) $ (209,902,000)

Cash and cash equivalents 81,828,000 24,212,000 29,583,000 4,565,000 0

Accounts payable and accrued expenses 3,200,000

Common stock issued during the period 4,312,500

Price per share $ 5.07 $ 19.00

Public Offering Net Proceeds $ 76,800,000

X

- Definition

Public offering, net proceeds.

+ References

No definition available.

+ Details

Name: rprx_PublicOfferingNetProceeds

Namespace Prefix: rprx_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19,20)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 20

-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 19

-Article 5

+ Details

Name: us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash

-URI http://asc.fasb.org/extlink&oid=6506951

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash Equivalents

-URI http://asc.fasb.org/extlink&oid=6507016

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 1

-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.1)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3044-108585

+ Details

Name: us-gaap_CashAndCashEquivalentsAtCarryingValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Cumulative net losses reported during the development stage.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 915

-SubTopic 210

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6472335&loc=d3e37729-110921

+ Details

Name: us-gaap_DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Details

Name: us-gaap_ProductInformationLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.

+ References

No definition available.

+ Details

Name: us-gaap_SaleOfStockPricePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition

Number of new stock issued during the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30

-Article 5

+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

XML 18 R6.htm IDEA: XBRL DOCUMENT v2.4.0.8

CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Parenthetical) (USD $)
9 Months Ended

Sep. 30, 2013

Sep. 30, 2012

Issuance of 871,634 shares of common stock for the cashless exercise of Series A Warrants 872,133

Issuance of shares of common stock for the cashless exercise of Series B Warrants stock options 716,463

Exercise of Series B Warrants to purchase common stock for cash, share price $ 2.49 $ 2.49

Issuance of shares of common stock for the cashless exercise of stock options 8,332 27,915

Issuance of shares of common stock, offering costs $ 5,200,000 $ 777

Issuance of 100 shares of common stock at a share price $ 5.07

Exercise of stock option to purchase common stock for cash, share price $ 18.74

Sale Of Stock Price Per Shares $ 4.50

Sale Of Stock Price Per Shares 1 $ 11.00

Issuance of shares of common stock, offering costs 1 $ 586

Maximum [Member]

Exercise of stock option to purchase common stock for cash, share price $ 10.88

Minimum [Member]

Exercise of stock option to purchase common stock for cash, share price $ 1.33

X

- Definition

Common Stock Option Shares

+ References

No definition available.

+ Details

Name: rprx_CommonStockoptionShares

Namespace Prefix: rprx_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

The cash outflow for cost incurred directly with the issuance of an equity security.

+ References

No definition available.

+ Details

Name: rprx_PaymentsOfStockIssuanceCosts1

Namespace Prefix: rprx_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.

+ References

No definition available.

+ Details

Name: rprx_SaleOfStockPricePerShares

Namespace Prefix: rprx_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition

Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.

+ References

No definition available.

+ Details

Name: rprx_SaleOfStockPricePerSharesOne

Namespace Prefix: rprx_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition

Number of warrants exercised during the current period.

+ References

No definition available.

+ Details

Name: rprx_StockIssuedDuringPeriodSharesWarrantsExercised

Namespace Prefix: rprx_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

Number of warrants exercised during the current period1.

+ References

No definition available.

+ Details

Name: rprx_StockIssuedDuringPeriodSharesWarrantsExercised1

Namespace Prefix: rprx_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

Exercise price of the option.

+ References

No definition available.

+ Details

Name: rprx_Stockoptionexerciseprice

Namespace Prefix: rprx_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition

Exercise price of the warrants.

+ References

No definition available.

+ Details

Name: rprx_WarrantsExercisePrice

Namespace Prefix: rprx_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition

The cash outflow for cost incurred directly with the issuance of an equity security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 15

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3291-108585

+ Details

Name: us-gaap_PaymentsOfStockIssuanceCosts

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.

+ References

No definition available.

+ Details

Name: us-gaap_SaleOfStockPricePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

XML 19 R8.htm IDEA: XBRL DOCUMENT v2.4.0.8

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Parenthetical) (USD $)
In Thousands, unless otherwise specified
313 Months Ended

Sep. 30, 2013

Proceeds from sale of subsidiary, operating losses during 1990 phase-out period $ 12,345

X

- Definition

Operating Losses During Phase-out Period From Divestiture of Interest in Consolidated Subsidiaries

+ References

No definition available.

+ Details

Name: rprx_OperatingLossesDuringPhaseOutPeriodFromDivestitureOfInterestInConsolidatedSubsidiaries

Namespace Prefix: rprx_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

XML 20 R11.htm IDEA: XBRL DOCUMENT v2.4.0.8

Accrued Expenses
9 Months Ended

Sep. 30, 2013

Accrued Expenses [Abstract]

Accrued Expenses

NOTE 3 — Accrued Expenses

Accrued expenses consist of the following (in thousands):

September 30, 2013

December 31, 2012

Patent costs

$

152

$

245

Research and development costs

87

192

Personnel related costs

42

30

Other

101

91

Total

$

382

$

558

X

- Details

Name: us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 19

-Subparagraph a

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19(a),20,24)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 20, 24

-Article 5

+ Details

Name: us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 21 R9.htm IDEA: XBRL DOCUMENT v2.4.0.8

Organization, Operations and Liquidity
9 Months Ended

Sep. 30, 2013

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Organization, Operations and Liquidity

NOTE 1 — Organization, Operations and Liquidity

Repros Therapeutics Inc. (the “Company”, “RPRX,” “Repros,” or “we,” “us” or “our”) was organized on August 20, 1987. We are a development stage biopharmaceutical company focused on the development of new drugs to treat hormonal and reproductive system disorders.

Our primary product candidate, Androxal®, is a single isomer of clomiphene citrate and is an orally active proprietary small molecule compound. We are developing Androxal® for men of reproductive age with low testosterone levels. Androxal® treats the underlying mechanism that causes secondary hypogonadism and restores normal testicular function. We have completed two pivotal efficacy Phase 3 studies for Androxal® conducted under a Special Protocol Assessment (“SPA”).

Proellex®, our product candidate for female reproductive health, is a new chemical entity that acts as a selective blocker of the progesterone receptor and is being developed for the treatment of symptoms associated with uterine fibroids and endometriosis. We completed a low dose study in late 2011 to demonstrate both safety and signals of efficacy in low oral doses of Proellex® and in November 2012 we initiated a Phase 2 study in the treatment of endometriosis. Additionally, we have completed a Phase 1/2 vaginal administration study for uterine fibroids in the first quarter of 2013.

Our product development pipeline is summarized in the table below:

Product Candidate (Indication)
Androxal®

Status

Next Expected Milestone(s)

Secondary Hypogonadism

Phase 3

Complete DEXA study (Q4 2014) pending FDA guidance

Proellex®

Uterine Fibroids

Phase 2B (vaginal)

Initiate a Phase 2B study (vaginal delivery) (Q1 2014)

Phase 2 (oral)

Lift full clinical hold and initiate efficacy study (low dose oral) (Q1 2014)

Endometriosis

Phase 2

Complete Phase 2 study (oral delivery) (Q3 2014)

We also continue to maintain our patent portfolio of our phentolamine-based products for the treatment of sexual dysfunction.

On June 25, 2013, we completed a public offering of 4,312,500 shares of our common stock at a price per share of $19.00. Net proceeds to us, after deducting underwriter’s fees and offering expenses, were approximately $76.8 million.

As of September 30, 2013, we had accumulated losses of $230.5 million, approximately $81.8 million in cash and cash equivalents, and our accounts payable and accrued expenses were approximately $3.2 million. We anticipate that our current liquidity will be sufficient to continue the development of our product candidates through the NDA filing of both products. We continue to explore potential corporate partnering opportunities for assistance in the clinical development funding and commercialization of our products, as appropriate; however, there can be no assurance that an acceptable corporate partnering opportunity will be successfully completed or that our current liquidity will be sufficient to fund all of our product development needs.

X

- Details

Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 50

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=28200181&loc=SL6228881-111685

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 720

-SubTopic 15

-URI http://asc.fasb.org/subtopic&trid=2122524

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6359566&loc=d3e326-107755

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 10

-Section 45

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=7668296&loc=d3e288-107754

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-URI http://asc.fasb.org/subtopic&trid=2197480

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=18733093&loc=d3e5614-111684

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 915

-SubTopic 235

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6472506&loc=d3e38932-110933

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 852

-SubTopic 10

-URI http://asc.fasb.org/subtopic&trid=2209116

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 272

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055

Reference 11: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 275

-SubTopic 10

-URI http://asc.fasb.org/subtopic&trid=2134480

Reference 12: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 10

-URI http://asc.fasb.org/subtopic&trid=2122150

+ Details

Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

EXCEL 22 Financial_Report.xls IDEA: XBRL DOCUMENT begin 644 Financial_Report.xls M[[N_34E-12U697)S:6]N.B`Q+C`-"E@M1&]C=6UE;G0M5'EP93H@5V]R:V)O M;VL-"D-O;G1E;G0M5'EP93H@;75L=&EP87)T+W)E;&%T960[(&)O=6YD87)Y M/2(M+2TM/5].97AT4&%R=%\T8V4W-F8Y.5\S-#=B7S0P-V-?.#8R.5\P.6,Y M-&4W9#EA93(B#0H-"E1H:7,@9&]C=6UE;G0@:7,@82!3:6YG;&4@1FEL92!7 M96(@4&%G92P@86QS;R!K;F]W;B!A'!L;W)E&UL;G,Z=CTS1")U&UL;G,Z;STS1")U&UL/@T*(#QX.D5X8V5L5V]R:V)O;VL^#0H@(#QX M.D5X8V5L5V]R:W-H965T5]);F9O#I%>&-E;%=O#I%>&-E;%=O#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/D-/3E-/3$E$051%1%]35$%414U%3E137T]&7U-4 M3SPO>#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O M#I.86UE/@T*("`@ M(#QX.E=O#I%>&-E M;%=O#I.86UE/D]R9V%N:7IA=&EO;E]/<&5R871I M;VYS7V%N9%],:3PO>#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I. M86UE/E!A=&5N='-?86YD7U!A=&5N=%]!<'!L:6-A=&EO;CPO>#I.86UE/@T* M("`@(#QX.E=O#I% M>&-E;%=O#I.86UE/D%C8W)U961?17AP96YS97,\ M+W@Z3F%M93X-"B`@("`\>#I7;W)K#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE M/D-O;6UI=&UE;G1S7V%N9%]#;VYT:6YG96YC:65S/"]X.DYA;64^#0H@("`@ M/'@Z5V]R:W-H965T4V]U#I%>&-E;%=OF%T:6]N7T]P97)A=&EO M;G-?86YD7TQI,3PO>#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I. M86UE/D%C8W)U961?17AP96YS97-?5&%B;&5S/"]X.DYA;64^#0H@("`@/'@Z M5V]R:W-H965T4V]U#I%>&-E;%=O#I%>&-E;%=OF%T M:6]N7T]P97)A=&EO;G-?86YD7TQI,CPO>#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/D]R9V%N:7IA=&EO;E]/<&5R871I;VYS7V%N9%], M:3,\+W@Z3F%M93X-"B`@("`\>#I7;W)K#I%>&-E;%=O'!E;G-E#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I!8W1I=F53:&5E=#XP/"]X.D%C=&EV95-H M965T/@T*("`\>#I0#I%>&-E;%=O7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\ M:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E M;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^4V5P(#,P M+`T*"0DR,#$S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)U$S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^)SQS<&%N/CPO6UB;VP\+W1D/@T*("`@("`@("`\=&0@8VQA M'0^)SQS<&%N/CPO'0^)U)%4%)/4R!42$5205!%551)0U,@24Y# M+CQS<&%N/CPO2!#96YT3PO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^)S`P,#`X.32!&:6QE3PO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^)T%C8V5L97)A=&5D($9I;&5R/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^)SQS<&%N/CPO M7!E.B!T97AT M+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^ M#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT M/3-$)W1E>'0O:'1M;#L@8VAA'0^)SQS<&%N M/CPO'!E;G-E&5D M(&%S'0^)R9N8G-P.R9N8G-P.SQS<&%N/CPO2!S=&]C:RP@,3$R+#,U,"!S:&%R97,\+W1D/@T*("`@("`@("`\ M=&0@8VQA3PO=&0^#0H@("`@("`@(#QT9"!C;&%S7!E.B!T97AT+VAT;6P[(&-H87)S970] M(G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T M<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@ M8VAAF5D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XW-2PP,#`L M,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S2!S=&]C:RP@7!E.B!T97AT+VAT;6P[(&-H87)S M970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@ M:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M M;#L@8VAA&-E<'0@4VAA M'0^)SQS<&%N/CPO'!E;G-E'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'!E;G-E/"]T9#X-"B`@("`@("`@/'1D(&-L M87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0O:F%V87-C M3X-"B`@("`\=&%B;&4@ M8VQA'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO&5R8VES92!O9B!S M=&]C:R!O<'1I;VYS("AI;B!S:&%R97,I/"]T9#X-"B`@("`@("`@/'1D(&-L M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`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`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ-S<\ M'0^)SQS<&%N/CPO'0^ M)SQS<&%N/CPO'!E;F1I='5R97,\+W1D/@T*("`@("`@("`\=&0@8VQA'0^)SQS<&%N/CPO6UE;G1S(&]N(&YO=&5S('!A>6%B;&4\+W1D/@T*("`@("`@("`\=&0@8VQA M'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA MF%T:6]N+"!/<&5R871I;VYS(&%N9"!,:7%U:61I='D\8G(^ M/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L3PO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^)R`\9&EV('-T>6QE/3-$)V-L96%R.F)O=&@[($9/3E0M M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE. M.B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L M(%-E6QE/3-$)V-L96%R.F)O=&@[($9/3E0M1D%- M24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1% M3E0Z(#`N-6EN.R!-05)'24XZ(#!I;B`P:6X@,'!T)R!A;&EG;CTS1&IU3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0G/E)E<')O3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0G M/B8C,38P.SPO9F]N=#X\+V1I=CX@/&1I=B!S='EL93TS1"=C;&5A6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM M97,@3F5W(%)O;6%N)RPG2!H>7!O9V]N861I6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG28C,38P.U!H87-E(#,@ M6QE/3-$)V-L96%R M.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z M(#$P<'0[5$585"U)3D1%3E0Z(#`N-6EN.R!-05)'24XZ(#!I;B`P:6X@,'!T M)R!A;&EG;CTS1&IU"8C,36UP M=&]M2!A;F0@2!I;B!L;W<@;W)A;"!D;W-E"8C,32P\+V9O;G0^(#QF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P="<^ M=V4@:&%V92!C;VUP;&5T960@82!0:&%S92`Q+S(@=F%G:6YA;"!A9&UI;FES M=')A=&EO;B!S='5D>2!F;W(@=71E6QE/3-$)T9/3E0M1D%-24Q9 M.B`G5&EM97,@3F5W(%)O;6%N)RPG6QE/3-$)V-L96%R.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2 M;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P:6X@,&EN(#!P="<@86QI M9VX],T1J=7-T:69Y/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P="<^ M)B,Q-C`[/"]F;VYT/CPO9&EV/B`\9&EV('-T>6QE/3-$)V-L96%R.F)O=&@[ M($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0G M/CPO9&EV/B`\9&EV('-T>6QE/3-$)V-L96%R.F)O=&@[($9/3E0M1D%-24Q9 M.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P:6X@ M,&EN(#!P="<^(#QF;VYT('-T>6QE/3-$)T-/3$]2.B!B;&%C:SL@1D].5"U3 M25I%.B`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`\+W1D/B`\+W1R/B`\='(^(#QT9"!S='EL M93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/ M3E0M1D%-24Q9.B!4:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE M/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO28C,38P.W-T=61Y)B,Q M-C`[*&QO=R8C,38P.V1O6QE/3-$)U1%6%0M M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q) M1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ M(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)V-L96%R.F)O=&@[($9/3E0M1D%-24Q9 M.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0G/CPO9&EV/B`\9&EV M('-T>6QE/3-$)V-L96%R.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2 M;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#`N-6EN.R!-05)' M24XZ(#!I;B`P:6X@,'!T)R!A;&EG;CTS1&IU3X\9F]N="!S='EL93TS M1"=&3TY4+5-)6D4Z(#$P<'0G/E=E(&%L6QE/3-$)V-L96%R.F)O M=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P M<'0[5$585"U)3D1%3E0Z(#`N-6EN.R!-05)'24XZ(#!I;B`P:6X@,'!T)R!A M;&EG;CTS1&IU3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0G M/D]N($IU;F4@,C4L(#(P,3,L('=E(&-O;7!L971E9"!A('!U8FQI8R!O9F9E M6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@ M3F5W(%)O;6%N)RPG'!E;G-E6QE/3-$)T9/3E0M1D%- M24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG3X\9F]N="!S='EL93TS1"=&3TY4+5-) M6D4Z(#$P<'0G/B8C,38P.SPO9F]N=#X\+V1I=CX@/&1I=B!S='EL93TS1"=C M;&5A2`D/&9O;G0@ M6%B;&4@86YD(&%C8W)U960@97AP96YS97,@=V5R92!A<'!R;WAI;6%T96QY M("0\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@)U1I;65S($YE=R!2;VUA M;B6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W M(%)O;6%N)RPG2!W:6QL(&)E('-U9F9I8VEE;G0@=&\@9G5N9"!A M;&P@;V8@;W5R('!R;V1U8W0@9&5V96QO<&UE;G0@;F5E9',N/"]F;VYT/CPO M9&EV/B`\+V1I=CX@/'1A8FQE(&)O6QE/3-$)W=I9'1H M.C$P,"4[('1A8FQE+6QA>6]U=#IF:7AE9#LG(&-E;&QS<&%C:6YG/3-$,"!C M96QL<&%D9&EN9STS1#`^/'1R/CQT9#X\+W1D/CPO='(^/"]T86)L93X\'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA#L@1D].5#H@,3!P="!4 M:6UE6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O M;6%N)RPG6QE/3-$)V-L96%R.F)O=&@[($9/3E0M1D%- M24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P M:6X@,&EN(#!P=#L@5$585"U)3D1%3E0Z(#`N-6EN)R!A;&EG;CTS1&IU3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0G/D%S(&]F(%-E<'1E M;6)E&EM871E;'D@)#QF;VYT('-T M>6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG6QE/3-$)T9/ M3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG&%L)B,Q-S0[(&%N9"`D/&9O;G0@"8C,36QE/3-$)T9/3E0M M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG6QE/3-$)V-L96%R.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2 M;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P:6X@,&EN(#!P=#L@5$58 M5"U)3D1%3E0Z(#`N-6EN)R!A;&EG;CTS1&IU3X\9F]N="!S='EL93TS M1"=&3TY4+5-)6D4Z(#$P<'0G/E-H;W5L9"!W92!N;W0@8V]N=&EN=64@9&5V M96QO<&UE;G0@;V8@96ET:&5R(&1R=6<@8V%N9&ED871E(&]R('-H;W5L9"!W M92!N;W0@8V]N=&EN=64@87,@82!G;VEN9R!C;VYC97)N+"!T:&4@F5D('!A=&5N="!A;F0@<&%T96YT(&%P<&QI8V%T:6]N M(&-O2!N;W0@8F4@3X-"CPO:'1M;#X-"@T*+2TM+2TM M/5].97AT4&%R=%\T8V4W-F8Y.5\S-#=B7S0P-V-?.#8R.5\P.6,Y-&4W9#EA M93(-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO-&-E-S9F.3E?,S0W M8E\T,#=C7S@V,CE?,#EC.31E-V0Y864R+U=O'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R#L@1D]. M5#H@,3!P="!4:6UE6QE/3-$)V-L96%R.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2 M;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P:6X@,&EN(#!P="<@86QI M9VX],T1J=7-T:69Y/CQS=')O;F<^/&9O;G0@6QE/3-$)T9/3E0M1D%- M24Q9.G1I;65S(&YE=R!R;VUA;BQT:6UE6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG'!E M;G-E6QE M/3-$)V-L96%R.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM& M3TY4+5-)6D4Z(#$P<'0G/B`F(S$V,#L\9F]N="!S='EL93TS1"=&3TY4+5-) M6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE3X\9F]N="!S='EL M93TS1"=&3TY4+5-)6D4Z(#$P<'0[($-/3$]2.B!B;&%C:R<^/&9O;G0@6QE/3-$)V-L96%R.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2 M;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P:6X@,&EN(#!P=#L@5$58 M5"U)3D1%3E0Z(#`N-6EN)R!A;&EG;CTS1&IU6QE/3-$)T9/3E0M1D%-24Q9.G1I;65S M(&YE=R!R;VUA;BQT:6UE3X@/&1I M=B!S='EL93TS1"=C;&5A#IA=71O.R!"3U)$15(M3$5&5#H@(SEE8C9C92`P M<'@@6QE/3-$)T9/ M3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@ M5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,#L@1D]. M5"U35%E,13H@;F]R;6%L.R!415A4+4%,24=..B!L969T)R!W:61T:#TS1#4W M)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@5D52 M5$E#04PM04Q)1TXZ(&UI9&1L93L@1D].5"U714E'2%0Z(#0P,#L@1D].5"U3 M5%E,13H@;F]R;6%L.R!415A4+4%,24=..B!L969T)R!W:61T:#TS1#$E/B`\ M9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@"!S M;VQI9#L@1D].5"U714E'2%0Z(#6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I M;65S($YE=R!2;VUA;CL@5D525$E#04PM04Q)1TXZ(&UI9&1L93L@1D].5"U7 M14E'2%0Z(#0P,#L@1D].5"U35%E,13H@;F]R;6%L.R!415A4+4%,24=..B!L M969T)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@ M"!S;VQI9#L@1D].5"U714E'2%0Z(#6QE/3-$)T9/3E0M4TE: M13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@5D525$E# M04PM04Q)1TXZ(&UI9&1L93L@1D].5"U714E'2%0Z(#0P,#L@1D].5"U35%E, M13H@;F]R;6%L.R!415A4+4%,24=..B!L969T)R!W:61T:#TS1#4W)3X@/&1I M=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@ M,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@5D525$E#04PM M04Q)1TXZ(&UI9&1L93L@1D].5"U714E'2%0Z(#0P,#L@1D].5"U35%E,13H@ M;F]R;6%L.R!415A4+4%,24=..B!L969T)R!W:61T:#TS1#$E/B`\9&EV/B8C M,38P.SPO9&EV/B`\+W1D/B`\=&0@"!S;VQI9#L@1D].5"U&04U)3%DZ M(%1I;65S($YE=R!2;VUA;CL@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D]. M5"U714E'2%0Z(#0P,#L@1D].5"U35%E,13H@;F]R;6%L.R!415A4+4%,24=. M.B!L969T)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\ M=&0@"!S;VQI9#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@ M5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,#L@1D]. M5"U35%E,13H@;F]R;6%L.R!415A4+4%,24=..B!R:6=H="<@=VED=&@],T0Q M,B4^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=&3TY4 M+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)T9/3E0M4TE: M13H@,3!P=#L@0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@0D]21$52+51/ M4#H@(S`P,#`P,"`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`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@"<@=VED=&@],T0Q,B4^(#QD:78^ M,C0U/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[ M($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)T9/ M3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@ M5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D%#2T=23U5.1#H@(V9F9F9F9CL@ M1D].5"U714E'2%0Z(#0P,#L@1D].5"U35%E,13H@;F]R;6%L.R!415A4+4%, M24=..B!R:6=H=#L@4$%$1$E.1RU224=(5#H@-7!X)R!W:61T:#TS1#$R)3X@ M/&1I=CXX-SPO9&EV/B`\+W1D/B`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`\9&EV/B8C M,38P.SPO9&EV/B`\+W1D/B`\+W1R/B`\='(^(#QT9"!S='EL93TS1"=&3TY4 M+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)T9/3E0M4TE:13H@,3!P M=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@5D525$E#04PM04Q) M1TXZ(&UI9&1L93L@0D%#2T=23U5.1#H@(V-C9F9C8SL@1D].5"U714E'2%0Z M(#0P,#L@1D].5"U35%E,13H@;F]R;6%L.R!415A4+4%,24=..B!L969T)R!W M:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@"<@=VED=&@],T0Q,B4^(#QD:78^-#(\+V1I=CX@/"]T9#X@/'1D M('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S M($YE=R!2;VUA;CL@5D525$E#04PM04Q)1TXZ(&UI9&1L93L@0D%#2T=23U5. M1#H@(V-C9F9C8SL@1D].5"U714E'2%0Z(#0P,#L@1D].5"U35%E,13H@;F]R M;6%L.R!415A4+4%,24=..B!L969T)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P M.SPO9&EV/B`\+W1D/B`\=&0@"<@=VED=&@],T0Q,B4^ M(#QD:78^,S`\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@ M,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@5D525$E#04PM M04Q)1TXZ(&UI9&1L93L@0D%#2T=23U5.1#H@(V-C9F9C8SL@1D].5"U714E' M2%0Z(#0P,#L@1D].5"U35%E,13H@;F]R;6%L.R!415A4+4%,24=..B!L969T M)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\+W1R/B`\ M='(^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9 M.B!4:6UE6QE/3-$)T9/3E0M4TE:13H@ M,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@5D525$E#04PM M04Q)1TXZ(&UI9&1L93L@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U714E' M2%0Z(#0P,#L@1D].5"U35%E,13H@;F]R;6%L.R!415A4+4%,24=..B!L969T M)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@"!S;VQI9#L@1D]. M5"U714E'2%0Z(#0P,#L@1D].5"U35%E,13H@;F]R;6%L.R!415A4+4%,24=. M.B!L969T)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\ M=&0@"!S;VQI M9#L@1D].5"U714E'2%0Z(#0P,#L@1D].5"U35%E,13H@;F]R;6%L.R!415A4 M+4%,24=..B!R:6=H=#L@4$%$1$E.1RU224=(5#H@-7!X)R!W:61T:#TS1#$R M)3X@/&1I=CXQ,#$\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE: M13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@5D525$E# M04PM04Q)1TXZ(&UI9&1L93L@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U7 M14E'2%0Z(#0P,#L@1D].5"U35%E,13H@;F]R;6%L.R!415A4+4%,24=..B!L M969T)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@ M"!S;VQI9#L@ M1D].5"U714E'2%0Z(#0P,#L@1D].5"U35%E,13H@;F]R;6%L.R!415A4+4%, M24=..B!L969T)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D M/B`\=&0@"!S M;VQI9#L@1D].5"U714E'2%0Z(#0P,#L@1D].5"U35%E,13H@;F]R;6%L.R!4 M15A4+4%,24=..B!R:6=H=#L@4$%$1$E.1RU224=(5#H@-7!X)R!W:61T:#TS M1#$R)3X@/&1I=CXY,3PO9&EV/B`\+W1D/B`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`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\ M=&0@"!S;VQI9#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@ M5D525$E#04PM04Q)1TXZ(&UI9&1L93L@0D%#2T=23U5.1#H@(V-C9F9C8SL@ M1D].5"U714E'2%0Z(#0P,#L@1D].5"U35%E,13H@;F]R;6%L.R!415A4+4%, M24=..B!L969T)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D M/B`\=&0@"!S;VQI9#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA M;CL@5D525$E#04PM04Q)1TXZ(&UI9&1L93L@0D%#2T=23U5.1#H@(V-C9F9C M8SL@1D].5"U714E'2%0Z(#0P,#L@1D].5"U35%E,13H@;F]R;6%L.R!415A4 M+4%,24=..B!R:6=H="<@=VED=&@],T0Q,B4^(#QD:78^)B,Q-C`[/"]D:78^ M(#PO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%- M24Q9.B!4:6UE6QE/3-$)T9/3E0M4TE: M13H@,3!P=#L@0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@6QE/3-$)T9/3E0M M4TE:13H@,3!P=#L@0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@ M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@5D525$E#04PM04Q)1TXZ M(&)O='1O;3L@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U714E'2%0Z(#0P M,#L@1D].5"U35%E,13H@;F]R;6%L.R!415A4+4%,24=..B!L969T)R!W:61T M:#TS1#4W)3X@/&1I=CY4;W1A;#PO9&EV/B`\+W1D/B`\=&0@6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U) M3%DZ(%1I;65S($YE=R!2;VUA;CL@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@ M0D%#2T=23U5.1#H@(V9F9F9F9CL@0D]21$52+4)/5%1/33H@(S`P,#`P,"`S M<'@@9&]U8FQE.R!&3TY4+5=%24=(5#H@-#`P.R!&3TY4+5-464Q%.B!N;W)M M86P[(%1%6%0M04Q)1TXZ(')I9VAT.R!0041$24Y'+5))1TA4.B`U<'@G('=I M9'1H/3-$,3(E/B`\9&EV/C,X,CPO9&EV/B`\+W1D/B`\=&0@6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U) M3%DZ(%1I;65S($YE=R!2;VUA;CL@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@ M0D%#2T=23U5.1#H@(V9F9F9F9CL@0D]21$52+4)/5%1/33H@(S`P,#`P,"`S M<'@@9&]U8FQE.R!&3TY4+5=%24=(5#H@-#`P.R!&3TY4+5-464Q%.B!N;W)M M86P[(%1%6%0M04Q)1TXZ(')I9VAT.R!0041$24Y'+5))1TA4.B`U<'@G('=I M9'1H/3-$,3(E/B`\9&EV/C4U.#PO9&EV/B`\+W1D/B`\=&0@6QE M/3-$)W=I9'1H.C$P,"4[('1A8FQE+6QA>6]U=#IF:7AE9#LG(&-E;&QS<&%C M:6YG/3-$,"!C96QL<&%D9&EN9STS1#`^/'1R/CQT9#X\+W1D/CPO='(^/"]T M86)L93X\'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^)SQS<&%N/CPO#L@1D].5#H@,3!P="!4:6UE M6QE/3-$)V-L M96%R.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-) M6D4Z(#$P<'0[34%21TE..B`P:6X@,&EN(#!P="<@86QI9VX],T1J=7-T:69Y M/CQS=')O;F<^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B`G M5&EM97,@3F5W(%)O;6%N)RPG6QE/3-$)T9/3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT/CPO M9&EV/B`\9&EV('-T>6QE/3-$)V-L96%R.F)O=&@[($9/3E0M1D%-24Q9.E1I M;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P:6X@,&EN M(#!P=#L@5$585"U)3D1%3E0Z(#`N-6EN)R!A;&EG;CTS1&IU2!D:79I9&EN9R!N970@;&]S2!T:&4@ M=V5I9VAT960@879E2!S=&]C:R!M971H;V0@=&\@<&]T96YT:6%L;'D@9&EL=71I=F4@;W5T6QE/3-$)V-L96%R.F)O=&@[($9/3E0M1D%-24Q9.E1I M;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P:6X@,&EN M(#!P=#L@5$585"U)3D1%3E0Z(#`N-6EN)R!A;&EG;CTS1&IU3X\ M9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($-/3$]2.B!B;&%C:R<^ M5&AE(&9O;&QO=VEN9R!T86)L92!P3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P M<'0[($-/3$]2.B!B;&%C:R<^("8C,38P.SPO9F]N=#X\+V1I=CX@/&1I=B!S M='EL93TS1"=C;&5A6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ M(%1I;65S($YE=R!2;VUA;CL@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D]. M5"U714E'2%0Z(#6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I M;65S($YE=R!2;VUA;CL@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D]21$52 M+4)/5%1/33H@(S`P,#`P,"`Q<'@@"!S;VQI M9#L@1D].5"U714E'2%0Z(#6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ M(%1I;65S($YE=R!2;VUA;CL@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D]. M5"U714E'2%0Z(#6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@0D]21$52+51/4#H@(S`P M,#`P,"`Q<'@@"!S;VQI9#L@ M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@5D525$E#04PM04Q)1TXZ M(&UI9&1L93L@1D].5"U714E'2%0Z(#"!S;VQI9#L@1D].5"U714E'2%0Z(#6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S M($YE=R!2;VUA;CL@5D525$E#04PM04Q)1TXZ(&UI9&1L93L@1D].5"U714E' M2%0Z(#"!S;VQI9#L@1D].5"U714E'2%0Z(#6QE/3-$)T9/3E0M4TE: M13H@,3!P=#L@0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@"!S;VQI9#L@1D].5"U&04U)3%DZ(%1I;65S($YE M=R!2;VUA;CL@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D]21$52+4)/5%1/ M33H@(S`P,#`P,"`Q<'@@6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ M(%1I;65S($YE=R!2;VUA;CL@5D525$E#04PM04Q)1TXZ(&UI9&1L93L@1D]. M5"U714E'2%0Z(#0P,#L@1D].5"U35%E,13H@;F]R;6%L.R!415A4+4%,24=. M.B!L969T)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\ M=&0@"!S;VQI9#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@ M5D525$E#04PM04Q)1TXZ(&UI9&1L93L@1D].5"U714E'2%0Z(#0P,#L@1D]. M5"U35%E,13H@;F]R;6%L.R!415A4+4%,24=..B!L969T)R!W:61T:#TS1#$E M/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@"!S;VQI9#L@1D]. M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@5D525$E#04PM04Q)1TXZ(&UI M9&1L93L@1D].5"U714E'2%0Z(#0P,#L@1D].5"U35%E,13H@;F]R;6%L.R!4 M15A4+4%,24=..B!R:6=H="<@=VED=&@],T0Q,R4^(#QD:78^)B,Q-C`[/"]D M:78^(#PO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M M1D%-24Q9.B!4:6UE6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@0D]21$52+51/ M4#H@(S`P,#`P,"`Q<'@@6QE/3-$ M)T9/3E0M4TE:13H@,3!P=#L@0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@6QE/3-$)T9/3E0M4TE: M13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@5D525$E# M04PM04Q)1TXZ(&UI9&1L93L@1D].5"U714E'2%0Z(#0P,#L@1D].5"U35%E, M13H@;F]R;6%L.R!415A4+4%,24=..B!L969T)R!W:61T:#TS1#$E/B`\9&EV M/B8C,38P.SPO9&EV/B`\+W1D/B`\+W1R/B`\='(^(#QT9"!S='EL93TS1"=& M3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U) M3%DZ(%1I;65S($YE=R!2;VUA;CL@5D525$E#04PM04Q)1TXZ(&UI9&1L93L@ M0D%#2T=23U5.1#H@(V-C9F9C8SL@1D].5"U714E'2%0Z(#0P,#L@1D].5"U3 M5%E,13H@;F]R;6%L.R!415A4+4%,24=..B!L969T)R!W:61T:#TS1#$E/B`\ M9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@6QE/3-$)T9/3E0M M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@5D52 M5$E#04PM04Q)1TXZ(&)O='1O;3L@0D%#2T=23U5.1#H@(V-C9F9C8SL@1D]. M5"U714E'2%0Z(#0P,#L@1D].5"U35%E,13H@;F]R;6%L.R!415A4+4%,24=. M.B!L969T)R!W:61T:#TS1#$E/B`\9&EV/B0\+V1I=CX@/"]T9#X@/'1D('-T M>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE M=R!2;VUA;CL@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D%#2T=23U5.1#H@ M(V-C9F9C8SL@1D].5"U714E'2%0Z(#0P,#L@1D].5"U35%E,13H@;F]R;6%L M.R!415A4+4%,24=..B!R:6=H="<@=VED=&@],T0Q,R4^(#QD:78^*#0L-3@S M*3PO9&EV/B`\+W1D/B`\=&0@6QE M/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2 M;VUA;CL@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D%#2T=23U5.1#H@(V-C M9F9C8SL@1D].5"U714E'2%0Z(#0P,#L@1D].5"U35%E,13H@;F]R;6%L.R!4 M15A4+4%,24=..B!L969T)R!W:61T:#TS1#$E/B`\9&EV/B0\+V1I=CX@/"]T M9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ M(%1I;65S($YE=R!2;VUA;CL@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D%# M2T=23U5.1#H@(V-C9F9C8SL@1D].5"U714E'2%0Z(#0P,#L@1D].5"U35%E, M13H@;F]R;6%L.R!415A4+4%,24=..B!R:6=H="<@=VED=&@],T0Q,R4^(#QD M:78^*#$P+#$R,RD\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE: M13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@5D525$E# M04PM04Q)1TXZ(&UI9&1L93L@0D%#2T=23U5.1#H@(V-C9F9C8SL@1D].5"U7 M14E'2%0Z(#0P,#L@1D].5"U35%E,13H@;F]R;6%L.R!415A4+4%,24=..B!L M969T)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\+W1R M/B`\='(^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%- M24Q9.B!4:6UE6QE/3-$)T9/3E0M4TE: M13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@5D525$E# M04PM04Q)1TXZ(&)O='1O;3L@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U7 M14E'2%0Z(#0P,#L@1D].5"U35%E,13H@;F]R;6%L.R!415A4+4%,24=..B!L M969T)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`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`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@"<@=VED=&@],T0Q,R4^(#QD:78^,C`L,#8V/"]D:78^(#PO=&0^ M(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4 M:6UE6QE/3-$)T9/3E0M4TE:13H@,3!P M=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@5D525$E#04PM04Q) M1TXZ(&)O='1O;3L@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U714E'2%0Z M(#0P,#L@1D].5"U35%E,13H@;F]R;6%L.R!415A4+4%,24=..B!L969T)R!W M:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D]. M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@5D525$E#04PM04Q)1TXZ(&)O M='1O;3L@0D%#2T=23U5.1#H@(V-C9F9C8SL@1D].5"U714E'2%0Z(#0P,#L@ M1D].5"U35%E,13H@;F]R;6%L.R!415A4+4%,24=..B!L969T)R!W:61T:#TS M1#,Y)3X@/&1I=CY"87-I8R!A;F0@9&EL=71E9"!L;W-S('!E6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@0T],3U(Z(&)L M86-K)SX@)B,Q-C`[/"]F;VYT/CPO9&EV/B`\9&EV('-T>6QE/3-$)V-L96%R M.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z M(#$P<'0[34%21TE..B`P:6X@,&EN(#!P=#L@5$585"U)3D1%3E0Z(#`N,C5I M;B<@86QI9VX],T1J=7-T:69Y/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@ M,3!P="<^4&]T96YT:6%L(&-O;6UO;B!S=&]C:R!O9B`\9F]N="!S='EL93TS M1"=&3TY4+49!34E,63H@)U1I;65S($YE=R!2;VUA;B2P@=V5R92!E>&-L=61E9"!F2!W97)E(&%N=&DM9&EL=71I=F4N/&9O;G0@6QE/3-$)T9/ M3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG6QE/3-$)T9/3E0M1D%-24Q9.B`G M5&EM97,@3F5W(%)O;6%N)RPG2`R,#$Q+CQF;VYT('-T>6QE M/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R M=%\T8V4W-F8Y.5\S-#=B7S0P-V-?.#8R.5\P.6,Y-&4W9#EA93(-"D-O;G1E M;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO-&-E-S9F.3E?,S0W8E\T,#=C7S@V M,CE?,#EC.31E-V0Y864R+U=O'0O:'1M;#L@8VAA'0^)R`\9&EV M('-T>6QE/3-$)V-L96%R.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2 M;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q M,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E6QE/3-$)V-L96%R M.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z M(#$P<'0[34%21TE..B`P:6X@,&EN(#!P="<@86QI9VX],T1J=7-T:69Y/CQB M/CQS=')O;F<^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B`G M5&EM97,@3F5W(%)O;6%N)RPG6QE/3-$)V-L96%R.F)O=&@[($9/3E0M1D%- M24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1% M3E0Z(#`N,C5I;CL@34%21TE..B`P:6X@,&EN(#!P="<@86QI9VX],T1J=7-T M:69Y/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F M;VYT/CPO9&EV/B`\9&EV('-T>6QE/3-$)V-L96%R.F)O=&@[($9/3E0M1D%- M24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1% M3E0Z(#`N,C5I;CL@34%21TE..B`P:6X@,&EN(#!P="<@86QI9VX],T1J=7-T M:69Y/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P="<^5&AE&%L('!R;V1U M8W0@8V%N9&ED871E(&EN8VQU9&5S(#QF;VYT('-T>6QE/3-$)T9/3E0M1D%- M24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG2!I;F1I M=FED=6%L(&AO;&1S(#QF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B`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`N-6EN M.R!-05)'24XZ(#!I;B`P:6X@,'!T)R!A;&EG;CTS1&IU3X\9F]N="!S M='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0G/D]N($IU;'D@,3DL(#(P,3,L('=E M(')E8V5I=F5D(&$@;&5T=&5R(&9R;VT@1'(N($AA6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM M97,@3F5W(%)O;6%N)RPG2!S=&%T=7,@;V8@=&AE M(&QA=W-U:70@86YD('5N8V5R=&%I;G1I97,@&5D.R<@ M8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,#X\='(^/'1D/CPO=&0^ M/"]T7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI M(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS M1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA7!E/3-$=&5X="]J879A2`H5&%B;&5S*3QB#L@ M1D].5#H@,3!P="!4:6UE6QE/3-$)V-L96%R.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE M=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P:6X@,&EN(#!P="<^ M(#QF;VYT('-T>6QE/3-$)T-/3$]2.B!B;&%C:SL@1D].5"U325I%.B`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`\+W1D/B`\+W1R/B`\='(^(#QT9"!S='EL93TS1"=415A4 M+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9 M.B!4:6UE6QE/3-$)U1% M6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO28C,38P.W-T=61Y)B,Q-C`[*&QO=R8C M,38P.V1O6QE/3-$)U1%6%0M04Q)1TXZ(&QE M9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[ M($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/ M3E0M4U193$4Z(&YO28C,38P.RAO6QE/3-$)W=I9'1H.C$P,"4[ M('1A8FQE+6QA>6]U=#IF:7AE9#LG(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D M9&EN9STS1#`^/'1R/CQT9#X\+W1D/CPO='(^/"]T86)L93X\'0O:F%V87-C3X-"B`@ M("`\=&%B;&4@8VQA'0^)SQS<&%N/CPO'!E;G-E'0^)R`\9&EV('-T>6QE/3-$)V-L M96%R.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-) M6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE M=R!2;VUA;BP@5&EM97,L(%-E3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P M<'0[($-/3$]2.B!B;&%C:R<^/&9O;G0@6QE/3-$)V-L96%R.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE M=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P:6X@,&EN(#!P=#L@ M5$585"U)3D1%3E0Z(#`N-6EN)R!A;&EG;CTS1&IU6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@0T],3U(Z M(&)L86-K)SX@/"]F;VYT/CQS=')O;F<^/&9O;G0@6QE/3-$ M)V-L96%R.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4 M+5-)6D4Z(#$P<'0[34%21TE..B`P:6X@,&EN(#!P="<^(#QS=')O;F<^/&9O M;G0@6QE/3-$)V-L96%R M.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z M(#$P<'0[5$585"U!3$E'3CH@:G5S=&EF>3L@34%21TE..B`P:6X@,&EN(#!P M=#L@5$585"U)3D1%3E0Z(#`N-6EN)SX@/'-T6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@0T],3U(Z(&)L86-K)SX\ M+V9O;G0^/"]F;VYT/CPO6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@0T],3U(Z(&)L86-K)SX\+V9O;G0^ M/"]S=')O;F<^/"]D:78^(#PO9&EV/B`\9&EV('-T>6QE/3-$)V-L96%R.F)O M=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P M<'0[34%21TE..B`P:6X@,&EN(#!P=#L@5$585"U)3D1%3E0Z(#`N-6EN)R!A M;&EG;CTS1&IU"!S;VQI9#L@34%21TE..B`P<'@Z875T;SL@0D]2 M1$52+4Q%1E0Z(",Y96(V8V4@,'!X('-O;&ED.R!724142#H@.#8E)R!C96QL M6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S M($YE=R!2;VUA;CL@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D]21$52+4)/ M5%1/33H@(S`P,#`P,"`Q<'@@6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@ M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@5D525$E#04PM04Q)1TXZ M(&)O='1O;3L@0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'@@6QE M/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2 M;VUA;CL@5D525$E#04PM04Q)1TXZ(&UI9&1L93L@1D].5"U714E'2%0Z(#0P M,#L@1D].5"U35%E,13H@;F]R;6%L.R!415A4+4%,24=..B!L969T)R!W:61T M:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\+W1R/B`\='(^(#QT M9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE M6QE M/3-$)T9/3E0M4TE:13H@,3!P=#L@0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@ M6QE/3-$)T9/3E0M4TE:13H@,3!P M=#L@0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U& M04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@5D525$E#04PM04Q)1TXZ(&UI9&1L M93L@1D].5"U714E'2%0Z(#0P,#L@1D].5"U35%E,13H@;F]R;6%L.R!415A4 M+4%,24=..B!L969T)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\ M+W1D/B`\+W1R/B`\='(^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[ M($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D]. M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@5D525$E#04PM04Q)1TXZ(&)O M='1O;3L@0D%#2T=23U5.1#H@(V-C9F9C8SL@1D].5"U714E'2%0Z(#0P,#L@ M1D].5"U35%E,13H@;F]R;6%L.R!415A4+4%,24=..B!L969T)R!W:61T:#TS M1#$E/B`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`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`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`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@"<@=VED=&@],T0Q,B4^(#QD:78^.#<\+V1I=CX@/"]T9#X@/'1D('-T M>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE M=R!2;VUA;CL@5D525$E#04PM04Q)1TXZ(&UI9&1L93L@0D%#2T=23U5.1#H@ M(V9F9F9F9CL@1D].5"U714E'2%0Z(#0P,#L@1D].5"U35%E,13H@;F]R;6%L M.R!415A4+4%,24=..B!L969T)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO M9&EV/B`\+W1D/B`\=&0@"<@=VED=&@],T0Q,B4^(#QD M:78^,3DR/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P M<'0[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U& M04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@5D525$E#04PM04Q)1TXZ(&)O='1O M;3L@0D%#2T=23U5.1#H@(V-C9F9C8SL@1D].5"U714E'2%0Z(#0P,#L@1D]. M5"U35%E,13H@;F]R;6%L.R!415A4+4%,24=..B!L969T)R!W:61T:#TS1#$E M/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@6QE/3-$ M)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA M;CL@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D%#2T=23U5.1#H@(V-C9F9C M8SL@1D].5"U714E'2%0Z(#0P,#L@1D].5"U35%E,13H@;F]R;6%L.R!415A4 M+4%,24=..B!L969T)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\ M+W1D/B`\=&0@6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D]. M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@5D525$E#04PM04Q)1TXZ(&)O M='1O;3L@0D%#2T=23U5.1#H@(V9F9F9F9CL@0D]21$52+4)/5%1/33H@(S`P M,#`P,"`Q<'@@6QE/3-$)T9/3E0M4TE:13H@,3!P M=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@5D525$E#04PM04Q) M1TXZ(&)O='1O;3L@0D%#2T=23U5.1#H@(V9F9F9F9CL@0D]21$52+4)/5%1/ M33H@(S`P,#`P,"`Q<'@@"<@=VED=&@],T0Q,B4^(#QD:78^,3`Q/"]D:78^(#PO=&0^(#QT M9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE M6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@ M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@5D525$E#04PM04Q)1TXZ M(&)O='1O;3L@0D%#2T=23U5.1#H@(V9F9F9F9CL@0D]21$52+4)/5%1/33H@ M(S`P,#`P,"`Q<'@@6QE/3-$)T9/3E0M4TE:13H@ M,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@5D525$E#04PM M04Q)1TXZ(&)O='1O;3L@0D%#2T=23U5.1#H@(V9F9F9F9CL@0D]21$52+4)/ M5%1/33H@(S`P,#`P,"`Q<'@@"<@=VED=&@],T0Q,B4^(#QD:78^.3$\+V1I=CX@/"]T9#X@ M/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I M;65S($YE=R!2;VUA;CL@5D525$E#04PM04Q)1TXZ(&UI9&1L93L@0D%#2T=2 M3U5.1#H@(V9F9F9F9CL@1D].5"U714E'2%0Z(#0P,#L@1D].5"U35%E,13H@ M;F]R;6%L.R!415A4+4%,24=..B!L969T)R!W:61T:#TS1#$E/B`\9&EV/B8C M,38P.SPO9&EV/B`\+W1D/B`\+W1R/B`\='(^(#QT9"!S='EL93TS1"=&3TY4 M+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)T9/3E0M4TE:13H@,3!P M=#L@0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@6QE/3-$)T9/3E0M4TE:13H@ M,3!P=#L@0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U) M3%DZ(%1I;65S($YE=R!2;VUA;CL@5D525$E#04PM04Q)1TXZ(&UI9&1L93L@ M0D%#2T=23U5.1#H@(V-C9F9C8SL@1D].5"U714E'2%0Z(#0P,#L@1D].5"U3 M5%E,13H@;F]R;6%L.R!415A4+4%,24=..B!L969T)R!W:61T:#TS1#$E/B`\ M9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\+W1R/B`\='(^(#QT9"!S='EL93TS M1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U) M3%DZ(%1I;65S($YE=R!2;VUA;CL@5D525$E#04PM04Q)1TXZ(&UI9&1L93L@ M0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U714E'2%0Z(#0P,#L@1D].5"U3 M5%E,13H@;F]R;6%L.R!415A4+4%,24=..B!L969T)R!W:61T:#TS1#$E/B`\ M9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@"!D;W5B;&4[($9/3E0M5T5)1TA4.B`T,#`[ M($9/3E0M4U193$4Z(&YO6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U) M3%DZ(%1I;65S($YE=R!2;VUA;CL@5D525$E#04PM04Q)1TXZ(&UI9&1L93L@ M0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U714E'2%0Z(#0P,#L@1D].5"U3 M5%E,13H@;F]R;6%L.R!415A4+4%,24=..B!L969T)R!W:61T:#TS1#$E/B`\ M9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@"!D;W5B;&4[($9/3E0M5T5)1TA4.B`T,#`[ M($9/3E0M4U193$4Z(&YO6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U) M3%DZ(%1I;65S($YE=R!2;VUA;CL@5D525$E#04PM04Q)1TXZ(&UI9&1L93L@ M0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U714E'2%0Z(#0P,#L@1D].5"U3 M5%E,13H@;F]R;6%L.R!415A4+4%,24=..B!L969T)R!W:61T:#TS1#$E/B`\ M9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\+W1R/B`\+W1A8FQE/B`\+V1I=CX@ M/"]D:78^(#PO9&EV/B`\+V1I=CX@/'1A8FQE(&)O6QE M/3-$)W=I9'1H.C$P,"4[('1A8FQE+6QA>6]U=#IF:7AE9#LG(&-E;&QS<&%C M:6YG/3-$,"!C96QL<&%D9&EN9STS1#`^/'1R/CQT9#X\+W1D/CPO='(^/"]T M86)L93X\'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^)SQS<&%N/CPO M#L@1D].5#H@,3!P="!4:6UE6QE/3-$)V-L96%R.F)O=&@[($9/3E0M1D%-24Q9 M.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P:6X@ M,&EN(#!P=#L@5$585"U)3D1%3E0Z(#`N-6EN)R!A;&EG;CTS1&IU6QE/3-$)V-L96%R M.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z M(#$P<'0[34%21TE..B`P:6X@,&EN(#!P=#L@5$585"U)3D1%3E0Z(#`N-6EN M)R!A;&EG;CTS1&IU"!S;VQI9#L@34%21TE..B`P:6X[($)/ M4D1%4BU,1494.B`C.65B-F-E(#!P>"!S;VQI9#L@5TE$5$@Z(#$P,"4G(&-E M;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`@86QI9VX],T1L969T/B`\ M='(^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9 M.B!4:6UE6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ M(%1I;65S($YE=R!2;VUA;CL@5D525$E#04PM04Q)1TXZ(&UI9&1L93L@1D]. M5"U714E'2%0Z(#6QE/3-$)T9/3E0M4TE:13H@ M,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@5D525$E#04PM M04Q)1TXZ(&)O='1O;3L@0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'@@6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S M($YE=R!2;VUA;CL@5D525$E#04PM04Q)1TXZ(&UI9&1L93L@1D].5"U714E' M2%0Z(#0P,#L@1D].5"U35%E,13H@;F]R;6%L.R!415A4+4%,24=..B!L969T M)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\+W1R/B`\ M='(^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9 M.B!4:6UE6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ M(%1I;65S($YE=R!2;VUA;CL@5D525$E#04PM04Q)1TXZ(&UI9&1L93L@1D]. M5"U714E'2%0Z(#"!S;VQI9#L@1D].5"U714E'2%0Z(#6QE/3-$)T9/ M3E0M4TE:13H@,3!P=#L@0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@"!S;VQI9#L@1D].5"U&04U)3%DZ(%1I M;65S($YE=R!2;VUA;CL@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D]21$52 M+4)/5%1/33H@(S`P,#`P,"`Q<'@@"!S;VQI9#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@5D52 M5$E#04PM04Q)1TXZ(&)O='1O;3L@0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q M<'@@6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@0D]21$52 M+51/4#H@(S`P,#`P,"`Q<'@@6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I M;65S($YE=R!2;VUA;CL@5D525$E#04PM04Q)1TXZ(&UI9&1L93L@1D].5"U7 M14E'2%0Z(#0P,#L@1D].5"U35%E,13H@;F]R;6%L.R!415A4+4%,24=..B!L M969T)R!W:61T:#TS1#,Y)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D M('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S M($YE=R!2;VUA;CL@5D525$E#04PM04Q)1TXZ(&UI9&1L93L@1D].5"U714E' M2%0Z(#0P,#L@1D].5"U35%E,13H@;F]R;6%L.R!415A4+4%,24=..B!L969T M)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@"!S;VQI9#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@5D525$E# M04PM04Q)1TXZ(&UI9&1L93L@1D].5"U714E'2%0Z(#0P,#L@1D].5"U35%E, M13H@;F]R;6%L.R!415A4+4%,24=..B!L969T)R!W:61T:#TS1#$E/B`\9&EV M/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@"!S;VQI9#L@1D].5"U&04U) M3%DZ(%1I;65S($YE=R!2;VUA;CL@5D525$E#04PM04Q)1TXZ(&UI9&1L93L@ M1D].5"U714E'2%0Z(#0P,#L@1D].5"U35%E,13H@;F]R;6%L.R!415A4+4%, M24=..B!R:6=H="<@=VED=&@],T0Q,R4^(#QD:78^)B,Q-C`[/"]D:78^(#PO M=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9 M.B!4:6UE6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@0D]21$52+51/4#H@(S`P M,#`P,"`Q<'@@6QE/3-$)T9/3E0M M4TE:13H@,3!P=#L@0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@6QE/3-$)T9/3E0M4TE:13H@,3!P M=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@5D525$E#04PM04Q) M1TXZ(&UI9&1L93L@1D].5"U714E'2%0Z(#0P,#L@1D].5"U35%E,13H@;F]R M;6%L.R!415A4+4%,24=..B!L969T)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P M.SPO9&EV/B`\+W1D/B`\=&0@"!S;VQI9#L@1D].5"U&04U)3%DZ(%1I M;65S($YE=R!2;VUA;CL@5D525$E#04PM04Q)1TXZ(&UI9&1L93L@1D].5"U7 M14E'2%0Z(#0P,#L@1D].5"U35%E,13H@;F]R;6%L.R!415A4+4%,24=..B!L M969T)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@ M"!S;VQI9#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@5D52 M5$E#04PM04Q)1TXZ(&UI9&1L93L@1D].5"U714E'2%0Z(#0P,#L@1D].5"U3 M5%E,13H@;F]R;6%L.R!415A4+4%,24=..B!R:6=H="<@=VED=&@],T0Q,R4^ M(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-) M6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)T9/3E0M4TE: M13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@5D525$E# M04PM04Q)1TXZ(&)O='1O;3L@0D%#2T=23U5.1#H@(V-C9F9C8SL@1D].5"U7 M14E'2%0Z(#0P,#L@1D].5"U35%E,13H@;F]R;6%L.R!415A4+4%,24=..B!L M969T)R!W:61T:#TS1#$E/B`\9&EV/B0\+V1I=CX@/"]T9#X@/'1D('-T>6QE M/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2 M;VUA;CL@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D%#2T=23U5.1#H@(V-C M9F9C8SL@1D].5"U714E'2%0Z(#0P,#L@1D].5"U35%E,13H@;F]R;6%L.R!4 M15A4+4%,24=..B!R:6=H="<@=VED=&@],T0Q,R4^(#QD:78^*#4L.3DX*3PO M9&EV/B`\+W1D/B`\=&0@6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@ M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@5D525$E#04PM04Q)1TXZ M(&UI9&1L93L@0D%#2T=23U5.1#H@(V-C9F9C8SL@1D].5"U714E'2%0Z(#0P M,#L@1D].5"U35%E,13H@;F]R;6%L.R!415A4+4%,24=..B!L969T)R!W:61T M:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`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`\9&EV/B8C,38P.SPO9&EV M/B`\+W1D/B`\=&0@"<@=VED=&@],T0Q,R4^(#QD:78^ M,34L-#(R/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P M<'0[($9/3E0M1D%-24Q9.B!4:6UE6QE M/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2 M;VUA;CL@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D%#2T=23U5.1#H@(V9F M9F9F9CL@1D].5"U714E'2%0Z(#0P,#L@1D].5"U35%E,13H@;F]R;6%L.R!4 M15A4+4%,24=..B!L969T)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV M/B`\+W1D/B`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`\9&EV/B8C,38P.SPO9&EV/B`\+W1D M/B`\+W1R/B`\='(^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/ M3E0M1D%-24Q9.B!4:6UE6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D]. M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@5D525$E#04PM04Q)1TXZ(&UI M9&1L93L@0D%#2T=23U5.1#H@(V-C9F9C8SL@1D].5"U714E'2%0Z(#0P,#L@ M1D].5"U35%E,13H@;F]R;6%L.R!415A4+4%,24=..B!L969T)R!W:61T:#TS M1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@ M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@5D525$E#04PM04Q)1TXZ M(&UI9&1L93L@0D%#2T=23U5.1#H@(V-C9F9C8SL@1D].5"U714E'2%0Z(#0P M,#L@1D].5"U35%E,13H@;F]R;6%L.R!415A4+4%,24=..B!L969T)R!W:61T M:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@6QE/3-$)T9/3E0M4TE:13H@,3!P M=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@5D525$E#04PM04Q) M1TXZ(&UI9&1L93L@0D%#2T=23U5.1#H@(V-C9F9C8SL@1D].5"U714E'2%0Z M(#0P,#L@1D].5"U35%E,13H@;F]R;6%L.R!415A4+4%,24=..B!L969T)R!W M:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@6QE/3-$)T9/3E0M4TE:13H@ M,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@5D525$E#04PM M04Q)1TXZ(&UI9&1L93L@0D%#2T=23U5.1#H@(V-C9F9C8SL@1D].5"U714E' M2%0Z(#0P,#L@1D].5"U35%E,13H@;F]R;6%L.R!415A4+4%,24=..B!L969T M)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@6QE/3-$)T9/3E0M4TE: M13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@5D525$E# M04PM04Q)1TXZ(&UI9&1L93L@0D%#2T=23U5.1#H@(V-C9F9C8SL@1D].5"U7 M14E'2%0Z(#0P,#L@1D].5"U35%E,13H@;F]R;6%L.R!415A4+4%,24=..B!L M969T)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\+W1R M/B`\+W1A8FQE/B`\+V1I=CX@/"]D:78^(#PO9&EV/B`\=&%B;&4@8F]R9&5R M/3-$,"`@&5D M.R<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,#X\='(^/'1D/CPO M=&0^/"]T7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S M8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I M=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA7!E/3-$=&5X="]J879A'0^)T-O;7!L971E($1% M6$$@"!;365M8F5R72!\(%5T97)I;F4@1FEB'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0@17AP M96-T960@36EL97-T;VYE*',I/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$ M=&5X=#XG3&EF="!F=6QL(&-L:6YI8V%L(&AO;&0@86YD(&EN:71I871E(&5F M9FEC86-Y('-T=61Y("AL;W<@9&]S92!O'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA2`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`@ M("`\=&%B;&4@8VQA'0^)SQS<&%N/CPO'0O M:F%V87-C3X-"B`@("`\ M=&%B;&4@8VQA'0^)SQS<&%N/CPO&-L=61E9"!F'0^)SQS M<&%N/CPO'0^)SQS<&%N/CPO&-L=61E9"!F3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\T8V4W-F8Y M.5\S-#=B7S0P-V-?.#8R.5\P.6,Y-&4W9#EA93(-"D-O;G1E;G0M3&]C871I M;VXZ(&9I;&4Z+R\O0SHO-&-E-S9F.3E?,S0W8E\T,#=C7S@V,CE?,#EC.31E M-V0Y864R+U=O'0O:'1M;#L@8VAA'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO7!E.B!T97AT+VAT;6P[(&-H87)S970] M(G5S+6%S8VEI(@T*#0H\>&UL('AM;&YS.F\],T0B=7)N.G-C:&5M87,M;6EC M'1087)T7S1C93 XML 23 FilingSummary.xml IDEA: XBRL DOCUMENT 2.4.0.8 Html 52 137 1 false 18 0 false 4 false false R1.htm 101 - Document - Document And Entity Information Sheet http://www.zonagen.com/role/DocumentAndEntityInformation Document And Entity Information true false R2.htm 102 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS Sheet http://www.zonagen.com/role/CondensedConsolidatedBalanceSheets CONDENSED CONSOLIDATED BALANCE SHEETS false false R3.htm 103 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) Sheet http://www.zonagen.com/role/CondensedConsolidatedBalanceSheetsParenthetical CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) false false R4.htm 104 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS Sheet http://www.zonagen.com/role/CondensedConsolidatedStatementsOfOperations CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS false false R5.htm 105 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY Sheet http://www.zonagen.com/role/ConsolidatedStatementsOfStockholdersEquity CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY false false R6.htm 106 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Parenthetical) Sheet http://www.zonagen.com/role/ConsolidatedStatementsOfStockholdersEquityParenthetical CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Parenthetical) false false R7.htm 107 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS Sheet http://www.zonagen.com/role/CondensedConsolidatedStatementsOfCashFlows CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS false false R8.htm 108 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Parenthetical) Sheet http://www.zonagen.com/role/CondensedConsolidatedStatementsOfCashFlowsParenthetical CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Parenthetical) false false R9.htm 109 - Disclosure - Organization, Operations and Liquidity Sheet http://www.zonagen.com/role/OrganizationOperationsAndLiquidity Organization, Operations and Liquidity false false R10.htm 110 - Disclosure - Patents and Patent Applications Sheet http://www.zonagen.com/role/PatentsAndPatentApplications Patents and Patent Applications false false R11.htm 111 - Disclosure - Accrued Expenses Sheet http://www.zonagen.com/role/AccruedExpenses Accrued Expenses false false R12.htm 112 - Disclosure - Loss Per Share Sheet http://www.zonagen.com/role/LossPerShare Loss Per Share false false R13.htm 113 - Disclosure - Commitments and Contingencies Sheet http://www.zonagen.com/role/CommitmentsAndContingencies Commitments and Contingencies false false R14.htm 114 - Disclosure - Organization, Operations and Liquidity (Tables) Sheet http://www.zonagen.com/role/OrganizationOperationsAndLiquidityTables Organization, Operations and Liquidity (Tables) false false R15.htm 115 - Disclosure - Accrued Expenses (Tables) Sheet http://www.zonagen.com/role/AccruedExpensesTables Accrued Expenses (Tables) false false R16.htm 116 - Disclosure - Loss Per Share (Tables) Sheet http://www.zonagen.com/role/LossPerShareTables Loss Per Share (Tables) false false R17.htm 117 - Disclosure - Organization, Operations and Liquidity (Product Development Pipeline) (Details) Sheet http://www.zonagen.com/role/OrganizationOperationsAndLiquidityProductDevelopmentPipelineDetails Organization, Operations and Liquidity (Product Development Pipeline) (Details) false false R18.htm 118 - Disclosure - Organization, Operations and Liquidity (Additional Information) (Details) Sheet http://www.zonagen.com/role/OrganizationOperationsAndLiquidityAdditionalInformationDetails Organization, Operations and Liquidity (Additional Information) (Details) false false R19.htm 119 - Disclosure - Patents and Patent Applications (Additional Information) (Details) Sheet http://www.zonagen.com/role/PatentsAndPatentApplicationsAdditionalInformationDetails Patents and Patent Applications (Additional Information) (Details) false false R20.htm 120 - Disclosure - Accrued Expenses (Details) Sheet http://www.zonagen.com/role/AccruedExpensesDetails Accrued Expenses (Details) false false R21.htm 121 - Disclosure - Loss Per Share (Calculation of Loss Per Share) (Details) Sheet http://www.zonagen.com/role/LossPerShareCalculationOfLossPerShareDetails Loss Per Share (Calculation of Loss Per Share) (Details) false false R22.htm 122 - Disclosure - Loss Per Share (Additional Information) (Details) Sheet http://www.zonagen.com/role/LossPerShareAdditionalInformationDetails Loss Per Share (Additional Information) (Details) false false R23.htm 123 - Disclosure - Commitments and Contingencies (Additional Information) (Details) Sheet http://www.zonagen.com/role/CommitmentsAndContingenciesAdditionalInformationDetails Commitments and Contingencies (Additional Information) (Details) false false All Reports Book All Reports Element us-gaap_IntangibleAssetsNetExcludingGoodwill had a mix of decimals attribute values: -3 0. 'Monetary' elements on report '118 - Disclosure - Organization, Operations and Liquidity (Additional Information) (Details)' had a mix of different decimal attribute values. Process Flow-Through: 102 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS Process Flow-Through: Removing column 'Sep. 30, 2012' Process Flow-Through: Removing column 'Dec. 31, 2011' Process Flow-Through: Removing column 'Aug. 19, 1987' Process Flow-Through: 103 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) Process Flow-Through: 104 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS Process Flow-Through: 106 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Parenthetical) Process Flow-Through: 107 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS Process Flow-Through: 108 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Parenthetical) rprx-20130930.xml rprx-20130930.xsd rprx-20130930_cal.xml rprx-20130930_def.xml rprx-20130930_lab.xml rprx-20130930_pre.xml true true XML 24 R3.htm IDEA: XBRL DOCUMENT v2.4.0.8

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) (USD $)

Sep. 30, 2013

Dec. 31, 2012

Preferred Stock, par value $ 0.001 $ 0.001

Preferred Stock, shares authorized 5,000,000 5,000,000

Preferred Stock, issued 0 0

Preferred Stock, outstanding 0 0

Common Stock, par value $ 0.001 $ 0.001

Common Stock, shares authorized 75,000,000 75,000,000

Common Stock, shares issued 23,121,959 17,272,505

Common Stock, shares outstanding 23,009,609 17,160,155

Treasury stock, shares 112,350 112,350

X

- Definition

Face amount or stated value per share of common stock.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition

The maximum number of common shares permitted to be issued by an entity's charter and bylaws.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockSharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29

-Article 5

+ Details

Name: us-gaap_PreferredStockParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition

The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29

-Article 5

+ Details

Name: us-gaap_PreferredStockSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29

-Article 5

+ Details

Name: us-gaap_PreferredStockSharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29

-Article 5

+ Details

Name: us-gaap_PreferredStockSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28,29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30

-Article 5

+ Details

Name: us-gaap_TreasuryStockShares

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

XML 25 R14.htm IDEA: XBRL DOCUMENT v2.4.0.8

Organization, Operations and Liquidity (Tables)
9 Months Ended

Sep. 30, 2013

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Product Development Pipeline

Our product development pipeline is summarized in the table below:

Product Candidate (Indication)
Androxal®

Status

Next Expected Milestone(s)

Secondary Hypogonadism

Phase 3

Complete DEXA study (Q4 2014) pending FDA guidance

Proellex®

Uterine Fibroids

Phase 2B (vaginal)

Initiate a Phase 2B study (vaginal delivery) (Q1 2014)

Phase 2 (oral)

Lift full clinical hold and initiate efficacy study (low dose oral) (Q1 2014)

Endometriosis

Phase 2

Complete Phase 2 study (oral delivery) (Q3 2014)

X

- Details

Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Tabular disclosure of product information that are included in the discussion of the nature of an entity's operations.

+ References

No definition available.

+ Details

Name: us-gaap_ScheduleOfProductInformationTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 26 R5.htm IDEA: XBRL DOCUMENT v2.4.0.8

CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (USD $)
In Thousands, except Share data

Total

Common Stock

Additional Paid-in Capital

Treasury Stock

Deficit Accumulated During the Development Stage

Beginning Balance at Dec. 31, 2011 $ 4,666 $ 12 $ 197,769 $ (1,380) $ (191,735)

Beginning Balance (in shares) at Dec. 31, 2011 12,470,694 112,350

Stock based option compensation 1,902 0 1,902 0 0

Issuance of 100 shares of common stock at a share price of $5.07 (in shares) 100 0

Issuance of shares of common stock, net of offering costs (in shares) 2,463,537 0

Exercise of stock options to purchase common stock for cash 121 0 121 0 0

Exercise of stock options to purchase common stock for cash (in shares) 16,488 0

Issuance of shares of common stock for the cashless exercise of stock options (in shares) 11,173 0

Exercise of Series B Warrants to purchase common stock for cash @ $2.49 per share 301 0 301 0 0

Exercise of Series B Warrants to purchase common stock for cash @ $2.49 per share (in shares) 121,079 0

Issuance of shares of common stock, net of offering costs 1 23,018 2 23,016 0 0

Issuance of shares of common stock, net of offering costs 1 (in shares) 2,145,636 0

Issuance of shares of common stock, net of offering costs 10,310 3 10,307 0 0

Net loss (10,123) 0 0 0 (10,123)

Ending Balance at Sep. 30, 2012 30,195 17 233,416 (1,380) (201,858)

Ending Balance (in shares) at Sep. 30, 2012 17,228,707 112,350

Beginning Balance at Dec. 31, 2012 23,034 17 234,299 (1,380) (209,902)

Beginning Balance (in shares) at Dec. 31, 2012 17,272,505 112,350

Stock based option compensation 2,258 0 2,258 0 0

Issuance of shares of common stock, net of offering costs (in shares) 4,312,500 0

Issuance of 871,634 shares of common stock for the cashless exercise of 872,133 Series A Warrants 0 1 (1) 0 0

Issuance of 871,634 shares of common stock for the cashless exercise of 872,133 Series A Warrants (in shares) 871,634 0

Issuance of 614,564 shares of common stock for the cashless exercise of 716,463 Series B Warrants 0 1 (1) 0 0

Issuance of 614,564 shares of common stock for the cashless exercise of 716,463 Series B Warrants (in shares) 614,564 0

Exercise of stock options to purchase common stock for cash 47 0 47 0 0

Exercise of stock options to purchase common stock for cash (in shares) 2,500 0

Issuance of shares of common stock for the cashless exercise of stock options (in shares) 5,407 0

Exercise of Series B Warrants to purchase common stock for cash @ $2.49 per share 107 0 107 0 0

Exercise of Series B Warrants to purchase common stock for cash @ $2.49 per share (in shares) 42,849 0

Issuance of shares of common stock, net of offering costs 76,764 4 76,760 0 0

Net loss (20,579) 0 0 0 (20,579)

Ending Balance at Sep. 30, 2013 $ 81,631 $ 23 $ 313,469 $ (1,380) $ (230,481)

Ending Balance (in shares) at Sep. 30, 2013 23,121,959 112,350

X

- Definition

The number of common stock issued during the period.

+ References

No definition available.

+ Details

Name: rprx_IssuanceOfCommonStockDuringPeriodShares

Namespace Prefix: rprx_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

Number of new stock issued during the period.

+ References

No definition available.

+ Details

Name: rprx_StockIssuedDuringPeriodSharesNewIssues1

Namespace Prefix: rprx_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

Stock issued during period for exercise value of warrant.

+ References

No definition available.

+ Details

Name: rprx_StockIssuedDuringPeriodSharesWarrantsExercisedCash

Namespace Prefix: rprx_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

Stock Issued During Period, Shares, Warrants Exercised Cashless

+ References

No definition available.

+ Details

Name: rprx_StockIssuedDuringPeriodSharesWarrantsExercisedCashless

Namespace Prefix: rprx_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

Stock Issued During Period, Shares, Warrants Exercised Cashless1

+ References

No definition available.

+ Details

Name: rprx_StockIssuedDuringPeriodSharesWarrantsExercisedCashless1

Namespace Prefix: rprx_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.

+ References

No definition available.

+ Details

Name: rprx_StockIssuedDuringPeriodValueNewIssues1

Namespace Prefix: rprx_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Stock issued during period for exercise value of warrants.

+ References

No definition available.

+ Details

Name: rprx_StockIssuedDuringPeriodValueWarrantsExercisedCash

Namespace Prefix: rprx_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Stock Issued During Period, Value, Warrants Exercised Cashless

+ References

No definition available.

+ Details

Name: rprx_StockIssuedDuringPeriodValueWarrantsExercisedCashless

Namespace Prefix: rprx_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Stock Issued During Period, Value, Warrants Exercised Cashless1

+ References

No definition available.

+ Details

Name: rprx_StockIssuedDuringPeriodValueWarrantsExercisedCashless1

Namespace Prefix: rprx_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

This element represents the amount of recognized equity-based compensation related to stock options during the period, that is, the amount recognized as expense in the income statement (or as asset if compensation is capitalized).

+ References

No definition available.

+ Details

Name: us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 20

-Article 9

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Other Comprehensive Income

-URI http://asc.fasb.org/extlink&oid=6519514

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Net Income

-URI http://asc.fasb.org/extlink&oid=6518256

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.19)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.18)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.22)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=28358780&loc=d3e565-108580

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 19

-Article 5

+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

+ Details

Name: us-gaap_SharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 310

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SAB TOPIC 4.E)

-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 4

-Section E

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29-31)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30, 31

-Article 5

+ Details

Name: us-gaap_StockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Number of new stock issued during the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30

-Article 5

+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

Number of shares (or other type of equity) issued during the period as a result of any equity-based compensation plan other than an employee stock ownership plan (ESOP), net of any shares forfeited. Shares issued could result from the issuance of restricted stock, the exercise of stock options, stock issued under employee stock purchase plans, and/or other employee benefit plans.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30

-Article 5

+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

Number of share options (or share units) exercised during the current period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28,29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)(iv)(2)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30

-Article 5

+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30, 31

-Article 5

+ Details

Name: us-gaap_StockIssuedDuringPeriodValueNewIssues

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Value of stock issued as a result of the exercise of stock options.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29-31)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30, 31

-Article 5

+ Details

Name: us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

XML 27 R2.htm IDEA: XBRL DOCUMENT v2.4.0.8

CONDENSED CONSOLIDATED BALANCE SHEETS (USD $)
In Thousands, unless otherwise specified

Sep. 30, 2013

Dec. 31, 2012

Current Assets

Cash and cash equivalents $ 81,828 $ 24,212

Prepaid expenses and other current assets 193 406

Total current assets 82,021 24,618

Fixed assets, net 87 53

Other assets, net 2,734 2,161

Total assets 84,842 26,832

Current Liabilities

Accounts payable 2,829 3,240

Accrued expenses 382 558

Total current liabilities 3,211 3,798

Commitments and contingencies (note 5)

Stockholders' Equity

Undesignated Preferred Stock, $.001 par value, 5,000,000 shares authorized, none issued and outstanding 0 0

Common Stock, $.001 par value, 75,000,000 shares authorized, 23,121,959and 17,272,505 shares issued, respectively and 23,009,609 and 17,160,155 shares outstanding, respectively 23 17

Additional paid-in capital 313,469 234,299

Cost of treasury stock, 112,350 shares (1,380) (1,380)

Deficit accumulated during the development stage (230,481) (209,902)

Total stockholders' equity 81,631 23,034

Total liabilities and stockholders' equity $ 84,842 $ 26,832

X

- Definition

Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 19

-Subparagraph a

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19(a))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_AccountsPayableCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 20

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.20)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_AccruedLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 31

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.30(a)(1))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_AdditionalPaidInCapital

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.18)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 12

-Article 7

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 18

-Article 5

+ Details

Name: us-gaap_Assets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.9)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6801-107765

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 9

-Article 5

+ Details

Name: us-gaap_AssetsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Details

Name: us-gaap_AssetsCurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash

-URI http://asc.fasb.org/extlink&oid=6506951

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash Equivalents

-URI http://asc.fasb.org/extlink&oid=6507016

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 1

-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.1)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3044-108585

+ Details

Name: us-gaap_CashAndCashEquivalentsAtCarryingValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 450

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=25496072&loc=d3e14326-108349

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.25)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 25

-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 19

-Article 7

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 17

-Article 9

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.9-03.17)

-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-03.(a),19)

-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

+ Details

Name: us-gaap_CommitmentsAndContingencies

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Cumulative net losses reported during the development stage.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 915

-SubTopic 210

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6472335&loc=d3e37729-110921

+ Details

Name: us-gaap_DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 2

-Subparagraph ((a)(1),(b))

-URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16323-109275

+ Details

Name: us-gaap_IntangibleAssetsNetExcludingGoodwill

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.32)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 25

-Article 7

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 32

-Article 5

+ Details

Name: us-gaap_LiabilitiesAndStockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.21)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 21

-Article 5

+ Details

Name: us-gaap_LiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_LiabilitiesCurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29

-Article 5

+ Details

Name: us-gaap_PreferredStockValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 8

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

+ Details

Name: us-gaap_PrepaidExpenseAndOtherAssetsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 360

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.13)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 13

-Subparagraph a

-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 8

-Article 7

+ Details

Name: us-gaap_PropertyPlantAndEquipmentNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 310

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SAB TOPIC 4.E)

-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 4

-Section E

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29-31)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30, 31

-Article 5

+ Details

Name: us-gaap_StockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_StockholdersEquityAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 30

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656

+ Details

Name: us-gaap_TreasuryStockValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

XML 28 R23.htm IDEA: XBRL DOCUMENT v2.4.0.8

Commitments and Contingencies (Additional Information) (Details)

Sep. 30, 2013

Domestic [Member]

Commitments and Contingencies [Line Items]

Number of patents 8

Number of pending patent applications 4

Foreign [Member]

Commitments and Contingencies [Line Items]

Number of patents 61

Number of pending patent applications 52

Third Party [Member]

Commitments and Contingencies [Line Items]

Number of patents 2

X

- Details

Name: rprx_CommitmentsAndContingenciesLineItems

Namespace Prefix: rprx_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Number of Patents

+ References

No definition available.

+ Details

Name: rprx_NumberOfPatents

Namespace Prefix: rprx_

Data Type: xbrli:integerItemType

Balance Type: na

Period Type: instant

X

- Definition

Number of Patents Pending

+ References

No definition available.

+ Details

Name: rprx_NumberOfPatentsPending

Namespace Prefix: rprx_

Data Type: xbrli:integerItemType

Balance Type: na

Period Type: instant

XML 29 R13.htm IDEA: XBRL DOCUMENT v2.4.0.8

Commitments and Contingencies
9 Months Ended

Sep. 30, 2013

Commitments and Contingencies Disclosure [Abstract]

Commitments and Contingencies

NOTE 5 —   Commitments and Contingencies

Therapeutic uses of our Androxal product candidate are covered in the United States by eight issued U.S. patents and four pending patent applications. Foreign coverage of therapeutic uses of our Androxal product candidate includes 61 issued foreign patents and 52 foreign pending patent applications. The issued patents and pending applications relate to methods for treating certain conditions including the treatment of testosterone deficiency in men, the treatment of diabetes mellitus Type 2, the treatment of metabolic syndrome and conditions associated therewith, and the treatment of infertility in hypogonadal men. Androxal (the trans-isomer of clomiphene) is purified from clomiphene citrate. A third party individual holds two issued patents related to the use of an anti-estrogen such as clomiphene citrate and others for use in the treatment of androgen deficiency and disorders related thereto. We requested re-examination of one of these patents by the U.S. Patent and Trademark Office (“PTO”) based on prior art. The patent holder amended the claims in the re-examination proceedings, which led the PTO to determine that the amended claims were patentable in view of those publications under consideration and a re-examination certificate was issued. We subsequently filed a second request for re-examination by the PTO in light of a number of additional publications. The request was granted and all of the claims were finally rejected by the PTO in the re-examination. The patent holder appealed the rejections to the PTO Board of Patent Appeals and Interferences (the “PTO Board”) which ultimately reversed the rejections of several dependent claims in view of those publications under consideration. The patent holder filed a Notice of Appeal to the Federal Circuit on September 28, 2010 contesting the rejections maintained by the PTO Board. A decision was rendered by the Federal Circuit on December 12, 2011, affirming the rejection of the appealed claims. The PTO issued an Ex Parte Reexamination Certificate on April 29, 2013, cancelling the rejected claims and confirming patentability of the remaining claims. Nevertheless, we believe that our development of Androxal does not infringe any of the remaining claims and that all of the remaining claims are invalid on various grounds including additional prior art publications. We also believe that the second of these two patents is invalid in view of published prior art not considered by the PTO. If necessary, we intend to vigorously defend any and all claims against the holder of such patents in a court of competent jurisdiction in order to develop Androxal further. Adverse determinations in litigation proceedings could require us to seek licenses from patent holders which may not be available on commercially reasonable terms, or at all, or may subject us to significant liabilities, in which case we may not be able to successfully commercialize or out-license Androxal until such patents expire or are otherwise no longer in force.

On July 19, 2013, we received a letter from Dr. Harry Fisch threatening to file a lawsuit against us and two of our executive officers (Joseph S. Podolski, President and Chief Executive Officer and Ron Wiehle, Executive Vice President), seeking addition of Dr. Harry Fisch as an inventor on three of our patents, U.S. Patent Nos. 7,173,064, 7,737,185 and 7,759,360, covering therapeutic uses of Androxal®. We believe that these allegations are without merit and on August 2, 2013, we commenced a lawsuit against Dr. Fisch in the U.S. District Court for the Southern District of Texas seeking a declaratory judgment that he should not be added as inventor to any of these patents. On October 2, 2013, Dr. Fisch filed his answer and counterclaims to our complaint. Dr. Fisch asserted counterclaims seeking correction of inventorship of the three patents at issue to name Dr. Fisch as a co-inventor of the applications leading these patents. Dr. Fisch also seeks reasonable attorney’s fees. Due to the preliminary status of the lawsuit and uncertainties related to litigation, we are unable to evaluate the likelihood of either a favorable or unfavorable outcome.

X

- Details

Name: us-gaap_CommitmentsAndContingenciesDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for commitments and contingencies.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.25)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6449706&loc=d3e16207-108621

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 460

-SubTopic 10

-Section 50

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=6398077&loc=d3e12565-110249

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 450

-SubTopic 20

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=25496072&loc=d3e14435-108349

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 440

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6394976&loc=d3e25287-109308

+ Details

Name: us-gaap_CommitmentsAndContingenciesDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 30 R16.htm IDEA: XBRL DOCUMENT v2.4.0.8

Loss Per Share (Tables)
9 Months Ended

Sep. 30, 2013

Earnings Per Share [Abstract]

Calculation of Loss Per Share

The following table presents information necessary to calculate loss per share for the three and nine month periods ended September 30, 2013 and 2012 (in thousands, except per share amounts):

Three Months Ended Sept. 30,

Nine Months Ended Sept. 30,

2013

2012

2013

2012

Net Loss

$

(5,998)

$

(4,583)

$

(20,579)

$

(10,123)

Average common shares outstanding

23,006

15,422

20,066

14,746

Basic and diluted loss per share

$

(0.26)

$

(0.30)

$

(1.03)

$

(0.69)

X

- Details

Name: us-gaap_EarningsPerShareAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

+ Details

Name: us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 31 R12.htm IDEA: XBRL DOCUMENT v2.4.0.8

Loss Per Share
9 Months Ended

Sep. 30, 2013

Earnings Per Share [Abstract]

Loss Per Share

NOTE 4 — Loss Per Share

Basic loss per share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the period. Diluted loss per share is computed using the average share price for the period and applying the treasury stock method to potentially dilutive outstanding options. In all applicable periods, all potential common stock equivalents were anti-dilutive and, accordingly, were not included in the computation of diluted loss per share.

The following table presents information necessary to calculate loss per share for the three and nine month periods ended September 30, 2013 and 2012 (in thousands, except per share amounts):

Three Months Ended Sept. 30,

Nine Months Ended Sept. 30,

2013

2012

2013

2012

Net Loss

$

(5,998)

$

(4,583)

$

(20,579)

$

(10,123)

Average common shares outstanding

23,006

15,422

20,066

14,746

Basic and diluted loss per share

$

(0.26)

$

(0.30)

$

(1.03)

$

(0.69)

Potential common stock of 3,975,430 and 5,264,207 common shares underlying stock options and warrants for the periods ended September 30, 2013 and 2012, respectively, were excluded from the above calculation of diluted loss per share because they were anti-dilutive. Other potential common stock at September 30, 2013 includes Series A Warrants to purchase 877,137 shares of our common stock at an exercise price of $0.01 and Series B Warrants to purchase 810,109 shares of our common stock at an exercise price of $2.49 issued in February 2011. Other potential common stock at September 30, 2012 includes Series A Warrants to purchase 1,749,270 shares of our common stock at an exercise price of $0.01 and Series B Warrants to purchase 1,569,421 shares of our common stock at an exercise price of $2.49 issued in February, 2011.

X

- Details

Name: us-gaap_EarningsPerShareAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for earnings per share.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1278-109256

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1252-109256

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 55

-Paragraph 52

-URI http://asc.fasb.org/extlink&oid=32703322&loc=d3e4984-109258

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.21)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_EarningsPerShareTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 32 R7.htm IDEA: XBRL DOCUMENT v2.4.0.8

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)
In Thousands, unless otherwise specified
9 Months Ended 313 Months Ended

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Cash Flows from Operating Activities

Net loss $ (20,579) $ (10,123) $ (230,481)

Gain on disposal of discontinued operations 0 0 (939)

Gain on disposal of fixed assets 0 0 (102)

Adjustments to reconcile net loss to net cash used in operating activities:

Noncash financing costs 0 0 316

Noncash inventory impairment 0 0 4,417

Noncash patent impairment 0 0 2,614

Noncash other income 0 0 (709)

Noncash decrease in accounts payable 0 0 (1,308)

Depreciation and amortization 177 106 4,478

Noncash stock-based compensation 2,258 1,902 14,576

Common stock issued for agreement not to compete 0 0 200

Series B Preferred Stock issued for consulting services 0 0 18

Changes in operating assets and liabilities (net effects of purchase of businesses in 1988 and 1994):

Increase in receivables 0 0 (199)

Increase in inventory 0 0 (4,447)

(Increase) decrease in prepaid expenses and other current assets 213 (352) 110

Increase (decrease) in accounts payable and accrued expenses (532) 367 11,087

Net cash used in operating activities (18,463) (8,100) (200,369)

Cash Flows from Investing Activities

Change in trading marketable securities 0 0 (191)

Capital expenditures (63) (54) (2,486)

Purchase of other assets (776) (578) (6,310)

Proceeds from sale of PP&E 0 0 225

Cash acquired in purchase of FTI 0 0 3

Proceeds from sale of subsidiary, less $12,345 for operating losses during 1990 phase-out period 0 0 138

Proceeds from sale of the assets of FTI 0 0 2,250

Increase in net assets held for disposal 0 0 (213)

Net cash used in investing activities (839) (632) (6,584)

Cash Flows from Financing Activities

Proceeds from issuance of common stock, net of offering costs 76,764 33,328 284,195

Exercise of stock options & warrants 154 422 951

Proceeds from a shareholder transaction 0 0 327

Proceeds from issuance of preferred stock 0 0 23,688

Purchase of treasury stock 0 0 (21,487)

Proceeds from issuance of notes payable 0 0 2,839

Principal payments on notes payable 0 0 (1,732)

Net cash provided by financing activities 76,918 33,750 288,781

Net increase in cash and cash equivalents 57,616 25,018 81,828

Cash and cash equivalents at beginning of period 24,212 4,565 0

Cash and cash equivalents at end of period $ 81,828 $ 29,583 $ 81,828

X

- Details

Name: us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount of noncash expense included in interest expense to issue debt and obtain financing associated with the related debt instruments. Alternate captions include noncash interest expense.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.8)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 8

-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 8

-Article 9

+ Details

Name: us-gaap_AmortizationOfFinancingCosts

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The cash inflow associated with the acquisition of business during the period (for example, cash that was held by the acquired business).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Investing Activities

-URI http://asc.fasb.org/extlink&oid=6516133

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 12

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3179-108585

+ Details

Name: us-gaap_CashAcquiredFromAcquisition

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash

-URI http://asc.fasb.org/extlink&oid=6506951

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash Equivalents

-URI http://asc.fasb.org/extlink&oid=6507016

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 1

-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.1)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3044-108585

+ Details

Name: us-gaap_CashAndCashEquivalentsAtCarryingValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3521-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 830

-SubTopic 230

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6450594&loc=d3e33268-110906

+ Details

Name: us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 360

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_DepreciationAndAmortization

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Amount of gain (loss), after tax expense or benefit and not previously recognized, resulting from the sale of a business component.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 20

-Section 45

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6892542&loc=d3e957-107759

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 20

-Section 50

-Paragraph 1

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6360339&loc=d3e1361-107760

+ Details

Name: us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 470

-SubTopic 50

-Section 40

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6850294&loc=d3e12317-112629

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 470

-SubTopic 50

-Section 40

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6850294&loc=d3e12355-112629

+ Details

Name: us-gaap_GainsLossesOnExtinguishmentOfDebt

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Amount of gain (loss) on sale or disposal of assets utilized in financial service operations.

+ References

No definition available.

+ Details

Name: us-gaap_GainsLossesOnSalesOfAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 3

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16373-109275

+ Details

Name: us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInInventories

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: us-gaap_IncreaseDecreaseInOperatingCapitalAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The increase (decrease) during the reporting period in the value of prepaid expenses and other assets not separately disclosed in the statement of cash flows, for example, deferred expenses, intangible assets, or income taxes.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The increase (decrease) during the reporting period in the total amount due within one year (or one operating cycle) from all parties, associated with underlying transactions that are classified as operating activities.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInReceivables

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Charge to cost of goods sold that represents the reduction of the carrying amount of inventory, generally attributable to obsolescence or market conditions.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.2)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 330

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=28360613&loc=d3e4542-108314

+ Details

Name: us-gaap_InventoryWriteDown

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3521-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 26

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3574-108585

+ Details

Name: us-gaap_NetCashProvidedByUsedInFinancingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3521-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 26

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3574-108585

+ Details

Name: us-gaap_NetCashProvidedByUsedInInvestingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3521-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 25

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3536-108585

+ Details

Name: us-gaap_NetCashProvidedByUsedInOperatingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 20

-Article 9

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Other Comprehensive Income

-URI http://asc.fasb.org/extlink&oid=6519514

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Net Income

-URI http://asc.fasb.org/extlink&oid=6518256

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.19)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.18)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.22)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=28358780&loc=d3e565-108580

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 19

-Article 5

+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Other income or gains included in net income that result in no cash inflows or outflows in the period and are not separately disclosed.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_OtherNoncashIncome

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Other income (expense) included in net income that results in no cash inflows or outflows in the period. Includes noncash adjustments to reconcile net income (loss) to cash provided by (used in) operating activities that are not separately disclosed.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_OtherNoncashIncomeExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The net cash outflow or inflow from other investing activities. This element is used when there is not a more specific and appropriate element in the taxonomy.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Investing Activities

-URI http://asc.fasb.org/extlink&oid=6516133

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3095-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 9

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3098-108585

+ Details

Name: us-gaap_PaymentsForProceedsFromOtherInvestingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The cash outflow to reacquire common stock during the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 15

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3291-108585

+ Details

Name: us-gaap_PaymentsForRepurchaseOfCommonStock

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Cash outflow for purchase of trading, available-for-sale securities and held-to-maturity securities.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Investing Activities

-URI http://asc.fasb.org/extlink&oid=6516133

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 320

-SubTopic 10

-Section 45

-Paragraph 11

-URI http://asc.fasb.org/extlink&oid=6871852&loc=d3e26853-111562

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 13

-Subparagraph (a),(b)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3213-108585

+ Details

Name: us-gaap_PaymentsToAcquireMarketableSecurities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The cash outflow for acquisition of or capital improvements on other tangible or intangible assets not otherwise defined in the taxonomy.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Investing Activities

-URI http://asc.fasb.org/extlink&oid=6516133

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 13

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3213-108585

+ Details

Name: us-gaap_PaymentsToAcquireOtherProductiveAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Investing Activities

-URI http://asc.fasb.org/extlink&oid=6516133

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 13

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3213-108585

+ Details

Name: us-gaap_PaymentsToAcquirePropertyPlantAndEquipment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The cash inflow associated with the amount received by a corporation from a shareholder during the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 14

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3255-108585

+ Details

Name: us-gaap_ProceedsFromContributedCapital

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

This element represents the cash inflow during the period from the sale of a component of the entity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Investing Activities

-URI http://asc.fasb.org/extlink&oid=6516133

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 12

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3179-108585

+ Details

Name: us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The cash inflow associated with the deconsolidation of a previously consolidated subsidiary or the sale of investment in consolidated subsidiaries (generally greater than 50 percent).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Investing Activities

-URI http://asc.fasb.org/extlink&oid=6516133

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 12

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3179-108585

+ Details

Name: us-gaap_ProceedsFromDivestitureOfInterestInConsolidatedSubsidiaries

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The cash inflow from the additional capital contribution to the entity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 14

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3255-108585

+ Details

Name: us-gaap_ProceedsFromIssuanceOfCommonStock

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholders and which takes precedence over common stockholders in the event of liquidation.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 14

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3255-108585

+ Details

Name: us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The cash inflow from a borrowing supported by a written promise to pay an obligation.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 14

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3255-108585

+ Details

Name: us-gaap_ProceedsFromNotesPayable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Investing Activities

-URI http://asc.fasb.org/extlink&oid=6516133

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 12

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3179-108585

+ Details

Name: us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The cash inflow associated with the amount received from holders exercising their stock options. This item inherently excludes any excess tax benefit, which the entity may have realized and reported separately.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (j)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 14

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3255-108585

+ Details

Name: us-gaap_ProceedsFromStockOptionsExercised

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The cash outflow for a borrowing supported by a written promise to pay an obligation.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 15

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3291-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

+ Details

Name: us-gaap_RepaymentsOfNotesPayable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_ShareBasedCompensation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

XML 33 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; word-wrap: break-word; } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 34 R19.htm IDEA: XBRL DOCUMENT v2.4.0.8

Patents and Patent Applications (Additional Information) (Details) (USD $)

Sep. 30, 2013

Dec. 31, 2012

Finite-Lived Intangible Assets [Line Items]

Capitalized patent and patent application costs $ 2,734,000 $ 2,161,000

Androxal [Member]

Finite-Lived Intangible Assets [Line Items]

Capitalized patent and patent application costs 1,726,000

Proellex [Member]

Finite-Lived Intangible Assets [Line Items]

Capitalized patent and patent application costs $ 1,008,000

X

- Details

Name: us-gaap_FiniteLivedIntangibleAssetsLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 2

-Subparagraph ((a)(1),(b))

-URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16323-109275

+ Details

Name: us-gaap_IntangibleAssetsNetExcludingGoodwill

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

XML 35 R15.htm IDEA: XBRL DOCUMENT v2.4.0.8

Accrued Expenses (Tables)
9 Months Ended

Sep. 30, 2013

Accrued Expenses [Abstract]

Accrued Expenses

Accrued expenses consist of the following (in thousands):

September 30, 2013

December 31, 2012

Patent costs

$

152

$

245

Research and development costs

87

192

Personnel related costs

42

30

Other

101

91

Total

$

382

$

558

X

- Details

Name: us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Tabular disclosure of the components of accrued liabilities.

+ References

No definition available.

+ Details

Name: us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 36 R22.htm IDEA: XBRL DOCUMENT v2.4.0.8

Loss Per Share (Additional Information) (Details) (USD $)
9 Months Ended

Sep. 30, 2013

Sep. 30, 2012

Earnings Per Share Disclosure [Line Items]

Anti-dilutive shares of common stock excluded from computation of earning per share 3,975,430 5,264,207

Series A Warrants [Member]

Earnings Per Share Disclosure [Line Items]

Anti-dilutive shares of common stock excluded from computation of earning per share 877,137 1,749,270

Warrants, exercise price per share $ 0.01 $ 0.01

Series B Warrants [Member]

Earnings Per Share Disclosure [Line Items]

Anti-dilutive shares of common stock excluded from computation of earning per share 810,109 1,569,421

Warrants, exercise price per share $ 2.49 $ 2.49

X

- Definition

Antidilutive Securities Excluded from Computation of Earnings Per Share, Weighted Average Exercise Price

+ References

No definition available.

+ Details

Name: rprx_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareWeightedAverageExercisePrice

Namespace Prefix: rprx_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Details

Name: rprx_EarningsPerShareDisclosureLineItems

Namespace Prefix: rprx_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Antidilution

-URI http://asc.fasb.org/extlink&oid=6505113

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Diluted Earnings Per Share

-URI http://asc.fasb.org/extlink&oid=6510752

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Contingent Stock Agreement

-URI http://asc.fasb.org/extlink&oid=6508534

+ Details

Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

XML 37 R20.htm IDEA: XBRL DOCUMENT v2.4.0.8

Accrued Expenses (Details) (USD $)
In Thousands, unless otherwise specified

Sep. 30, 2013

Dec. 31, 2012

Schedule Of Accrued Liabilities [Line Items]

Patent costs $ 152 $ 245

Research and development costs 87 192

Personnel related costs 42 30

Other 101 91

Total $ 382 $ 558

X

- Definition

Accrued Patent Expense, Current

+ References

No definition available.

+ Details

Name: rprx_AccruedPatentExpenseCurrent

Namespace Prefix: rprx_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Accrued Personnel Expense Current

+ References

No definition available.

+ Details

Name: rprx_AccruedPersonnelExpenseCurrent

Namespace Prefix: rprx_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Accrued Research and Development Expense, Current

+ References

No definition available.

+ Details

Name: rprx_AccruedResearchAndDevelopmentExpenseCurrent

Namespace Prefix: rprx_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: rprx_ScheduleOfAccruedLiabilitiesLineItems

Namespace Prefix: rprx_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 20

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.20)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_AccruedLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Carrying value as of the balance sheet date of obligations incurred through that date and payable arising from transactions not otherwise specified in the taxonomy. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 20

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Current Liabilities

-URI http://asc.fasb.org/extlink&oid=6509677

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6935-107765

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.20)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6911-107765

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 9

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e7018-107765

+ Details

Name: us-gaap_OtherAccruedLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

XML 38 R1.htm IDEA: XBRL DOCUMENT v2.4.0.8

Document And Entity Information
9 Months Ended

Sep. 30, 2013

Nov. 01, 2013

Document Information [Line Items]

Document Type 10-Q

Amendment Flag false

Document Period End Date Sep. 30, 2013

Document Fiscal Year Focus 2013

Document Fiscal Period Focus Q3

Trading Symbol RPRX

Entity Common Stock, Shares Outstanding 23,009,882

Entity Registrant Name REPROS THERAPEUTICS INC.

Entity Central Index Key 0000897075

Current Fiscal Year End Date --12-31

Entity Filer Category Accelerated Filer

X

- Definition

If the value is true, then the document is an amendment to previously-filed/accepted document.

+ References

No definition available.

+ Details

Name: dei_AmendmentFlag

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition

End date of current fiscal year in the format --MM-DD.

+ References

No definition available.

+ Details

Name: dei_CurrentFiscalYearEndDate

Namespace Prefix: dei_

Data Type: xbrli:gMonthDayItemType

Balance Type: na

Period Type: duration

X

- Definition

This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.

+ References

No definition available.

+ Details

Name: dei_DocumentFiscalPeriodFocus

Namespace Prefix: dei_

Data Type: dei:fiscalPeriodItemType

Balance Type: na

Period Type: duration

X

- Definition

This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.

+ References

No definition available.

+ Details

Name: dei_DocumentFiscalYearFocus

Namespace Prefix: dei_

Data Type: xbrli:gYearItemType

Balance Type: na

Period Type: duration

X

- Details

Name: dei_DocumentInformationLineItems

Namespace Prefix: dei_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.

+ References

No definition available.

+ Details

Name: dei_DocumentPeriodEndDate

Namespace Prefix: dei_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: duration

X

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word "Other".

+ References

No definition available.

+ Details

Name: dei_DocumentType

Namespace Prefix: dei_

Data Type: dei:submissionTypeItemType

Balance Type: na

Period Type: duration

X

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation 12B

-Number 240

-Section 12b

-Subsection 1

+ Details

Name: dei_EntityCentralIndexKey

Namespace Prefix: dei_

Data Type: dei:centralIndexKeyItemType

Balance Type: na

Period Type: duration

X

- Definition

Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.

+ References

No definition available.

+ Details

Name: dei_EntityCommonStockSharesOutstanding

Namespace Prefix: dei_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.

+ References

No definition available.

+ Details

Name: dei_EntityFilerCategory

Namespace Prefix: dei_

Data Type: dei:filerCategoryItemType

Balance Type: na

Period Type: duration

X

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation 12B

-Number 240

-Section 12b

-Subsection 1

+ Details

Name: dei_EntityRegistrantName

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

X

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name: dei_TradingSymbol

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

ZIP 39 0001144204-13-059444-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001144204-13-059444-xbrl.zip M4$L#!!0````(`%U-9T,EF9?!3C\``!E[`P`1`!P`"TR,#$S,#DS,"YX M;6Q55`D``_&F>U+QIGM2=7@+``$$)0X```0Y`0``[%UI<^,XDOV^$?L?M/XN MFZ=(5535A,M'CV.J+(_MGNZ-C0T'3<(VMBE20U(NNS?VOR]`4C9/9/+2X5%' M1U>U>.3+Q$-F`@02G__R,G='SR0(J>]].9`/I8,1\6S?H=[CEX-?;\_'YL'H M+U___=\^_\=X//J%>"2P(N*,[E]'IU9DW0:6_4>X>G[$'C\T1^POTF1\Z3^/ M%4E61_\EZ9_4R2=5^>_1_U[]^+_1V$,5O.+3]^6@\7LGY M9H5,!GO/[]^NOX^40SF]]G(?N/03_^^(P?;"3\$B>/ER\!1%BT]'1_R5?_J> M]4@\_KXC+EV:JDRCY&:7>G_D;N8O.O2#1W:GI![QR_=,\.IV?M6A;P]D;YX< M)1??;BV]^J<:WRM/I].C^.K;K2&MNI&]5#[Z_2.U0,.603$YDU;^\STR`KLP'?)T8-E1V/RLG`MSXK\X/6< M_?_J1;:_]*+@-6^VD-B'C_[S47HQ;IFQ)(]5^>VQ91`PWM4]EU[E#RKY!QU" MJY]A%RKDD!?[J?I^?J7B`>H]DS"J?B2Y5O&09U$[K'XFOL0?D?./A-2N?H!= MJ+H]6@0U][,K%0\LP_&C92W>GGFPPONX9=,+%5J\N`+^_/X]0^IE%`AHPZX> ML-X[&GWF'>%3&%/\FCR,XH[Q*7I=D"\'(9TO7,[?^+>G@#Q\.>"]>[SJQ8]%Y"4:W1`[8KXG=A!,1.(B[/0B972^DN0[]B^GSJTO3>]4 M*?Y[`NGM">)%-'I-?WO[E3K\]P=*@E$,F^347)G\Y.)O!U\E]H\Y-21#_WQ4 M?'@EZJ@@*X=@00+J.T4$K%\'$7.UY.N*^Y*\>L_[M=6K,NHXF8>F8U5Z%^ZD MCV0A982O?DIMF+Y;:%@U8UAU%PVKMC&L.IQAC0_$6&.;&&M$,8V-^R`C#69 M)>_DJ6GLM&&Y`F/)9$%G6PQ[',Z\G7,!23H:5?3EU96^+;,K5,M81AW4,O); M;-Y%R\C9:-RW990[5=[9WL3^50>WC+Q[EI$'M0P+;_(T#F\[9IE50).GG2S# M!URG=$Z\>)JG[9#K[@?UZ'PY_T'F]R18AGS<>6UYC^3XA89K-FPQ!2"/3+OH M35YZP6%`7A8NM6F4@!XY*RM\.4A'SI\R*JQ^RBGZ^:CR5>^Z'55A^+"#Q0(E MK)=_$4ID%=U3HAR-[T[\^=SW;B+?_B-+AYN(B>-6./OGDJG-[EKX'OO?<+Z>#ZO;A`;ZV-RX#8@5 M+H/7O8?(,:+"+!^;!\>VO9PO7?ZQZI0\(F>Z1["GR MYC0:6>R#L:?Z*\4^V]BR;&.KO\=44VB?K.Q&LK*#U-KG.MN7Z^P@C?:ITD=) ME;:9?/DORC+5Q8Y]E;'66L3X?L<\R/EZ6,1Q[:I8I[;.- M[`[2SN: M!3*9VO&_K[H:PUSE6\/K7UX7_R#RO0\-T\Q8O2Y,^$[X]%+X]<,(,_N@' M]$^+>^S=9EJ5:0Z^<@-\RENRGCU-Q,8O;FC:^!E!:^V7:`FZ`[,U<5WR`G:' M7R,FU2/G]#[PJ1/*^Y[P3KZ\$3?<$ZH;:M$!)W@S'/\.8G8"T,:MB0VNB?M M>\#0/:"B.??TC^D_X36:4OJSO^L)_2^N9KF<>7D?4H_*\D^?;GCWU[,FOKME[GFWT/%NV M.$;(G;WGV3;/LV7L*22WYWY`Z*-729=?B/\86(LG:EON!Z%+6:68+CDK?+`D MM]#@I_ZI:5@1_6\W[?[TYO6.@[F[X2PIB M'/K,6K.H,G_TE16R$GX5=[2S)*]J+$P]R/7HVA=723ZG(0M%_TFLX)S] M$C:6K26R\U(++ZV7F\!K)UD_^/KW2KF9EV8EWP86/R/RYG5^[[N-I4T.OEY? M7?^>R,N]*BOC+';&F;7PL:,*9\N(NU?^3%YPX=R3K$#C8,0[0WQ?ZE9'#K'I MG-'JR\'%Y3DSO"I)4]-4$E"P[#+2:_)(PX@/2BZM>7/BF6E5-B+-5U@N1>>0U[^1EX;PYCF(WOMB[.23^(# M&C-,;=OY9.G@ZWBUN5?TYK+>Y]0E0?KQJ[G6_,R38]LF;GK`:?RVK/:YUZ^D MOT^RDP?"@#HQ55@V,@OBG,7YA^4N">M",7O*;*T#HV3HFH_2&=8R1R4=2GST MV0Q&7^`S!^GDP*N;`Y]TTHLP7+(F1%M;@YV#5(9B1+=N[[9KO<@,/0"N\[`TTW`3EKF>!D]\?4.#;J\ M(L%\,'0I_J<2;%%R)Y`U-E7D=8-LZ#@5!9-5R8H\U:<"@-4."@VNSGHJ#$XV M%$/1);T[N#:N4T'$G3@IG4@B\^$<4WO?J2!"D&S($TG61884P,SM94ONQAL1 M$7]D65'U3!>ID-<*4IW!$,&F!:2JH-3&]9DPNI)3$WP6/9'@.`Q)%*9C/+R=%3%D>:H6.0') M[@5NG855,5Q-FG2%V]*.&L!715+D'+0N(.JLHT/\F\@F'L15X+/4,WJ]I'_>'P7'@O2C_3>)8F9V2UG M+[:[Y''[%]]W?E+7Q=O1!-K64+4<4HST?A#7678*()8GE`,95I'D6EO+:HZHP# M^'15T:1VJ`(VW/A.K7OJTHB2QCY=`WRZ:BI%7-42.T"KLQG@Z77=;`>MB[D` M3Z\J-J=D033X?;I;/:H#[KDV[ZS)`&$F=80"WW`Q)9FS: MS"`ZX(D5M6XJIB6.&G/H@&N6C48X:JH+X.LJPV:.I,!'CE%FB*!6;.&))@$="0I'5HLI5I M*DO2X&T)^&_6(S4S[\&[HUN'OG6M!40(16)T5@;6-V[Y)]]U2!`F)8CP[06$ M%%.>J/GF*@MK`Z?.G%"ZKTJ%$0H,)Q.3V5BK@ZTFC?-^2'1WJ#5VG#0>*S2% MRF,8C>;Q3)/GG#!))*4Z]A/231]TO!Q'+-`]&1YVDUMFF%(,@ MJ=^IS6=^PFO6#[VB*Y<,>'4-$&!RS9`3U0Y);J]"'@D07/I"@EAQ!`2*OI$( M;`*X\+Z0F+S:ASPUC7J;0-,SIJ'KA5XK!'3MOUHN7Z'4DK?X+#\OJ16.^A8R M`,?;#PZ8LP;@5?O%(;`'D-_W@P/FJP%D\Q,E/^X!P"0_GP?^_!>^FJZX9A+F MJX'WLR5A;=$(6@GO:SNC07`7[V][0R.P#=[G=D:#X#'@=_F*B3R1(4P7WC,) MXSSEPK/].;G@.3[[I3FE`1>L%B:_J\5VA%??CB;@F8MS\[W"0ZS@!1SV9!WP M!-:#OIL."0_N%B;@WMG04#);0?S%HE[XW0]9YC+S>(&G7VOR!![+O"9_B#(!#;#Y_Z](H-[PA0*%Y*4 MSU:0^-)DJWEHF$*?7JMRNKKTLKGGGT(3^5W$(R@,./9)'^(%V@-^NY/V"#(" M;EDS)5E#0@B)%=A\A5UF'CY=#-:FO`='*S(MX,8GAK$F'L!]29:@K[:RHDX[,.$7XK$(X+)[CYTY M]>+=E!%])FT[F2Q!7W05.3^/"B#H!["(#E"LT`I+"`<%C.EMT#J=C0`661A: MRJ-JYOH`8SH=$,'TB6IT,G&A$EH$@ MQ>)_/J861;:$)&I5(`QINJGU"0G3&Z`%19)NZD-@$ID)'-O(2J]VPG`=^G8\ MFRV&+)ND+:)WRO#>F!,#'6I]/BG#*$HC?<@B97@,@Q M9EVC^"UF<-R([J,`P63,^H\QW11PD<&!`#/FG6SM%D=T1`4(.F-%D9,UG/TA M/Z6AG3Q$G/=G+DDT>[BU7IKW4@7_4:4)D`&4$#$(_^5E0TI@^B_^\\R&E1"U M!/X;SH:4P/1K(,".2YN)N^A2>3?_=L1?-_/8Y84?6N[LH?+&#CT?/XSK!^): M%1=P%-HKOIN*(SP,M-]\MQ47M3A^"+M#BB,\&;3_?:KF$\)AM'_WCM_(@Q^0 MLY&-IP+QJ-](5Z8W81=0T@=1*-=G;6+AA?"61CPM'4SAM&1!@@PQ..UG;6 M,!A?"V6-BJ)(A672PUOFDOS,WN5[[*]V7(UX%@A>DY MG75S)PC5!BFGGSF!;="(N-8XZ6N-!N,&FJ=:G>&(C-,\P6D-!],5P+2BO,]> MB.?,"CS6!<)5D==O5DAMOGB'NLNH6",0Q6U4`5J%094.ET^FK7'_1NCC$_O]^)D$UB.Y M7/(S:&8/I5*H\6N:LSU7UT10.C9#]$:(AE!'U"B(2KCL)D79`G4P?0-1,5=A MC;,-K8/I,I@2NYJA#:Q.VM.`0L:HWH,\#016J`[3,"J)V@A1U1?7@]:C$J87 M(E42M-($478>UY,@E>*CT=X6DR7[OY+B/E=/5DC8$^FY/O&70KZ+ MDD;+@,P>5ELH+[P3WPM]ESJ\+M#-\CZD#K6"4N$33/8(58=AF:R6K*D:$':I MM-C<#R+Z9_S-8/9P3CV+#<:\QWB14G.REDO+U`Z<18)[`"FB'S"@'1XDABS0 M+BHYOU&A"5*^7]B+_.#UMX!&Y-3_Z;5HZ2;+/(KB6@,2M6J3)1N=`6%:$!B[ M:IIH;85/;>>0&Q3J*8MK#4C`A`85>WH`A&E3(/08TK2\-%Z(*K>Q M_>R%YPM+&CXE+#@E]\VK=\@-ZOF`TON"*VKDEJ4>AH"+H0`0I^1B=8_&H$_) M(F"OC%,!OBLIDQFT(`.TZ-[(!S&!\.XX12P`"T),AL>):7YH)[)FF&V!KF;D MB'/BS_GF@I9M#I474I1"B?)JP9W@"9H:*B\D%TN_]@@/T<)@>2%-+VPRQN$K MQX+6VTBA$D/"""3:U]@`GJB!\0&H=WB8!H:^V"F%PYC0(/DI:VS^*34P-((B M5F$)9"=5/)N7*R>G)/GSPKLF-J'/_`R.-D1J,,(22>X#IH`H#0H=#083002H MZI$\+:UM[()U-KM>`$&`_ETAK4%L`&54_$):CF1F%_[Q9IAZ$@N,)&EM:B7N%D M*#[4*1U\U(*;T(H=785:#P-L4/5$W(3JU$X@_[$Q[6!N*E`A+$9-AG4EK1AH33NR+UU%.@ M4EKC>!W M!FU9A1\QHQ#T"5O$(?S4[=I@8R@#3>$6JK+U@[WV^-(6=`&"?L$!X:'TKH2( M/%"E+FW32F"H!)V\I!4*4_:H1IR>L<>=)7=7I&7ZKT#5O8HE%7$X>D4O8!%4 M]DLO3,>O$3V"/E`]L.04L>[P`]\FQ(D+*O#BV;.''IT15"XLBQZ/HW\51"1J M$'XWH0*&2=#YXTJ^W%<'/7CJE+(O7L$6_SVDK;Y5*5"ALFSAK7JYW2&*V(&? MKQX$(J;U@5A:.-`5CS)+DVX++#%<:'(\;FM/9"`IN&;1(JJ)Z87)P*A"#TA5E$$*CFMZ*L%S.&'D"T MG>IR?YA9SAX%])YO[SNQ%C2RFF]H4:#Z6#58RZ)[`2IB`W[GS8!`,12`/C@7 MBFJU1_ON3*Z"=&7!:N%;\@-A%UO&E`:5G]I!&E0Q`8\:5'':(L40O(,J,C'? M9&+B:6/]WK/L:[)8!G:\_[9;1@,55*I.\FO$]P98Q*KF7Y<'!(QA"S29+6N% MA2,M<&?X=>E'9+7"I`4?&@QB:X1V!"=J^W8AM`=PF':&3M\H#C2Q$!D'4D+, M'CHV+GY.NDYH1W""QBU675H?.$3C%DLKE7>>E0X6Q$&L&=Z^[9GO,O51K*M4 M'JU.Y5)M.22:WO40,0,ZPTDU=-3JKB'UP)`(FL$U3:-`701T0LZ7DJ7"MUD0[I@*`9$2+-T M0D7_NAPSR@;!*V/G/RQW65#B.)QYLG*GQHTB%\!#!_;J$QV!O2"_)]#,^O(T MMGX!-#ZFKA5N#=DGT';::;'"9R/4<;&@.$7EPQSBI(6"8C8EA9%6&\4Z3+'E M:A?5E&PR#456U;1Z43-`'7216RBCP,H8\D2;M%-&SFE3O'P54+N%]R\6+:HM MV*@<:M,4=J7H'+C,^,:/Y^82E5K`0Y0N-%5529'5R"W3(+E*4@46+6VG(VTG MFX>&EFWS"O%UX]=T7^9JJJ%=`2U%6,5(9T&^N+=8)+ZTPSU>IQ7?%U-A5<2S M@2LSD);4#R4CL\&]1G`/MA0D&:)R1A)?EVHT,V.+'B-"AZGK9TQEO4&7$6E1 MYR<%$$45B)@!=7.28A/*[=*I<^#N?E"/SI?S'X07_UN&O.&N>:GPXQ<:%I!C MR_+*A_F()>CP/>"W7K#XL>5Y9>G0-)LHT"0HU?!:$"YR[B5 M+"]O(BN**_8GK^!U21BK>!):YBJT&R8_TUK&UU\>)EYY:[I5%V?@I_;;4 M5AMH&8ZJ*87]^+UK=,M'?LO@M5.K@.*!:4`FP- MO@^&F8@AH2PKJEZL=%0#_MCYGV48K7:G5'?JZDI)V;4%UR19BT[2DBC)2.V: MV/ZCUW*+`530J50.:TV:;+$!^^@=#:KT[NW=;Q"$"G#M&5]N@5Y<*GYE]M[B M0^<7#:JEK;DQ1'.2\=1P:4J2SR2[I,6!4`JBV%I[..M1J(]@!%87E7;!$#U' M"2@!WQ&K].&Y$:7FMMX.`_M3J,S=X":J^5RS9ENI`J(>:3 MNX71KO98#SM4"3$SK2GFVX?)YHJLPPZ]4`*1;+:G1#>OVCBA4J%2C;)D=`B9 MPVO3![6'RBG7H'VOZ9,*U8[<>C+TTK_A.;HI;L@TL;B:H%!K!&S*SOWWWYIM@K5W]0JUM\T M0;06E7I@.U3)<_MMT&^`A&J#[@8O^NCV#2J,;JD5!HZ5#>J7#F6@U*ENTG_H M<'#X?_:NO;E-9,M_E2[/*ZDBC@`]+'LG54KL9+SKV+ZV9V?N_C.%4*]%1T?=L@,+D;3Y3A6OID7 MU_2%7:IHET9-8+:N6D(`%UM<'^84E$@W%[D7"!K+HIEYD8U(7NI[SHYT&BNL M4$=*ZST'1+1RU49<_$X+-&]M_>=LV46SV/D3`<7$RN>^,=;"B6;3-Y9;TJKTTLA MLZXFL$@]"%_[R,/[44NH:"G/2O*P]&2UW2VCU(BSO>0"S)94:E2=X>1AT'X` MQ6LOP<@4H'%MM0Y7PU$+[`,J,)V1^YT^CU(CWAI6($%LDU*C(MJU`C%%S0.; M;7>[W3+KZF0>ZI"W=[9QU=QF%/#UHWFPM'*_URO%C\8HXJ+EN4>QEERR*9?N M1W.+4OMR3^V44[+)Q7`*;"#)2KO7ZO;;7$LV^6A8NTC%:6-*-I65\`1J'@ZN MO%P8?)#E5`D&P>\XO_D.@GF@PD+CTQ+@XE*++]D(CI<=7^3A/N^X M9#/S?(STKDE5WKK`!I\\SZ`KV/?2Z.5BJP4V];:DE\MF'G<)%]C*4]I=M:,6 M30$K9Q.S!$ES3/0J9:MD3>R:!\HMMY8/]:U\HX>WHN9!?69AG'KIX?:@M.6#)@RMY:XD9Z^)UR+#C[L2* M;QO6E`>3M0+I%5F>[;<1[ MK6$&*G^K*8(Y7V$V[B:E*]Q5H\#^K2S+/;6FI3PE*$]KJ+`R'*L]K< M`R'4MEQ&QB=O^]W1@1`5&G+^@1#RR1)P>0$:BR4Z\S"<@@="*">]!&;'V[.T M^6@8KP,A\B=H\_V.0H=:\9!,D?QYQ)M3NT4FF(O^ET8S%X'RPF7=C-[DEM;F MYY:IN<<7J-'ILAMTHZ2>\U#.O-/NZT(JWX$Y#Y\?I=RM"^EO3DXP4G_ MZ!/YV?3.AL8S<;V927\]TDVJ.:>/MC<^(U]OKA\^?!U\O[SZ]^F#,:$N@7Z2 M.WNB66?LVOWE_UV<$KDU]@T3G MJD*FQI2:AD6)X1+7GTPTQ_@'8AEHS!M3XJ%,R"/<_7**;7[$1O%U[`M06#:U M1#.-)^O7(TPF-4:SHZCMS8@G/VN3Z=D/X*[.=DJ%#ARG#E<5(0\7?SY\N+P^ MOT`%A0;/R!^7YP^_X>763XNF`DF&C7V^N3N_N/OP^>;AX>;[*?FA3Q^[.D5- M)ZYM&L,S$MYQ=?'U(?-ZK(WYS2"'J\'M/?1,MTU3F[KTC-S\[\7=UZN;/T[) ML^$:T(7YW0\WM^M:OKO\]EM6TT=$IZ;I3C4=?`X>D\J^3S48^H+O"XJ=B-S? M+H*7*?"6V/5A=)VQ<'!U^0W$9M*1%RG1P[^O@!@+'929E,JR$S@CH1+^P(X/ M;J74\(P`(QXNOPRNHH9`U)X]"6_\(^QA#S&&7XRA-_[U2%5^2F@*?@Z]YD*= MOVC6T!B"=U_\].X2?M*92WT?T_N$!3PZ']FK!];0L5\U,[S::Z=-XJ,W;`S+ M%#7-,AS[?+?19+4[:;*N86Q=IYSW M%*+:H>;,%OSX;3:UGV#*-C3<2>.<5)X&WXXU-S8RJ8TF,$NO"4ZE3!H??L\O M_APLOKF>/XQ)^]V_VHLO,(5IQT;H*;4PAEG\\/4\]J(G'X9Y2Z?"E]?>`0I? MO@^^O$`H#A,/^MK@T+F62EN-X^:BQ,*A"H:XHS(^1++-1/+%!IBX]K^+$< M.8?L6?PRI*;Q3)W9^WAX+2^'U\*[U]TE"N^^6^^^1\JXL3_;2CF7G5;,_]A. MM0Z\')4E5\8HMK@\\LV8V]5-PS+TN"/&]*Z8=[=B7XR4\Z>C$3RMSU8[>M-^ MB3EY.\[J@+W"W3?91PIWW[!@?JN5[@MK:$^HYQBV:]0ZAN>QKJTTFL""Z]JK M1[UE!XY>.B=,5[?UVQ]9'L/B:^*9E5_"-!;;&5*'Y0Q$$F$L.`VR&-A-'TQM M9OO>Z'.PP5T,_S[< M[H_GAH5ON7%"B#5,"?MKOE$5WYX*GL*FPV?<^4/N_($O,-H_V8[Q#^M].K^L MWSKZQ%2)J&$F68*,+`)QJSO:X)YO:S>&7OGH4V1,!/>&"#,7\NY?;<)4GX3[ M/N3K^8!$NSQ)UF0R@"^GHM7L7$Z%"S71\HS,ATG*T:=HG8!H)-`/Y7/$JG#J M3^:N!+@G!]S;DE$;V$QB)-N2VL+L76*+&MF*4KZM[)+.=LQ&0H(CV>-@DA"\ MNK'@WX2AUP7N1,R"SYV`69>W-XG\6O_1-88&\.1>0S?.6LJ@LT`!/:]#SQ;] MN'4"X$SV1$:1RINI6LH3_VM*G;]88W'B%(3(/4X0MJ*+2;7V'TU#OQF-T.L\ M75,/!*Y3.G3+(&1=_G<'S[MB!5Q1!O3*KJ4`8G7=]BW/O=5F.)C#H`2_."#/ M*T-[-$QP>]3]XCL.IN.N.>EAJ;/K\K2ALZK22E:;;="+-WK,'8\E_=!IYBRS M%_6H)1(^"@E7>!".(7V*\.6EJ75$1XIRXSQI5MC*%]MB6;=!D];P%GP.*`C[ M>C/Z"HRT=$,SY_4%[KGAZJ;M^LX;,OG;+?D@,OE7Y;:[GF-;3]&W>*9[:K(7 M3WUGSU_?/%P0.?.Y:$KYRU)??Y%^<9'@7U*3R:.,!8TH=3Y*J>_(V;WDW%I< M*25R`T,,^^@2S1J2*^-OB)L-;Y9XAGU)\I)WKG\R]_ZX@]GWVU8Q;,"-)I)R M1Z>.[9*',4AN2GW/T%UR:>G'Y!W6F02$GBA*ZPP#0]=W53]F^$[OXGKQH+MS!])$.B6V1@?\$W("X5")R M_Z1W3/Z`68R#,YEXI8V+55GDT;"G$.5,-)TQ`8);/2"8C&S==X,7(DOBC]HC M8H'DAH[_Y!+/)IY#-8^,;6>"Q7[,!AP:5O=`H$S-5Y\] MLH2@$@M"-6 MP^;.H`EXLT5PN#=G1`L4`MJ!)JF';;H0))ID8IM4]TW*U`\"P^%Q%6X\-(Q0 MMW'5(TTN&()#0.V1Q(16H_F\&-Z8F/8+\7".!UKNX/S6Q/>YE5"0T5]FC2XS M6N`C=[BF04V]K3G@,-P:GYD'@O-ID:S[8'W4MOY(7+>FSF#I,))L<,=B$# M?)RH!]P"S;Z'B3M$D03"4IB9V289N,`KE[F^=S%'?'\[B#OB*KC1*&]3KT+( MBBE+Y^-*Q(X5OOS@YDCB::.[*TTOG17E1]?>`6-.63I;B=?7<6^`TF#-I:595((``"I?\ M%H)@] MC:4O.B53Z@1WXHT_\NP7JS)/=*F2'-9KZJ$]!;7I8).^*Q%MA)FT0\H2S$$" MK-[AQ3'@UZB.0>Z=@?E1&B1RSV5%7Z?4O%0(UV6FEEA@[5PCNT_C=D3U^<#,C+,<`AB]1]1X)'R,:EL^ZJ=4%#9 ML@BM0'JF#7*;VAA5&:Q5:V`:NG(9U72$:L:7/K9#`(OE<`O^M)\S!QX)3SX48[N)5-WW4@F^V/62:O`:1IS"^W!+I MZFKHGA8[@3QYW'V1;G(G;2LDKW9KS/'I1X]%H@N5Z#45#$I4ZIHI%H@G%NVO!-,%X//9#"=FF%YBYL> M/!]3VE/&["1#DY8+L7#*TH2)5MFDY$^TRILC*%)/;4NMY34;-LUA9\6S4L=P M"1%5+/JX4#'PK2[HGT-')AM=$:_&@!\>-9/%F^Z84J^2)9<;K+;'8OT)SKXD MSLM($@S#:4XYU`PF.'8A+JV`P,!G./<61E8NO4TG\=9ODM9X%[!'WNQ^;/L0 MLK_@K--;3)V7E@FH@1-4!F`5`^*P<0TX\W&&K_%DX[P4?M.I8[$I+B@T[G6P MGS?T5Q-MQIIX9(@<-DR:<;X&/G=LZ&/RPGH!4S+?])@W'&O.4V`X=H`U!TT& MEQE>PLCW?(>M8AOV7DU9"P37*:C9.7IY&E`TB5Z^15C>K5=87F^#S(BTU[EF MC_44@6X<1C3[+C'GG)YR5#7_>!LO-J"L.CX.EE>"P0QP<3"""QK9IFF_H(=Y MQY8*;=\%5^:^/]WWL3"#SR1%SP9HJ(7R1$)0C!A9:<2(;$@1/K;#OBP!SI0- MC%(,7">/IK1L2J`CGA$4JE+F/E>F#G(F>#LW44CL*4M]"^CO1@W5R3_PZD,2 M?"5ES:O`9A((,-QQ6=:BP.3CS2S"E==3S??LP@@T)]V?THBH2PK9Y!92>2%JB5H M[16A-=2T.;4J*JF-.FI%"\IQTN?+8S&LA):4R)$LBIT@Q%L_\9Y3?5FZDD3\L,+*JAXQ]YE0QW@:QRCE42$DM%-HI]#. MO1K\YF'0X,O_?+N[^?WZ'-1"UT4==JCEZ4'<13R78]2#*B>:Z>BA!'E=7==(3JEH_6>XY>5L&?OU=!GX[%V9] M1M4R)Z+4<6W+HF:8%SK<^7"Z\VBJ$;+MH2SWG+SM5%5M';*J MUFH,9[8<<,U4CN0V3%00#2IPCM&2A[TT4]\$S8#M][Q^TNN\T,:FJ M*?&N=MSK%:]5E3LAJ.=(?7W3281X!?5"N?=WD*YZIOU@>YIYR*'83@-O%5S" MT/8?RTD4W&7F2JF$;[EN>'+0VW`-EK=0](T4O=,Y.61%WPK`O[&@(L410I:Q M108ALNYM`*P[L(;I-_#!_^L=`M#(2I"&MU:?5U=A7Q5TH%I%(]5"!T8X)!DR>P5Q\EL'+J*,L])T]@Y31Y M-!58.4VU6($=4COL$(&5TU!Q'SP#!%9.0P9Q@953,\.N,Z#&85-?WW02(5Y! MO5#N_1VD!59.?8RX_,!;0(@(K!RAZ$+1!5;.*C&O&Y2W`\*I.?;-E@@V$1". M,W5>3\,GYGO2(8#'%]]Q@D2O&-C-P+VQ5H+*:+.=(M9\AU8(]BY(+06W/%ZF%6[-06=_3=KJC13K`K^,K M6:RN[[C:>E/'(U_!MLG2[F%S/K=S-*(EL_X6:_>MO5S)U,[Z7O;?TLD+S;'` MC[O@'N['VIN@P>2N@`;;$FP#P;I(._.Y1B-I7=FN2T"U"-.MQ#7V90VD2#G2 MXX4RM([J)I+R67,-G9@HKBF(RT5Q$0.!I"93'[/Z'F<$R#`PYB,6]8);X4>$ MEWJA&*[#3=HS=;0G2BP?Z_`1?8J]R,5/\*:);4$?T+=`=.EZFL7>-O0=_`]? M!$T;]O"X"LT\-TQ&UQJ2?3?J5T17<,_4,73$U')B?69%!=IT:LZB9SR':A"I MSD**)]0;PVV>3:8VAA2&9IK(4NB%\4P3#+&GGF%;;B5LN+1`8TS66:'#3ASDQ0`<\#O&\@_28,RFXR;(]8EBZ MZ0^!N0R'C(;,UI!@5))AIE2JX$23+3@3\JPRW[0G^'L/"9R\8+(\!=_%E-RP M1CAO9VIJ49VZK@:6#<:L:Z;N8][SLB.)W(,W=BBS"`)A%B5@0]XXLC%"+32% M.2P-45L2P;B*W8^!8!*O3R+T58>;8\UH$S9I?G\J]'=K_5V%6\6!:3D88DMK M,W4'#4-4PX)X84AP8<`PMOZUNRVGQ(+=-L!$:G_WB].9L`M;H2SMGI8*,:64 M?AQ3JI/>)F3N^SMZ;9=^P",$]6U#;]JDEE6OB<2 MA*[)[5:%=C9`:`=#J-#.!@KM8`@5VME`H1T,H4([ZS%Q*!/A)VLV<4T]ECY6 MK4SK58G7".'5K"Z%6WUHAJ=YUY'Z_9/W0B7K)[R#5H`0=2 M"B_(V[R:/<-E*:K4:G6%NM9/GGM.WG;J*G>DMB*`1FHHSSTG;TOOVI):7>%= M:RC//2=O2^_:EGKM@U;7^LQ>2MST",JPV0%EF96PASQ];810#VE)I76L=`]Z M0:6NLCM@C51;0B-K*+N#U4CYN'78B\YUE=W!:F3KN'O86W-;(6D.!4Q*Y<`< MA2A3WH)Z=9L-;V2/2.;36R(.$57J]SI2.SR_;8Z]A-,\KNUT)*7;EI16+]E. MO1?J9SU)RUJ$_DD>J:[R*$#IUEP$Q5@H_%P!17P6!I7A9'0H@KE^$1 MPG\#\D?$543_\AU]K`%57"5_TNM)LKHD]P7VFNT[J9YK%HB'.KKA1HAF<../ M/'O5.@[/]DIH?,B5SU5P!3?]6_UZ<44Y;B_UR'!=/T!$^TH?'1^1I4"1Y'KJ MM[(3_9:E7KLO*;U6O62YZ^/Z=`WZZAXP0FX)X*5F`""DS`_3;-/4:-$J!A!RU^@0FXW_(5YGW0XA>8@`(3 ML!$"K#^@SL$0*I"#&BBT@R%4:&<#A78PA`KM;*#0#H90H9WUF#@(3,!:66=] MA'=("?4"$["NPCM8E128@'45WL&JI,`$K*WT#E8G!29@C:8-`A-P'[V2(&^= M>Q*8@'LCSSTG3V`"[I<\]YP\@0FX7_+<<_($)F#39R\"$W`/#5HLJ0A,0*&1 M=:9*8`(*C:P750(34&ADO:@2F(`E80(V"9QF2\R99>B:@>49$?[:/=5]Q_`, MZEZ$,&]?'7ORQ9Y,?8^AHJ3;&C!DDBV`;$Z.B&\9P1/!]LT1&5+=`'UP?SVZ MO/YZ]$GM]SIMM;4@F4M?JV2`$F.`LL2`?CX#.DJWK;1Z#69`0@/^"F"T0@RM M[PP,QW>Q#_?P-8]*]H^JD%G,2/)$[:HD`G:7=G,$B"23K] M.*`EVF8KBUI2BN/]]7L.25F2[;R:1[N=+T%L2[RO<\^]I`2R.$J%M:?C87X(^W:=N6V[GL6+O887 M/YT?_YU+\[=3K>G,_HMWW`OM[>]U>]_#GQ^-#W#BX M(R"Y"=W/!CL?>P/WRJHOJ=`/G(;MS[QQ+D)D<^)+/W[P#( MO?U#U*2?'Y`/\>/PAV;(E6M/2AH(8SC.:?U.ULJ\9,5UP]LG#?T[3!KZ@VYW MOP;3MZGVI`;>,"GHWV%2T-M#W_%#&GB':=_@#AU\'P'\,2-XAVG=H'>'".X. M=Q_=0"3S3!6D$HN+CJ`W[I%9C)P_5C9.M2W-0W:>'?3_"3O/7KNOZ:CZY[X; MG'+UIK6MZ>B[FV`+H[/))H.:^EU]H$].+SY$>QL=\O!JUT7W]UW;]WS\WTK3%0'7(&=MF?(14+3A`([6?K"W0NNV4SF> M\821)[?E8@J:SB7ZJC@J;;TG.UC7Z"N11KG121FCPR9O)]PTFELXQQKT[O=+ MYX;1GU`CN!LE^S\;C19K<'H(R"-74=JP#MNU?]H^WXYR4;C]KA_]N)(Q'-$6 MFTM7O(+(2.1YJF+7%1;]GL;'3@..C^5 M#_?Z;;%+>3E7W-"^.C'0;F1?X?WK]LOG5N=\TK2HXN6M(6VA01I2;0Y8P4BR^(%48Y+.NLW)$J,)"$_ MDVFJBM)&%XM+7$]T)A(@"Y=LUSA[Z6\5F=U2%C(-[T8?-5/Y5&;R%1S. M(R#46%6GX=0_1K'"G87$<-!`&8;%.(%@.)64&'ZJT^21$5O,]4;(5I#PD4\8 M>MK&@WA@DLC\(3R2I0>E*+)E/(5'-YCC/*KI80\:CA#XK.5C01]RJ`8B_-MN MUCU-:ZC":!5Z._HL\=U_2BB!;XW4*$ER<'GG`1[`%K.BHEI9V% MM("4"R,2.1/F:W0Z'G.*_M+#ZZ#?[[XYNSA=?NJ]>16-A(5`",F-@D6(DL^F MD&:,$B(O9GX/?XJ+4Z%FMK)[15604RPE#TXG.=M.;)T?E:DBVBLJ+&(K&2"55%Q\5X9,?B?AD''E#7'13_* MW!3&_9_X%"5O-[3V/JZ&IC83KHQ0+E5/TQ#LEDO&D)M"02._R)C7MN6O1V-C M)/-7O;D', MPZ!,"\P!"^D,0+FSZSI`I.5/<%8BR=V47L/M?B#89'P5VA-=A#-BO&V5]1]E MXJ0?*1.7JF!:+$^M:%#T@3N^HNOGD+:H"D/#DADJ"*M(.TC.-:1$SH#H9#YL!R2/'F4\K.E0`6L;;^]%[Q2'&^P(4E#22#G/5 M-VAY0AS@IU1:$@E/3DL5OO.DP7XHP:=4YQ7E+LM6H@',3!T>E*WH-MD$NZ;0^E!KI9 MDCR*V9+HE5W*;^2!&]A.6>"6PFAXE08M\&U'OXWK,UV<2P%1F;EJ>*DF&L98 MY"8J%K^DSRHJJKPP@5>L5S;D$Q.6Q7*I)Z@7XDOC0A+K62Y=^GU!FV`3Y8&) MBUP1],7`!;&.WKADU`V2)'$FRV`J&U:9#^Z*:=9]'N)N/>6+#LG+\527;H"ELJB8#TCHH^1+?\6QBRBC\HB]#R* MB=%WA*Q=S>,=8FY93:HL+@/W@67"!%->R=@]+,$7;!N1'2]_1Z7-IQ'[2YWH MU'Y5G>C,2-)+:#:/IDJ.44*J>WW+:=QO?R*%/BLY366G<<5?++W+05YU7)8V MV9,*K1HEJ"Y)$+<0_EDX<2KH'N#>:?7")QI\.^STAH-.=W^W@W^'`WP\V'/* MX=/>86>PW^WXZ7>H7VMS[RJ[`KJ&NV^>Y13#SW*M1%B6CE1.`A4RH3G/`Q5@ MYF:4CPI0!>F$;XO93)Q-=I9P3HW=41=L5W"QE_8.K2`;%VP MZ\G.\QP=F46G<:'9NR^]5[O'=X]312C:>MH&9?(Z%\.)XP3]D"/HO6 MM8;"XG[_V*:I51696!M3=X>5Q^U4Y57KXY-JN812^"Z19F68I+4DN4J_56?D MLMVLNW*0:[5J\LR!;"C*9HL.L,T"+@KHG,E%-4_I#=^@/Y#RF;3S+G6'$1LD M.=L;I(HM!->#@B>7:0J0E5E8E6+[T%S&J'LAE^:DA#*K.@B)CK%T2UT<3GV% MI*G6KL64RAV2*J*QN-3&MSL&MS8^E@50O*$K>*PJ_'_[WO']'C2VWL.H'FV> MA01K/81\;T^SQEME86UXX\L2_Y)Z@D*%%E*DZR]+#)JOD^5E^QV)[HMW^]4[ M.ROJW*3J65A)?2*-=V_6>*^_6>.@U3?[^!@(1V,6?XO*>S>K?/`T/GZ(QOLW M:[S[-#Z^X/(OUQ<6&W4^QQR&\^D-^@YOUO<:3#A%W_ZRM?51Z^)$@_[.0\W# M0%M;E1VIRKZ^'N,2-"+R#WR(KMQ71I-IID61O][9F<_GVU"TR,#$S,#DS,%]C86PN>&UL550) M``/QIGM2\:9[4G5X"P`!!"4.```$.0$``.U=;6_CN!'^7J#_0>?[[#@OO;U- ML.DAL9.%@6P@:(XT-(H)E8F79)R["OZWV\HV?&+)(I*[#6MZZ=X;,)\'E#U?-KX^W38_-KQ?_O[7OWSZ MH=GT/@,#010$WF#F=8@B3X+XW^1"WD/QHX\>?CC^T+SGD^;I\W,GY^7DK^16;2GHA$_D[[A.5N*K4+J^PA?Y7<]&LJ;]JGIPV MSTZ.IC)HH`\\[Y/@$3Q"Z"4&7*C9&"X;DH[&D38\^6XH(+QLB+&8)FX^/C\[ MUO(_7OF^B"&XF8Z!29`-3ZOZ^MA=L_AWSL@S,.WVEOZ]E9%JH1W;M:0#BM#H MC0:]"F_!KC9G@58:X`?)(QKHB+XFD0Z+_A!`V=IHHVA7]O:QZ\`(F)*]L#?6 MO1*C\EV&%VG\'@C:1`YO(_ZR-0`K"E_M]TGDQU$"ZPZM7<,!4P6H,E@@T4]Y M4X`FW1W!%D1*+KY)?-H\ M/IF/%#_.O_YM;LD=)0,:445!MF,AT`^+AT5D`%%BPF\6,@M_V8+(TJV_63SA M`:<&SAA$HB7CT2C1UJ081@OY M4/"1M>OF-O`*@&*)MO&Q?BZ)&AX7`0B>N48#=AJAH?N2(' M2T8NFGPF3G?)Q"-(0,3#*Q9T8`(1'X^J,F.GXE"9LD.7S]S9^YC;SMC<4T,0 M;QF@RP0/B5%;3/D\_BW+(X)N;\,8R7CCB46V127'Q;6: M/>`DHM!\'9%)5G,/9@Y-8LZ05\R:R7R'Z>HR1=@S'420`D1[;Z9^%.L-TL^< M!R\TB@RTV8D[3Y\=#.L\_$^>OZWDOM@5^HK[WX8\0F=)W2W4S!!/Y:+[Z2:5 MUC:.KF=L:=GL'/9+&2=R"5R`\1CSGP[S540T-2N!UR$=UF;C*DBIA50H<1!D52(PN&S MAR*1 M]CD$G5C@0GM3PL#F-I0?%/O;`)P?+3_E1,M^]R\*"G7VL)%Q#ZK+T%BXX])T M'K71;E\[>0L+KB'D`FZF2A`DF3(B9EWTJ,YWVVF0T`GVAX0]0Y?- M%Y`8.0\8/CY=*7O*W??;_L,/W>%,=0GW%OV%'15-C]'ZU1HZ MBS@I%G:`]]WUG>+@*7:(P\'PB+,*B\%$^;*)4\26!>\F44L8#M-Q1_VD.G-N MK'%/>J.E`^1L!E-VXWG#9H>9>.0S$JE9.1&;#0^`ATV3'5Z_SVW4G?VS(,Q8 M1933]A#(R%KM\!J]RR8@E4[FTY&XJ]"[+$^B?!/6%J#9Q(Z`*),YIQ`&05&A[ M/D,?7&"HS:72JX7E53/#QOYF4P7O&G(53GBCL;W_26'IOS!J,<@XP6!2! MV4S"B,3A9#N]IQNAX5?!B#(JE4C7Y:7LE4H>$'^E6!S.TY.170-=XNPM!OFR MR:Q0[("X,P-Q.J%?G1XZ5/KI#`'!E^P3(T#Q.YKA[#,-0[W M\5S3==ZML?48_CSFDD2],+>A11!MZP%_JO#:EM,<'J/NX675(;A^B)F?G"CV MA,%CZT[ML=?#(./)W[8?Y4`P6IV";1^Y]5#FSO'T\C4,>SB=SK_V]0""\@!] MJNM%H`/I7],JM)*:??5HI>W#,)M09/!Z]A5)Z;+7E.G*QU$QJ>DTG]);*W&@ M%[Z%WFPGM8?L\'KO_748>QQ**P9N#H6KF!QFZ?_YWO>,B]WF<6[LT=7Q8.+] MS%<_NCAS@LVK$1>*_IXXJ1?>XM(&4T+VG&R9F`JLC6*U8-0,T>&30WW!/NKP%U9RL+O9N!;TY0%S^`RQ.QH3*I*56KAY\;G2W>]J>NI!=37,#I]3 M+LY6?72(]2'R:N-:\)D'+)^TGYV80]?F_INI!AE3.4P#L@,#4V&-A6PM.+7` MF4_Q1R<5,1?$@1-GTYL;Z%WV"#[0B7YW M2LE])I-PIB%B![X@1)S8 M\BKP2GIGYYU5!+E*'(B$'581Y$)VN!X1`SO5`S[Q.RPYK>37"_N:##(3"=_16X=R@I)[$&P"[7#J0P9$D,@@F MB+4/H#1!M%503]8+P+I<7H#6^@!!4C6OJR)ZX9LZ?!4M]>"^"F*':Q&23">- MWD!C23Y+6K+9;I2J!;]&A`Z7*:S&98 M=VFM13R\RP,.%S04XKJ.)66@CX.3JD?MOO3WY56`*H%B5%?O"#%"+R^;V'LR M>,O%*K8DR:FV^J^LJ1X!416UR_45!>YXK;I\SRY0KA('0F"'NT"YD!V^'+@: MP,L#S9675%O."06R#I!=/3,%X5-I/>L7R-:. MX0*<+N_DKEBOWU`CZ"#&'*3\9>UE@K7C-@_DP0W.Z_^W`\YCZ1>@_Y.K-XW8 MY0IK%PA5P#N\R;.2B3[".!;^$#,6Z^G;0K@>Q%L`M7\;_'Z'@7NN8''F;-G1 MUT7JP6@A/(=W9##VYH'8"RUI+!:I!8W%\.POG>2__>)32S]P@/T\\=,?4$L# M!!0````(`%U-9T/'@F08TAX``"_>`0`5`!P`"TR,#$S,#DS,%]D968N M>&UL550)``/QIGM2\:9[4G5X"P`!!"4.```$.0$``.U=6W/CN')^3U7^@^/S M[+$E^::IG9SR^#+'R8RE&GNS2:52+)J$9&0I4@7__Y'__AEW\Z.-C[0F+"_(R$>X^O>U=^YC\P/_@]7?;?@^X?SO?@AZ/3 M@[OD^:!_U!OL_>?1RWM_<*2B'PGD[U"UH_9ZYQ\VD_I;!YQC,7OGAB9?-IG<_92,'(T'!SQ1_UE MQ*9^3/\H`(WFG%GX(;V(PZ_T[SD-:?8Z9DF8!]D5>291,I^1.!O3.8%!R17) M?!JE^WO\\;]^OUU1R!])[$])S%D]Y'\_M/*D0\#K'/%%"/^%7_K1;3Q)V*QH M81NL^B$6<([A)8TS_LSRIXOY/*+!0I#-$;8?W@*VBR!@.0FO7^8D3DEJ)KFL MLP6YOB9I.B;L_LEGY-*/@CPJ9\"D^@W@BP.^73ECTV3B(9\"?[L1WP=NW\B)-,'T3S05N0= MPX2(LR>2P5?^^;X)"-J(=!,+'W&=)\/M3$H6P M=;N&92E[U0>@/>!6Y6\YI]J-OHVY=>FG3S=1\L/:U*H,N%7YK;WM.J-;0':5 M!#E_"GSHK^$[G[U6ONN:XJN'>)/19\%2S,6/U9'?-OTTS@Y#.CMQ&VD70V\L M;#'.P8S,'@FS*>GJN)N*^002L2!_)`=O*K`HK'#T346.D^S"ZKNT'/!-,)BQ M-"ZVAU]AN)4'D1>PG4(2+A_%)7)O1A=.`Q`L2H(5:2+NV4B8$'>!>>*GCP7P M/#V8^O[\D'\S#TF4IPI7QE\6OO850E4\@Z(+)(T#4V-?KK^)ZGSP7;!4A3.#E M@Q9SV6C5F+!D9J;MQ<.3-HCR%*1+YJ6-M+^7,-A6?=KOP:#%V_,Q`&L*7H;K MJ%C;X0TD4_[#^]^C!#8"G_8S,-V[XGV!;\3N"7NF`;EXH1J3=Z6YUQ\Z9%?Q M]:VSK<>;F',I-#'-_8X9XY_'A:3IUMWL<;'#GD3K8;D;ZF=>4KN9+@ M$1,V^%D(\VJ[19?$K>YZG3+W#DS,X+$Y@W4CB/_&@Z>SY,6/OJUL/2L\"%IY M@YY+C8OVPE)M2R;^JLIE&,3*/;&F7)"11!%Y42MWM94WZ.^@<@48Q,H]M:G< M0L:W]RV])[#/"'WV>NEG9)JPQ3Y:LI";#^(-!KN\O+<$+.;Q;/L\2I>*-L-X M@^-.E_N69&S":`6XF-,6)A?LT(`\O^ACZRA(9I3TV)N+4W./TYV%#` MDQ#1LTW$9/'LOA81:ZUA*_63O!H.S MGX,#&3:)_ELX"M0;`A[>RYLVXV4C;^#2EV9F!VGZ3"4@),JU9\,O'GG'/:PO MB.\&9D.ZYJN M2>TDU.).S3@<):WU[2!`8FE]R1]36,1A7W[O\_>WR#-L""5+^WC'+JUPYU\D M/7S6@C"6"'P7\\=.34GM,+.:$PF/>NBL!7YVA5`< MWU+GS#9]25TZM3;>L#'X`:SLTF?L%3#\FQ_EJBFAU=\[P9.P8LBZ/CY[ M<24[S,)T3/*8G]EZY?M#`+$XFOF5^H\T`O63]#)GK/04R/@U&,4[P9,Y8\BR M*4I[H2M+>RR^DMVF:;[\](P)HTE8'`M-[\B/XD]*$TAK`._$I7_-*<,&`.T% MPZQOH,>,!F1YWE=OV[S2Q3MQFG7CE$`5)/?QL_PQHL%H,N$QU.D=R0!$0$@H MCZ7).G@G'<:3VU&@`4@=8]M29*=UT80.8CHW'#;Y2I])>!MG?CRE?-U)4Y*E M.L$=G>[>>6=[CW=OE4)0_7!/TR#>FJGOB"':,` M`\H#/V=X$MWTE2O`@"SNL[X(@LEP_1)$.2]\^"5)PA_T?5\E"AAH=/?.$?@5 M-]P!:N-4!GVV9&%)BKL9V4^RTPQO&ZFZZTUE$>EW]L[M'9I2/5!FU^AU],Y= MNFB$MHRA"@5?(SU4>*P7MWELYRZM42WKQ("4539E<'8JB>WWS(D+DN)[!X_G>2$L#,8^Z5]`DC"8,MD%W.0<_FA1[G%&>\8NJ M>)SELY_2@!M1-,JS]\V4@+!V`WJ](P3''HRHW00HLD#DM<]B$/5MU[5R15.^-1GZ::IYIE_4!M>`(3VK1UV"*BL$ARYJL"MF8 M?5=O#)BZC6=J:EU,E0P/LD1)"QSAL*4MMPW.E"#Z_+L M&XJZ9L=?O\#NC*:D.$(IC:.[>R3HK.L8[28FAW/-**.[6S*]VU[$:\,25SR[ MT137Z>OU^O9>3<4#E<9X4S^8"MU8X_H:%+P;>JCPV.-N0X:]'@XK6X^5YAAB M@6>G@HB]'KXTX$*+#6&M0NZ=BB."Q#B,WPU4CC:4^&;(WP"O<3HG`9U0$C97.I3U`81.C6US_U]=_Q+"U)"0F=[6 M2'89]FKVD^UW@ZDQ)!.H7X%!-MH,0YD6;^6(U)] ME^ZD+2].8G38JCYN&N[H._7BV`A)]:4GKF5XL!5PM$`2TB5H<[::UA^+MXC] M2Q[3A/$O,@WHW.??A#&T)XR1L)!*O2YI=@=0"*IGREX-P3IEA`M=2<7E3/Q" MDBGSYT\T\"/=]6N]#T#L_%Y:>^N7&)V]`HN6""S=@E5AFS?KLCX`L=O+:#5) MD#"GAF7O]C.DS"%=XZQ1V+C4V2%+[GZA5MM16(B*"@:<-+(%B_1"@D M"K9WR/DF881.8[5^5QJ!8!W>!-M>O0(0$NW:$PSY@?* M]-N5AH`)0<*ZV0(A0H`L^EZ*N*B[HDW*6GM`AB#%7:1M%2]"$,CB[-NY<:PW M0!#]59`B"7;H8T-6TFO,R-RGR\K`@*$L9555@()3C=Y>[QC!&7IC1K61(8OP MZS*WC@3!@7ACC@08D,7KQRP!ZR%['8/IGL$DXA^'HM;?'5&_5O)N@!-!P%%_ M@6O&@BU^OXT"^+UC!#?RZ9.HCPG;#8NEO(T?0A`>P0U[IMO&4FIL0?I*$45^ M+0;/*7A*(A`JY>\^F([-6WO=(4`!&()81I:8&39L`?QZA4PS.FO+^S&",)D9 M)8VT"C%BB^>O79UK?*/P^[8+@2^D2?F2CZ@"D;V8/<9ZO;UC!$Z2UJ2I0-E+ M!7#UO33Z3@(H!/Z0=DS)T-C+)[#DV)+'DE7N+'DOKW>"P.5A8U%K!&DO7\%6 MH+?%;E.EFQ,$CA$;3#9A5.<]=.*7K.0D-_F6!:T!%@(_29/:I4X>&/'3G+UJO5#UQ@`*A3>D#4\R-!**.O-_5.[KN<]X+:`X M(VS.:$JN0-D!S<`^R6?\<@X27N4,MDOK/124;CXX*`V!/Z7=%+"%7C)E.JP$ ML:X-H[TH@$+@86E'J0R-A*+.O"M-.^P-7-4`&)>OQ8:'4X%40NTIL@3JL<\= M$D\DXV:-LJE/:^N, M%,!N95.?.K6$VV53[>RJ4\'B+.I]52.-IMZU6L%"^R(%6]P6)AS MRUJJVEX\V0"@`Q16KLF"8H(,65;VJNB%G.E%GCTEC/ZAO(1'W1&PHC!4V[,H M1H0L:5LD\FV:YL;,E9T`(PI;=%/6JFCP)637Q*UQ.KS/D)2S MWT#E:!W>W\DSB7.B4T!DO:G7.T=J!LH7"3$&9.[JKS3@>Z!T(:PR<6.E):!! M8.J)=2SF0P@`F?_Y>_+J1]EK,QNK#0$+`AO.A`R1_,@\RPO9^&V'7_AUJJK] M=ZTM($)@KADQ(H:`S%M\&S^3M#AA=(C_$;!C:P+X$.0IFU"D1H) M,E?P%T"??DU2^.*.XGL_@G\FC=4%Y)T`(X(PM@E;35BP>8&+BCUW29R4;H]X M6DXR!5N2'@`/0:S:A"HE$&P^X"4PC>TS`$`0?VZQ"BTDQ^;%O4S2XF3GHLR5 MCB4CZP(`D8:7Y1:-&@NVTAO?24I`';S07.7@PT)VY$($[H0V+6L"P%>,HEE>.]AWL M:+G2-FTO)-T`*`+W0QL&FU%AJ\FQCM)@M0-`"!P3;6@2(\%6BZ/](-IH\^"_: MI*J'`44@\(!L0J\./FRE.H0R3'4W(; M+XJW%==7TCB@#3T!+@)WF!E?6I"P%47YC=#I$TAW\0R;E2E9 M7LE7RW[6\$B;#N7UCQ`XR\PX;H<16YD5713%#+;`>#$.J`*!9ZT=@9M-A@I\ M=546-#-A\$Y!4']I1T\K]#O+JS; M]KQ"_\BEA\3TO$*A0/&<%\F-Y[R"!>+*:7^9S.9)7%1?%I]GT.H'ZG'IJ=CD MA$-!7`/%V!V1.[?_&LQ$&^I>8(W)83HY.("`,QQ$+ M=\RA/8%1.3?[;67+I3XS7+8%9`A\,XK711;(%>)`=@Y#4G>YD25E/T"*P#MC MS)@&)F3'-E8..C=R)F@-FS<$/A9CIJ1(D!WEJ%9"+FLCBPLB-[]N1@.!+A"X M4LS?OQ8@D1T3V;2&=+^',^]%:>.)42`[%J)98&:E%$N_AS--1<5&37YLQSTN MPO_.R\-$Z4,B67*7\1%>(V/&\^"*/(EBIHT*).EW`E,MI1FY)^R9!KPZ%4W" M[R1(IB5#RKW+5B0`]>-,9%%,GZVJQMX!%S9G+\5\.QH.CHK9QG_C\=>`EQ(? M32J;\7)-*462%L0QZ>[U^SO#LSDN;$=A"F'+[UM=Y#ORH_B3V@>G,P"`W\V5 M6!.9O4,SDG=/(DQ12O`WGQ4G?:]?"`LH_Y#XZ5-$A.D:[0<#5>',_)*]EQN@ MM'>"QHS.0$7@VG/]BBY@VCM> M8_4=-:6T:3@`B\#YY_PM7>#$=C!'-4&K6_0W/.8[)?E8L+78F15W0Y#83O$H M)[$EXA6#@5)V9FG>%"6VWN`G M,H#68=D[C=+F/6M-T7IW`+,S>QMS7-@.G&A-L)9&2]4'NGN1/7U@V,Z3M#N2 MU^_OS*=1`0#+/;N:&?P[?]_NH+N3\JW3^0]K?MS6]*I1?%1Q9 MVGTK]>/Z6K7AH>E[U%G0\YO_0F?YK)&1E7:`"$'4HC;5Q4P()$>6^?X-=*?% M0;4=($&09:?+05UR:SGN5@()=H((\$'`Z>X4&*:MX=E+BK?"G*4QG@$G57LM#+QZC3\B7-O?XQ MSL"G3.5*'-@N-1C[KU6?\?((05&M6K':J[H!4)SI!@H/:#,>;'<9\`N`%M(6 M[_2R^IS*K2GI`@`1[)@-7=9*+-M)LBX?0!9?UKEJ,9&U!W$1;)1-%W8I$/>I MT!+:Y2<29!U`8)RA8JGFU4CL)2R;JGX4RZ>]H@\`_4D(>`-C+WE8PH%JF9+: M&LI.W@!I5K^,!0TTZD3>[87F0W[11RB+T?.,MYLH^9'N8C2^?[)[T?ACE^X/ MX^)Z)]K1^&.Y7Z.#:+SN3>EKEXT+>!)=2=X_=NGGV"BF="R\+%T(P$DDW=45 M]?UCIPM`8P1)JL6ZLNMR.PF!.]0TCF#1!BI'&[N^(QE?4<::P4']^_14^ M>+?QVU5H%T%>')6I=LF@\&'W2<3@_%0M,6);*@>( M+,"^*U=5]4\0>&7L3@Z;FD&6)F#[9OC^"0+'A%WVF]`B2SJHE*NZ2^(`]%`L M9@\)KS45!S0B*]^ZA\3>TN_ZT:!O!%6E[,ZN[>@,6>'!BUG",OI'\7D<36YH M[`/2>-H4.5-U`YP(ZBQLATW)3&K4#K:RA[?Q,V@J8:^_,9J1J^2'*N6YWAA` M(VTH;%#>U+Q35=:%EO#*`0A&BZG`,RG6!+IEG9 M95^_<*`Y39_*R7M%'E7[SL:^7O\401Y4E]-`4T78,G6NR)R1@!9[FHLXK&YQ M5)X,>2^`B<#7V.5,:%2.O00@BU7*C+:!:RH!EO%QO=JW$6B"GRFEKG8-PE;%%!/1^PR\JDR^\)H M'%`%`M]EI_:"N;JPU7P$S?![<,@5*?^MZ&)1JE_#CZD_""@!@4>R6Q>$F:ZP M58JLRP]*(_29)ZXH/RVJ?@`5@3/2E!I=@FM`[=5_=,7ITE%FM]`.H"+R- MKCBM`;57$-(5IV-&YC[EUV(1QDBXV-#`HE5L=AJ#F.T&!.4@<"JZF@7Z&K!7 M:=+5]+@(@B2'%7'LO_)/%3=U@X#E)/Q*_4<:%0NX64D6\^^YUD_!MV3X*<-;WX6OT!.@+_8EO*Q!/``+BZIB<" MSD$E\*G*7L>1'V>P=/$28_/%00]MXJ6#@!(0N!@=L]^`7C(%.O,BUN0O=K$` M(LRY'DBCB:`W`(!'X#=T3+T"N83VSER`(&5`2)C>@([*M7GW]44`-")R` MEB>`*7S)+.C,K\=UL9B[(0=1_)PV78.KZ`4P$?CT[++<"%=R1JPSSUYU6E[1 M`G.6P]>)IS<1!O][&Z^<&^0RF@ MSWD*=A!/BBD.:7`=EG]77@769CA0#`*_X9;F2:,>)!.D,^_ANW,25JU.[.$U@1&TR7C-''/.,7)Q;!4$V2 MZQT!+%[/GP6&98@E]*+P^+U_?<9LD<:P3&8L?T'@C^V^X4T#@G+P^@&M?MCU M-"&9)IVY!"N&R7Q2LCLS'T',^^M<*4FF;(N`!"O&ZXEF6JL$C([<[7I8[=B M38,2\#K86A)NBEXR!3KSK151I[BXMIP'$9_]B$_>\I:+]:3#IEB=YC!>?XC` MOV;F3#'')R&Z,P^:&,$%S%[&7F&B%OE3PK]W=V\IL< M/@TTAL"NTEM^G*M!6=1Y2UNTJR3(N29X9F8QLV_C2<)F9:V4UOLPW0_&\NF5 MAZKV7TU=O,'1EKYT`BEDNR]5[*-%7N^,X,TV7B`89M M6!IX$WA[.TP,V'1A>$?@Y+8*79U?@"PAE^KDGOH[#*]CT-LSYE;:`H<,X^*:37P#%R94-IG3+1@PS=%!,5-E7I=/BYSQE;V'^K=L*PY0.GP($!; M5M1HW!2*-WM1;FA$V"6(-$V8^C59:0D`=M`XEP)1EVL71A]^.>3#/_HI*93P M?U!+`P04````"`!=36=#%:N;E18Q``"*LP(`%0`<`')PU)U>`L``00E#@``!#D!``#5?6MSW#B6Y?>- MV/^`=7=,V!$I6[++KE)-]\S*DERC'94RUU)-[T3%1`5%(E.88I)9)%.6>F+^ M^^)!,OG`DP\`^M!=@7_^I__Y/_[ROXZ.P$\P@5E0P`C'Y]\`+\>?_SQPZWH$C\.W; MM[<1KJ&@-;P-TRTX.B*_$Z/D]_L@AP`KEN1_??50%+L?W[TCY9_NL_AMFFW> MO3\^_O"N*OB*E?SQ*4>MTM\^5&5/WOV_GZ]OPP>X#8Y0DA=!$AZD2#4\N9/3 MT]-W]%M<-$<_YE3^.@V#@C:54B\@+$'^=505.R(?'9V\/_IP\O8ICU[A-@#@ M+UD:PZ]P#:@"/Q;/._C75SG:[F*B./WL(8-KOA9QEKTC\N\2N"&=17[AE/S" MR2?R"W\J/[X.[F'\"I"2OWR]$AITVJJK%'J'M;2EYPIF*(TNDV$*=Z7M:WY; M!%DQ0O>FO$WM[](BB`?IW92TJ?$-'-;.!SFK[8N=)AS6O@W)J34N^MH:-VJO M-6/R[VNL0TL[^%3`)()1I1^1EOA56CGUQ]1%DFK3L%5A3)QSFG'MI76M@_R> M5KC/CS9!L'M'!JAW,"[RZA,Z9!T=GY3>^$_EQ[\MLTV0H+]3WW^>)GD:HXC^ MXRR)5AG,85+0?R[77U""QQ<4Q)BW!=SB+_*S^YP,K*M=W`_M=YX+,:UDRD'3(Y^N7WU3\UZ%Z!5,PB2"#3K M!ND:U+6#0_7@U^H'_N,OS)!.ZYQE;?P$65B9BO]4-$]9XEV8XMG$KCAJM=0Z M2[>S='"I;CI++S31\T*H=8'R,$[S?0;OL#OYC-7\?2Z6<7_J91&.WUHR[JFH MMQ10[_!+X%?R6X#^F("'HQNM:`R(OK3<`BQW9+&$_\QINUVC/_8H0L7S"W=& M$LI-ZI>4?+/GHGY*T^@;BF.L]A56.=F@^QB>Y3EL:JDQRAO68]VYF-K9Q7\E M3_%^J`&P*EI.P:.A>5#O=J$^HFOMX5BLF<[HJ25M';-Z-G61*@?G_"/6(\SN M4_68-,,<-CEF3$([;'K+`S3/6[W5?`< M$/V2"'^2[6%TC8)[%*,"P?Q\GV6X/S3&BD&U66??,)N[@"UEP.73#B8Y]&OE M-J);N^`=W:=^@=EL^!A@UO/$54V@K(JZY`KMC=I\7"]-V@HM>K\,3AL, M2I-`VQZW+X,L08-(_PC@=+9:B+('@W.T^T6%2R6GD3G M:5)@]6`2MIR^AH\UK,K<+F1']*QG,-9Q\:85 M^0EDF0_51[(G<_EY+7XA+%6.+&.`:X^GY"!;M(_AP$<8ISL"7;!" M.XA_S(.IG3E2NXP<"E,7;.PO^0>P45V)0S9J6"AC(R_NQ1"'^[@^6>A;O&0DX,4,'X%VCR:_8^:\/DYU%605SW`]B)UH M=Y;QM,\5_$IUEMDMS!Y1",^>4"Y!'+^X=9`)M!8L)M@"ORQ*MN)Q:0_`)&OZ M+G[4[6X=,B2B4+7I1;H-4*+_&%7BX^FLBB)7W!T/BOA``2=41.FC*=MD3 MQ9AQ,<$M90P%?Q][2IRP`?F5%'':UI%&K MSE6VZ(CNQ("!<0R?Y-W9+66W.WLZ#D85"E[_,#AZ_K@*TZW`^F1C>J5VT#>U1 M&V`4SB^&5>,I(-6S$#U(.I^=C.G<8;"<>`Y3_\J_/._239H$$XOO&D?-XKZ,E!H]T4*,=C>,0,9$FO%U*#1DG?!'I M+^IS4AY4`J"6<,\G74,$!KS.WWA`N5E[PS8EI=3@,52#%Z83O1R&;S?IX[L( M(C;'PW]TIW;XH]^NX2:(+Y,"%<^"6"^WE#7*\G7L7?XA)0`KXCP8*VG6JO.5 M;3I7=[/?$P92^T6L=G1'N]Y=M;)_G47S>N`.&%[`;B<17BN3/*X05< MHQ`59R%>9I"#S3"ZV&37(3M=MN'&9^T#`_8N87#Q!$C2;(Q4U@D]?3L:;K$*:FC,6+X$'^ M0.Z_XO]<_K%'CWAX(S=BB_,@RYZQGO\6Q'N9L]"4MW_M6].N_H60_(%=>B9_ M-$07("A`)0VH^`+0Y/=.[WJ/-3,D?\"#Z$S&['JO&]@SB73H+!K)\2?*RRT>E7?Q+OT;NB;NQ:_4N:5V?TDWM.H%B]3XQUL')H. M;P'*.CQPIQ-9O&M8')060V]N"@^`[HC$;7LOY>,HG\,J2 M)GC!02Q%S-+&HF36D5_W\O)0V\@7Y#4S,L#GM#3Y*VQ8O``)+,B'Z7H-J=%A MFF-_]!HEI81@6]-J[,V(F+WXVP!6.HD%KS(4PNIZM5X$N"/B,N[;U5X1[:7% M51?G+;D.?2.8UM@G,'+,M2!(/DZI>-,3G!P?"[P!60\$[#NP(S5ZP'T% M/R31=@DYQIS;V=_'*%R6[O(&%JLL#2&,Q*?:Q`*63^Q(-.\!G98%56$\R!>@ M*N[RK([?)N@=U3&WH1J M9]%/&J*NQ&'V$`T+96E$F/@1E><\W.-A1A'=+A6G%C'K3WNPE>AUK7&30$_< M.E0UK>J"5`7,:U^N&;BRSR;[3)#9Y9TY+-T]BX7'KLNG,-Z31]"K=[UD)RBT MQ)T_C"6P2ODRUH).K%[7LJ`2?N-!=':@D>?!#F'-T=\QZW;LA2P2F*W^/#R6 MQ:(E?CT"IFGCLGC`R]B@[$,\KW3O0$R(IGKX2\VR,3?:57DO16M!#4'+M]LU M+#%-VBJ=#MI98XTR*QU@EKTK_+K0:U_D-\/=3-20S4]-A/VAB&SNIJ3)_)/3 MT5S1LD_$%R\FI^:@U";.B(FI*-L;^XT5GMJD20+C,E>T^%2`EI3E;'`J&T2) ML6N)*D5VM$E=""RU8E)\93M0(` MR5U^Z'XCZNI5X83*FM:)T-1B1_-.@F=D'VCF87S+(+M_X`OK9^XWS_R""0=Y M?L*<@/;"Q32P-N1HKTK0>HA8:0D_ILA;##IT&^.L<1\5U<-3-QYJ`B:K9^"' MG'CWAA&&9[LU'GP:CWVRQZ+"OHG>SC=MAC2R5V?EC4_&^T52DN@*DO%4>?BE M4]#!N?:.IKQ<:+2`^^B]O'7[AY;%3>L`";+(O:RP.T1((]<'5'@1HU8WMQ`> M(V+0TT#D!A9729AN(7D(38*.3CGKP.CJV4_K1K)ZD@+@-2GR!IP518;N]P6] MEU6D8!5XNU1[6\0;1X*&)T]PBS8P)L] MR2>R7-/C[=A/@DGAU9HG;R#+>_"KJH(E#4!5A79HF7W@4"C M.LZ[EBYI/UDC5+97-S_*JR"'*MR3*J;>DE M)]1Y7M:#0=CZY;VX`C<=PW\T;TCT213UV,8 M,6G$EE3W=RY0'F)4[#,H/4:H%+.[]:2V0LUR_A;S?C7T4&8IY16VG]&+I[$* M+]YD'!6W=R_MD:*Q1[W=EB&8_RW(LB`I5&^V<8K:?JN-IVW_C392"I3%?'B0 MR4COLTKSW(,$J"J0=)Z34R!D-%`_&R"U6]8%5'OZ"OK\LRVTJ@_@#%1K,N$ MVV;#0&CQ6$Q2(!HS08_P%H;[C!X#8/<78?0%VW^>;G=[YMN6ZZXE9UN26D\R M&Y^H?OO';29JEUX$O%$O.%0,JIH!J1HTZB8;!+S()/L%MY&[.1OIJ&XE0<(H M6+48(2GYJFXQ7!*RGU*%.*V>SIF2:;V3/-/3;,QQ]W':=#9-+I]@%J(W?+AFOP84[9.+6MIE-DNGP2Y+O8(C6"$;JI_S$,@YR18KU M%\%F`1JE/=HY4_9%/^NC5D>,&(GO'E`6K8*L>)9O3?3+V1UI.7KV[@>1(H"6 M<;\;X9>^6@/_I"I;&]=%`&Z-XW+TCJ#/_]DG*,U(S2A$NX!,#U:X/,PR&-%M M;SFKM,7MDDW?JBY`F"1HB8):MCK*X`=R#/NN!:A!'>=@?O@33#=9L'M`81#K MSA'[,N[FB1S]NY!K%O%OOBCJ`.&<4=[Z%B$$-UUUU/-&L8Q]"$GTET/(G^FB MJ@MZ(-)K_Q'C':X.YMCGR8>U;BF[HU=/Q]YSKV4!][-$;U35FB`JM?WE[:WK MMQ_X`&V-W3)TCJ#&ES2#:)/(F=$I9)<870U[2=W9]^YIX8FB6J30U-4Q+;C@ M;+%"@LQY`OW7JL-9>K+>!/RO)6>8%`'RZ]F/9ZDY]U(M&[NG,:=Q/FQN]&BF MN\$AX-@(9U#=;V7)%(6\[Q6S2_&^EKT<`?7=[+*,,])JZTH>TIY55RT:FJ@K M;5IKQ!)`ML4A*5ZGH\L*TLO@FJRI2SLEST%G)8=`6=87+BE5IV_3TS*<]U=\ MHIF.)5J=X(IU'>3+R,>%O8.X*WVF+<#C:!"OZ*.I:7)VGQ=9$,J.0^N)NXO& MRJT29[-:TI?ZF""H),&OE:P/H3:#CA.&;K5[S>(!?OKFD`;TN@7M'ZGO:MH[ M+E@^+:=`S;PCA;ZVM[>7=[?N@>4?0[>LM0'!9 MT"LDJY6OM&;E?0&V`"Q\?$N18@_FJPSN`A25Z7?QLINE1&ZJ*`&]EK1U"NC9 MU'^UGDK5.?Q)C*5,U5T^_^=!>NYQIE7Y?ZEM*;4M+)D4>,(D`SQV>64,1D># MB>X@XGKP$`X:-1-FSC"FE;-;H3%5T#N4:^'9"^2NLG0'L^)YA5NUP)RZ_&./ MZ#,2-U`^,,C$'(P(4BOZ_I(57P`J0-UE+4*?\O4@MYZA35_0$XS\>LE6!UM] M)Z\++-O>7>G6G?ESB2/WQ'\+';=?#EONJ5W!K_$F`B8$/?#YD,81]B&$',6S MQN)5OPKK$#:PKI=[L_&T#G'A36'`I#U9]XXQ\NKL\]7UU=W5Y2TXN[D`MW?+ M\W_]E^7UQ>77VW_XTX?3?P27__>7J[M_=\\A4YQV638,I$YXJ!\VD@FYY)HZ M!L-YN,H_-NF'DAI"7E%%,ZBDBR.KKUB13!WY*G@FMU.UGK#B"KAXOXJO.>== M)5H0E"5]B!"9*[]C)=VC7HX8SHM02KBX=/Y&3M\+9R]W\CY%??2?:*M#/['? M_EW?KSO+;"P^G2>!NE3*?JYCJ0U&)RY=^OAQ9H2M@Z.OD[2`X.,;]Z30`%@O MI[,NNFR>NAFP_O9JQ6VT_/1W33W8C'+53$7S?RKA]&_G?@G@O>S"3 M6]K%)C)'9\[.:NLV.2WG>(-80^U?D@CF:)/0Q]T[-BS`G]\>'Y_@94$&'HG\ M`GQ<'!\?D_]5"2Z#??&09NCOY)&A)$T@0'E.'IBE^\H^/9$E01YG^U@..[M3 MK331(DN_J)-)54=;WA0D37SAB*'"'$)\+V7$^P^+D_3)I^/%R<>/G.?GVN+N MF2;"+&_*)@:LQ?!4%-%#L4&\"E!TE9P'.X37B[+XE$C"?H!*J'LOR%.7!*0H M0`DH"WNP@SW(#'+$YPB;$;+"[H&O`%(O;*6#(GLTN,M@D.^S9ZW!AE?8.OBY M&O=B/V6A.8><4Z9O`C=D&J4"NY;:YVE>D!LP1:5^S@:@DY/WBP\?J\'&/>;% MJ.G"7049EPMSHP6Y%PMQS06XDT>Y=>*V6A:QN&W>6Y%#R8I\M/H[F*$43_V# MK)C$B,]P@Q*:U_]S@+^8+:LXT_LR4?H?+:TOV15"J$*:V0),LK+QO1-&U8E'&Y?UD1AM-.JS@0!&VQ9-@BQ56Z/N6&)DS\+G35XAUG1((P2:D\W?`>L=+6F76\0&RX#V)JRW MRYPIC/-H@6.`/\G>KF]+FX9J!NL:J91+%FFL`5IG+KQ:S@RWP\N%C`:T)$3Q M90G34TFY?A%*N">&<,[?!A,KO/!@X3+4@M:)(@^I(%^V:"'((07T%BQR,?=D MD$_M^8SP9*4RRI;^F3D/":*Q3M''EZ-C0TPKW7-#56FW!X=JG14GAVXE)V[L M<,!0[;P)?O>`EP!%>E2(AQ)[\+Y*PG0+ZURJ&C=XA!+682[6O8L95A(<4N/Z ME`17T05=\&BUOST`?86/,-E#G62W_:+6(HY7@@;KK\:%P6M2^@U($W"!\EWUQ$ZZ+C/I@W6:-=[@N879 M(YX^@N4.9K.^5_4(L_M4S19S>[%Q$3446X.M7#=2+;N]=&C!%)N^0,VEKC?0 M)9(]?T`?);A)DY2A/=DP-R5Q!D()ZYY`K'L72^SAC&;1A3TD`T8.;:Q(MV0VUK`K/'EYV\64"U^U_4=33W:Y_ M3K/'E>_&Z(3LQ2(.=ON%VO.2"Y0W,JMW@/P(YAO84!5Q#VL5;/J[^#J8L>F6 M69@#JW1Q"'*4VDE]M53.@0.7VR$-[S0D*E+X$&@=8U(C8N6>)%H@ZP$V@BS MN(R'"9Y-Q5BGLVB+$D3(2U)OJ0FCE+2_H%?:TEL:,@D*L+:,1[099U;0DG%/ M'4W`]1:$FBSO.HE0^!A!%Q6RQ/5TEY3"SLZ2:FP2'"HLMP"(=T*#I*-/0Y_D[0-,IL49]:& M!VM3Q8Z._?.D.O#D'RW5QZ8KREV@O&Q[&!UTNX'%1DTS_66B'FKEG#2!K#UVH'K#-ZLI;IHI]/[07@GDI@.]PB$>(-4NH-YAV2-1=K MLS49;]>?[SK<'F7PH`$\\)W3^I2N5YW#H;B8#7V&ZS2#ET]%%J19A)(@>[XJ MX):^$;7?[F,6$5NO88@U/G_`:(!72?F>()[8K3*4A&@7RZ*Z<_R8PYG5A"VF ML2!J3+KNZ0^#UB\#^M->K81F;!\RT,1DUE8V15C7!R"MD#BDD%9)GF\(ZDK! MKJK5O5^:CWOBF=\\Q+/GKV[@MZ8V:8+_#.GMQ64F4;=MT9*X7>41LNE_RKJO MFJ&U^DS\!@Y5@-:/D-13YS4)6Z7*7UJ`RYJN94D\JR#L=G_RS4+CG;]$MS47 M!;M.:U[^V7-9?X-H\X`GZV=XU1)LX,U^>P^SY;J7ED+C#)5Y5=9=S@!KNZRH MJ@!E'8!50N),_9R0\Q_'TEQL3FEX4!I>9F/9YY"^0D5G/'@:R#X'81"'U'VD MR8_NW<)0F'=I/P[C_M'ZMCBX7Z39`B013@O+6L2326X4A\"LKZ@&(I$W?!8]&NSM)I_LS)..Y]&AK MKZS+Q+FUOM*DZK^R8H[OSIDI[1[00EA(\M[R,.'\J7@EJ!5ROCP;+\1-Y_'X MH\/C\5Y`?SISW)-""V*:3\F[)4LKBZ^2(MS2;C-#"_'3R0SM`P6&*.X>[!*( M2'-".QX%PO)D!HPNX!J%J+C89RC9-.ZHXKG[!JJ'!<.*[(\3II;V/.VA`E#6 M`"):1>O&-:W$"QZ-MKBRLF4YL[AX@'VKW9-P&)Q[0]`(+%L,C>@]:./X%1O% MPR]6'JO9P0RE$>ZRK%!Q1J'N9[A!24((\#G`7X00O,83+K8+_&96[2\3Y6%B MA>Z7;#M>6W&K026-=W5\>$SG+/K//_R]A6E3E.))/*90P!M0Q[?`'5X`)?61C);5 M[-W":FU(5DIL"O?6G6,;0M/**PWGZ`B70NMG<[WFK]!7=_\69#3Q^^43S$)$ M/&"0/\0P%SJ8@979=3=#+>8/KJRBCL-ASTM7E8&Z-E!5YR):,:GQ3;_TP_:2V+4-AOXN/)PY`MR60#, MX77@%^?S-'V%CM,SFJ;IYS9G?CF]"][FF?J_33F>9ZZ/UVG,<%,;X`#G.JBA]A=-W2IK#\LN'>F`=,2Q.+%.RPV@\!_K+G M(HE[=+^[.!CJ_5LUHW#NG-S,%TW$;FEEOM!;;C'W<-31?>^P`3@CWGO#[BC> M/X-FN57P3#\^^Q9DT>)P'J'ZG9SDJ6#*N#U^,$D+C?`#GAV`&LP03:>@30]? MO`+W?,-@MR"HS3._(+)YR#17Y#SJ)+!?TFP-4;'/YG[+8!*'H-LTS473D,52 MVXN\(!\AY8N9D]`@B\T8\&3A7T^B(5)+IPKZ^A*J-&U"WNDH,"M]JVLV/6IH\%T'Q?-=1C(G2Z& MZXG#DMLZ6>36/Y=E9OCD/NOEQF^B\-_H\,QUJ9<-W`;_2;89OL36DO M/%7?)N/Y%,F7S,2!A]M(:@/5"Z`%2-@*,%VO(6V`D+YN-Y>YH^=(4GO++#=H MNPM8>F:RM*N=2()[4W$JFV2RCO<1;J>RN^^CU%X:#+L ML@*00^Q!(I+O);LX M$#2CM<#8-$$QK^9Q/!NG"(;Y.JG3L7>JJRDOX>*=?JL<)GU55+XVMC7M"_<9 M>2[[)4S_A`0?$?5RY)HF.G3MUR*3:^44WLG;-:>6Q6./!_3C^JT#`R_'2\G7 MIB9NZN1E^:DI3DM/%_[J5KTB:3)$_DA0V*[7$6G<>\"DZSD`+>G0>^AJ/G(? M;]',>.+2(1C;6^=H(23WY?R`E"$M#FO08P13&WE/F+.7)S42%K?+5K'6LGSJ M[(3HO`F*U#=']76?]-"?2\H.ZRZ@T5_6^*K@28NQ6B2Q%XXJS\[GY4,X%:K. M21A0$J&2BUD/6BFLZ`*I*DY'NWH]0-ET+HY_CK9BE^:(O*NKBO<:6J,3YO4M MOJL#NVXX3Q]S8Y?1C)B5M]S)YJ?B\@X6QGR]N2M@YCY;TP;7BUP][4777U[0 M)'6(M:UY*I-U/4M54:6_V%3R9`QQ@QB6GH&B&2]FY;-5B8!EZDHT[W$7EZV? MZ&.K2Q*]FG?:J@=J`RM6]6G/8$N>2@<9#"$>&"-RLR_?W^WD!8D;W$I8Z2OL MCJA_ MEEZR9C\,R"^3+U^B-W+AS3!I4]?EPECYCS:?;\MPP5\"+])DN9 MPBMLG0M82]EI*5V!'M?+DDAK*B%=VCW@Q4KHX5\'$(KKK M]ENNKY("-S:ZC^%9GD.RZT]N\6'^_92FT3<4][JO:;M9/?8Y86AGCRZU/`D* M'FH`K`KPNJX$5+6\F3<'D!ZK1II=$6X7%,1TK]@V!+D](@Z'K3V.+HL'F%5S M3CK!E!"15]@ZV[@:=[%%"QT6?+38U%PY9?HF<$.>GE6Q14OM2N&4JH\D:MMD M@Q@C7RR(N&K'74Z]C311.5 M`:^9U!N`5R-M03+:$-&9QA(S?@PQL*)+!$/R1CND20#"D.S+Y7A8>0ZPOW5/ M'VTH=MEDB$-[Y+J`NPR&B"ZESI*HN;*2T$HJ99U0OC8,(OH1(E"YUIX7#X1IB,TYYQQ;(H>;@DT&V3&3)"W(M@]E2^'!%$P)-O5"AHLT MB[&TO'K1EQZFPB-9=7_F2YJ53X;GR^P\#M!6MK5B6(_]6)JAG;(3Y>RD(9G% MU-?!"$RK6LA1.U:/TRC:2(/K*V\KC#:899B+MUUB8I;D^YANM^9EC>XY.0C1 MO1C;<#C;W.5AR].+*^GV(8NR M@OE/6&@FOA]EZ_D#2>R2=XY`L#`_<50Q"NY1S(Z4O":G)N!Z#4-VW:>^(H#_ MOM_G*(%Y^4#(R>D//U#QD]/3[]YX<(["'/']7:QA<'?)ZJ_T*#@).DE'8+F< M!]QMVR&DZ^M*X@W!8$/(BPGM8+.P+=FAI(]N M5]G6LA&1]"KT@&&:EFM2KZP-E-70N1,+TK":/.7CP$9X7=7TIK53MBL;`;)J MV`24[3Q7*8/8S-1'3ILP04UV+%0PGV32CR^2,C;K>M=(+Q_!J]_8?=-WG`O[C35;> MJG%/6G/@#K\OZ!DYK^C=_XEN_4HK\X6LI(-:B5;'>&IE[)`GK?8GNP,:\EW5/2")ZB9&0&V'1(/.PL M\#!?/*]P3Q5X0DX>$-N1(B;LDU3BGH(R"W5X6,DO`*UA0==N=25^$M+$YFH# MF"Y#(_8$NH<45`)5R4--E#HD(PV'K(QF[(I)S>1JCB$Q>;JNLJ(J0R9A:G0YO MYFT@]/R4?(WZR#2SJI'$1)MU@F:E;J.A,[5&:QP\)-==`/HDQ)]/WB\^?/>1 MGG`_['S$]+YL]?[1R>GI,=@1'W"4[JLGD-S[@0D8)!M91]''`S_RN3[=?`/+ MW*[L>^[#E..J\\=SR*V6DZ3I,C!7#E4M:&K#M$S[6]7GV51YLF:H?`7)G%V> MJO=EZ!\#=FVN:R/=?@SI2YHUU:;K<<[&CT8P2;LF9U$E?5N%\5U4_T]<:1O9O2B&>OM^S50+8FB[5A[68I?+C3WGAP47/=*Y!UNL@5 MV2,/@M6)',B3-8W7,_T)=!G;13F'&@DJV@\=)FRA[MU[A[K0E*U2-7#I:/OU M\*+@X<%PW4U7OJS;K5:!/8H-UL:[M(WM)D%$_0*9VXEL@'KH9(E;O$%QZ964,] M0\!>*WQ(XPAFS7<(_>*0&'$R`JG@YGK^5Z=TJI(;L0\@_G+8I%!=H2/WS2EW`ZTTUS=#N9$OD*ZS. MJ&BO]C2$76Y\B"V2[G4\`W>W3"PK''NJ"!;&_OLV1OB:8-/LFNAA3PW MH^=-6L#J_K;F^-@6<3H"=K27CW&T<)6\P)"WA"54&N\R=JOPI1L"!(# MRAXG,$5+OB[7FIP0BUCGA$3[+J(.1G#R<<=LDITRKW?(S+>S>7M%_FYGZYO,GB!KF'QX[/(%;&E+P#M\ M,\SIS8LD(O\AMT`>@Y@XCQ4]L]O-U2.AJ%DU;NYFZ%O)O^201(RKC1H6@-4! M.-FN/"#J2+,)55'CG%A8-0/]`QYJ=$_5(3#FWOH8A&$=NF:[[(F2\/CTPS&E M(/GDMSJ?#GMSZH(>H5_15=Z^8+\]S96/67_-&J'G;;/>&R+U#0?V2X#]%%BQ MF,F^J.COVQ42Z0K2;ANJ+Y9,<(]D=(-%:;@GTV;NJU!^X8XVA@AW:0-WR!AW M-CRV!:]7.79K+F^$_[\H@4=NX2;X]Y^ODG6:;=G3:>)#A`:R=GVSICV]-_!* M,7!&;I=30="05!X(M(97%KR%)H+013"T&TM$/XZ#1]A1C]=I\;)'>X6@4P6!$G8"BU$P*` M?.]'CS?;D=?+_4:_Q,%&T+6=,E;[MJM?MW/K[P$IX+9WN6W9 M[%Y)0\[-7#:WN4RB"SQY45"X4]8)E[OZ"DE=SGUQ24"*^L%O;FOSB"YIZKD1 M\07E81#_.PRR+_@37I!`6MH)*OHZ"W'!B@)2%M#"?B!#T.H\;$B;W`XZRA61 M-CY:Y1TBI*VW"B/5\MDWE'!:7XP38=//A90[EJ#U]GE[G_).%W/*6$5$5[\N M"LKO`2O@MM^Y;=GL:TE#SM6_;%W:.%M$7Z_.E_LB+X*$:"/H=!U!JTC0LJ1W MDX&%'9KGX!:`"8*&I%O69G@T>S+(BOD@@^_2M\EON7;ED7+J6GK\B+L(*` ME@2XJ`]X$+0VQU/(FGHN1)RS!]`.DV#YVE5A#><:,C8W455Z-^%",W5O5R75^VH!`EQU(N79*Z;"HH,#C/8 MI,7!%ORQ&'YQCD[\GHX`0/2C!ZFPX,`2^T$(4W!!H/PH93O MY*V@=SAP-;A0GL8T*13)OLB^:]P7?NMXLUR'AJU-\.S^3H!8MT7ZSC]!N="Q([R%V,/\U!LDU72R?#[QV?4\4(MQK8F@`=U&>(++)$JWL,A0 MFJ-VRGJ]M/YS4*.6!PUU)U>`L``00E#@``!#D!``#M75MSX[AR?D]5 M_H,SY]EC2_)X[*W=G/+XLL>)UU*-O6>32J58-`7)R-*D#DEY[$WEOZ=!2C8E MH7$A(:&EV9<=KP1`^/IKW/H"_/C7EZ=X[YEE.4^3GSYT/AY^V&-)E`YY,O[I MPZ_W5_LG'_;^^J___$\__LO^_M[/+&%96+#AWL/KWD58A/=9&/V>S^OO0?6/ M)WOPQ^'Q_FWZO-\][/3V_NOPTP^]XQ]ZW?_>^]_!+_^W=WEWO[>_]^W;MX]# M:*$H6_@8I4][^_OB=V*>_/X0YFP/.I;D/WUX+(K)#P<'HOS+0Q9_3+/Q0??P ML'Y^-+/OP`,MC;^S%+ M8_:5C?;*#OQ0O$[83Q]R_C2)1C-'LJ>_UA3[3[Z]?KA>[_D2;AF"6"@P/Q_8&ZB0/H8)J)_#P%-4[@%R-N+!EE"QL9`_?A0VS<7?/FW.N:54>1NH[USJI+LHH; M87B0I<-I5%RP9Q:G$Z%K`SYAT"B[8$7(8W?D&_S21A"?#>&_\&$8U]84UV#5 M/^)D=DF&0GO%M)"G,1^*/=&7,!8;B[M'Q@KS24;?T)K7+P>,-&_>_5QDUW.L MLN/9Z#R,HVE<:>RH_H5=;^V:=(S!@9Z8-[?>'8`#*(U;W\CL,P`!)\4C*V`4 MQLZFHJ56UX7D#@Z%K)1L?_0^O[=!@;7H!H'T9^Z*-/K],8V'<#*^A&7)^$1C MT^!&^]]0IYJUO@G=.@_SQZLX_>9,M6H-;K3_SD:[2>MOR"89R^&+4-Q M^,#BLOG`N&[0.^R\B\>TLS.1E/:AG$4?Q^GSP9#Q`]%_\4<)9/^P,[,._04^ M>NM-K1/EJ472>U5QZ'!WH<-U1L^RQN3Q MFR:,LO2ID61GO4E-@4USZ&(ZJ5;B#WMI!I/-3Q^@(8`Y8EG&AC>5G%`8)892 MF)OA]8:-P[B2PMD+SQ$ZETH%O7,%\5@HOT*>0)0E:] M",`\]LV45/*K!*UV6\Y.CS`[$J6$98I=PPJ'#2U5%=#EGF_V;,>9'H^FM70*(H`S"."M"W1@%/WCD%.U2?"5)T!@*$`<16'8X2KA3(`E.):IB5+ M`D+.UC%AMN;`!RSC*6S&AA=P&-",L(6R`-S[^M9FJ$G`R%G\O`4L7O$=S!9"DACA,6%,@#T=!N9DX!`SN.'A.FJCD'"U)\FI&0 MODGF'$20"??;D+W\.WM5#]+%LH#>`8YQFZD&Y4!)0;Z4)!X6"$-C&E`-2.5AV MR*W)46<0"YB'XC2?9NP>U.4+=//W=4E* M\E.!U\'OG/_%>6*=0G/D`"U8EK,;+U.-,F;>PR3SA"%U(IXF(27P5'E#@;M:I&QX^\)@7G.6S;;3!@&S06G#J:UB:=-9NJ#9L M,?!KPFI)GGP4MQ'%]B^X"VE8'D;U99@E/!F_!XGKARY6)5BRXWA$83($T3J! M7Q.&D9CE0TD-:1?6056*H(?1H^B.U?;4JIU@*?R0&EZ3P6?74.`WC*\Y2_)A MV@#\]B]TQMFR?YJR$%-&Y\37L!<7.0RG,>N/9DFMR^&0)D/>O)&@X]4#[YXU M^31@*9!=6+[EF>C?Y6&VVS)UQ<5H7NUE@]&L:R3H>G7OMN5(-W:-X&__\BVY ML&'+3ZO=(_\#<+ES7\*<1Z":%SR>%FS88#1:M1ATO09_&U&D&W_V@'=A(75Q M_CV:_:.D&/A/<()4S)+P+';Y8L MM<0 MK-^TV+;$HXM=DV:"GM?`QH8$MM&"&FZ_B;6('KQU^V^ODW0,/1OR_$D]0RNJ M!#VOYHS&U$@8UJ'TFUJ+L/EKP3*>L"O^D*5\F'?41,I+!SVOKEZ7'"H`^LVC M5=,WFO6W:T3?4FG8:^S,&%0A=)5:NVI$=$#D93),GUB1\33GN9I%2=&@YS5& MV"6#&#I"J;*M30.&ERT9U`IZ).R##FQ!*#I7^;5K&;:SS@MCI_3"B=5"08^$ M]4XG=7P'6X/A*F=VG=3.?VG9PWQVAQYBQ!?KV?MB(15R1U'33UK1^["S,G?`GM$(DO6C)-% M/C$T=!QFZ[H/]LC[98"(1$I`D^%GAHW./;$M&'_')>XXZH_NLS#)89%16?;-*P=')+*9U3PBW)N! MHW,#;8N<]D$?M4&ME`F.:-@@S.B1<[L(ALZUM)1,34\>(LBJ9/XFDL-KR89CP9+]=0:$G[QH-/ MY(TI1VATDR/X;?V!IY6V);`[+69EO>68AOFC2(N$?\1#1<\P%8OC:7$>9MDK MX/][&$]5"F54/_A$*=K*4F?,$3KR,R[GG9#.UU*HAD4KP2=*H5^6"F*+TY4W MT[^>E%NVZSR?SF?+Z@KKZLK<6_:M_$IYX#1J(/A$PN#73#LL(+IRE!)0C/<= M_2#C$7M_^MKD`+I0)?A$PO+7D'P5*%?NT39T8QZXZ4/,H_YH)&(RQK>L`/@1 M8T/<48I5"#Z12'JSH\\`TOH>D`-/"=F50/ M.CU_OK%Y_[2.L(6"T&42JZ"Y>+'UXK3IXG/*6^:WFRFEB]%PM#(*@X:K2CC$=AEUP254WQ9K$4(/8`208'+F4_)_H*G`6E_3(RH-,2#B<9$RI.)7"<.1J\D_M9DS`'1K1 MLPI"VYA_.WA0K;43RK]&##(V"?G\XC!`WR\>6;8@.J4G4EL[Z-`(R;76!F-L MCE+&_.N"*>O+,B#A\;'F5X+"E5/0JC"A`RJ@\A(6*7,%<`< ME2MW#(6@D@JK=OH&X"0L5+8;]*K?SAPJWJ?JFN=87$,B_$>/:0QP._&A*M@(9QOH3W.BFRI M.$A8VIJQC.%!Z+4WKGG?VZD>U5$86?%:08=&2+:+15P+$]&#+32L-=K5JZ1* M(\C:A1;H4")*L(61UH-Y?TO(.D^+I#0(A(0%3D<9:DZ7`T+B3+;0""=FM#0Q MHG>Y*(B"A'&M&;=R-`BQ6QCC_'XGR2#DP^OD/)SP(E095)$:(!@21K=F-"M! M(6QO-,39#=OW&0OS:?9J-)!7"X,XB%C9FG",X4'H-;>K$4J$HYYVV?E$PE+7 M3(%\'@9"PWC53"`P/0K"]Y<[[,5]W#FKAN@%14;/C MN;#:*[`B:F%OW%M2BPWFV@Q@PJFL&M5?9Y-)S*/957?$KK>;^\&AL\ON"+NBB>\8#?\F:WTV/S>.ETCP6<2>T%[=I"YW`XXG60?OV]!?::Q MG[,C#S/C(/CHI`M1>13J,XE-&TJ8DE\$SNX\"O69Q+9*+>U%AC`4N_,HU&<2 MSDQK3B0H=N%Z.<4B<6.0KV=2/3@AX+468')?96>E MTR1/ARK=4^UCS2L')_[?]6HRPBP1DCQGSCH]@/U.FB0LGFT[\&!:@UK!B5?; M@"4M,B.!'AZ!RRHTC):>$SLZ)56"$Z\V!7=<8M@(7$VA)O(K"!R$)2Y6J#GZ MK8@U:2(X]6I*<$:T,=:=N8&BNE:A0?*+NF)PZM5PT$HA+!#NSN433M.?3KU& M2CLA7PUN35=5;-!0=)/F^?R2W/,PCD1(&!=OJ-6_\&@^N@RSA"?CMZX8V(BP M*L&IOWB'AE>0GI*(6U`*%`E16,7QO5AZ3FF$&:P2H+?LG)**(%B79>?4JZ$` MD[O&LG/JW>]/X[;14Q(1`]K1I4&P"U>-WK+B.H%]!!,[!06)"^6"4Q+1!0@M M<@Y7`1"PV[CA\#?&QX\%&YX]LPSVA;=3$3O1'Y6K?']:Y$68".?HES#GD3@+ M\WA:O.\N)60W:S#H'-((0;!1BS90"=B+UK,]-]<434V0$XF0`RN5,,*T_<$% M]:,AM4AZE^?%SJ&[R('E'WD/^%;BJ01=)A`VH12BQLQKAHG-B=+#?/8_# M/#=\%1JK`V+Q'T9@1)UF-RP'1N?HV>+V@1HR;=3Z:F$0!"WS@9PI.;T8')H1 M"2SC+/\MS+(P*=0!TI*B`(Q$7@$FB:58ZSJI8 M:S:\`L&>IT^3:3%S-:WL'I]$#*K*X^BB_:#3\1^L8*P=B'?2G2!(/.B.YI:U M@KEDJ;E\85G$_H,B&BK>9F3C*)S"\U.?Z,6*U&PFBJY: MW3Y@U0XP[Z><]W<12\*,IZ:&S'IY$(?_3(TF`\\`U2[X M]>>H?DWR"8OXB+.AUI")U@&QD+"_*#A#2%8C\GNU`+(+NG_DV7`09L6KVE"V M7`X@T8C*4,MKD.B,7K!?3NYF@Y,E=/??IEG(V7$>HWR%@=D`L)"Y.& M.(1M-2I7[WFZG;JAARR'V4D]0R^6`CPD,G$T`I?,QS() MFIN%0@")1L2,-342&!3>S;0WL6M]_"9U00#;:1:R1$CA54R$XGD(^^SF;(S- MI6(`R_]-'>;REY`G!43A24LSG@:L3#0PI&M6&D#ZCZEQR=H"KG6]3;E1_S&4 M3W(FQ)*G,1^*]S.^A'&81.SND3%Q1YL0\",KQ%KCPV_\MFEI/7SWH'!]Z/]E9)FUWCFD98;3BU1SE:JB^&]_P,0F[BXP"`V?P,?Z> M'V&FK)W!QUY-):CD=<[@8]0.LJ7.8-7V7Y%&USFF9?A`QY@.PRXX?1=MM+"S MZ& MJPERHA7ZTYCW%5`[<]U?[]JQG0=C"O'-4&6S99V5340$2WC6#.^ M5Q!1\(J[(7WA]?@*K8)K26D0B%?;6C.*42#K\JK[]@:]B2?OC_H3EE5O&_OP M!%7WX[WUQ\#Y@]0`PCYY-VC:^GMH/"RKE*B9BP=_078'73PT'H:546#@XL&? M@=TI%X_?]V%1R>M76K.\G]R%,?PS MJEX(5_",5P+ID`ARL6%:A\:5WX/"[83E>VZW:9)6)K-D7"FW@FND!HB&A.7' MAF@EE-WQ>\Q%8G#(`>@D+$$-UMU9WYUY+I:>H?/AKLK+5)#92YLF9U6L"HB& M;/@)?F95HZ&0'NAJ?"H>6%4.6D4]$!()>Y.:1&Q$:X%1R!QTM.%B":P^,6`] M&S[QA`OQB,M$]?QK:@8=OP\0M]$`(V@4LA(=[L*$G-[%U)_O271;,:0:B(B$ M8:L)^WI"$&MO__*^?7M_)J^Z!%KD\TY! M@6O!";J(`%5E$!<)"YG=ELX4%Z(&]E8S8FH@+BBN0+/A.^9;5O1']^&+L4*H MFP$1DK"NM5$-$X2(DFRAT4V*5IBAA#CZ"7P]2?,P[H^D!0W4Q\T/@-A)&//L M%,LE=B3,9"M-?^\#[@L;I1GLK6'-!D0\";/74JKB'HKITS2NMMZC$8M`%N>/ M83)FU\E9%(D',\H[[7@2\8DR3,S]CP$A)`R.366NE]P;QEW^HH MTP3^C*J[&S*%&!8EU4_>'BI6**7KGP(J2%A/[51R/5)`%'(+(\B;O>W=(?8X MNZ$JK$!`>+0WLWJ?6-;X/#/9A]P57!N!0MC?\'N(;OA7O5%>SX`Q\+/8-A5T MR;[IKM"09B@1E;&VRFZ3RI1CQX&^E.V`&$E8;IO1WTZ5:@)`]&@+(QH1\+.) MUB85T;(E$"0)\_`&-$DM`D276D=5;C;I39KK5B;X/:8Q(,HO_S'EQ:OGVP]7 M.V1W_2%>'[@\\C6&F^;#=?T^4M]`OO)A)X-%)SO.`:^5*,1;G6DB1I;IJP6R M>B`>6J:I&FD:>G$X=#+L6AP!%]%I7RJ0E@=QT++RX)PA)S\F@Z_=Q^\8LHUAV)MGO+(HJ7Q<;7K`1CWAQ,? MB8M#`=U7%J7CI&Q1N8'?2`^`/EJ6.B,%W*AP7&5$MO/L(>]`B4$HG@/JCVHG MX6IS5,%![_ZSJ1YTB;Q]:*0E]LA<94]2<-Z60*NY>17N+?M6?J7>0IHT`(+; MUIV((397F99K&?<(D/)^ZM_"K+R(X_*%91$7$V"8/\9,&L75O#$0,RUKOWY. M:(&30N*EG2I4.NU*%S2M@9!H.0<:*X,14`HIF"XGAH[3F:$#0B+A35CWU#`# MNJZ7)KW-#;;JH&L.Q$3"W[#VV6&&U%4V)^'M9#DPZH>I-UG8[RSQMF`CMD5[ MC)8PG25_$K!8*P:/(Z51-`;BW*+-2%NHH@-+(ZW2UDW6VB07AD/"3KG/_6F%TE3^Y2050[,'<[5M!/"2")]:Z9:U` MNDI9W/@D\&:O:W1\?:\=]';JN+H,S%4JX^;'>&."EZN#(+9H1VB/;)?R%8U4 MN^$ALV[AWT:_NSDT5^F(_@^3S?+0N]TMFM(5$'8G';!UY%-WBVR(.ARN,O.J M>)G+9+A]@4^]+=I?XP@0(JV-=C(B2:99#DJQ/K*"1P!X=W,N>UU_$V7#G,L> MK8`,O7RQ.7,5UI\YEVC"6X_61K9&FH9>',Z?.9=O.1$]6G%W.&=RLA6H=B'G M\JNX`TPS?-_*`&Q:SDSM4%WJ^DZ\@"@@:=.J:J6"'@U?P!(7"L+J_7:4#>F5 MLE_"%_XT?=*2ME`.X)-PY*TP(B=.TG='R8Y^J>.)&77U<@"?Q$;6E+K5OCM* M/:2Q6[UIEG78(^8_,]^7+F'PFW7HQ#7JQBT*PJ/J1"F):NT2K0`Z2DHDX!%W M%,;9`;E0-::[(7Z&D,8#APCURYT>9#R2&8?PP@"2J@4=HU&!@W167BWEK.JB M.@L/*1YTCVBMH7K"E$B*I65@A[9#$",0P,\KC*V5DG< M;.C'4+Q$.<1B0$2D^%6T3&^H6#6V MU1H:.B$=.8L^CM/G@R'C%9/PQS*!\%%PP\9A?)D4(HY%[O.5E`*PM(QG-0H6 MR4([3R<[,==<-TSP^D3"B-64/U85EB#MS\_6V//G<_43"QN=6L5S*IFV,RVFED0EL M>PKF-WU%2"`7(A#V&6&Z@4/O&?R?TI>#5P+YD+!7N=4='=ZV83*$]*%VN^QM MFD0@PW+YOD_%U;!)Q&.V,$/?I^ZV.^O^:>"*1$"Y6]W]5E4#"9&(;=^,)B!:J)6/JP`C_RITG3R#C-/L];>, M%^PB_:9*;5DM#.(@8<_TJ2Z85%P%-A%0DJ=)R+/*7'P-Y"9C_A"S:M-P^1+% M4_%2Z<]I.OS&XUBE/S;M@!!)V%N]JI:]P'8G-JM?/+)L+O)2O@K56BT,XB#A MJ?2I/YA46L=R$=KD+YQG+E^$D*8\?ZP&S05[4.W2M76#[C$)@[1/)3(44NN8 M,4(Z=<&@SQ&O6$Z&]0VARF*%UP(1D;!E^]0CK7@H7,;N\!X5JQM.D;L]CTE8 MQ7UJC4HR%.YK7]=>Y_)%@+7;\LSJ@'!(V+QI[7P6A-,Z:H_08O7^0%(9WP93 MZSS;YBK-9B]BY?WL/`ZYTAUOU0Z(D81MW.OIS%Y@NW,U/,A4O.[++ECU;TV* MLW?;#*SDYHV`^$C8N_T:FNRDM4L7RJ]B!X$S_BSBB(F$L=N66%/U M6(':^IIX2LO>"MRY(99;:D2M'HB)A#U[71JQ`K7UO?&D-6*0L4G(Q5/C)9+9 M%A`6ZG)[J`T-:-8@"):$X7I=.F0N@]87TI-6KK,H2J>P#QB$KV**%2:-*,JF MT$\>/O"X7-:ME,ND01`L":OVNI3+7`:N;L/WOY4VCZ%P$E\;=#^3L&D[C[6T MPN_JIOTB!5VGJ#YBJ<]=A6DK&@-QDC!M.PG3UN)T=1T_A3/5/#'R/CV+_C'E M&?LES'YGA9AW[U@TS713CE%]$!L)&W93PN7J8P&]]<7_A#9!*[!!G##!%J^# M.$P*6*S%-;$34<1&;=!&0(`D#-EKUAT-_M9/#%!6H/+,``(83H4,F?9(9M8` M"(Z$=7K-BJ/`WOHY`TI*DZ418\/\"N1;7D)9I)8&HUQ9&2\\WAU=I5A='N464B-5@ MBVW8$@B2A$5Z/7MM*R$@VK258=7FXG1B30RZ)Y2-T@VUR!8_HD"[8Y1^2Z9S M8916-`;BW!VCM!8GHC9;&#A=GVO?P^MJEU$;[H>D=4%8E$W16IKUFQ\%;$1' MK&.EJ6VD2XC]$I?RG0SCNB`NRD9G!UJB@(UHB?5MIK1F$CAB%AE_F,*>:A:< M8*@@JQ5!3)0MRPZT`\.,J,86AB[+9\S!',4\F+OZ@,&7S58>78,@5LI69J?+ MD9DL$!7;0H-S[?CXE4VF6?08YN8;&6UE$!=E\W-3U3'$C=RMN)51S/7AS>]E5[<9"C^$0[]YS`6@Z9Z-V\Y MX%KG_39L)NB>DK#>VIG;[!$B2K*%]EDY]C,8,UGV"L/C[V$\M=>.I?H@M"VT MPEI`0_3!VO`ZJ1ZU+,*L^"ZT@H09=CU:@9I:CZQ-K9567";UW0C)]V0&I;P? M6<$C`+PKC\N<'OD:AHT?ESDE85#2BU4^Q&1HOIO'94Y)&'1D%"R2A7;^.WA< MYM2K?065_"I!J]W^\W$9(2P29A']&--A\/NX#/+6X%NF9755X.RU]M*$.RVJ M0Y6;8-LU_AJ(EX0I!"-^44W6+H@UO4F#[&%_/!#H'J#GI?S_'U!+`P04```` M"`!=36=#DAZ:+HL*```(9@``$0`<`')P'-D550)``/Q MIGM2\:9[4G5X"P`!!"4.```$.0$``.U<;8_;-A+^7J#_0><##BEP7J_739K= MR[9P;6^S/6?MBYU+#X=#04NT340B59+:]?9P__V&>K%E6:0E>9,HA;XDLC@S M?(;/;=G_?O\^57O MQ57OXC_6?Z=O_F>-9G.K;3T\/)PY8$&&%LYLYEGMMJI'V&OL(4LBOL+R#GE8 M^,C&UZVUE/Y5IZ/T?F<4K3!52AU5Q?EE3\%VL8>IO&'<&^(E"EQYW?HM0"Y9 M$NRT+/"3BBON\TT!6Z'PGMQ#[XSQ%8B<=SN_O!G/0I2)59?0#WO2FP5W$_E> M1Q4OD,")N"IUY%8A+?R\$Q5N15V#W5_&8#AME!B$"14247L'X@!T[&+W\O*R M$Y8FHH%HKQ#RM\)+)!:A:%P0-ES[O-ON=1,5FP54\L=]'P6VSU;LOA,7YJD% MG$/XZ?3B4J5XL:_H8)*O`P4Y]>"-O8R'S5:*R'"6*B"WR=<(B MI=+=5Q'$SE>`@AQQ($`^^ECD4A.6Y,`2TN>:2J`DIQ8'^QS;JM]KX^NR@[C- MF8L!@2W;>..[B"+)^.,-_-XV"*,T\/*-.))W%.(."+5!"G-B;_6.*\4*D$$L MZQ6BE$%J@904_E9O?)_0)8M_P@L5WU<*\!S4+?7P[NVM-C.$G@V9':@,TZ?. MB$HB'V_!(O?">EH6@<8Q2FSK3FIW\))0$J+LGGST:S6<-;95IFR)(_7*-)0%X13G<5S(3VJM" MJ/5LKXIO&H++$+QM;C%93GPULP1$I@ZJ43`3^VTQ8F=S^._-Z`Y(G=Q8D^GH M;7]^"P(-I7I*[2=-/E:8'2*QO7/90 M-$OOY,TD?UYXE*[85F)O](MOL2M<"92O4 M;AI=.Y?P/"*].//`G$`2"@(VP=O9H%[`3$DO2TG*5)B9]HPU#%4>\N=HX29T M%98V<_=MM>'?>A99;R9P!4>8-'7Y16:>GA\;;1I&R@P[:3IRWINY>&$>@AHF M3L]T4\ZQ<&&RN&TJB&EQ+QJL*M^LDP7[%%52L-, MX,$N3'8NEK)OL66FN.ESY>@]GF0+2YMI/;++T^30ZGP:]GF.TUM5V=T2Q/-==5XX?+?F>'G=4N>GV\DYZ5_!Z;.- MYR8BJ@;#">0P=K+M%%> M;KEH4=8M4,%N?3V"#E#6HTR?>5J_HOZ6/FT,O]*GD<-7X!;CTJ*YMQMTQ_:C MBQ%C%BT"#"KJ5SO1:ZM7[>Y%N]<]VPAGU_IE0.Q\+`Q@5XKD37MGJI3_AAL&)D`Y:O'SJ4#R;FX409+62WZ< MC"7O-D@A,&G%[:_VSDPE.`<71XI`V2J%3Z>VR.&EDB(8=EK18WMGH!**[$V5 M(A@2'?5P54.":-WE<&8[ZQ5'WE#6WJ*XONB(:#K%JQ%.=L@]PWV%IBWK&@"&EU8NW*8 MAPB]E=A3"ZB6A19"W5N5URW)`S4_57RR'6>+[5>OWHLQ6CR"'"JTWT&M%I/'HG`0+%-V3!&7%$MS;. MZ("9_5C&XA=U\^,`F+EOJ3/F0>'4L42N^+@])\%C1GV'-VJ&@VV8_[TA+JS9 M&,7U<4(#3^=3L'")/5DN%7^K.RS!BHVQDV'%`QL2^EPIEZ(-#GGH422ZB.Z! M@NMX060)/_60=0D-)BA.X.+),O[R-R9H05RB=H?"8SR?8_1:@R:W@P7.C%X% MP%9P#*9N%ACI3#$7D.ZP&W_#'81[!/(31JW-L5,F;(\! M/^)O>,;@BW,V%[79T[=88%A,KF%VG3I6]:5Y7LP+34N,$*?0+7=?R;>?S6J7 MK8Y"U9T<9V`P<[-YQY`^;Y@8R/IF2K>H_):@WSJ/X]YFB%1QOH`T3@*2?V MMA[)41#(:IH%AH.)H&L(*!ZYLG(7O/O'86QBI;OJHY)41[*2U M_HG<`,>3-Y&,R([Z*PXN%D^Q*:/W_,2%3T6'RC5/U*@%V^>SQ$55X$\9)MT_ M7)QTGSA0NE]LI)1N"7W#_J&BY`D#Y(N,C4IA<8W]=#S`2AR!.LA%:KU'S8WFLW8S3_V'U M?MP,GW][J!C*LAUB0D_OX!^O3TQ,QS_08_HOP":;&@,F9+WGA$>`Z[YW48=Y M&.*."2)JL_^:BTIY\*H3':T-G?D_4$L!`AX#%`````@`74UG0R69E\%./P`` M&7L#`!$`&````````0```*2!`````')P&UL550%``/Q MIGM2=7@+``$$)0X```0Y`0``4$L!`AX#%`````@`74UG0Z4`_<+I"0``^(@` M`!4`&````````0```*2!F3\``')P`Q0````(`%U-9T/'@F08TAX``"_> M`0`5`!@```````$```"D@=%)``!R<')X+3(P,3,P.3,P7V1E9BYX;6Q55`4` M`_&F>U)U>`L``00E#@``!#D!``!02P$"'@,4````"`!=36=#%:N;E18Q``"* MLP(`%0`8```````!````I('R:```"TR,#$S,#DS,%]L86(N>&UL550% M``/QIGM2=7@+``$$)0X```0Y`0``4$L!`AX#%`````@`74UG0V3L);.5(0`` M?#("`!4`&````````0```*2!5YH``')P`Q0````(`%U-9T.2'IHNBPH` M``AF```1`!@```````$```"D@3N\``!R<')X+3(P,3,P.3,P+GAS9%54!0`# I\:9[4G5X"P`!!"4.```$.0$``%!+!08`````!@`&`!H"```1QP`````` ` end XML 40 R21.htm IDEA: XBRL DOCUMENT v2.4.0.8

Loss Per Share (Calculation of Loss Per Share) (Details) (USD $)
In Thousands, except Share data, unless otherwise specified
3 Months Ended 9 Months Ended 313 Months Ended

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Net loss $ (5,998) $ (4,583) $ (20,579) $ (10,123) $ (230,481)

Average common shares outstanding 23,006 15,422 20,066 14,746

Basic and diluted loss per share $ (0.26) $ (0.30) $ (1.03) $ (0.69)

X

- Definition

The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements. Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period. Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.

+ References

No definition available.

+ Details

Name: us-gaap_EarningsPerShareBasicAndDiluted

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 20

-Article 9

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Other Comprehensive Income

-URI http://asc.fasb.org/extlink&oid=6519514

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Net Income

-URI http://asc.fasb.org/extlink&oid=6518256

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.19)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.18)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.22)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=28358780&loc=d3e565-108580

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 19

-Article 5

+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).

+ References

No definition available.

+ Details

Name: us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (USD $) In Thousands, except Share data, unless otherwise specified	3 Months Ended		9 Months Ended		313 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013
Revenues
Licensing fees	$ 0	$ 0	$ 0	$ 0	$ 28,755
Product royalties	0	0	0	0	627
Research and development grants	0	0	0	0	1,219
Interest income	3	1	6	1	16,308
Gain on disposal of fixed assets	0	0	0	0	102
Other Income	0	0	0	0	1,003
Total revenues and other income	3	1	6	1	48,014
Expenses
Research and development	4,786	3,131	17,132	6,776	212,391
General and administrative	1,215	1,453	3,453	3,348	56,373
Other Expense	0	0	0	0	388
Total expenses	6,001	4,584	20,585	10,124	269,152
Loss from continuing operations	(5,998)	(4,583)	(20,579)	(10,123)	(221,138)
Loss from discontinued operations	0	0	0	0	(1,828)
Gain on disposal of discontinued operation	0	0	0	0	939
Net loss before cumulative effect of change in accounting principle	(5,998)	(4,583)	(20,579)	(10,123)	(222,027)
Cumulative effect of change in accounting principle	0	0	0	0	(8,454)
Net loss	$ (5,998)	$ (4,583)	$ (20,579)	$ (10,123)	$ (230,481)
Loss per share - basic and diluted:	$ (0.26)	$ (0.30)	$ (1.03)	$ (0.69)
Weighted average shares used in loss per share calculation:
Basic	23,006	15,422	20,066	14,746
Diluted	23,006	15,422	20,066	14,746

Organization, Operations and Liquidity (Additional Information) (Details) (USD $)						0 Months Ended
	Sep. 30, 2013	Dec. 31, 2012	Sep. 30, 2012	Dec. 31, 2011	Aug. 19, 1987	Jun. 25, 2013 IPO [Member]
Product Information [Line Items]
Deficit accumulated during the development stage	$ (230,481,000)	$ (209,902,000)
Cash and cash equivalents	81,828,000	24,212,000	29,583,000	4,565,000	0
Accounts payable and accrued expenses	3,200,000
Common stock issued during the period						4,312,500
Price per share			$ 5.07			$ 19.00
Public Offering Net Proceeds						$ 76,800,000

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Parenthetical) (USD $) In Thousands, unless otherwise specified	313 Months Ended
	Sep. 30, 2013
Proceeds from sale of subsidiary, operating losses during 1990 phase-out period	$ 12,345

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) (USD $)	Sep. 30, 2013	Dec. 31, 2012
Preferred Stock, par value	$ 0.001	$ 0.001
Preferred Stock, shares authorized	5,000,000	5,000,000
Preferred Stock, issued	0	0
Preferred Stock, outstanding	0	0
Common Stock, par value	$ 0.001	$ 0.001
Common Stock, shares authorized	75,000,000	75,000,000
Common Stock, shares issued	23,121,959	17,272,505
Common Stock, shares outstanding	23,009,609	17,160,155
Treasury stock, shares	112,350	112,350

CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (USD $) In Thousands, except Share data	Total	Common Stock	Additional Paid-in Capital	Treasury Stock	Deficit Accumulated During the Development Stage
Beginning Balance at Dec. 31, 2011	$ 4,666	$ 12	$ 197,769	$ (1,380)	$ (191,735)
Beginning Balance (in shares) at Dec. 31, 2011		12,470,694		112,350
Stock based option compensation	1,902	0	1,902	0	0
Issuance of 100 shares of common stock at a share price of $5.07 (in shares)		100		0
Issuance of shares of common stock, net of offering costs (in shares)		2,463,537		0
Exercise of stock options to purchase common stock for cash	121	0	121	0	0
Exercise of stock options to purchase common stock for cash (in shares)		16,488		0
Issuance of shares of common stock for the cashless exercise of stock options (in shares)		11,173		0
Exercise of Series B Warrants to purchase common stock for cash @ $2.49 per share	301	0	301	0	0
Exercise of Series B Warrants to purchase common stock for cash @ $2.49 per share (in shares)		121,079		0
Issuance of shares of common stock, net of offering costs 1	23,018	2	23,016	0	0
Issuance of shares of common stock, net of offering costs 1 (in shares)		2,145,636		0
Issuance of shares of common stock, net of offering costs	10,310	3	10,307	0	0
Net loss	(10,123)	0	0	0	(10,123)
Ending Balance at Sep. 30, 2012	30,195	17	233,416	(1,380)	(201,858)
Ending Balance (in shares) at Sep. 30, 2012		17,228,707		112,350
Beginning Balance at Dec. 31, 2012	23,034	17	234,299	(1,380)	(209,902)
Beginning Balance (in shares) at Dec. 31, 2012		17,272,505		112,350
Stock based option compensation	2,258	0	2,258	0	0
Issuance of shares of common stock, net of offering costs (in shares)		4,312,500		0
Issuance of 871,634 shares of common stock for the cashless exercise of 872,133 Series A Warrants	0	1	(1)	0	0
Issuance of 871,634 shares of common stock for the cashless exercise of 872,133 Series A Warrants (in shares)		871,634		0
Issuance of 614,564 shares of common stock for the cashless exercise of 716,463 Series B Warrants	0	1	(1)	0	0
Issuance of 614,564 shares of common stock for the cashless exercise of 716,463 Series B Warrants (in shares)		614,564		0
Exercise of stock options to purchase common stock for cash	47	0	47	0	0
Exercise of stock options to purchase common stock for cash (in shares)		2,500		0
Issuance of shares of common stock for the cashless exercise of stock options (in shares)		5,407		0
Exercise of Series B Warrants to purchase common stock for cash @ $2.49 per share	107	0	107	0	0
Exercise of Series B Warrants to purchase common stock for cash @ $2.49 per share (in shares)		42,849		0
Issuance of shares of common stock, net of offering costs	76,764	4	76,760	0	0
Net loss	(20,579)	0	0	0	(20,579)
Ending Balance at Sep. 30, 2013	$ 81,631	$ 23	$ 313,469	$ (1,380)	$ (230,481)
Ending Balance (in shares) at Sep. 30, 2013		23,121,959		112,350

CONDENSED CONSOLIDATED BALANCE SHEETS (USD $) In Thousands, unless otherwise specified	Sep. 30, 2013	Dec. 31, 2012
Current Assets
Cash and cash equivalents	$ 81,828	$ 24,212
Prepaid expenses and other current assets	193	406
Total current assets	82,021	24,618
Fixed assets, net	87	53
Other assets, net	2,734	2,161
Total assets	84,842	26,832
Current Liabilities
Accounts payable	2,829	3,240
Accrued expenses	382	558
Total current liabilities	3,211	3,798
Commitments and contingencies (note 5)
Stockholders' Equity
Undesignated Preferred Stock, $.001 par value, 5,000,000 shares authorized, none issued and outstanding	0	0
Common Stock, $.001 par value, 75,000,000 shares authorized, 23,121,959and 17,272,505 shares issued, respectively and 23,009,609 and 17,160,155 shares outstanding, respectively	23	17
Additional paid-in capital	313,469	234,299
Cost of treasury stock, 112,350 shares	(1,380)	(1,380)
Deficit accumulated during the development stage	(230,481)	(209,902)
Total stockholders' equity	81,631	23,034
Total liabilities and stockholders' equity	$ 84,842	$ 26,832

Commitments and Contingencies (Additional Information) (Details)	Sep. 30, 2013
Domestic [Member]
Commitments and Contingencies [Line Items]
Number of patents	8
Number of pending patent applications	4
Foreign [Member]
Commitments and Contingencies [Line Items]
Number of patents	61
Number of pending patent applications	52
Third Party [Member]
Commitments and Contingencies [Line Items]
Number of patents	2

Patents and Patent Applications (Additional Information) (Details) (USD $)	Sep. 30, 2013	Dec. 31, 2012
Finite-Lived Intangible Assets [Line Items]
Capitalized patent and patent application costs	$ 2,734,000	$ 2,161,000
Androxal [Member]
Finite-Lived Intangible Assets [Line Items]
Capitalized patent and patent application costs	1,726,000
Proellex [Member]
Finite-Lived Intangible Assets [Line Items]
Capitalized patent and patent application costs	$ 1,008,000

Loss Per Share (Additional Information) (Details) (USD $)	9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012
Earnings Per Share Disclosure [Line Items]
Anti-dilutive shares of common stock excluded from computation of earning per share	3,975,430	5,264,207
Series A Warrants [Member]
Earnings Per Share Disclosure [Line Items]
Anti-dilutive shares of common stock excluded from computation of earning per share	877,137	1,749,270
Warrants, exercise price per share	$ 0.01	$ 0.01
Series B Warrants [Member]
Earnings Per Share Disclosure [Line Items]
Anti-dilutive shares of common stock excluded from computation of earning per share	810,109	1,569,421
Warrants, exercise price per share	$ 2.49	$ 2.49

Accrued Expenses (Details) (USD $) In Thousands, unless otherwise specified	Sep. 30, 2013	Dec. 31, 2012
Schedule Of Accrued Liabilities [Line Items]
Patent costs	$ 152	$ 245
Research and development costs	87	192
Personnel related costs	42	30
Other	101	91
Total	$ 382	$ 558

Document And Entity Information	9 Months Ended
Document And Entity Information	Sep. 30, 2013	Nov. 01, 2013
Document Information [Line Items]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Sep. 30, 2013
Document Fiscal Year Focus	2013
Document Fiscal Period Focus	Q3
Trading Symbol	RPRX
Entity Common Stock, Shares Outstanding		23,009,882
Entity Registrant Name	REPROS THERAPEUTICS INC.
Entity Central Index Key	0000897075
Current Fiscal Year End Date	--12-31
Entity Filer Category	Accelerated Filer